1 00:00:05,000 --> 00:00:07,520 >>I WILL GO AHEAD AND GAVEL 2 00:00:07,520 --> 00:00:08,040 US IN FOR THE 30th MEETING 3 00:00:08,040 --> 00:00:08,560 OF THE NATIONAL CENTER FOR 4 00:00:08,560 --> 00:00:09,040 ADVANCING TRANSITIONAL 5 00:00:09,040 --> 00:00:09,600 SCIENCES ADVISORY COUNCIL. 6 00:00:09,600 --> 00:00:09,840 WELCOME. 7 00:00:09,840 --> 00:00:13,160 TAKE IT AWAY. 8 00:00:13,160 --> 00:00:22,080 >> . 9 00:00:22,080 --> 00:00:24,640 >> I WILL START WITH THE 10 00:00:24,640 --> 00:00:34,800 ROLLCALL. 11 00:00:44,600 --> 00:00:54,760 [ROLL CALL] 12 00:01:10,440 --> 00:01:10,960 >> WE HAVE A FULL COMPLEMENT 13 00:01:10,960 --> 00:01:13,760 OF MEMBERS TODAY. 14 00:01:13,760 --> 00:01:16,760 IN THE SLIDE YOU CAN SEE THE 15 00:01:16,760 --> 00:01:20,120 FIRST DAY OF THE TODAY MEETING 16 00:01:20,120 --> 00:01:21,760 CALLED TO ORDER I WILL DO SOME 17 00:01:21,760 --> 00:01:22,640 ANNOUNCEMENTS AND WE'LL HAVE 18 00:01:22,640 --> 00:01:25,160 THE DIRECTORS REPORT AND A 19 00:01:25,160 --> 00:01:26,080 PRESENTATION AND THEN A 20 00:01:26,080 --> 00:01:30,040 PROGRAM UPDATE FOR CLINICAL 21 00:01:30,040 --> 00:01:30,440 INNOVATION. 22 00:01:30,440 --> 00:01:32,920 AND WE WILL RECONVENE 23 00:01:32,920 --> 00:01:36,800 1:00 O'CLOCK P.M. TOMORROW DAY 24 00:01:36,800 --> 00:01:37,320 TO OF THE OPEN SESSION. 25 00:01:37,320 --> 00:01:39,240 THE INVITED SPEAKER TODAY 26 00:01:39,240 --> 00:01:41,720 CHIEF OFFICER OF SCIENTIFIC 27 00:01:41,720 --> 00:01:43,240 WORKFORCE DIVERSITY AT NIH 28 00:01:43,240 --> 00:01:44,360 WILL BE DELIVERING A 29 00:01:44,360 --> 00:01:47,160 PRESENTATION TO ENSURE THAT 30 00:01:47,160 --> 00:01:52,440 ALL ARE OUT AT THE TABLE. 31 00:01:52,440 --> 00:01:53,960 AFTER WE HAVE THE INVITED 32 00:01:53,960 --> 00:01:55,840 PRESENTATION WE WILL HAVE THE 33 00:01:55,840 --> 00:01:58,840 PROGRAM UPDATE DELIVERED BY 34 00:01:58,840 --> 00:02:01,160 THE DEPUTY DIRECTOR OF 35 00:02:01,160 --> 00:02:03,440 PROGRAMS FROM THE DIVISION OF 36 00:02:03,440 --> 00:02:05,600 PRECLINICAL INNOVATION. 37 00:02:05,600 --> 00:02:06,760 TOMORROW THE PROGRAM UPDATE 38 00:02:06,760 --> 00:02:09,520 WILL BE THE DIRECTOR OF THE 39 00:02:09,520 --> 00:02:12,600 OFFICE OF SPECIAL INITIATIVES 40 00:02:12,600 --> 00:02:15,120 AND IN SEVERAL PRESENTATIONS 41 00:02:15,120 --> 00:02:17,040 TOMORROW. 42 00:02:17,040 --> 00:02:17,520 ANNOUNCEMENTS. 43 00:02:17,520 --> 00:02:22,120 >> EVERYONE IN THE ZOO MEETING 44 00:02:22,120 --> 00:02:22,640 IS A PANELIST TODAY YOU'RE 45 00:02:22,640 --> 00:02:25,600 FREE TO SPEAK HOWEVER TO 46 00:02:25,600 --> 00:02:29,800 MAINTAIN A SMOOTH FLOW PLEASE 47 00:02:29,800 --> 00:02:31,240 USE THE RAISED HAND FEATURE ON 48 00:02:31,240 --> 00:02:32,800 —- FEATURE AND THEN WAIT UNTIL 49 00:02:32,800 --> 00:02:35,640 YOU ARE CALLED UPON. 50 00:02:35,640 --> 00:02:37,200 BUT THE SPEAKERS TO THE 51 00:02:37,200 --> 00:02:42,960 PRESENTATIONS WE ARE USING THE 52 00:02:42,960 --> 00:02:43,680 VIDEOCAST FEATURE TODAY 53 00:02:43,680 --> 00:02:46,960 AUDIENCE MEMBERS CAN SUBMIT 54 00:02:46,960 --> 00:02:51,640 COMMENTS THROUGH JUNE 4th 55 00:02:51,640 --> 00:02:57,840 BEING ON THE SITE OR THE 56 00:02:57,840 --> 00:03:00,440 ADDRESS THAT YOU SEE ON THE 57 00:03:00,440 --> 00:03:01,760 SLIDE. 58 00:03:01,760 --> 00:03:04,640 PLEASE MAKE SURE WHEN SPEAKING 59 00:03:04,640 --> 00:03:13,200 YOUR CAMERA IS ON FOR THOSE 60 00:03:13,200 --> 00:03:13,800 WHO VIEW BY VIDEO CAN SEE THAT 61 00:03:13,800 --> 00:03:14,400 YOU ARE SPOTLIGHTED IF YOU ARE 62 00:03:14,400 --> 00:03:14,960 NOT IN CAMERA THE PREVIOUS 63 00:03:14,960 --> 00:03:21,040 SPEAKER REMAINED SPOTLIGHTED. 64 00:03:21,040 --> 00:03:22,120 NOW LOOKING AT THE 65 00:03:22,120 --> 00:03:23,880 JANUARY 2022 MEETING PROVIDED 66 00:03:23,880 --> 00:03:29,160 TO THE NUMBERS CAN I HAVE A 67 00:03:29,160 --> 00:03:32,880 MOTION TO APPROVE THE OF THE 68 00:03:32,880 --> 00:03:33,800 JANUARY MEETING? 69 00:03:33,800 --> 00:03:36,280 >> I SECOND. 70 00:03:36,280 --> 00:03:44,320 ALL IN FAVOR? 71 00:03:44,320 --> 00:03:47,200 ALL THOSE OPPOSED? 72 00:03:47,200 --> 00:03:55,920 >> I HAVE STAYED I HAVE NOT 73 00:03:55,920 --> 00:03:59,760 READ THE MINUTES. 74 00:03:59,760 --> 00:04:05,920 >> THANK YOU. 75 00:04:05,920 --> 00:04:06,480 I DO BELIEVE ALL MEMBERS OF 76 00:04:06,480 --> 00:04:08,440 HAD AN OPPORTUNITY TO READ THE 77 00:04:08,440 --> 00:04:10,920 MINUTES AND A SUFFICIENT 78 00:04:10,920 --> 00:04:11,240 NUMBER DID SO. 79 00:04:11,240 --> 00:04:11,520 THANK YOU. 80 00:04:11,520 --> 00:04:13,120 NEXT SLIDE. 81 00:04:13,120 --> 00:04:16,160 THE FUTURE MEETING DATES FOR 82 00:04:16,160 --> 00:04:18,440 THE COUNCIL SEPTEMBER 22nd 83 00:04:18,440 --> 00:04:24,520 OF THIS YEAR A VIRTUAL ONE DAY 84 00:04:24,520 --> 00:04:26,120 MEETING AND THEN THE MEETINGS 85 00:04:26,120 --> 00:04:30,360 WILL BE JANUARY 26. 86 00:04:30,360 --> 00:04:30,840 THAT WILL BE VIRTUAL. 87 00:04:30,840 --> 00:04:33,640 MAY 25th AND SEPTEMBER 28 88 00:04:33,640 --> 00:04:36,200 AND 2024 JANUARY 18 AND 19. 89 00:04:36,200 --> 00:04:39,400 THAT WILL BE VIRTUAL AND MAY 23d 90 00:04:39,400 --> 00:04:41,600 AND SEPTEMBER 26. 91 00:04:41,600 --> 00:04:45,240 WOULD LIKE TO TURN IT BACK TO 92 00:04:45,240 --> 00:04:46,520 DELIVER THE DIRECTORS REPORT. 93 00:04:46,520 --> 00:04:54,120 >> . 94 00:04:54,120 --> 00:05:04,200 >> . 95 00:05:05,680 --> 00:05:06,880 >> WHILE SHE IS DOING THAT 96 00:05:06,880 --> 00:05:12,040 WORD YOU MIND THOSE DATES AND 97 00:05:12,040 --> 00:05:14,360 BY SO QUICKLY INTO THE CHAT 98 00:05:14,360 --> 00:05:19,240 SOMEWHERE? 99 00:05:19,240 --> 00:05:19,840 I JUST WANT TO MAKE SURE IT'S 100 00:05:19,840 --> 00:05:26,240 IN MY CALENDAR. 101 00:05:26,240 --> 00:05:27,560 >> WILL MAKE SURE THE DATES 102 00:05:27,560 --> 00:05:30,240 ARE IN THE CHAT. 103 00:05:30,240 --> 00:05:35,840 >> YOU DO HAVE CONTROL OF THE 104 00:05:35,840 --> 00:05:39,160 MINUTES. 105 00:05:39,160 --> 00:05:45,760 WE CAN GET STARTED. 106 00:05:45,760 --> 00:05:46,640 WELCOME AND IT IS THE 30th 107 00:05:46,640 --> 00:05:52,240 MEETING THIS CAPS OFF OUR 108 00:05:52,240 --> 00:06:03,560 ANNIVERSARY. 109 00:06:03,560 --> 00:06:04,160 GOING FORWARD IF THIS WORKS I 110 00:06:04,160 --> 00:06:08,800 WOULD LOVE YOUR FEEDBACK I AM 111 00:06:08,800 --> 00:06:09,920 USING A HIGH TECH AND 112 00:06:09,920 --> 00:06:12,240 INTERACTIVE APPROACH FOR THE 113 00:06:12,240 --> 00:06:13,160 SLIDES TODAY IF YOU HAVE THE 114 00:06:13,160 --> 00:06:15,520 CELL PHONE ON HIS FIRST SLIDE 115 00:06:15,520 --> 00:06:19,280 YOU CAN USE IT TO TAKE A 116 00:06:19,280 --> 00:06:24,320 PICTURE OR HOLD YOUR CAMERA UP 117 00:06:24,320 --> 00:06:24,680 TO THE QR CODE. 118 00:06:24,680 --> 00:06:27,280 THAT WILL TAKE YOU TO THE 119 00:06:27,280 --> 00:06:37,200 WEBPAGE LANDING PAGE I SHOW 120 00:06:37,200 --> 00:06:41,480 YOU THE SLIDES BUT YOU CANNOT 121 00:06:41,480 --> 00:06:42,040 CLICK ON THEM SO I'M HOPING 122 00:06:42,040 --> 00:06:44,040 THAT THIS WILL GIVE A BETTER 123 00:06:44,040 --> 00:06:51,520 SENSE THIS IS THE HIGH TECH 124 00:06:51,520 --> 00:06:53,480 INTERACTIVE VERSION - - 125 00:06:53,480 --> 00:07:00,240 VERSION OF OUR MEETING. 126 00:07:00,240 --> 00:07:00,800 SO TODAY ALSO WE SAY GOODBYE 127 00:07:00,800 --> 00:07:05,120 TO ONE OF OUR OWN REVIEW BOARD 128 00:07:05,120 --> 00:07:10,840 MEMBERS MICHAEL HAS BEEN OUR 129 00:07:10,840 --> 00:07:11,360 MEMBER ON THE REVIEW BOARD 130 00:07:11,360 --> 00:07:14,280 SINCE 2019 THROUGH NOW AND HE 131 00:07:14,280 --> 00:07:15,280 HAS BEEN PART OF THE GROUP 132 00:07:15,280 --> 00:07:18,880 THAT SUPPORTED TWO MAJOR 133 00:07:18,880 --> 00:07:20,400 INITIATIVES INCLUDING GENE 134 00:07:20,400 --> 00:07:23,360 THERAPY INITIATIVE AND THE 135 00:07:23,360 --> 00:07:27,040 DRUG REPURPOSE SEEING 136 00:07:27,040 --> 00:07:27,360 INITIATIVE. 137 00:07:27,360 --> 00:07:28,080 MIKE IS HOW THE VARIETY OF 138 00:07:28,080 --> 00:07:31,640 LEADERSHIP ROLES IN INDUSTRY 139 00:07:31,640 --> 00:07:32,520 AND PHARMACY AND CURRENTLY THE 140 00:07:32,520 --> 00:07:36,040 SENIOR PARTNER AT FLAGSHIP 141 00:07:36,040 --> 00:07:37,880 PIONEERING AND CAMBRIDGE IT 142 00:07:37,880 --> 00:07:40,680 WILL CONTINUING IN THAT ROLE I 143 00:07:40,680 --> 00:07:41,480 WOULD LIKE TO THINK HIM FOR 144 00:07:41,480 --> 00:07:47,400 HIS SERVICE OVER THE YEARS AND 145 00:07:47,400 --> 00:07:48,000 WE DID FAREWELL AND THANK YOU 146 00:07:48,000 --> 00:07:56,080 FOR YOUR SERVICE. 147 00:07:56,080 --> 00:07:56,760 FOR THE REMAINDER OF THE 148 00:07:56,760 --> 00:07:57,320 TALKING WANT TO OUTLINE A 149 00:07:57,320 --> 00:07:58,920 VARIETY OF TOPICS AS WE MOVE 150 00:07:58,920 --> 00:08:01,840 THROUGH TO KEEP TRACK IN THIS 151 00:08:01,840 --> 00:08:05,440 WAY WITH NIH UPDATES WE WILL 152 00:08:05,440 --> 00:08:11,440 TALK ABOUT THE BUDGET THERE IS 153 00:08:11,440 --> 00:08:13,040 A LOT TO TALK ABOUT. 154 00:08:13,040 --> 00:08:16,320 I WILL ALSO GIVE YOU AN 155 00:08:16,320 --> 00:08:18,840 OVERVIEW OF THE PROBLEMATIC 156 00:08:18,840 --> 00:08:22,240 UPDATES I WILL BROWN THAT OUT 157 00:08:22,240 --> 00:08:24,760 FOR THE DIVERSITY EQUITY AND 158 00:08:24,760 --> 00:08:27,440 INCLUSION AND REQUEST FROM THE 159 00:08:27,440 --> 00:08:32,680 COUNCIL FROM THE LAST TIME ON 160 00:08:32,680 --> 00:08:33,280 THE TRY ANNUAL REPORT WHAT WE 161 00:08:33,280 --> 00:08:33,840 ARE DOING TO MITIGATE THOSE 162 00:08:33,840 --> 00:08:38,600 MEASURES OF THAT REPORT I WILL 163 00:08:38,600 --> 00:08:40,040 REALLY FOCUS MY EFFORTS ON 164 00:08:40,040 --> 00:08:45,840 THOSE ACTIVITIES CLEAR WILL 165 00:08:45,840 --> 00:08:48,000 MODERATE THE SESSION SO PLEASE 166 00:08:48,000 --> 00:08:50,440 FEEL FREE TO BUT THEM IN THE 167 00:08:50,440 --> 00:08:55,240 CHAT OR USE THE RAISED HAND 168 00:08:55,240 --> 00:08:57,120 FUNCTION SO IN TERMS OF 169 00:08:57,120 --> 00:08:58,520 ANNOUNCEMENTS AND ACTIVITIES 170 00:08:58,520 --> 00:09:03,360 RELATED TO NIH THERE ARE 171 00:09:03,360 --> 00:09:07,640 VARIETY OF LEADERSHIP SEARCHES. 172 00:09:07,640 --> 00:09:13,680 AS YOU KNOW FRANCIS COLLINS 173 00:09:13,680 --> 00:09:14,240 STEP DOWN DECEMBER 2021 AND 174 00:09:14,240 --> 00:09:14,800 LARRY TAILBACK HAS BEEN THE 175 00:09:14,800 --> 00:09:17,560 ACTING NIH DIRECTOR AND THAT 176 00:09:17,560 --> 00:09:23,080 IS STILL AN OPEN LEADERSHIP 177 00:09:23,080 --> 00:09:26,360 POSITION CURRENTLY UNDERWAY. 178 00:09:26,360 --> 00:09:27,880 WE HAVE NO NEWS TO UPDATE AT 179 00:09:27,880 --> 00:09:29,320 THIS POINT. 180 00:09:29,320 --> 00:09:31,760 THAT IS A PRESIDENTIAL 181 00:09:31,760 --> 00:09:34,680 APPOIN APPOINTEE. 182 00:09:34,680 --> 00:09:35,240 WE WILL AWAIT FOR THE WHITE 183 00:09:35,240 --> 00:09:36,800 HOUSE TO MAKE THOSE 184 00:09:36,800 --> 00:09:41,160 ANNOUNCEMENTS. 185 00:09:41,160 --> 00:09:43,760 OUR BUT AGE WAS TO BE UNDER 186 00:09:43,760 --> 00:09:48,440 THE RUBRIC OF HHS AS WELL AS 187 00:09:48,440 --> 00:09:51,320 NIH SO THAT IS IN EITHER 188 00:09:51,320 --> 00:09:55,080 ONGOING LEADERSHIP SEARCH 189 00:09:55,080 --> 00:09:59,480 HOPEFULLY THAT IS ALSO 190 00:09:59,480 --> 00:10:04,920 PRESIDENTIAL APPOINTEE THAT 191 00:10:04,920 --> 00:10:05,480 DOES NOT CURRENTLY REQUIRE 192 00:10:05,480 --> 00:10:06,040 SENATE CONFIRMATION AND THEN 193 00:10:06,040 --> 00:10:06,520 THERE ARE A VARIETY OF 194 00:10:06,520 --> 00:10:08,920 OPENINGS WITHIN THE NIH 195 00:10:08,920 --> 00:10:09,520 LEADERSHIP POSITIONS ACROSS 196 00:10:09,520 --> 00:10:18,200 THE INSTITUTES MEANT TO HAVE A 197 00:10:18,200 --> 00:10:24,040 VACANCY THE ACTING DIRECTOR 198 00:10:24,040 --> 00:10:26,400 SINCE HE HAS STEPPED DOWN AND 199 00:10:26,400 --> 00:10:30,880 THE NIH DIRECTOR HAS STEPPED 200 00:10:30,880 --> 00:10:31,640 DOWN. 201 00:10:31,640 --> 00:10:34,120 LIKE ME REMAINING IN THAT 202 00:10:34,120 --> 00:10:40,240 POSITION UNTIL THE DIRECTORS 203 00:10:40,240 --> 00:10:41,760 NAMED. 204 00:10:41,760 --> 00:10:42,320 I MENTIONED ARPA-H I WANT TO 205 00:10:42,320 --> 00:10:45,600 GIVE YOU A SENSE OF WHERE YOU 206 00:10:45,600 --> 00:10:56,000 ARE AND WHAT WE KNOW. 207 00:10:57,200 --> 00:10:57,680 AND WITH THOSE SESSIONS THAT 208 00:10:57,680 --> 00:10:59,680 WENT ON AND IN MARCH CONGRESS 209 00:10:59,680 --> 00:11:02,920 PASSED THE OMNIBUS THAT ALLOWS 210 00:11:02,920 --> 00:11:06,680 $1 BILLION FOR THREE YEARS FOR 211 00:11:06,680 --> 00:11:10,120 OUR PAGE TO START ACTIVITIES 212 00:11:10,120 --> 00:11:12,680 AND TO BE PRESIDENTIALLY 213 00:11:12,680 --> 00:11:13,480 APPOINTED AND THEN HIRING 214 00:11:13,480 --> 00:11:18,680 THOSE FLEXIBILITIES SO IT IS 215 00:11:18,680 --> 00:11:19,240 MEANT TO BE THAT ARE BUT AGE 216 00:11:19,240 --> 00:11:21,560 WILL BE COMPLEMENTARY AND NOT 217 00:11:21,560 --> 00:11:25,480 DUPLICATE OF NIH PROGRAMS SO I 218 00:11:25,480 --> 00:11:27,680 THINK THAT WILL BE VERY 219 00:11:27,680 --> 00:11:30,440 IMPORTANT TO SEE HOW THAT 220 00:11:30,440 --> 00:11:36,200 CONTINUES TO EVOLVE AND THEN 221 00:11:36,200 --> 00:11:38,720 PASSING THE OMNIBUS THERE IS 222 00:11:38,720 --> 00:11:45,120 LANGUAGE THAT DELEGATED THE 223 00:11:45,120 --> 00:11:45,720 RESPONSIBILITY OF WHERE ARPA-H 224 00:11:45,720 --> 00:11:46,320 WORD AND ABOUT THAT DISCUSSION 225 00:11:46,320 --> 00:11:48,760 OF HHS SECRETARY AND THEN 226 00:11:48,760 --> 00:11:53,560 TRANSFERRED TO NIH THAT IS THE 227 00:11:53,560 --> 00:11:56,840 HOME FOR THE PROGRAM GOING 228 00:11:56,840 --> 00:11:59,160 FORWARD AND IN THE PRESIDENTS 229 00:11:59,160 --> 00:12:06,520 BUDGET THERE IS $5 BILLION 230 00:12:06,520 --> 00:12:14,520 SUGGESTED FOR OUR PH HFI 23. 231 00:12:14,520 --> 00:12:20,720 MANY OF YOU ARE AWARE BUT YOU 232 00:12:20,720 --> 00:12:21,280 HAVE HEARD A NEW BILL THAT 233 00:12:21,280 --> 00:12:27,120 COULD MOVE IT BACK INTO HHS 234 00:12:27,120 --> 00:12:35,000 STAY TUNED OF COURSE THIS IS 235 00:12:35,000 --> 00:12:35,600 EVOLVING BUT THIS IS WHERE WE 236 00:12:35,600 --> 00:12:36,200 ARE NOW AND WE WILL CONTINUE 237 00:12:36,200 --> 00:12:42,040 TO PROCEED AS SUCH ANOTHER 238 00:12:42,040 --> 00:12:46,480 ANNOUNCEMENT IN TERMS OF THE 239 00:12:46,480 --> 00:12:53,480 OMNIBUS FROM NIH INSTITUTIONS 240 00:12:53,480 --> 00:12:56,040 MANDATORY WHEN IT COMES TO 241 00:12:56,040 --> 00:13:04,120 HOSTILE WORKING CONDITIONS AND 242 00:13:04,120 --> 00:13:04,680 PREVIOUSLY NIH LACKED CLEAR 243 00:13:04,680 --> 00:13:05,240 AUTHORITY TO REQUIRE FUNDED 244 00:13:05,240 --> 00:13:07,600 INSTITUTIONS TO REPORT NIH 245 00:13:07,600 --> 00:13:08,200 WHETHER PERSONAL CHANGES WERE 246 00:13:08,200 --> 00:13:12,920 RELATED TO HARASSMENT THE 247 00:13:12,920 --> 00:13:13,520 PROVISION THAT THEY SHOULD BUT 248 00:13:13,520 --> 00:13:16,280 NOT REQUIRED TO SO PASSAGE OF 249 00:13:16,280 --> 00:13:22,080 THIS BILL ENSURES THAT WHEN 250 00:13:22,080 --> 00:13:22,680 THE PERSONAL CHANGES IS DUE TO 251 00:13:22,680 --> 00:13:23,520 HARASSMENT AND THEREFORE 252 00:13:23,520 --> 00:13:26,760 STRENGTHENS THE ABILITY TO 253 00:13:26,760 --> 00:13:27,280 TAKE NECESSARY ACTION TO 254 00:13:27,280 --> 00:13:30,560 ENSURE SAFE WORK ENVIRONMENTS 255 00:13:30,560 --> 00:13:33,120 WHENEVER THOSE ACTIVITIES ARE 256 00:13:33,120 --> 00:13:34,560 CONDUCTED THIS GIVES US MORE 257 00:13:34,560 --> 00:13:38,200 TEETH IN THE SPACE AND HERE IS 258 00:13:38,200 --> 00:13:46,040 THE QR CODE. 259 00:13:46,040 --> 00:13:48,520 >> THERE ARE LONG-STANDING 260 00:13:48,520 --> 00:13:51,640 POLICIES ALL PROTECTING THE 261 00:13:51,640 --> 00:13:54,280 INFORMATION FROM THOSE 262 00:13:54,280 --> 00:13:55,280 PROVIDING AND IT HAS BEEN 263 00:13:55,280 --> 00:14:05,760 UPDATED AS A SPEAK AND WITH 264 00:14:09,800 --> 00:14:10,360 THE NEW POLICIES AND WHEN THEY 265 00:14:10,360 --> 00:14:17,440 ARE COMING INTO PLAY. 266 00:14:17,440 --> 00:14:22,120 AND THEN TO ENSURE ROBUST AND 267 00:14:22,120 --> 00:14:26,560 OF THAT DATA THAT'S IN AND 268 00:14:26,560 --> 00:14:29,240 THEN TO PUBLIC TRUST AND 269 00:14:29,240 --> 00:14:32,040 RESEARCH MATERIALS SO 270 00:14:32,040 --> 00:14:34,520 OBVIOUSLY THIS IS AN IMPORTANT 271 00:14:34,520 --> 00:14:39,160 PIECE OF WORK THAT THE NIH 272 00:14:39,160 --> 00:14:39,600 SUPPORTS AND I'M ALSO 273 00:14:39,600 --> 00:14:49,640 PROVIDING FOR A QR CODE WITH 274 00:14:49,640 --> 00:14:50,240 THE EFFORTS AROUND THIS SPACE 275 00:14:50,240 --> 00:14:50,880 AND THE DEADLINES THAT WILL BE 276 00:14:50,880 --> 00:14:55,680 POSTED ON THIS SITE. 277 00:14:55,680 --> 00:14:56,200 AS IT STANDS NOW YOU BE 278 00:14:56,200 --> 00:14:57,240 PROVIDING SUPPLEMENTAL 279 00:14:57,240 --> 00:15:01,960 INFORMATION AND PRIVACY 280 00:15:01,960 --> 00:15:02,560 PROTECTIONS AS WELL AS SAMPLE 281 00:15:02,560 --> 00:15:03,160 PLANS AND ADDITIONAL WEBINARS 282 00:15:03,160 --> 00:15:06,040 AS WELL. 283 00:15:06,040 --> 00:15:10,240 ONCE A POLICY TAKES EFFECT 284 00:15:10,240 --> 00:15:10,760 WE'LL BE DOING ON BOARD 285 00:15:10,760 --> 00:15:11,680 ASSESSMENTS TO PROVIDE 286 00:15:11,680 --> 00:15:14,640 INCENTIVES THAT IT HAPPENS IN 287 00:15:14,640 --> 00:15:14,920 THIS WAY. 288 00:15:14,920 --> 00:15:17,280 I ENCOURAGE YOU TO LOOK MORE 289 00:15:17,280 --> 00:15:19,280 DEEPLY AT INFORMATION PROVIDED 290 00:15:19,280 --> 00:15:25,120 ON THE WEBSITE. 291 00:15:25,120 --> 00:15:25,640 SO NOW WE WILL TURN TO THE 292 00:15:25,640 --> 00:15:29,440 EVENTS AND OTHER ANNOUNCEMENTS. 293 00:15:29,440 --> 00:15:32,000 I WILL START OFF BY TALKING 294 00:15:32,000 --> 00:15:37,200 ABOUT THE ORGANIZATIONAL 295 00:15:37,200 --> 00:15:39,720 CHANGES EVOLVE AND AWARE WE 296 00:15:39,720 --> 00:15:44,120 WANTED TO CHANGE OUR OFFICES 297 00:15:44,120 --> 00:15:51,720 TO ELEVATE TO HER THEY STAND 298 00:15:51,720 --> 00:15:52,240 WITHIN THE NIH IN TERMS OF 299 00:15:52,240 --> 00:15:54,000 OTHER DIVISIONS WITHIN OUR 300 00:15:54,000 --> 00:15:54,840 STRUCTURE. 301 00:15:54,840 --> 00:15:57,720 I AM PLEASED TO SAY WE HAVE 302 00:15:57,720 --> 00:16:01,920 FINALLY ENACTED THIS ELEVATION 303 00:16:01,920 --> 00:16:04,240 PROCEDURE. 304 00:16:04,240 --> 00:16:04,720 WE NOW HAVE DIVISION OF 305 00:16:04,720 --> 00:16:09,120 EXTRAMURAL ACTIVITIES AND THE 306 00:16:09,120 --> 00:16:13,400 DIRECTOR OF THAT DIVISION AND 307 00:16:13,400 --> 00:16:19,080 WEIRD DISEASE INNOVATION THERE 308 00:16:19,080 --> 00:16:19,600 ARE MANY WAYS TO SAY THIS 309 00:16:19,600 --> 00:16:20,200 ACRONYM AND I ENCOURAGE YOU TO 310 00:16:20,200 --> 00:16:21,160 SAY ALL OF THEM WHICHEVER YOU 311 00:16:21,160 --> 00:16:25,680 LIKE THE BEST I'M PLEASE TO 312 00:16:25,680 --> 00:16:28,360 SAY THAT PJ BROOKS IS ARE 313 00:16:28,360 --> 00:16:36,280 ACTING DIRECTOR AND WE ARE 314 00:16:36,280 --> 00:16:36,840 CONDUCTING A SEARCH FOR A 315 00:16:36,840 --> 00:16:37,400 DIRECTOR IN THIS RULES THAT 316 00:16:37,400 --> 00:16:38,680 WILL TAKE PLACE RELATIVELY 317 00:16:38,680 --> 00:16:41,520 SOON. 318 00:16:41,520 --> 00:16:51,960 >> AND THEN WERE ALWAYS 319 00:16:52,880 --> 00:16:55,040 PLEASED TO SEE IN THE 320 00:16:55,040 --> 00:16:57,400 LIMELIGHT. 321 00:16:57,400 --> 00:17:03,760 SO FROM THE ASSOCIATION OF AA 322 00:17:03,760 --> 00:17:04,240 AND SEE WITH THE 2022 323 00:17:04,240 --> 00:17:05,840 INNOVATION TO BOLSTER TRUST 324 00:17:05,840 --> 00:17:11,200 AND SCIENCE AWARD WINNERS 325 00:17:11,200 --> 00:17:15,320 THREE LEADERS ARE RECOGNIZED 326 00:17:15,320 --> 00:17:22,880 RECEIVING FIRST PLACE AND ALSO 327 00:17:22,880 --> 00:17:26,960 THIRD-PLACE IN A TIE. 328 00:17:26,960 --> 00:17:28,040 SO WE ARE EXCITED TO SEE THAT 329 00:17:28,040 --> 00:17:31,080 ONCE AGAIN COMING TO COMMUNITY 330 00:17:31,080 --> 00:17:31,800 ENGAGEMENT. 331 00:17:31,800 --> 00:17:33,680 OF COURSE THERE IS MORE WORK 332 00:17:33,680 --> 00:17:40,680 TO DO BUT THESE ARE A FEW OF 333 00:17:40,680 --> 00:17:45,560 THEM WE'RE IN A GREAT POSITION 334 00:17:45,560 --> 00:17:48,160 TO CONTINUE TO DO BETTER WHEN 335 00:17:48,160 --> 00:17:49,080 IT COMES TO BOLSTERING 336 00:17:49,080 --> 00:17:54,800 COMMUNITY TRUST I'M EXCITED TO 337 00:17:54,800 --> 00:17:55,760 SEE STUDENTS AWARD WINNERS. 338 00:17:55,760 --> 00:18:01,960 IN ADDITION OF FRIDAY AFFORDS 339 00:18:01,960 --> 00:18:02,560 WERE GIVEN I WANT TO HIGHLIGHT 340 00:18:02,560 --> 00:18:08,520 TWO OF THE TRAINEES WITHIN THE 341 00:18:08,520 --> 00:18:08,760 PROGRAM. 342 00:18:08,760 --> 00:18:14,560 POSTDOC ON THE LEFT AND OUR 343 00:18:14,560 --> 00:18:18,040 PRE- DOCTORAL FELLOW. 344 00:18:18,040 --> 00:18:21,000 CONGRATULATIONS AND THEIR WORK 345 00:18:21,000 --> 00:18:23,920 TO BE RECOGNIZED WHAT THEY ARE 346 00:18:23,920 --> 00:18:25,000 DOING. 347 00:18:25,000 --> 00:18:27,520 LASTLY I WANT TO ROUND OUT 348 00:18:27,520 --> 00:18:34,440 THIS AWARD ANNOUNCEMENT WITH 349 00:18:34,440 --> 00:18:38,360 THE PUBLIC SERVICE AWARD 2022 350 00:18:38,360 --> 00:18:41,880 FOR WORK AND CONSISTENTLY 351 00:18:41,880 --> 00:18:47,280 FOSTERING THERAPY THROUGH 352 00:18:47,280 --> 00:18:47,840 WORKING WITH THE GOVERNMENT 353 00:18:47,840 --> 00:18:48,440 AGENCIES WORKING TIRELESSLY IN 354 00:18:48,440 --> 00:18:51,360 THE SPACE AND THIS MEETING IS 355 00:18:51,360 --> 00:18:54,280 HAPPENING AS WE SPEAK. 356 00:18:54,280 --> 00:18:56,160 CONGRATULATIONS FOR RECEIVING 357 00:18:56,160 --> 00:18:59,040 THIS AWARD. 358 00:18:59,040 --> 00:19:02,880 MUCH-DESERVED. 359 00:19:02,880 --> 00:19:08,560 ALSO WHILE I AM I'M GENE AND 360 00:19:08,560 --> 00:19:14,440 CELL EDITING I MENTIONED THE 361 00:19:14,440 --> 00:19:19,120 PROGRAM WE ARE NOW IN PHASE 362 00:19:19,120 --> 00:19:21,840 NUMBER TWO AND ANNOUNCEMENTS 363 00:19:21,840 --> 00:19:22,440 ARE ON THE STREET I WANT YOU 364 00:19:22,440 --> 00:19:23,080 TO BE AWARE OF THESE 365 00:19:23,080 --> 00:19:29,200 ANNOUNCEMENTS TO DEVELOP NOVEL 366 00:19:29,200 --> 00:19:29,800 TECHNOLOGIES AND GENE TO BUILD 367 00:19:29,800 --> 00:19:30,600 FOUNDATIONS FOR MEDICAL 368 00:19:30,600 --> 00:19:31,720 APPLICATIONS FOR GENE EDITORS 369 00:19:31,720 --> 00:19:35,080 AND DELIVER RESOURCES SO 370 00:19:35,080 --> 00:19:36,520 THAT'S THE FOCUS OF THESE 371 00:19:36,520 --> 00:19:43,160 ACTIVITIES WITH THE S ECG 372 00:19:43,160 --> 00:19:43,760 PROGRAM AND WE ARE EXCITED HOW 373 00:19:43,760 --> 00:19:44,280 THIS WILL TURN OUT BECAUSE 374 00:19:44,280 --> 00:19:45,480 IT'S GETTING INTO THE CLINICAL 375 00:19:45,480 --> 00:19:46,840 SPACE WHERE WE REALLY NEED TO 376 00:19:46,840 --> 00:19:50,680 DO A BONE ON —- A BIG PUSH TO 377 00:19:50,680 --> 00:19:57,080 BRING THERAPIES TO ALL PEOPLE. 378 00:19:57,080 --> 00:19:57,680 I WANTED TO LET YOU KNOW ABOUT 379 00:19:57,680 --> 00:20:00,680 A COUPLE OF MEETINGS WE HAVE 380 00:20:00,680 --> 00:20:02,600 HELD. 381 00:20:02,600 --> 00:20:03,160 THIS IS COMING IN THE FUTURE 382 00:20:03,160 --> 00:20:06,000 JUNE 7 AND JUNE 8 HERE IS THE 383 00:20:06,000 --> 00:20:10,600 QR CODE THIS IS ON THREE D 384 00:20:10,600 --> 00:20:14,920 TISSUE MODELS AND HOSTED BY 385 00:20:14,920 --> 00:20:16,360 THE BILL AND MELINDA GATES 386 00:20:16,360 --> 00:20:23,160 FOUNDATION AND IT WILL PROVIDE 387 00:20:23,160 --> 00:20:23,680 HIGH-LEVEL PERSPECTIVES ON 388 00:20:23,680 --> 00:20:24,240 INFECTIOUS DISEASE AND THE 389 00:20:24,240 --> 00:20:24,920 POTENTIAL VALUE OF THREE D 390 00:20:24,920 --> 00:20:29,040 TISSUE MODELS AS WELL AS TOOLS 391 00:20:29,040 --> 00:20:29,640 FOR UNDERSTANDING AND MODELING 392 00:20:29,640 --> 00:20:31,800 THOSE INFECTIOUS DISEASES IT'S 393 00:20:31,800 --> 00:20:34,600 AN IMPORTANT MEETING AS THREE 394 00:20:34,600 --> 00:20:42,000 D TISSUE MODELS AND MICRO 395 00:20:42,000 --> 00:20:42,600 PHYSIOLOGICAL TAKES OVER THESE 396 00:20:42,600 --> 00:20:46,520 MEETINGS WILL BE MORE 397 00:20:46,520 --> 00:20:47,120 IMPORTANT WITH USEFULNESS AND 398 00:20:47,120 --> 00:20:55,640 THE APPLICABILITY TO RESEARCH. 399 00:20:55,640 --> 00:20:56,960 THIS MEETING WAS LAST MONTH I 400 00:20:56,960 --> 00:21:00,240 JUST WANT TO HIGHLIGHT BECAUSE 401 00:21:00,240 --> 00:21:00,840 WE HAVE HELPED TO PROVIDE SOME 402 00:21:00,840 --> 00:21:02,960 OF THE INFORMATION RELATED IN 403 00:21:02,960 --> 00:21:10,320 THE MEETING AND WE HAD ABOUT 404 00:21:10,320 --> 00:21:10,720 THOSE AWARDEES WHO 405 00:21:10,720 --> 00:21:12,880 PARTICIPATED IN THIS RESEARCH 406 00:21:12,880 --> 00:21:22,360 SESSION AND EXPLORING TRENDS 407 00:21:22,360 --> 00:21:26,000 AND THOSE STAKEHOLDERS SO THEY 408 00:21:26,000 --> 00:21:26,920 CAN HEAR ABOUT THEIR CONCERNS 409 00:21:26,920 --> 00:21:31,800 AND IDEAS AND AS WE THINK 410 00:21:31,800 --> 00:21:33,560 ABOUT THE INVESTMENT OF THE 411 00:21:33,560 --> 00:21:38,040 SCIENCE AND THE SOLUTIONS TO 412 00:21:38,040 --> 00:21:44,720 MOVE THE OPIOID EPIDEMIC AND 413 00:21:44,720 --> 00:21:50,040 THOSE PAIN RELATED DISEASES TO 414 00:21:50,040 --> 00:21:59,560 MOVE THOSE THINGS FORWARD. 415 00:21:59,560 --> 00:22:00,000 AND THAT WHAT HAS BEEN 416 00:22:00,000 --> 00:22:00,600 SUPPORTED WITH THAT VARIETY OF 417 00:22:00,600 --> 00:22:01,200 PRESENTATION I JUST WANT TO 418 00:22:01,200 --> 00:22:09,840 GIVE YOU AN UPDATE AND WITH 419 00:22:09,840 --> 00:22:10,400 THOSE OPPORTUNITIES THAT WE 420 00:22:10,400 --> 00:22:12,560 ARE DOING IN THAT SPACE. 421 00:22:12,560 --> 00:22:17,960 SO YESTERDAY SO THE 422 00:22:17,960 --> 00:22:23,520 STAKEHOLDER TEATIME THAT WAS 423 00:22:23,520 --> 00:22:30,960 VERY WELL ATTENDED AND TO TALK 424 00:22:30,960 --> 00:22:37,400 ABOUT HOW THOSE TO BRING THE 425 00:22:37,400 --> 00:22:40,920 COMMUNITIES TOGETHER OF HOW TO 426 00:22:40,920 --> 00:22:41,800 FLUSH THOSE GOALS OUT A LITTLE 427 00:22:41,800 --> 00:22:45,920 BIT MORE AND THAT IS SO 428 00:22:45,920 --> 00:22:52,280 IMPORTANT. 429 00:22:52,280 --> 00:22:54,800 AND VERY EXCITED ABOUT THE 430 00:22:54,800 --> 00:22:57,640 TURNOUT. 431 00:22:57,640 --> 00:23:03,560 >> TURNING TO THE BUDGET THIS 432 00:23:03,560 --> 00:23:04,160 IS CONFUSING BECAUSE OF THE 433 00:23:04,160 --> 00:23:09,240 TIMING HOW EVERYTHING HAPPENED. 434 00:23:09,240 --> 00:23:17,880 AS I MENTIONED ON MARCH 15 AND 435 00:23:17,880 --> 00:23:27,240 OF THE FIVE.2 PERCENT. 436 00:23:27,240 --> 00:23:33,360 ALSO THREE.1 PERCENT INCREASE 437 00:23:33,360 --> 00:23:33,920 THERE WAS A THREE.3 PERCENT 438 00:23:33,920 --> 00:23:40,560 INCREASE AT NIH AND ALSO 439 00:23:40,560 --> 00:23:43,720 PROVIDED $60 MILLION FOR THE 440 00:23:43,720 --> 00:23:45,800 NETWORK TO CONDUCT ITS 441 00:23:45,800 --> 00:23:52,560 BUSINESS SO THIS WAS ENACTED 442 00:23:52,560 --> 00:23:57,520 MARCH 15. 443 00:23:57,520 --> 00:24:00,040 AND WITH THE FY 23 BUDGET IS 444 00:24:00,040 --> 00:24:09,440 BECAUSE THROUGH THE CONTINUING 445 00:24:09,440 --> 00:24:10,000 RESOLUTIONS ARE FY 22 SO THE 446 00:24:10,000 --> 00:24:14,600 TIMING OF THE RELEASE AND THE 447 00:24:14,600 --> 00:24:17,040 PRESIDENT'S BUDGET WAS NEARLY 448 00:24:17,040 --> 00:24:20,280 IDENTICAL. 449 00:24:20,280 --> 00:24:20,840 IT WOULD HAVE TAKEN A LOT OF 450 00:24:20,840 --> 00:24:21,440 WORK TO GO BACK AND REDO THE 451 00:24:21,440 --> 00:24:23,440 ENTIRE BUDGET BASED ON THE 452 00:24:23,440 --> 00:24:26,880 APPROPRIATIONS WHEN YOU'RE 453 00:24:26,880 --> 00:24:33,920 FAMILIAR WITH THE PRESIDENTS 454 00:24:33,920 --> 00:24:34,440 BUDGET THIS IS THE INITIAL 455 00:24:34,440 --> 00:24:35,000 STAGE OF THE CONVERSATIONS I 456 00:24:35,000 --> 00:24:35,560 DO EXPECT THERE WILL BE MORE 457 00:24:35,560 --> 00:24:38,360 UPDATES GOING FORWARD BUT THAT 458 00:24:38,360 --> 00:24:38,960 IS THE WRINKLE BECAUSE IT DOES 459 00:24:38,960 --> 00:24:40,840 MAKE THE NUMBERS ARE 460 00:24:40,840 --> 00:24:50,240 DIFFERENT. 461 00:24:50,240 --> 00:24:53,400 AND THEN WITH THAT ENACTED 462 00:24:53,400 --> 00:24:54,880 BUDGET. 463 00:24:54,880 --> 00:24:56,080 BUT WHEN YOU LOOK AT THE 464 00:24:56,080 --> 00:25:06,560 PERCENT CHANGE IT'S NOT THAT 465 00:25:10,440 --> 00:25:15,280 FAR AWAY. 466 00:25:15,280 --> 00:25:17,800 AND JUSTIN THE PRESIDENTS 467 00:25:17,800 --> 00:25:25,640 BUDG BUDGET. 468 00:25:25,640 --> 00:25:26,240 WE WILL SEE HOW THAT PLAYS OUT 469 00:25:26,240 --> 00:25:26,480 AS WELL. 470 00:25:26,480 --> 00:25:27,080 THE CONGRESSIONAL HEARINGS ON 471 00:25:27,080 --> 00:25:35,880 THE NIH BUDGET AND THOSE WERE 472 00:25:35,880 --> 00:25:46,320 WELL RECEIVED SO SO THIS 473 00:25:47,760 --> 00:25:56,720 INCREASE OF 35.SEVEN BUT THIS 474 00:25:56,720 --> 00:25:59,040 IS REFERRING TO THE 5 BILLION 475 00:25:59,040 --> 00:26:03,920 INCREASE AND ALSO A 476 00:26:03,920 --> 00:26:06,840 12 BILLION-DOLLAR EXPENDITURE 477 00:26:06,840 --> 00:26:16,640 FOR THE PANDEMIC PREPAREDNESS. 478 00:26:16,640 --> 00:26:17,680 AND IT WILL CONTINUE TO KEEP 479 00:26:17,680 --> 00:26:19,560 YOU POSTED. 480 00:26:19,560 --> 00:26:26,320 >> SO WITH THOSE ACTIONS A 481 00:26:26,320 --> 00:26:29,840 COUNSELOR TAKE IT ON WITH 482 00:26:29,840 --> 00:26:34,880 THOSE FUNDING OPPORTUNITIES 483 00:26:34,880 --> 00:26:45,040 THEY WITH THE FAMILIAR TO YOU 484 00:26:45,040 --> 00:26:49,080 WITH A RARE DISEASE AND 485 00:26:49,080 --> 00:26:53,360 HONESTY TSA PROGRAM. 486 00:26:53,360 --> 00:26:53,960 I ENCOURAGE YOU TO TAKE A LOOK 487 00:26:53,960 --> 00:27:00,040 AT THOSE AS WELL. 488 00:27:00,040 --> 00:27:02,000 >> THIS IS THE SAME FOR THE 489 00:27:02,000 --> 00:27:05,760 FUNDING OPPORTUNITY TO SEE A 490 00:27:05,760 --> 00:27:07,320 FRIDAY OF FUNDING 491 00:27:07,320 --> 00:27:10,400 OPPORTUNITIES AND THESE ARE 492 00:27:10,400 --> 00:27:16,920 THE ONES TO LEARN MORE OF THE 493 00:27:16,920 --> 00:27:27,440 BUSINESS TO GO ON THE QR CODE. 494 00:27:32,600 --> 00:27:33,120 A COUPLE OF PROGRAMS WE ASKED 495 00:27:33,120 --> 00:27:33,640 THEM TO PROVIDE THEIR OWN 496 00:27:33,640 --> 00:27:35,400 UPDATE TO YOU AND NOW THE 497 00:27:35,400 --> 00:27:45,920 OFFICE OF SPECIAL INITIATIVES 498 00:27:47,720 --> 00:27:48,280 AND THEN DAN FROM THE SPECIAL 499 00:27:48,280 --> 00:27:54,600 INITIATIVES OFFICE. 500 00:27:54,600 --> 00:28:05,080 I AM SUPER EXCITED THIS IS A 501 00:28:06,400 --> 00:28:14,920 CAPSULE THAT HAS WITH THE 502 00:28:14,920 --> 00:28:19,720 FIRST-EVER FDA DRUG APPROVAL 503 00:28:19,720 --> 00:28:22,600 AND TO THE THEIR PUTATIVE 504 00:28:22,600 --> 00:28:33,120 DEVELOPMENT BRANCH SO ANOTHER 505 00:28:35,760 --> 00:28:45,920 CONCEPT THIS IS A TWO-PHASE 506 00:28:45,920 --> 00:28:50,240 COMPETITION FROM THE PROGRAM 507 00:28:50,240 --> 00:28:50,680 AND LOOKING AT NATURAL 508 00:28:50,680 --> 00:28:54,000 LANGUAGE PROCESSING ABSTRACT 509 00:28:54,000 --> 00:28:58,240 LOOKING AT HOW THEY COULD BE 510 00:28:58,240 --> 00:28:58,800 CONCEPTS COULD BE PULLED OUT 511 00:28:58,800 --> 00:29:07,480 OF THE ABSTRACT THAT IS THE 512 00:29:07,480 --> 00:29:08,040 CONTEXT BY WHICH THEY APPEAR 513 00:29:08,040 --> 00:29:11,960 IN THE ABSTRACT. 514 00:29:11,960 --> 00:29:15,240 THAT IS ONE OF THE THINGS THEY 515 00:29:15,240 --> 00:29:17,280 COULD DO EFFECTIVELY SO THIS 516 00:29:17,280 --> 00:29:21,120 IS A RESULT OF RUNNING THE 517 00:29:21,120 --> 00:29:24,480 NATIONAL LANGUAGE PROCESSING 518 00:29:24,480 --> 00:29:34,320 SYSTEM AND THEN THOSE SCORES 519 00:29:34,320 --> 00:29:34,840 WOULD APPLY TO GENERATE 520 00:29:34,840 --> 00:29:37,880 WINNERS FOR THIS PARTICULAR 521 00:29:37,880 --> 00:29:40,920 CHALLENGE OVER 200 522 00:29:40,920 --> 00:29:43,280 PARTICIPATING TEAMS AROUND THE 523 00:29:43,280 --> 00:29:46,320 WORLD AND THE HIGHEST SCORING 524 00:29:46,320 --> 00:29:48,480 TEAM IS REPRESENTED ON THE MAP 525 00:29:48,480 --> 00:29:50,760 HERE WE WILL BE REWARDING 526 00:29:50,760 --> 00:29:54,120 $100,000 IN PRIZES TO US 527 00:29:54,120 --> 00:29:56,560 CITIZENS AND PERMANENT 528 00:29:56,560 --> 00:29:58,200 RESIDENTS FOR THESE DIVERSE 529 00:29:58,200 --> 00:29:58,400 TEAMS. 530 00:29:58,400 --> 00:30:02,280 WE WILL HEAR MORE BECAUSE 531 00:30:02,280 --> 00:30:02,800 THERE IS NORMALLY HAVE TO 532 00:30:02,800 --> 00:30:06,160 APPROVE TO THE PROCESS SO STAY 533 00:30:06,160 --> 00:30:08,640 TUNED TO HEAR MORE ABOUT THOSE 534 00:30:08,640 --> 00:30:12,000 WE ARE GETTING CLOSER TO MAKE 535 00:30:12,000 --> 00:30:15,080 THIS IDEA A REALITY. 536 00:30:15,080 --> 00:30:16,560 THERE HAS BEEN OVERALL 537 00:30:16,560 --> 00:30:18,680 EXCITEMENT SO WE ARE 538 00:30:18,680 --> 00:30:19,960 ENCOURAGED BY THAT AND WE HOPE 539 00:30:19,960 --> 00:30:26,320 THAT YOU AR ARE. 540 00:30:26,320 --> 00:30:26,840 ANOTHER ACTIVITY WE ARE 541 00:30:26,840 --> 00:30:29,600 INVOLVED IN CONNECTED TO THE 542 00:30:29,600 --> 00:30:30,480 PROGRAM YOU'LL NOT NECESSARILY 543 00:30:30,480 --> 00:30:38,320 SEE THEM THAT THIS IS THE GENE 544 00:30:38,320 --> 00:30:38,920 THERAPY CONSORTIUM THAT YOU 545 00:30:38,920 --> 00:30:39,480 HEARD ABOUT AND TO PROVIDE A 546 00:30:39,480 --> 00:30:43,880 VERY BRIEF UPDATE WITH THAT 547 00:30:43,880 --> 00:30:46,240 BIOLOGY APPLICATIONS ON THE 548 00:30:46,240 --> 00:30:51,960 STREET AND WE ARE AWARDING FOR 549 00:30:51,960 --> 00:30:52,520 THOSE APPLICATIONS AND THEN 550 00:30:52,520 --> 00:30:56,000 ALSO CONDUCTING THIS 551 00:30:56,000 --> 00:30:58,240 PARTICULAR PROGRAM CBS AND IH 552 00:30:58,240 --> 00:31:04,680 AND IN ADDITION AND WITH THAT 553 00:31:04,680 --> 00:31:08,720 MANUFACTURING AREA AND THEN TO 554 00:31:08,720 --> 00:31:16,920 DEVELOP THOSE ATTRIBUTES AND 555 00:31:16,920 --> 00:31:17,400 THEN TO ENSURE WE HAVE A 556 00:31:17,400 --> 00:31:27,880 ROBUST MANUFACTURING PROCESS 557 00:31:27,880 --> 00:31:28,440 WITH THE TOXICOLOGY SIDE IN 558 00:31:28,440 --> 00:31:29,000 TERMS OF MANUFACTURING AND 559 00:31:29,000 --> 00:31:30,440 PRODUCTION OF THESE TYPES OF 560 00:31:30,440 --> 00:31:31,920 GENE THERAPIES AND THEN 561 00:31:31,920 --> 00:31:34,200 ULTIMATELY WE ARE FINALIZING 562 00:31:34,200 --> 00:31:44,360 THE DISEASE NOMINATION PROCESS 563 00:31:44,360 --> 00:31:44,840 AND WITH THOSE DISEASE 564 00:31:44,840 --> 00:31:45,400 NOMINATIONS FOR THE GENE 565 00:31:45,400 --> 00:31:48,720 THERAPY TRIALS AND A LITTLE 566 00:31:48,720 --> 00:31:55,360 OVER THOSE PROPOSALS THAT WE 567 00:31:55,360 --> 00:31:55,960 HAVE AN ANNOUNCEMENT WE EXPECT 568 00:31:55,960 --> 00:31:58,080 TO DO IN THE FALL I DO GIVE 569 00:31:58,080 --> 00:32:01,760 YOU AN UPDATE IN SEPTEMBER 570 00:32:01,760 --> 00:32:11,360 PROGRESS IS BEING MADE. 571 00:32:11,360 --> 00:32:12,880 WE HAVE HAD A VARIETY OF 572 00:32:12,880 --> 00:32:23,240 DISCUSSIONS WITH THOSE 573 00:32:23,560 --> 00:32:30,880 INTERWOVEN PLANS AND THEN TO 574 00:32:30,880 --> 00:32:33,200 HOLD A ROUNDTABLE BACK IN 575 00:32:33,200 --> 00:32:40,040 MARCH AND THIS WAS A VERY 576 00:32:40,040 --> 00:32:40,520 SMALL GROUP OF PEOPLE TO 577 00:32:40,520 --> 00:32:40,960 DISCUSS A VARIETY OF 578 00:32:40,960 --> 00:32:41,520 ACTIVITIES OF CHALLENGES AND 579 00:32:41,520 --> 00:32:44,920 OPPORTUNITIES AS THE FIELD 580 00:32:44,920 --> 00:32:45,480 TRAINS AND EDUCATES THE NEXT 581 00:32:45,480 --> 00:32:53,000 GENERATION IN THE SPACE EACH 582 00:32:53,000 --> 00:32:53,600 OF THE PARTICIPANTS WERE ASKED 583 00:32:53,600 --> 00:32:54,600 TO PROVIDE A ONE WORD RESPONSE 584 00:32:54,600 --> 00:32:58,680 BUT THEY THINK OF TRAINING AND 585 00:32:58,680 --> 00:33:00,960 EDUCATION AND THOSE ARE THE 586 00:33:00,960 --> 00:33:03,240 KEYWORDS HIGHLIGHTED IN THE 587 00:33:03,240 --> 00:33:09,240 BUBBLES ARE VERY OPTIMISTIC 588 00:33:09,240 --> 00:33:09,840 TONE HOW TRAINING EDUCATION IS 589 00:33:09,840 --> 00:33:16,080 BEING PERCEIVED. 590 00:33:16,080 --> 00:33:16,640 I KNOW JESSICA AND HER TEAM 591 00:33:16,640 --> 00:33:24,520 ARE UP TO THE CHALLENGE. 592 00:33:24,520 --> 00:33:25,000 IS DIFFERENT FROM THE 593 00:33:25,000 --> 00:33:34,160 ROUNDTABLE SHOWN HERE. 594 00:33:34,160 --> 00:33:35,720 AND THEN TO GENERATE 595 00:33:35,720 --> 00:33:41,320 EXCITEMENT AND WITH THIS 596 00:33:41,320 --> 00:33:49,120 DIGITAL BADGING PROGRAM. 597 00:33:49,120 --> 00:33:51,640 NOT JUST WITHIN TRANSLATIONAL 598 00:33:51,640 --> 00:34:00,480 SCIENCE TO BRING MORE 599 00:34:00,480 --> 00:34:09,120 ENGAGEMENT TO THAT IDEA AND 600 00:34:09,120 --> 00:34:09,680 THEN WITH THOSE EDUCATIONAL 601 00:34:09,680 --> 00:34:10,240 OPPORTUNITIES AND THERE ARE 602 00:34:10,240 --> 00:34:12,600 MORE OF THE BEING PLANNED. 603 00:34:12,600 --> 00:34:21,960 WITH OTHER SOCIAL MEDIA SITES 604 00:34:21,960 --> 00:34:22,520 AND THEN TO CREATE AWARENESS 605 00:34:22,520 --> 00:34:22,840 AROUND THAT. 606 00:34:22,840 --> 00:34:28,200 THIS IS ONE OF THE ACTIVITIES 607 00:34:28,200 --> 00:34:29,720 ALSO THE INTER- AGENCY 608 00:34:29,720 --> 00:34:35,360 FELLOWSHIP WE INITIATED THIS 609 00:34:35,360 --> 00:34:39,960 AS YOU REMEMBER LAST YEAR SO 610 00:34:39,960 --> 00:34:40,520 THESE ARE THE TWO INCOMING 611 00:34:40,520 --> 00:34:41,160 FELLOWS FOR THIS YEAR WANT TO 612 00:34:41,160 --> 00:34:45,800 WELCOME THEM BOTH. 613 00:34:45,800 --> 00:34:48,360 AND THEIR PARTICIPATION IN THE 614 00:34:48,360 --> 00:34:57,520 PROGRAM. 615 00:34:57,520 --> 00:34:58,520 THIS IS A SECOND CLASS TO GO 616 00:34:58,520 --> 00:35:04,320 THROUGH THIS AND WE CONTINUE 617 00:35:04,320 --> 00:35:04,880 TO SEE TOP-NOTCH FELLOWS FOR 618 00:35:04,880 --> 00:35:05,200 THIS PROGRAM. 619 00:35:05,200 --> 00:35:15,600 IT IS QUITE COMPETITIVE. 620 00:35:21,200 --> 00:35:21,760 SO WHAT I WANT TO POINT OUT IS 621 00:35:21,760 --> 00:35:22,280 JUSTICE BECAUSE THAT BIDEN 622 00:35:22,280 --> 00:35:22,760 ANNOUNCED THAT NIH HAS 623 00:35:22,760 --> 00:35:23,360 LICENSED 11 COVID-19 RESEARCH 624 00:35:23,360 --> 00:35:25,000 TOOLS AND EARLY-STAGE 625 00:35:25,000 --> 00:35:28,600 DIAGNOSTIC CANDIDATES TO THE 626 00:35:28,600 --> 00:35:36,280 PATENT POOL THROUGH THE WHO. 627 00:35:36,280 --> 00:35:38,760 AND THIS IS MEANT TO BENEFIT 628 00:35:38,760 --> 00:35:40,120 PEOPLE LIVING IN THE LOWER 629 00:35:40,120 --> 00:35:49,920 MIDDLE INCOME COUNTRIES AND 630 00:35:49,920 --> 00:35:55,640 THROUGH THE AND ID. 631 00:35:55,640 --> 00:35:58,120 SO LET'S GIVE A SHOUT OUT FOR 632 00:35:58,120 --> 00:36:02,080 THIS DEVELOPMENT FOR THIS 633 00:36:02,080 --> 00:36:02,680 EXCITING ACTIVITY TO TRANSLATE 634 00:36:02,680 --> 00:36:07,760 THESE TECHNOLOGIES. 635 00:36:07,760 --> 00:36:18,160 IN ADDITION TO NATIONAL SEE ON 636 00:36:18,160 --> 00:36:20,560 —- BNC THREE WE ARE PLEASED TO 637 00:36:20,560 --> 00:36:24,440 SEE DEPARTMENT OF THE SERVICES 638 00:36:24,440 --> 00:36:25,040 IT WAS CALLED OUT SPECIFICALLY 639 00:36:25,040 --> 00:36:31,520 IN THIS PLAN AS A TOOL TO 640 00:36:31,520 --> 00:36:32,040 ACCELERATE ADVANCEMENTS IN 641 00:36:32,040 --> 00:36:32,640 SCIENTISTS AND RESEARCH FOR 642 00:36:32,640 --> 00:36:32,800 ALL. 643 00:36:32,800 --> 00:36:35,120 WE ARE VERY EXCITED IT'S IN 644 00:36:35,120 --> 00:36:38,040 THE STRATEGIC PLAN SO WANT TO 645 00:36:38,040 --> 00:36:44,000 HIGHLIGHT FOR THAT AS WELL 646 00:36:44,000 --> 00:36:44,520 ALSO THERE'S BEEN A LOT OF 647 00:36:44,520 --> 00:36:49,520 ACTIVITY IN THE SPACE TOO MUCH 648 00:36:49,520 --> 00:36:50,360 TO RELAY ADEQUATELY THAT WE 649 00:36:50,360 --> 00:36:52,240 ARE ENHANCING THE DATATYPES 650 00:36:52,240 --> 00:36:57,160 COMING INTO THE PROGRAM WITH 651 00:36:57,160 --> 00:37:01,920 THE ARRANGEMENT THE CMS AND 652 00:37:01,920 --> 00:37:02,920 NOW TO MAKE SURE THEY ARE 653 00:37:02,920 --> 00:37:06,280 FORMATTED CORRECTLY WITH 654 00:37:06,280 --> 00:37:08,960 ACCESS BY THOSE USERS WE ALSO 655 00:37:08,960 --> 00:37:11,760 HAVE SOCIAL DETERMINANTS 656 00:37:11,760 --> 00:37:14,680 MORTALITY DATA AND CLINICAL 657 00:37:14,680 --> 00:37:20,920 DATA AS WELL AS VACCINE DATA A 658 00:37:20,920 --> 00:37:21,520 COUPLE OF STATES THAT ARE IN 659 00:37:21,520 --> 00:37:22,240 THAT AND C-3 SO WE HAVE A MUCH 660 00:37:22,240 --> 00:37:24,840 BIGGER PICTURE FOR THOSE 661 00:37:24,840 --> 00:37:27,680 PATIENTS AND THAT HELPS US TO 662 00:37:27,680 --> 00:37:31,960 ROUND OUT THE AVAILABLE 663 00:37:31,960 --> 00:37:32,400 INFORMATION TO HELP US 664 00:37:32,400 --> 00:37:34,320 UNDERSTAND MORE ABOUT THIS 665 00:37:34,320 --> 00:37:38,560 VIRUS AND HOW TO TREAT AND 666 00:37:38,560 --> 00:37:42,240 DIAGNOSE IT IS OUR EXCITING 667 00:37:42,240 --> 00:37:52,520 DEVELOPMENTS WE HAVE A 668 00:37:52,520 --> 00:37:53,120 RELATIONSHIP WITH THE RECOVER 669 00:37:53,120 --> 00:37:53,680 PROGRAM SUPPORTING SOME OF 670 00:37:53,680 --> 00:37:56,800 THESE NC3 ACTIVITIES. 671 00:37:56,800 --> 00:37:57,400 ON THE LEFT-HAND SIDE IT IS AN 672 00:37:57,400 --> 00:37:59,760 UPDATE OF THE STATUS OF THE 673 00:37:59,760 --> 00:38:05,000 DATA OF AN ERCOT WE HAVE 674 00:38:05,000 --> 00:38:05,600 CROSSED THE 5 MILLION MARK FOR 675 00:38:05,600 --> 00:38:10,600 COVID POSITIVE PATIENT WITHIN 676 00:38:10,600 --> 00:38:11,800 AND THREE C IT'S UNFORTUNATE 677 00:38:11,800 --> 00:38:15,400 WE STILL HAVE SOME WAY PEOPLE 678 00:38:15,400 --> 00:38:15,960 CONTRACTING THE VIRUS BUT AT 679 00:38:15,960 --> 00:38:18,680 THE SAME TIME ALLOWS US HAVE 680 00:38:18,680 --> 00:38:23,480 MORE DATA IT IS VERY HELPFUL 681 00:38:23,480 --> 00:38:24,000 IF YOU WANT TO LEARN ABOUT 682 00:38:24,000 --> 00:38:30,120 OTHER TYPES OF DATA SET FOR 683 00:38:30,120 --> 00:38:30,560 THE RECOVER PROGRAM 684 00:38:30,560 --> 00:38:32,560 SPECIFICALLY LOOKING AT LONG 685 00:38:32,560 --> 00:38:34,120 COVID THE ENTRY TEAM HAS 686 00:38:34,120 --> 00:38:39,360 IDENTIFIED OVER 200,000 ADULTS 687 00:38:39,360 --> 00:38:47,960 WITH LONG COVID AND MAYBE 688 00:38:47,960 --> 00:38:48,520 READY FOR THE STUDIES I WENT 689 00:38:48,520 --> 00:38:49,040 TO HIGHLIGHT THE WORK THEY 690 00:38:49,040 --> 00:38:49,560 HAVE DONE IN THIS PHASE 691 00:38:49,560 --> 00:38:52,400 RECENTLY PUBLISHED THIS WEEK 692 00:38:52,400 --> 00:38:53,000 WITH THE QR CODE ON THE LOWER 693 00:38:53,000 --> 00:38:58,960 RIGHT HAND SIDE IS THE 694 00:38:58,960 --> 00:38:59,560 FIVE-STEP ANALYSIS TO IDENTIFY 695 00:38:59,560 --> 00:39:06,760 LONG COVID ON POST PATIENT. 696 00:39:06,760 --> 00:39:07,760 THEY HAD TAKEN THE HR ON 697 00:39:07,760 --> 00:39:09,320 PATIENTS WHO HAVE BEEN 698 00:39:09,320 --> 00:39:14,600 DIAGNOSED WITH THE CODE FOR 699 00:39:14,600 --> 00:39:15,440 LONG COVID WE CAN USE THAT 700 00:39:15,440 --> 00:39:19,040 IDENTIFY PATIENTS AND THEN GO 701 00:39:19,040 --> 00:39:27,640 BACK TO FIND THE PATTERNS 702 00:39:27,640 --> 00:39:28,240 WITHIN THE STATIONS AND APPLY 703 00:39:28,240 --> 00:39:28,800 THAT TO THOSE HAVE NOT BEEN 704 00:39:28,800 --> 00:39:29,400 DIAGNOSED WITH LONG COVID PER 705 00:39:29,400 --> 00:39:30,360 SE BETTER IN THE DATABASE 706 00:39:30,360 --> 00:39:39,160 USING THESE PHENOTYPES THROUGH 707 00:39:39,160 --> 00:39:39,760 THE LEARNED PATTERNS THIS IS A 708 00:39:39,760 --> 00:39:41,560 NICE WAY TO IDENTIFY THE COLD 709 00:39:41,560 --> 00:39:42,920 WAR FOR A LONG COVID AS WELL 710 00:39:42,920 --> 00:39:47,240 AS OTHERS BUT IN ADDITION ONE 711 00:39:47,240 --> 00:39:54,640 OF THE KEY TAKEAWAYS AND THEN 712 00:39:54,640 --> 00:39:56,560 THOSE DIFFERENT PHENOTYPES IS 713 00:39:56,560 --> 00:39:59,520 IMPORTANT AND THEN CONDUCT 714 00:39:59,520 --> 00:40:02,000 CLINICAL TRIALS AND THAT COULD 715 00:40:02,000 --> 00:40:08,000 BE HELPFUL AND THAT THEY TAKE 716 00:40:08,000 --> 00:40:10,520 AWAY IS THAT PROCESS THAT IS 717 00:40:10,520 --> 00:40:13,760 USED TO HELP US IDENTIFY THESE 718 00:40:13,760 --> 00:40:18,800 CASES THEN THEY WILL BE 719 00:40:18,800 --> 00:40:21,040 RECRUITED TO PARTICULAR 720 00:40:21,040 --> 00:40:26,720 STUDIES SO THIS IS A BIG LEAP 721 00:40:26,720 --> 00:40:31,440 FOR N3C THAT QUITE A BIT OF 722 00:40:31,440 --> 00:40:38,960 RESULTS ARE REPORTED AS WELL 723 00:40:38,960 --> 00:40:39,520 LOOK AT VACCINE INFORMATION 724 00:40:39,520 --> 00:40:40,120 RELATED TO THOSE WHO HAVE LONG 725 00:40:40,120 --> 00:40:41,560 COVID COMPARED TO THOSE WHO 726 00:40:41,560 --> 00:40:48,720 DON'T AND USE THAT DATABASE 727 00:40:48,720 --> 00:40:49,320 LOOKING AT DIFFERENT DOSING OF 728 00:40:49,320 --> 00:40:51,560 THE VACCINES AND THE ANALYTICS 729 00:40:51,560 --> 00:40:57,160 AND USING THOSE CONTROLS THE 730 00:40:57,160 --> 00:40:57,720 VACCINATION BEFORE THE ACUTE 731 00:40:57,720 --> 00:40:58,640 INFECTION REDUCE THE 732 00:40:58,640 --> 00:41:02,000 LIKELIHOOD OF LONG COVID BY 733 00:41:02,000 --> 00:41:02,760 18 PERCENT. 734 00:41:02,760 --> 00:41:06,400 THAT IS PRETTY ROBUST 735 00:41:06,400 --> 00:41:07,880 CONFIDENT SO IT STARTS TO 736 00:41:07,880 --> 00:41:15,560 DEMONSTRATE THAT THERE IS 737 00:41:15,560 --> 00:41:16,040 POWER BEHIND USING THE 738 00:41:16,040 --> 00:41:19,960 ELECTRONIC HEALTH RECORDS AS 739 00:41:19,960 --> 00:41:21,440 REAL-WORLD EVIDENCE TO 740 00:41:21,440 --> 00:41:25,000 PRIORITIZE HOW WE MIGHT TACKLE 741 00:41:25,000 --> 00:41:29,520 LONG COVID AS WELL AS OTHERS 742 00:41:29,520 --> 00:41:29,840 RELATED TO IT. 743 00:41:29,840 --> 00:41:32,440 THAT IS EXCITING AND FINALLY 744 00:41:32,440 --> 00:41:37,440 TWO MORE THINGS THEY ARE 745 00:41:37,440 --> 00:41:43,480 CONTINUING TO COLLECT DATA FOR 746 00:41:43,480 --> 00:41:44,000 THE DATA PORTAL OVER 10000 747 00:41:44,000 --> 00:41:44,560 DATA POINTS IT IS REMARKABLE 748 00:41:44,560 --> 00:41:52,400 THE WORK IN A QR CODE. 749 00:41:52,400 --> 00:41:59,200 AND THOSE ARE VISIBLE AND THEN 750 00:41:59,200 --> 00:42:00,600 TO HAVE VERY DETAILED 751 00:42:00,600 --> 00:42:02,720 INFORMATION AND THEN LASTLY 752 00:42:02,720 --> 00:42:04,280 ROUNDING OUT THIS SECTION I 753 00:42:04,280 --> 00:42:08,080 WILL NOT TALK TOO MUCH ABOUT 754 00:42:08,080 --> 00:42:08,640 THE COVID CLINICAL TRIALS I 755 00:42:08,640 --> 00:42:12,760 MENTIONED IT BEFORE WE ARE IN 756 00:42:12,760 --> 00:42:13,280 A HOLDING PATTERN WE ARE 757 00:42:13,280 --> 00:42:17,480 EXPECTING RESULTS ANY MOMENT 758 00:42:17,480 --> 00:42:18,120 THAT PROBABLY THE NEXT COUPLE 759 00:42:18,120 --> 00:42:18,680 OF WEEKS YOU MAY HEAR ABOUT 760 00:42:18,680 --> 00:42:20,480 TOP LINE RESULTS FROM THE 761 00:42:20,480 --> 00:42:24,720 DIFFERENT CLINICAL TRIALS. 762 00:42:24,720 --> 00:42:28,160 I JUST WANTED TO REMIND YOU OF 763 00:42:28,160 --> 00:42:29,160 THAT. 764 00:42:29,160 --> 00:42:33,680 STAY TUNED. 765 00:42:33,680 --> 00:42:37,640 SO NEXT I WILL END 766 00:42:37,640 --> 00:42:39,960 PRESENTATION ON THE SECTION OF 767 00:42:39,960 --> 00:42:43,600 RESPONDING TO A QUESTION THAT 768 00:42:43,600 --> 00:42:46,080 WE PROVIDED A REPORT ON THE 769 00:42:46,080 --> 00:42:49,120 TRIENNIAL ON MONITORING 770 00:42:49,120 --> 00:42:52,480 ADHERENCE TO THE POLICY ON THE 771 00:42:52,480 --> 00:42:52,920 INCLUSION OF WOMEN AND 772 00:42:52,920 --> 00:42:54,560 MINORITIES IN CLINICAL 773 00:42:54,560 --> 00:42:59,400 RESEARCH. 774 00:42:59,400 --> 00:43:02,120 AS YOU MIGHT RECALL WE COULD 775 00:43:02,120 --> 00:43:06,320 DO MORE TO HELP ADDRESS WOMEN 776 00:43:06,320 --> 00:43:07,400 AND MINORITIES IN CLINICAL 777 00:43:07,400 --> 00:43:11,640 RESEARCH AND THE DATA IS 778 00:43:11,640 --> 00:43:15,320 DIFFICULT TO INTERPRET THAT IS 779 00:43:15,320 --> 00:43:17,600 SAFE TO SAY THAT WE CAN DO 780 00:43:17,600 --> 00:43:20,160 BETTER SO I REALLY WANTED TO 781 00:43:20,160 --> 00:43:26,240 FOCUS AND NEXT SEVERAL SLIDES 782 00:43:26,240 --> 00:43:26,760 HOW WE ARE ADDRESSING THIS 783 00:43:26,760 --> 00:43:27,360 PARTICULAR ACTIVITY WITHIN THE 784 00:43:27,360 --> 00:43:29,840 WORK THAT WE DO GOING FORWARD 785 00:43:29,840 --> 00:43:31,360 THAT GIVES ME A GOOD 786 00:43:31,360 --> 00:43:34,560 OPPORTUNITY OF THE THREE 787 00:43:34,560 --> 00:43:39,280 AUDACIOUS GOALS AND IN 788 00:43:39,280 --> 00:43:42,400 ADDITION TO ALL PEOPLE BEING 789 00:43:42,400 --> 00:43:48,040 AT THE CENTER STAGE THERE ARE 790 00:43:48,040 --> 00:43:50,440 THINGS THAT UNDERLIE WHAT CAN 791 00:43:50,440 --> 00:43:54,760 GO INTO HOW WE NEED TO ADDRESS 792 00:43:54,760 --> 00:43:59,200 THAT. 793 00:43:59,200 --> 00:43:59,760 SO THESE ARE TWO OF THE MAIN 794 00:43:59,760 --> 00:44:07,800 PROGRAMS THAT ADDRESS THIS AND 795 00:44:07,800 --> 00:44:08,360 THEN WHEN THEY GIVE THEIR 796 00:44:08,360 --> 00:44:08,920 UPDATE THEY WILL TOUCH UPON 797 00:44:08,920 --> 00:44:14,360 THESE EFFORTS SO THIS WILL BE 798 00:44:14,360 --> 00:44:14,920 A THEME THAT GOES THROUGHOUT 799 00:44:14,920 --> 00:44:18,240 THE PRESENTATION TODAY AND 800 00:44:18,240 --> 00:44:21,720 TOMORROW SO FOR THEIR RARE 801 00:44:21,720 --> 00:44:24,320 DISEASE SPACE THIS WILL NOT BE 802 00:44:24,320 --> 00:44:27,480 A SURPRISE TO YOU BUT THERE 803 00:44:27,480 --> 00:44:28,040 ARE HEALTH DISPARITIES THAT 804 00:44:28,040 --> 00:44:31,160 INTERSECT WITH THE CHALLENGES 805 00:44:31,160 --> 00:44:34,280 DISEASE PATIENTS THEY HAVE 806 00:44:34,280 --> 00:44:35,120 EXPERIENCED AND WE KNOW FOR 807 00:44:35,120 --> 00:44:41,360 EXAMPLE THAT PAIN MANAGEMENT 808 00:44:41,360 --> 00:44:41,880 IS A BIG ISSUE PEOPLE WITH 809 00:44:41,880 --> 00:44:46,000 SICKLE-CELL DISEASE. 810 00:44:46,000 --> 00:44:46,600 SO THOSE OF AFRICAN-AMERICAN 811 00:44:46,600 --> 00:44:49,600 DESCENT IT IS AN AMPLIFIED 812 00:44:49,600 --> 00:44:50,200 ISSUE FOR SICKLE-CELL PATIENTS 813 00:44:50,200 --> 00:44:54,360 WHO ARE TRYING TO RECEIVE PAIN 814 00:44:54,360 --> 00:44:54,920 MANAGEMENT. 815 00:44:54,920 --> 00:44:57,200 THAT ODYSSEY IS ANOTHER 816 00:44:57,200 --> 00:45:04,040 CHALLENGE. 817 00:45:04,040 --> 00:45:06,520 ESPECIALLY THOSE UNDERSERVED 818 00:45:06,520 --> 00:45:15,760 VOICES AND THEN TO OBTAIN A 819 00:45:15,760 --> 00:45:23,240 BETTER UNDERSTANDING WE LOOKED 820 00:45:23,240 --> 00:45:30,280 AT 22 PRIORS AND THE BASELINE 821 00:45:30,280 --> 00:45:32,840 AND THAT WE CAN INVOKE GOING 822 00:45:32,840 --> 00:45:35,280 FORWARD TO ADDRESS ANY 823 00:45:35,280 --> 00:45:39,520 DISPARITIES THAT WE HAVE AND 824 00:45:39,520 --> 00:45:40,960 ISSUES AROUND THAT INCLUSION 825 00:45:40,960 --> 00:45:51,200 THAT WE HAVE. 826 00:45:51,800 --> 00:45:52,320 SO RARE DISEASES AFFECT A VERY 827 00:45:52,320 --> 00:45:52,840 SMALL POPULATION WITH THE 828 00:45:52,840 --> 00:45:55,400 INDIVIDUAL DISEASE SO THAT IS 829 00:45:55,400 --> 00:46:02,280 MOSTLY UNKNOWN BUT THAT STILL 830 00:46:02,280 --> 00:46:02,840 MEANS WE NEED TO DO MORE TO 831 00:46:02,840 --> 00:46:03,440 FIND OUT HOW WE NEED TO MAKE 832 00:46:03,440 --> 00:46:08,240 SURE WE ARE INCLUDING THOSE 833 00:46:08,240 --> 00:46:11,040 MINORITIES AS WELL WITH THE 834 00:46:11,040 --> 00:46:13,320 INCLUSION OF THE WORK THAT WE 835 00:46:13,320 --> 00:46:21,440 DO. 836 00:46:21,440 --> 00:46:28,240 WITH VERSION FIVE IT OUT AS WE 837 00:46:28,240 --> 00:46:29,760 HAVE ADMINISTRATIVE 838 00:46:29,760 --> 00:46:35,960 SUPPLEMENTS AND ALSO PROMOTING 839 00:46:35,960 --> 00:46:41,680 SPECIAL INTEREST GROUPS AND 840 00:46:41,680 --> 00:46:52,160 WITH PATIENT ADVOCACY GROUPS. 841 00:46:56,560 --> 00:46:57,480 AND WITH THAT AMNESTY PROGRAM 842 00:46:57,480 --> 00:47:00,360 WE HOPE THAT ALLOWS US TO 843 00:47:00,360 --> 00:47:05,360 BRING THE INNOVATIONS TO BE 844 00:47:05,360 --> 00:47:09,640 APPLIED AS WELL. 845 00:47:09,640 --> 00:47:10,200 SO THIS TO BE A VARIETY OF 846 00:47:10,200 --> 00:47:11,160 WAYS TO INCREASE THESE 847 00:47:11,160 --> 00:47:16,120 ACTIVITIES FOR THE PROGRAM. 848 00:47:16,120 --> 00:47:22,920 IN ADDITION AND THEN TO MAKE 849 00:47:22,920 --> 00:47:30,640 THAT ACCESSIBLE AND THE ALSO 850 00:47:30,640 --> 00:47:31,160 MAKE SURE IT'S ENGLISH AND 851 00:47:31,160 --> 00:47:33,880 SPANISH AND I WANT TO 852 00:47:33,880 --> 00:47:34,440 EMPHASIZE THE WORD REVAMPING 853 00:47:34,440 --> 00:47:41,440 WE JUST STARTED SO WE ARE A 854 00:47:41,440 --> 00:47:47,680 BETA SITE LOOKING FOR INPUT 855 00:47:47,680 --> 00:47:48,240 FROM THE COMMUNITY FOR WHAT 856 00:47:48,240 --> 00:47:48,840 THEY WOULD LIKE TO SEE HER HOW 857 00:47:48,840 --> 00:47:51,040 THEY THINK AND LOOKING FOR 858 00:47:51,040 --> 00:47:55,320 THAT FEEDBACK SO THERE WILL BE 859 00:47:55,320 --> 00:47:58,320 MORE THINGS TO COME SO PLEASE 860 00:47:58,320 --> 00:48:00,800 STAY TUNED THIS WILL TAKE US 861 00:48:00,800 --> 00:48:01,600 NINE MONTHS BEFORE WE ARE 862 00:48:01,600 --> 00:48:05,960 COMPLETELY FINAL WITH THE 863 00:48:05,960 --> 00:48:06,480 WEBSITE BUT I THINK THESE 864 00:48:06,480 --> 00:48:07,080 CHANGES ARE IMPORTANT AND GET 865 00:48:07,080 --> 00:48:11,080 TO THE IDEA OF THAT 866 00:48:11,080 --> 00:48:11,560 ACCESSIBILITY FOR THE 867 00:48:11,560 --> 00:48:16,600 INFORMATION THAT IS DISPLAYED. 868 00:48:16,600 --> 00:48:18,080 >> VERY SIMILAR KINDS OF 869 00:48:18,080 --> 00:48:20,040 ACTIVITIES IN TERMS OF 870 00:48:20,040 --> 00:48:24,800 DOUBLING DOWN ON THE EFFORTS 871 00:48:24,800 --> 00:48:32,560 FOR DIVERSE POPULATIONS AND 872 00:48:32,560 --> 00:48:33,080 THINK HOW THEY HAVE TO BE 873 00:48:33,080 --> 00:48:38,920 REPRESENTATIVE OF THOSE AND 874 00:48:38,920 --> 00:48:39,520 HAVING THEM START TO LOOK FOR 875 00:48:39,520 --> 00:48:44,000 THOSE ACTIVITIES LOOKING AT 876 00:48:44,000 --> 00:48:46,400 THE RECRUITMENT INNOVATION 877 00:48:46,400 --> 00:48:47,840 CENTERS BUT THERE ARE A 878 00:48:47,840 --> 00:48:52,160 VARIETY OF PROGRAMS THAT ARE 879 00:48:52,160 --> 00:48:55,880 AN INCREDIBLE RESOURCE FOR 880 00:48:55,880 --> 00:48:57,360 ACTIVITIES AROUND COMMUNITY 881 00:48:57,360 --> 00:49:01,800 ENGAGEMENT AS WELL AS CULTURAL 882 00:49:01,800 --> 00:49:02,560 AMBASSADORS FOR THE WORKFORCE 883 00:49:02,560 --> 00:49:05,560 AS WELL I WENT TO HIGHLIGHT A 884 00:49:05,560 --> 00:49:07,760 FEW THINGS ON THE RIGHT-HAND 885 00:49:07,760 --> 00:49:12,920 SIDE THE COUNCILS OF FAITH AND 886 00:49:12,920 --> 00:49:13,920 USED ACROSS THE BOARD WITHIN 887 00:49:13,920 --> 00:49:17,720 THE COMMUNITY AND WE ALSO HAVE 888 00:49:17,720 --> 00:49:24,080 A LOT HEALTH TO CALL AND 889 00:49:24,080 --> 00:49:24,840 SPECIFICALLY THE UNIVERSITY OF 890 00:49:24,840 --> 00:49:27,480 SOUTH CAROLINA THEY ARE THE 891 00:49:27,480 --> 00:49:29,840 TELEHEALTH CENTER OF 892 00:49:29,840 --> 00:49:30,880 EXCELLENCE. 893 00:49:30,880 --> 00:49:31,720 WE DO HAVE A LOT OF THE 894 00:49:31,720 --> 00:49:33,800 LEADERSHIP HERE TO HELP US 895 00:49:33,800 --> 00:49:40,600 WITH THESE ACTIVITIES. 896 00:49:40,600 --> 00:49:46,200 >> IN ADDITION TO THAT WE ARE 897 00:49:46,200 --> 00:49:52,280 FINALIZING THIS ON OUR 898 00:49:52,280 --> 00:50:01,320 COMMUNITY ENGAGEMENT EFFORTS 899 00:50:01,320 --> 00:50:01,880 IN MANY OF THESE THAT I TALK 900 00:50:01,880 --> 00:50:02,440 ABOUT TODAY. 901 00:50:02,440 --> 00:50:07,560 IN ADDITION THE CTS A PROGRAM 902 00:50:07,560 --> 00:50:08,120 STEERING COMMITTEE HAS ASKED 903 00:50:08,120 --> 00:50:12,200 WE PULLED TOGETHER A DIVERSITY 904 00:50:12,200 --> 00:50:13,760 TASK FORCE TO MAKE 905 00:50:13,760 --> 00:50:16,360 RECOMMENDATIONS TO THE 906 00:50:16,360 --> 00:50:20,440 STEERING COMMITTEE ON FOCUSED 907 00:50:20,440 --> 00:50:25,000 EFFORTS AND IN TURN APRIL THAT 908 00:50:25,000 --> 00:50:25,920 PUBLICATION FROM THE TASK 909 00:50:25,920 --> 00:50:29,040 FORCE AND I REALLY RECOMMEND 910 00:50:29,040 --> 00:50:30,280 YOU TAKE A LOOK AT THIS 911 00:50:30,280 --> 00:50:34,280 PUBLICATION THEY PROVIDE A 912 00:50:34,280 --> 00:50:39,600 ROADMAP FOR SOME OF THESE 913 00:50:39,600 --> 00:50:40,160 ACTIVITIES AND IT TURNS OUT 914 00:50:40,160 --> 00:50:40,720 THE STEERING COMMITTEE HAS 915 00:50:40,720 --> 00:50:41,320 ELEVATED THE TASK FORCE TO AN 916 00:50:41,320 --> 00:50:42,680 ENTERPRISE COMMITTEE SO IT'S A 917 00:50:42,680 --> 00:50:44,320 CONTINUING ASPECT OF 918 00:50:44,320 --> 00:50:46,560 LEADERSHIP SO WE ARE EXCITED 919 00:50:46,560 --> 00:50:51,360 TO SEE THAT IS ALSO THE CALL 920 00:50:51,360 --> 00:50:56,360 FOR MANUSCRIPTS THROUGH J CTS 921 00:50:56,360 --> 00:50:59,640 TO FOCUS ON CLINICAL AND 922 00:50:59,640 --> 00:51:03,040 TRANSACTIONAL SCIENCE SO THAT 923 00:51:03,040 --> 00:51:06,080 CALL IS STILL UNDERWAY SO THIS 924 00:51:06,080 --> 00:51:10,400 IS SOMETHING ELSE THAT WILL 925 00:51:10,400 --> 00:51:11,920 HELP TO RAISE AWARENESS OF THE 926 00:51:11,920 --> 00:51:14,760 ACTIVITIES WITHIN THE PROGRAM 927 00:51:14,760 --> 00:51:18,480 TO PROVIDE THAT LEADERSHIP TO 928 00:51:18,480 --> 00:51:22,280 OTHERS IN THE COMMUNITY WITH 929 00:51:22,280 --> 00:51:24,760 THE RECRUITMENT INNOVATION 930 00:51:24,760 --> 00:51:34,520 CENTER I DON'T KNOW IF WE WILL 931 00:51:34,520 --> 00:51:35,120 EVER HAVE A REALLY GOOD WAY TO 932 00:51:35,120 --> 00:51:35,720 MEASURE A CREDIBLE BENEFIT OF 933 00:51:35,720 --> 00:51:36,520 THESE ACTIVITIES BUT I WANTED 934 00:51:36,520 --> 00:51:42,480 TO HIGHLIGHT A FEW OF THEM THE 935 00:51:42,480 --> 00:51:43,080 FASTER TOGETHER IS A PLATFORM 936 00:51:43,080 --> 00:51:43,960 DEDICATED TO IMPROVING THE 937 00:51:43,960 --> 00:51:46,280 REPRESENTATION OF RACIAL AND 938 00:51:46,280 --> 00:51:48,720 ETHNIC MINORITIES AND RESEARCH 939 00:51:48,720 --> 00:51:52,600 TO HELP TEACH AND TRAIN PEOPLE 940 00:51:52,600 --> 00:51:54,880 HOW TO DO THIS HELPS TO 941 00:51:54,880 --> 00:51:59,240 HIGHLIGHT PARTICULAR 942 00:51:59,240 --> 00:51:59,840 COMMUNITIES THAT DO THIS VERY 943 00:51:59,840 --> 00:52:00,400 WELL SO PEOPLE CAN REACH OUT 944 00:52:00,400 --> 00:52:01,000 TO THEM AND PARTNER WITH THEM 945 00:52:01,000 --> 00:52:05,680 MOVING FORWARD ALSO ROBUST 946 00:52:05,680 --> 00:52:08,400 ACTIVITY WITH THE METHODS TO 947 00:52:08,400 --> 00:52:09,480 ENCOURAGE DIVERSE GROUPS OF 948 00:52:09,480 --> 00:52:17,240 STAKEHOLDERS TO IMPLEMENT ALSO 949 00:52:17,240 --> 00:52:20,720 A COMMUNITY ADVISORY BOARD TO 950 00:52:20,720 --> 00:52:22,240 HELP PROVIDE INPUT AND 951 00:52:22,240 --> 00:52:26,680 RECOMMENDATIONS AND THERE ARE 952 00:52:26,680 --> 00:52:28,680 12 MEMBERS ON THE BOARD 953 00:52:28,680 --> 00:52:31,080 REPRESENTING A VARIETY OF 954 00:52:31,080 --> 00:52:38,240 PEOPLE FOR THESE ACTIVITIES SO 955 00:52:38,240 --> 00:52:38,840 THIS IS ONE OF THE THINGS THAT 956 00:52:38,840 --> 00:52:42,000 HAS SHOWN TREMENDOUS BENEFIT 957 00:52:42,000 --> 00:52:46,840 AND NOW WE EVALUATE THIS MORE 958 00:52:46,840 --> 00:52:47,880 TO UNDERSTAND WITH THE BENEFIT 959 00:52:47,880 --> 00:52:56,040 LOOKS LIKE BECAUSE THAT RICK 960 00:52:56,040 --> 00:53:01,720 CONSULTS SO IT'S DIFFICULT TO 961 00:53:01,720 --> 00:53:05,680 OBTAIN THAT ENROLLMENT DATA 962 00:53:05,680 --> 00:53:06,280 BUT WE HOPE WE CAN FIGURE OUT 963 00:53:06,280 --> 00:53:09,240 WAYS TO ENHANCE THAT AND WE 964 00:53:09,240 --> 00:53:10,960 ARE WORKING WITH THE INCLUSION 965 00:53:10,960 --> 00:53:13,520 OFFICER AND THE VANDERBILT 966 00:53:13,520 --> 00:53:16,200 TEAM TO FIGURE OUT BEST 967 00:53:16,200 --> 00:53:20,080 METHODOLO METHODOLOGIES. 968 00:53:20,080 --> 00:53:21,160 I HOPE I CAN TALK MORE ABOUT 969 00:53:21,160 --> 00:53:31,560 THIS AND JUST A FEW MORE 970 00:53:32,640 --> 00:53:36,840 THINGS AND JUST WANT TO 971 00:53:36,840 --> 00:53:37,400 MENTION IT HERE BECAUSE THAT 972 00:53:37,400 --> 00:53:40,080 IS ONE OF THOSE THINGS TO 973 00:53:40,080 --> 00:53:41,560 FOCUS ON THE UNDERSERVED 974 00:53:41,560 --> 00:53:52,080 POPULATIONS AND IT ENSURES ALL 975 00:53:52,760 --> 00:53:53,200 AMERICANS HAVE ACCESS TO 976 00:53:53,200 --> 00:53:53,760 COVID-19 TESTING AND FOCUSES 977 00:53:53,760 --> 00:53:54,320 ON COMMUNITIES MOST AFFECTED 978 00:53:54,320 --> 00:53:56,280 BY THE PANDEMIC SO IT HAS BEEN 979 00:53:56,280 --> 00:54:03,720 A FANTASTIC PROGRAM FOR NIH 980 00:54:03,720 --> 00:54:04,320 AND THE CTS A IS A BIG PART OF 981 00:54:04,320 --> 00:54:04,480 IT. 982 00:54:04,480 --> 00:54:06,560 I ALSO WANT TO MENTION IN 983 00:54:06,560 --> 00:54:11,160 TERMS OF AN C-3 WE COLLECT 984 00:54:11,160 --> 00:54:11,760 DATA FROM HEALTH CENTERS 985 00:54:11,760 --> 00:54:16,080 ACROSS THE COUNTRY AND THAT 986 00:54:16,080 --> 00:54:19,160 INCLUDES FROM THE AMERICAN 987 00:54:19,160 --> 00:54:21,200 INDIAN AND ALASKA NATIVE IN 988 00:54:21,200 --> 00:54:26,680 THE DATABASE WE WANT TO MAKE 989 00:54:26,680 --> 00:54:27,200 SURE WE HAVE CONSULTATIONS 990 00:54:27,200 --> 00:54:30,320 WITH THE TRIBAL NATIONS TO 991 00:54:30,320 --> 00:54:31,320 UNDERSTAND HOW TO INCORPORATE 992 00:54:31,320 --> 00:54:36,240 THE VIEWS WE HAVE BEEN WORKING 993 00:54:36,240 --> 00:54:40,920 WITH THE WORKING WITH NIH WITH 994 00:54:40,920 --> 00:54:43,360 A VARIETY OF GROUPS ACROSS THE 995 00:54:43,360 --> 00:54:50,600 COUNTRY ON TRIBAL EFFORTS AND 996 00:54:50,600 --> 00:54:51,160 WE HAD TRIED TO LEARN FROM 997 00:54:51,160 --> 00:54:56,440 THEM —- PRACTICES SO TO DATE 998 00:54:56,440 --> 00:55:02,480 WE HAVE SCARE THE DATA FROM 999 00:55:02,480 --> 00:55:07,240 THE GROUPS AND AGGREGATE THEM 1000 00:55:07,240 --> 00:55:08,360 UNTIL WE UNDERSTAND FROM THE 1001 00:55:08,360 --> 00:55:13,160 TRIBAL NATION SO WE HAD A 1002 00:55:13,160 --> 00:55:18,080 CONSULTATION WITH 1003 00:55:18,080 --> 00:55:20,520 REPRESENTATIVES OF THOSE 1004 00:55:20,520 --> 00:55:23,320 GROUPS AND THEY ARE PROVIDING 1005 00:55:23,320 --> 00:55:25,000 US WRITTEN FEEDBACK AS WE 1006 00:55:25,000 --> 00:55:26,640 SPEAK AND THAT WILL GIVE OUT 1007 00:55:26,640 --> 00:55:28,520 IN THE SUMMER AND MAY BE 1008 00:55:28,520 --> 00:55:32,760 DELAYED A LITTLE BIT AND 1009 00:55:32,760 --> 00:55:38,560 RECEIVING SOME OF THE INPUT 1010 00:55:38,560 --> 00:55:38,960 DUE TO UNFORESEEN 1011 00:55:38,960 --> 00:55:39,560 CIRCUMSTANCES AND WE WILL GET 1012 00:55:39,560 --> 00:55:42,120 THAT OUT AS SOON AS WE CAN BUT 1013 00:55:42,120 --> 00:55:43,600 IT HAS BEEN A WORTHWHILE 1014 00:55:43,600 --> 00:55:45,080 EXPERIENCE AND I'M EXCITED TO 1015 00:55:45,080 --> 00:55:50,280 SEE 1016 00:55:50,280 --> 00:55:53,240 >> THIS IS A PREAMBLE TO WHAT'S 1017 00:55:53,240 --> 00:55:53,440 NEXT. 1018 00:55:53,440 --> 00:55:55,760 MARIE BERNARD, NIH CHIEF 1019 00:55:55,760 --> 00:55:56,720 OFFICERS OF WORKFORCE DIVERSITY 1020 00:55:56,720 --> 00:55:59,640 WILL TELL YOU MORE ABOUT NIH 1021 00:55:59,640 --> 00:56:00,280 EFFORTS TO PROMOTE DIVERSITY, 1022 00:56:00,280 --> 00:56:04,960 EQUITY, AND INCLUSION IN 1023 00:56:04,960 --> 00:56:06,480 BIOMEDICAL RESEARCH. 1024 00:56:06,480 --> 00:56:07,680 I'LL LEAVE BROADER UPDATES TO 1025 00:56:07,680 --> 00:56:07,880 HER. 1026 00:56:07,880 --> 00:56:11,880 BUT I DID WANT TO MENTION ONE 1027 00:56:11,880 --> 00:56:13,160 THING, THAT I MODERATED A 1028 00:56:13,160 --> 00:56:14,720 SESSION THROUGH THE UNITE 1029 00:56:14,720 --> 00:56:18,320 PROGRAM, FOR HEALTH CENTERS AND 1030 00:56:18,320 --> 00:56:21,160 SYSTEMS TO UNDERSTAND WHAT THEY 1031 00:56:21,160 --> 00:56:22,680 ARE THINKING AND WHAT INPUT THEY 1032 00:56:22,680 --> 00:56:24,640 COULD PROVIDE US WITH, IN TERMS 1033 00:56:24,640 --> 00:56:26,520 OF STRUCTURAL RACISM AND HOW WE 1034 00:56:26,520 --> 00:56:28,160 CAN START TO MITIGATE THESE 1035 00:56:28,160 --> 00:56:28,400 ISSUES. 1036 00:56:28,400 --> 00:56:30,440 WE TALKED ABOUT CHALLENGES FOR 1037 00:56:30,440 --> 00:56:31,200 PATHWAYS, RESEARCH 1038 00:56:31,200 --> 00:56:31,680 OPPORTUNITIES. 1039 00:56:31,680 --> 00:56:33,080 WE TALKED ABOUT OPPORTUNITIES 1040 00:56:33,080 --> 00:56:35,600 FOR ADDRESSING HEALTH 1041 00:56:35,600 --> 00:56:37,440 DISPARITIES AND HOW BEST TO GO 1042 00:56:37,440 --> 00:56:38,360 ABOUT DOING THAT, SOME IDEAS 1043 00:56:38,360 --> 00:56:40,680 THEY HAVE, AND SOME BARRIERS AND 1044 00:56:40,680 --> 00:56:43,800 SOLUTIONS FOR NIH TO BE 1045 00:56:43,800 --> 00:56:44,240 CONSIDERING. 1046 00:56:44,240 --> 00:56:45,320 THINGS AROUND ACTIONS, THINGS 1047 00:56:45,320 --> 00:56:46,760 AROUND POLICIES, THINGS ABOUT 1048 00:56:46,760 --> 00:56:47,760 OUR OWN ENGAGEMENT STRATEGIES 1049 00:56:47,760 --> 00:56:49,360 THAT COME OUT OF THE NIH. 1050 00:56:49,360 --> 00:56:52,160 AND TRYING TO THINK ABOUT HOW WE 1051 00:56:52,160 --> 00:56:55,960 CAN REVAMP THOSE TO, AGAIN, DO A 1052 00:56:55,960 --> 00:56:59,120 BETTER JOB AND ENGAGING AND 1053 00:56:59,120 --> 00:57:00,200 ENROLLING THESE UNDERSERVED 1054 00:57:00,200 --> 00:57:01,280 MINORITIES INTO THE CLINICAL 1055 00:57:01,280 --> 00:57:04,320 RESEARCH THAT WE DO. 1056 00:57:04,320 --> 00:57:06,680 AND THEN LASTLY, I THINK THIS IS 1057 00:57:06,680 --> 00:57:09,280 MY LAST SLIDE, I'M NOT SURE, BUT 1058 00:57:09,280 --> 00:57:10,640 LASTLY, I'VE TALKED ABOUT THE 1059 00:57:10,640 --> 00:57:12,560 WORK BEING DONE ON THE 1060 00:57:12,560 --> 00:57:13,840 EXTRAMURAL SIDE FROM NCATS, BUT 1061 00:57:13,840 --> 00:57:17,480 THERE'S AN EQUALLY ROBUST AMOUNT 1062 00:57:17,480 --> 00:57:22,080 OF ACTIVITY THAT IS LOOKING 1063 00:57:22,080 --> 00:57:23,320 INWARD AT NCATS. 1064 00:57:23,320 --> 00:57:24,720 WITHIN OUR OWN STAFF AND WITHIN 1065 00:57:24,720 --> 00:57:26,360 OUR BUSINESS PRACTICES. 1066 00:57:26,360 --> 00:57:27,200 THESE EFFORTS DON'T MEAN MUCH 1067 00:57:27,200 --> 00:57:29,600 UNLESS I AND OUR NCATS STAFF 1068 00:57:29,600 --> 00:57:30,760 DON'T PRACTICE WHAT WE PREACH 1069 00:57:30,760 --> 00:57:31,280 HERE. 1070 00:57:31,280 --> 00:57:32,120 SO THAT'S ANOTHER IMPORTANT 1071 00:57:32,120 --> 00:57:33,240 ASPECT THAT I WANTED TO RELAY 1072 00:57:33,240 --> 00:57:42,240 THAT WE HAVE OUR OWN NCATS 1073 00:57:42,240 --> 00:57:42,880 IDeA COMMITTEE AND HEALTH 1074 00:57:42,880 --> 00:57:43,840 DISPARITIES ACTION PLAN TO FIND 1075 00:57:43,840 --> 00:57:45,400 AND BENCH MARK SOME OF THESE 1076 00:57:45,400 --> 00:57:47,480 STANDARDS FOR US TO BE THINKING 1077 00:57:47,480 --> 00:57:48,720 ABOUT MOVING FORWARD. 1078 00:57:48,720 --> 00:57:50,240 AND SO, THESE ARE SOME OF THE 1079 00:57:50,240 --> 00:57:51,720 ACTIVITIES THAT WE'RE DOING. 1080 00:57:51,720 --> 00:57:53,120 WE'VE DONE A SURVEY, AND WE'RE 1081 00:57:53,120 --> 00:57:54,800 USING THAT SURVEY TO REALLY HELP 1082 00:57:54,800 --> 00:57:57,520 US THEN FIGURE OUT HOW WE CAN 1083 00:57:57,520 --> 00:58:01,280 BETTER INTEGRATE THESE IDEAS 1084 00:58:01,280 --> 00:58:03,240 INTO OUR PRACTICES AND HOPEFULLY 1085 00:58:03,240 --> 00:58:05,640 ELEVATE THAT EVEN MORE, FROM THE 1086 00:58:05,640 --> 00:58:06,680 INTERNAL PERSPECTIVE. 1087 00:58:06,680 --> 00:58:08,800 SO, OUR COLLECTIVE EFFORTS IN 1088 00:58:08,800 --> 00:58:10,360 ADDRESSING INCLUSION, WOMEN AND 1089 00:58:10,360 --> 00:58:11,720 MINORITIES IN CLINICAL RESEARCH, 1090 00:58:11,720 --> 00:58:15,280 ARE REALLY TO DOUBLE DOWN ON 1091 00:58:15,280 --> 00:58:17,120 RAISING AWARENESS ON THESE 1092 00:58:17,120 --> 00:58:17,760 ONGOING EFFORTS. 1093 00:58:17,760 --> 00:58:19,560 THERE ARE STILL GAPS IN THIS 1094 00:58:19,560 --> 00:58:21,480 SPACE THAT WE NEED -- WE HAVE 1095 00:58:21,480 --> 00:58:24,120 GOT TO CONTINUE TO ADDRESS 1096 00:58:24,120 --> 00:58:24,520 TOGETHER. 1097 00:58:24,520 --> 00:58:29,360 AND WE WANT TO HONE OUR 1098 00:58:29,360 --> 00:58:30,800 AUDACIOUS GOAL AND BUILD METRICS 1099 00:58:30,800 --> 00:58:32,560 I TALKED ABOUT HERE TODAY, INTO 1100 00:58:32,560 --> 00:58:33,760 OUR NEXT STRATEGIC PLAN WHEN 1101 00:58:33,760 --> 00:58:35,960 WE'RE READY TO DO THAT. 1102 00:58:35,960 --> 00:58:37,480 AND ENSURE THAT THESE CHANGES 1103 00:58:37,480 --> 00:58:41,200 AND ACTIVITIES REALLY DO TAKE 1104 00:58:41,200 --> 00:58:41,520 ROOT. 1105 00:58:41,520 --> 00:58:42,760 I THINK THAT'S MY LAST SLIDE. 1106 00:58:42,760 --> 00:58:45,680 I THINK NOW WE CAN OPEN IT UP TO 1107 00:58:45,680 --> 00:58:46,080 DISCUSSION. 1108 00:58:46,080 --> 00:58:47,440 SO THANK YOU FOR YOUR ATTENTION. 1109 00:58:47,440 --> 00:58:49,440 AND I WILL TURN IT OVER TO 1110 00:58:49,440 --> 00:58:51,520 CLAIRE TO MODERATE THE 1111 00:58:51,520 --> 00:58:53,680 DISCUSSION. 1112 00:58:53,680 --> 00:58:57,720 1113 00:58:57,720 --> 00:58:59,280 >> OKAY. 1114 00:58:59,280 --> 00:59:02,320 THANK YOU VERY MUCH, JONI. 1115 00:59:02,320 --> 00:59:07,760 DO WE HAVE ANY QUESTIONS? 1116 00:59:07,760 --> 00:59:08,600 PAULA? 1117 00:59:08,600 --> 00:59:08,760 1118 00:59:08,760 --> 00:59:11,240 >> YES, THANK YOU. 1119 00:59:11,240 --> 00:59:13,880 I REALIZE ARPA-H HAS BEEN KIND 1120 00:59:13,880 --> 00:59:16,320 OF A FOOTBALL BEING PASSED BACK 1121 00:59:16,320 --> 00:59:20,800 AND FORTH TO MULTIPLE PLACES. 1122 00:59:20,800 --> 00:59:22,720 WHEN DO YOU THINK -- I KNOW 1123 00:59:22,720 --> 00:59:26,560 READING THE TEA LEAVES -- A 1124 00:59:26,560 --> 00:59:28,280 DECISION WILL BE MADE WHERE IT'S 1125 00:59:28,280 --> 00:59:29,880 GOING TO LAND ESPECIALLY THOUGH 1126 00:59:29,880 --> 00:59:31,280 IT SEEMS IT'S BEING FUNDENED AND 1127 00:59:31,280 --> 00:59:38,960 WE DON'T HAVE A HOME FOR IT? 1128 00:59:38,960 --> 00:59:40,240 >> I APOLOGIZE IF THAT'S 1129 00:59:40,240 --> 00:59:41,160 CONFUSING BUT ARPA-H RIGHT NOW 1130 00:59:41,160 --> 00:59:43,400 IS WITHIN THE NIH. 1131 00:59:43,400 --> 00:59:47,440 SO ITS HOME IS HERE. 1132 00:59:47,440 --> 00:59:50,200 AND, YOU KNOW, I THINK TO -- 1133 00:59:50,200 --> 00:59:52,040 THERE'S NOT AN INTERIM DIRECTOR 1134 00:59:52,040 --> 00:59:53,040 NAMED AS YET. 1135 00:59:53,040 --> 00:59:56,000 SO I THINK THAT'S PART OF THE 1136 00:59:56,000 --> 00:59:57,320 NEXT PROCESS THAT WILL BE 1137 00:59:57,320 --> 00:59:59,440 UNDERWAY BEFORE WE KNOW MORE HOW 1138 00:59:59,440 --> 01:00:01,600 THAT'S GOING TO HAPPEN. 1139 01:00:01,600 --> 01:00:02,440 BUT UNTIL THEN, I THINK THERE 1140 01:00:02,440 --> 01:00:05,840 ARE A VARIETY OF THINGS WE CAN 1141 01:00:05,840 --> 01:00:06,560 DO. 1142 01:00:06,560 --> 01:00:11,520 FOR EXAMPLE, WE HAVE A LOT OF 1143 01:00:11,520 --> 01:00:13,840 SYSTEMS AND -- SYSTEMS AS IN 1144 01:00:13,840 --> 01:00:15,360 OPERATIONAL SYSTEMS, HOW WE DO 1145 01:00:15,360 --> 01:00:17,120 OUR GRANTS MANAGEMENT, HOW WE -- 1146 01:00:17,120 --> 01:00:19,120 OUR DATABASE FOR THOSE GRANTS, 1147 01:00:19,120 --> 01:00:23,000 IT'S CALLED THE ELECTRONIC 1148 01:00:23,000 --> 01:00:24,320 RESEARCH ADMINISTRATION 1149 01:00:24,320 --> 01:00:26,320 DATABASE, ERA. 1150 01:00:26,320 --> 01:00:27,960 WE CAN START TO BUILD AN 1151 01:00:27,960 --> 01:00:33,720 ALLOWANCE FOR ARPA-H TO USE 1152 01:00:33,720 --> 01:00:35,080 THAT DATABASE. 1153 01:00:35,080 --> 01:00:36,160 OTHER AGENCIES USE THAT SAME 1154 01:00:36,160 --> 01:00:37,120 KIND OF DATABASE. 1155 01:00:37,120 --> 01:00:39,440 THOSE ARE AN EXAMPLE OF SOME 1156 01:00:39,440 --> 01:00:42,520 FEATURES WE'RE DOING NOW TO HELP 1157 01:00:42,520 --> 01:00:43,880 START TO STAND IT UP. 1158 01:00:43,880 --> 01:00:45,560 WHEN I MENTION IN THE NEWS YOU 1159 01:00:45,560 --> 01:00:47,840 PROBABLY HEARD ABOUT SOME OTHER 1160 01:00:47,840 --> 01:00:49,960 ACTIVITIES IN THIS SPACE, THOSE 1161 01:00:49,960 --> 01:00:53,000 WERE IN DISCUSSION, AND SO UNTIL 1162 01:00:53,000 --> 01:00:54,200 SOMETHING HAPPENS OR DOESN'T, I 1163 01:00:54,200 --> 01:00:55,560 THINK RIGHT NOW WE'RE JUST 1164 01:00:55,560 --> 01:00:56,960 MOVING FORWARD WITH THE IDEA 1165 01:00:56,960 --> 01:00:58,800 THAT IT IS WITHIN THE NIH AND 1166 01:00:58,800 --> 01:01:05,280 WE'RE CONTINUING TO PLAN FOR 1167 01:01:05,280 --> 01:01:06,400 THAT ACCORDINGLY. 1168 01:01:06,400 --> 01:01:06,880 >> THANKS. 1169 01:01:06,880 --> 01:01:07,560 PAUL, YOU'RE NEXT. 1170 01:01:07,560 --> 01:01:09,880 >> JONI, ON THE SAME TOPIC, 1171 01:01:09,880 --> 01:01:12,240 ASSUMING IT STAYS IN THE NIH, 1172 01:01:12,240 --> 01:01:13,000 YOU MENTIONED THAT OF COURSE 1173 01:01:13,000 --> 01:01:15,720 THERE'S A GOAL TO KEEP IT 1174 01:01:15,720 --> 01:01:17,200 COMPLEMENTARY, NOT COMPETITIVE, 1175 01:01:17,200 --> 01:01:19,040 WITH OTHER INSTITUTES. 1176 01:01:19,040 --> 01:01:23,200 IT SEEMS LIKE NCATS WOULD BE THE 1177 01:01:23,200 --> 01:01:25,680 MOST VULNERABLE, IF YOU WILL, 1178 01:01:25,680 --> 01:01:28,440 INSTITUTE OR MOST AT RISK FOR 1179 01:01:28,440 --> 01:01:30,600 HAVING TO KIND OF WORK OUT THOSE 1180 01:01:30,600 --> 01:01:31,400 COMPLEMENTARY DETAILS. 1181 01:01:31,400 --> 01:01:35,320 WHAT'S THE PLAN AHEAD FOR THAT? 1182 01:01:35,320 --> 01:01:36,760 >> YES, THANKS FOR THAT 1183 01:01:36,760 --> 01:01:38,160 QUESTION, PAUL. 1184 01:01:38,160 --> 01:01:40,040 YEAH, YOU'RE RIGHT. 1185 01:01:40,040 --> 01:01:42,000 OFTEN TIMES WHEN ARPA-H IS 1186 01:01:42,000 --> 01:01:43,080 DISCUSSED, NCATS IS ONE OF THE 1187 01:01:43,080 --> 01:01:44,440 FIRST THINGS THAT GETS MENTIONED 1188 01:01:44,440 --> 01:01:45,840 IN TERMS OF WHAT WE DO AT THE 1189 01:01:45,840 --> 01:01:46,120 NIH ALREADY. 1190 01:01:46,120 --> 01:01:49,120 I DO THINK THERE WILL BE A LOT 1191 01:01:49,120 --> 01:01:50,440 OF COMPLEMENTARY APPROACHES. 1192 01:01:50,440 --> 01:01:54,800 THE KEY WORDS AROUND ARPA-H ARE 1193 01:01:54,800 --> 01:01:57,360 LARGELY AROUND ALZHEIMER'S 1194 01:01:57,360 --> 01:01:58,560 DISEASE, CANCER, DIABETES, FOR 1195 01:01:58,560 --> 01:01:58,800 EXAMPLE. 1196 01:01:58,800 --> 01:02:02,200 AND AS YOU KNOW, THE BIG FOCUS 1197 01:02:02,200 --> 01:02:03,680 FOR NCATS ISN'T ON ANY ONE 1198 01:02:03,680 --> 01:02:06,360 DISEASE BUT IF THERE IS A BOLUS 1199 01:02:06,360 --> 01:02:07,560 OF DISEASE IT'S CERTAINLY THE 1200 01:02:07,560 --> 01:02:10,560 RARE DISEASES THAT WE FOCUS ON 1201 01:02:10,560 --> 01:02:11,040 PRIMARILY. 1202 01:02:11,040 --> 01:02:13,680 BUT WE HAVE ACTIVITIES IN ALL OF 1203 01:02:13,680 --> 01:02:14,440 THIS SPACE. 1204 01:02:14,440 --> 01:02:18,880 I SEE -- I DO SEE A VERY GOOD 1205 01:02:18,880 --> 01:02:19,600 PATH TOWARDS WHAT THAT 1206 01:02:19,600 --> 01:02:20,480 COMPLEMENTARY APPROACH WOULD 1207 01:02:20,480 --> 01:02:23,080 LOOK LIKE. 1208 01:02:23,080 --> 01:02:24,280 OF COURSE, I EXPECT AND HOPE 1209 01:02:24,280 --> 01:02:26,720 THAT I WILL BE AT THE TABLE ONCE 1210 01:02:26,720 --> 01:02:29,760 THE INTERIM DIRECTOR IS 1211 01:02:29,760 --> 01:02:32,040 IDENTIFIED, AND THEN THE FINAL 1212 01:02:32,040 --> 01:02:33,720 DIRECTOR, ONCE THAT INAUGURAL 1213 01:02:33,720 --> 01:02:34,920 DIRECTOR IS APPOINTED TO HAVE 1214 01:02:34,920 --> 01:02:36,440 THOSE KINDS OF DISCUSSIONS ABOUT 1215 01:02:36,440 --> 01:02:40,840 WHERE WE CAN BE MOST 1216 01:02:40,840 --> 01:02:42,600 COMPLEMENTARY AND I THINK THAT 1217 01:02:42,600 --> 01:02:45,960 IS CERTAINLY A PERSPECTIVE THAT 1218 01:02:45,960 --> 01:02:50,240 WE ALL SHARE AND HOLD AND 1219 01:02:50,240 --> 01:02:50,720 PURSUE. 1220 01:02:50,720 --> 01:02:51,320 >> THANK YOU. 1221 01:02:51,320 --> 01:02:52,520 ONE MORE FOLLOW-UP. 1222 01:02:52,520 --> 01:02:53,840 FROM THE VANTAGE POINT OF MAKING 1223 01:02:53,840 --> 01:02:56,680 SURE THAT YOU ARE AT THE TABLE, 1224 01:02:56,680 --> 01:02:58,000 OR NCATS LEADERSHIP IS AT THE 1225 01:02:58,000 --> 01:03:00,720 TABLE, IS THERE ANYTHING THIS 1226 01:03:00,720 --> 01:03:03,920 COUNCIL CAN DO TO HELP MAKE THAT 1227 01:03:03,920 --> 01:03:04,440 HAPPEN? 1228 01:03:04,440 --> 01:03:08,600 >> WELL, THANK YOU FOR THAT. 1229 01:03:08,600 --> 01:03:09,800 AT THIS POINT, I THINK WE'RE 1230 01:03:09,800 --> 01:03:14,080 REALLY IN THIS SORT OF WAIT AND 1231 01:03:14,080 --> 01:03:15,600 SEE, AND REALLY UNDERSTANDING 1232 01:03:15,600 --> 01:03:17,240 WHO THE -- YOU KNOW, WHEN WE'RE 1233 01:03:17,240 --> 01:03:18,800 GOING TO START THINKING MORE 1234 01:03:18,800 --> 01:03:20,640 SCIENTIFICALLY, HOW THAT MIGHT 1235 01:03:20,640 --> 01:03:21,120 HAPPEN. 1236 01:03:21,120 --> 01:03:22,600 SO, I WOULD SAY, YOU KNOW, 1237 01:03:22,600 --> 01:03:25,560 CERTAINLY LET'S CONTINUE TO HAVE 1238 01:03:25,560 --> 01:03:28,440 THE CONVERSATION, BUT FOR NOW I 1239 01:03:28,440 --> 01:03:30,600 AM ANTICIPATING THAT THIS IS 1240 01:03:30,600 --> 01:03:32,680 SOMETHING THAT WE -- I'M EXCITED 1241 01:03:32,680 --> 01:03:36,360 ABOUT, AND I CAN SEE A VERY GOOD 1242 01:03:36,360 --> 01:03:37,040 PATH FORWARD. 1243 01:03:37,040 --> 01:03:39,200 AND WHETHER THAT'S A LETTER OF 1244 01:03:39,200 --> 01:03:40,440 EXCITEMENT AND ENTHUSIASM OR 1245 01:03:40,440 --> 01:03:43,080 MAYBE A HELP, A NUDGE IN THE 1246 01:03:43,080 --> 01:03:44,400 DIRECTION, I'LL CERTAINLY KEEP 1247 01:03:44,400 --> 01:03:46,200 YOU POSTED ON THAT. 1248 01:03:46,200 --> 01:03:49,080 THANK YOU FOR OFFERING. 1249 01:03:49,080 --> 01:03:52,920 1250 01:03:52,920 --> 01:03:53,360 >> OKAY. 1251 01:03:53,360 --> 01:03:57,320 DO WE HAVE ANY OTHER QUESTIONS 1252 01:03:57,320 --> 01:03:57,960 OR COMMENTS? 1253 01:03:57,960 --> 01:04:01,560 >> CLAIRE, I SEE IN THE CHAT 1254 01:04:01,560 --> 01:04:03,240 THAT KELLY MAY HAVE ASKED FOR A 1255 01:04:03,240 --> 01:04:05,400 PAPER THAT I AM NOT -- I MAY 1256 01:04:05,400 --> 01:04:07,360 HAVE MISSED THE QR CODE ON IT. 1257 01:04:07,360 --> 01:04:09,680 SO, KELLY, CAN YOU TELL ME WHICH 1258 01:04:09,680 --> 01:04:10,720 PAPER YOU WANTED AND I'LL MAKE 1259 01:04:10,720 --> 01:04:12,520 SURE YOU GET IT. 1260 01:04:12,520 --> 01:04:16,000 AND YOU'RE ON MUTE, BY THE WAY. 1261 01:04:16,000 --> 01:04:18,440 1262 01:04:18,440 --> 01:04:19,640 >> THANK YOU. 1263 01:04:19,640 --> 01:04:25,240 IT WAS THE ONE THAT YOU WERE 1264 01:04:25,240 --> 01:04:26,000 REFERENCING RELATED TO 1265 01:04:26,000 --> 01:04:26,920 DIVERSITY. 1266 01:04:26,920 --> 01:04:29,480 IT DIDN'T HAVE A QR CODE ON IT. 1267 01:04:29,480 --> 01:04:30,680 AND I WAS ACTUALLY WRITING NOTES 1268 01:04:30,680 --> 01:04:33,440 BUT I WOULD LOVE TO READ IT. 1269 01:04:33,440 --> 01:04:34,760 >> I WILL MAKE SURE -- I'LL GET 1270 01:04:34,760 --> 01:04:42,080 THE LINK AND PUT IT IN THE CHAT. 1271 01:04:42,080 --> 01:04:42,440 >> GREAT. 1272 01:04:42,440 --> 01:04:44,200 THANK YOU VERY MUCH. 1273 01:04:44,200 --> 01:04:45,560 >> YOU BET. 1274 01:04:45,560 --> 01:04:46,000 >> OKAY. 1275 01:04:46,000 --> 01:04:49,200 ANNIE, YOU HAVE A QUESTION. 1276 01:04:49,200 --> 01:04:50,400 >> A COMMENT AND THEN A 1277 01:04:50,400 --> 01:04:50,800 QUESTION. 1278 01:04:50,800 --> 01:04:52,360 I WANTED TO COMMENT ON THE WORK 1279 01:04:52,360 --> 01:04:55,000 BEING DONE ON THE GUARD PLATE. 1280 01:04:55,000 --> 01:04:59,040 WE WENT THROUGH THAT QUICKLY. 1281 01:04:59,040 --> 01:05:01,000 I WANT TO COMPLIMENT THE TEAM 1282 01:05:01,000 --> 01:05:04,400 WORKING SO HARD ON THAT EFFORT, 1283 01:05:04,400 --> 01:05:05,360 THAT'S REALLY CRITICAL 1284 01:05:05,360 --> 01:05:06,920 OUTWARD-FACING TOOL FOR OUR RARE 1285 01:05:06,920 --> 01:05:08,920 DISEASE COMMUNITY AND SO MANY 1286 01:05:08,920 --> 01:05:09,120 OTHERS. 1287 01:05:09,120 --> 01:05:12,360 AND I KNOW THAT WORKING ON, YOU 1288 01:05:12,360 --> 01:05:15,400 KNOW, DR. RUTTER, YOU FOCUSED ON 1289 01:05:15,400 --> 01:05:17,760 ACCESSIBILITY, I KNOW THE WORK 1290 01:05:17,760 --> 01:05:20,160 DONE ON THE INTEROPERABILITY OF 1291 01:05:20,160 --> 01:05:23,080 ICD CODES, MAKING SURE WE KEEP 1292 01:05:23,080 --> 01:05:24,120 THAT UPDATED AND STATE OF THE 1293 01:05:24,120 --> 01:05:24,280 ART. 1294 01:05:24,280 --> 01:05:26,320 AND THERE'S A LOT OF 1295 01:05:26,320 --> 01:05:27,160 COLLABORATION WITH PARTNER 1296 01:05:27,160 --> 01:05:29,480 ORGANIZATIONS AND OTHER 1297 01:05:29,480 --> 01:05:31,000 COMMUNITIES TO MAKE SURE THAT 1298 01:05:31,000 --> 01:05:33,640 WHAT'S OFFERED THROUGH GUARD 1299 01:05:33,640 --> 01:05:34,840 REMAINS REALLY THE MOST UPDATED 1300 01:05:34,840 --> 01:05:36,480 RESOURCE IN THE U.S. FOR THE 1301 01:05:36,480 --> 01:05:37,280 RARE DISEASE COMMUNITY. 1302 01:05:37,280 --> 01:05:39,680 SO I WANT TO THANK NCATS FOR THE 1303 01:05:39,680 --> 01:05:41,200 WORK YOU'RE INVESTING IN THAT. 1304 01:05:41,200 --> 01:05:47,880 >> THANK YOU FOR THAT COMMENT, 1305 01:05:47,880 --> 01:05:48,080 ANNIE. 1306 01:05:48,080 --> 01:05:50,280 ERIC SAID -- I THINK HE'S 1307 01:05:50,280 --> 01:05:51,360 SUPERMAN SOMETIMES. 1308 01:05:51,360 --> 01:05:53,760 HE HAS WORK TIRELESSLY ON THIS 1309 01:05:53,760 --> 01:05:56,000 AND HE HAS BEEN REACHING OUT TO 1310 01:05:56,000 --> 01:05:58,920 A VARIETY OF DIFFERENT GROUPS 1311 01:05:58,920 --> 01:06:01,120 AND INDIVIDUALS, TO HELP GET 1312 01:06:01,120 --> 01:06:03,000 INPUT AND FEEDBACK ON THE WORK 1313 01:06:03,000 --> 01:06:04,720 THAT WE'RE TRYING DO, IN TERMS 1314 01:06:04,720 --> 01:06:05,960 OF HARMONIZATION PROCESS AND IN 1315 01:06:05,960 --> 01:06:08,560 TERMS OF DATASETS THAT CAN BE 1316 01:06:08,560 --> 01:06:11,320 INCLUDED ON GUARD AND IT HAS 1317 01:06:11,320 --> 01:06:14,040 BEEN VERY, VERY, VERY HELPFUL 1318 01:06:14,040 --> 01:06:17,000 AND FRUITFUL IN TERMS OF HELPING 1319 01:06:17,000 --> 01:06:18,200 US NAVIGATE AND UPGRADE OUR 1320 01:06:18,200 --> 01:06:18,480 SITE. 1321 01:06:18,480 --> 01:06:20,720 AND I DO HOPE IT'S HELPFUL. 1322 01:06:20,720 --> 01:06:26,080 I SHOULD ALSO POINT OUT TOO THAT 1323 01:06:26,080 --> 01:06:27,600 ANNIE, AT EVERY LIFE, THERE ARE 1324 01:06:27,600 --> 01:06:28,280 WONDERFUL RESOURCES. 1325 01:06:28,280 --> 01:06:30,280 ONE OF THE BEST RESOURCES ON THE 1326 01:06:30,280 --> 01:06:31,800 I.C. CODES OUT THERE. 1327 01:06:31,800 --> 01:06:33,640 AND SO IF THERE ARE WAYS THAT WE 1328 01:06:33,640 --> 01:06:36,360 CAN ALSO MAKE SURE THAT WE HAVE 1329 01:06:36,360 --> 01:06:39,240 CONNECTIONS TO OTHER RESOURCES 1330 01:06:39,240 --> 01:06:39,880 THAT CAN COMPLEMENT OR 1331 01:06:39,880 --> 01:06:41,200 SUPPLEMENT ACTIVITIES WE HAVE OR 1332 01:06:41,200 --> 01:06:41,880 INFORMATION THAT WE HAVE, THAT'S 1333 01:06:41,880 --> 01:06:45,080 ONE OF THE OTHER THINGS THAT 1334 01:06:45,080 --> 01:06:46,440 WE'RE LOOKING TO DO. 1335 01:06:46,440 --> 01:06:49,080 HOPEFULLY WE WILL HAVE A 1336 01:06:49,080 --> 01:06:51,040 ONE-STOP SHOP THAT MAY NOT BE 1337 01:06:51,040 --> 01:06:53,560 EVERYTHING LOCATED ON OUR SITE 1338 01:06:53,560 --> 01:06:54,640 BUT CAN POINT TO WHERE OTHER 1339 01:06:54,640 --> 01:06:55,840 INFORMATION IS LOCATED SO RARE 1340 01:06:55,840 --> 01:06:57,040 DISEASE PATIENTS DON'T HAVE TO 1341 01:06:57,040 --> 01:06:58,520 WORK HARD TO FIND THE 1342 01:06:58,520 --> 01:06:59,680 INFORMATION THAT THEY NEED. 1343 01:06:59,680 --> 01:07:02,080 AND I SEE P.J. 1344 01:07:02,080 --> 01:07:03,600 P.J. MAY WANT TO SPEAK UP AS 1345 01:07:03,600 --> 01:07:05,200 WELL ON THIS TOPIC. 1346 01:07:05,200 --> 01:07:06,480 >> YEAH, ANNIE, THANKS YOU FOR 1347 01:07:06,480 --> 01:07:07,440 THE COMMENTS. 1348 01:07:07,440 --> 01:07:09,000 CERTAINLY ERIC DOES A GREAT JOB. 1349 01:07:09,000 --> 01:07:11,200 BUT I ALSO JUST WANT TO BE SURE 1350 01:07:11,200 --> 01:07:12,840 WE ACKNOWLEDGE THAT IT'S A REAL 1351 01:07:12,840 --> 01:07:15,600 TEAM EFFORT, AND THE NCATS 1352 01:07:15,600 --> 01:07:17,080 INFORMATICS PEOPLE AND MANY 1353 01:07:17,080 --> 01:07:19,520 OTHERS INVOLVED IN THIS 1354 01:07:19,520 --> 01:07:20,840 TRANSITION AT GUARD 2.0, WHICH 1355 01:07:20,840 --> 01:07:30,280 WE'VE BEEN VERY HAPPY WITH. 1356 01:07:30,280 --> 01:07:31,880 >> THANK YOU, P.J. 1357 01:07:31,880 --> 01:07:32,320 OKAY. 1358 01:07:32,320 --> 01:07:42,840 ANY OTHER QUESTIONS OR COMMENTS? 1359 01:07:44,960 --> 01:07:46,400 >> I LOVED THE QR CODES. 1360 01:07:46,400 --> 01:07:49,640 >> THANK YOU. 1361 01:07:49,640 --> 01:07:50,200 OH, YES. 1362 01:07:50,200 --> 01:07:50,640 YES! 1363 01:07:50,640 --> 01:07:52,600 FEEDBACK, YOU LIKE THOSE? 1364 01:07:52,600 --> 01:07:53,040 OKAY. 1365 01:07:53,040 --> 01:07:54,720 I ADDED THEM IF THE LAST MINUTE, 1366 01:07:54,720 --> 01:07:56,440 IF I'M BEING HONEST. 1367 01:07:56,440 --> 01:07:58,960 SO I MAY HAVE MISSED -- I 1368 01:07:58,960 --> 01:08:02,160 APOLOGIZE FOR ANY LINKS I DID 1369 01:08:02,160 --> 01:08:03,000 MISS. 1370 01:08:03,000 --> 01:08:04,960 AND I'M HAPPY TO -- I DON'T 1371 01:08:04,960 --> 01:08:05,960 THINK -- NEXT TIME I'LL BE SURE 1372 01:08:05,960 --> 01:08:08,520 TO DO IT AHEAD OF TIME. 1373 01:08:08,520 --> 01:08:09,200 >> THE DINOSAUR IS CUTE. 1374 01:08:09,200 --> 01:08:10,760 >> YOU KNOW, I DON'T KNOW WHERE 1375 01:08:10,760 --> 01:08:12,280 THAT DINOSAUR COMES FROM BUT I 1376 01:08:12,280 --> 01:08:15,440 THINK IT'S PRETTY CUTE TOO. 1377 01:08:15,440 --> 01:08:18,560 1378 01:08:18,560 --> 01:08:26,960 THE TECHNOLOGY IS NOT DINOSAUR. 1379 01:08:26,960 --> 01:08:30,080 IT'S VERY CURRENT. 1380 01:08:30,080 --> 01:08:30,920 ALL RIGHT. 1381 01:08:30,920 --> 01:08:34,920 WELL, YOU KNOW, IF THERE ARE NO 1382 01:08:34,920 --> 01:08:37,160 OTHER COMMENTS, WE MAY WANT TO 1383 01:08:37,160 --> 01:08:40,680 TAKE A QUICK BREAK BEFORE THE 1384 01:08:40,680 --> 01:08:41,440 NEXT SPEAKER. 1385 01:08:41,440 --> 01:08:45,200 ANNA, WHAT IS YOUR SENSE? 1386 01:08:45,200 --> 01:08:47,240 >> YES, I THINK WE CAN TAKE A 1387 01:08:47,240 --> 01:08:51,360 10-MINUTE BREAK. 1388 01:08:51,360 --> 01:08:52,320 1389 01:08:52,320 --> 01:08:52,960 >> OKAY. 1390 01:08:52,960 --> 01:08:54,840 >> WE'LL START AGAIN AT 2:20 OR 1391 01:08:54,840 --> 01:08:55,080 SO. 1392 01:08:55,080 --> 01:08:56,960 OUR NEXT TALK IS SUPPOSED TO 1393 01:08:56,960 --> 01:08:58,880 START AT 2:30. 1394 01:08:58,880 --> 01:09:01,840 WE MAY BE ABLE TO START IT A 1395 01:09:01,840 --> 01:09:07,520 LITTLE BIT SOONER. 1396 01:09:07,520 --> 01:09:09,320 1397 01:09:09,320 --> 01:09:10,280 2:10 TO 2:20. 1398 01:09:10,280 --> 01:09:11,440 >> THANK YOU. 1399 01:09:11,440 --> 01:09:13,200 WE'LL SEE YOU IN ABOUT TEN 1400 01:09:13,200 --> 01:09:13,440 MINUTES. 1401 01:09:13,440 --> 01:09:16,280 AND THANK YOU FOR YOUR INPUT. 1402 01:09:16,280 --> 01:09:18,560 IT IS MY PLEASURE TO INTRODUCE 1403 01:09:18,560 --> 01:09:21,760 TO YOU DR. MARIE BERNARD, SHE'S 1404 01:09:21,760 --> 01:09:24,680 CHIEF OFFICER FOR SCIENTIFIC 1405 01:09:24,680 --> 01:09:33,240 WORKFORCE DIVERSITY, ALSO KNOWN 1406 01:09:33,240 --> 01:09:35,000 AS COSWD, AND WILL LEAD 1407 01:09:35,000 --> 01:09:36,440 INTRAMURALLY AND EXTRAMURALLY 1408 01:09:36,440 --> 01:09:42,000 AND CO-LEADS THE NIH'S NEWLY 1409 01:09:42,000 --> 01:09:43,640 ANNOUNCED UNITE INITIATIVE TO 1410 01:09:43,640 --> 01:09:48,120 END STRUCTURAL RACISM. 1411 01:09:48,120 --> 01:09:51,000 PRIOR TO JOINING COSWD, SHE WAS 1412 01:09:51,000 --> 01:09:52,040 DEPUTY DIRECTOR OF THE NATIONAL 1413 01:09:52,040 --> 01:09:54,800 INSTITUTE ON AGING, AND SHE 1414 01:09:54,800 --> 01:09:56,760 SERVED AS PRINCIPAL ADVISER TO 1415 01:09:56,760 --> 01:09:57,440 NIA DIRECTOR. 1416 01:09:57,440 --> 01:09:59,280 SHE'S LED A VARIETY OF 1417 01:09:59,280 --> 01:10:00,200 ACTIVITIES WITHIN THE AGING 1418 01:10:00,200 --> 01:10:04,120 COMMUNITY BUT ALSO IN THIS SPACE 1419 01:10:04,120 --> 01:10:04,880 OF NIH-WIDE INCLUSION, 1420 01:10:04,880 --> 01:10:06,080 GOVERNANCE COMMITTEE, THE WOMEN 1421 01:10:06,080 --> 01:10:07,640 OF COLOR COMMITTEE OF THE 1422 01:10:07,640 --> 01:10:10,480 NIH-WIDE WORKING GROUP ON WOMEN 1423 01:10:10,480 --> 01:10:12,360 IN BIOMEDICAL CAREERS. 1424 01:10:12,360 --> 01:10:15,960 SHE IS ALSO IN THE NATIONAL 1425 01:10:15,960 --> 01:10:18,360 LEADERSHIP ON GERIATRIC 1426 01:10:18,360 --> 01:10:21,520 RESEARCH, TEACHING IN CLINICAL 1427 01:10:21,520 --> 01:10:22,240 PRACTICE, WIDELY RECOGNIZED IN 1428 01:10:22,240 --> 01:10:22,840 HER ACTIVITIES. 1429 01:10:22,840 --> 01:10:24,720 PRIOR TO JOINING NIH WAS AN 1430 01:10:24,720 --> 01:10:25,600 ENDOWED PROFESSOR AND FOUNDING 1431 01:10:25,600 --> 01:10:28,880 CHAIRMAN OF THE DONALD W. 1432 01:10:28,880 --> 01:10:30,840 REYNOLDS DEPARTMENT OF GERIATRIC 1433 01:10:30,840 --> 01:10:31,720 MEDICINE, UNIVERSITY OF 1434 01:10:31,720 --> 01:10:33,240 OKLAHOMA, COLLEGE OF MEDICINE. 1435 01:10:33,240 --> 01:10:35,320 SHE WAS ASSOCIATE CHIEF OF STAFF 1436 01:10:35,320 --> 01:10:36,720 FOR GERIATRICS AND EXTENDED CARE 1437 01:10:36,720 --> 01:10:38,720 AT THE OKLAHOMA CITY VETERANS 1438 01:10:38,720 --> 01:10:41,440 AFFAIRS AND MEDICAL CENTER, AND 1439 01:10:41,440 --> 01:10:42,680 SHE LECTURED ON TOPICS INCLUDING 1440 01:10:42,680 --> 01:10:45,280 NUTRITION AND FUNCTION IN OLDER 1441 01:10:45,280 --> 01:10:50,520 ADULTS WITH PARTICULAR FOCUS ON 1442 01:10:50,520 --> 01:10:52,560 UNDERREPRESENTED MINORITY 1443 01:10:52,560 --> 01:10:53,160 POPULATION, UNDERGRADUATE OF 1444 01:10:53,160 --> 01:10:55,360 BRYN MAWR COLLEGE, M.D. FROM 1445 01:10:55,360 --> 01:11:05,440 UNIVERSITY OF PENNSYLVANIA, 1446 01:11:05,440 --> 01:11:07,320 TRAINED IN INTERNAL MEDICINE, 1447 01:11:07,320 --> 01:11:08,280 CHIEF MEDICAL RESIDENT, IT'S OF 1448 01:11:08,280 --> 01:11:10,800 A DELIGHT TO HAVE HER TO TALK 1449 01:11:10,800 --> 01:11:12,480 ABOUT COMBATING STRUCTURAL 1450 01:11:12,480 --> 01:11:12,720 RACISM. 1451 01:11:12,720 --> 01:11:13,320 DR. BERNARD? 1452 01:11:13,320 --> 01:11:16,240 >> THANK YOU SO MUCH, DR. 1453 01:11:16,240 --> 01:11:16,720 RUTTER. 1454 01:11:16,720 --> 01:11:20,560 HOPEFULLY YOU CAN ALL NOW SEE MY 1455 01:11:20,560 --> 01:11:21,120 OPENING SLIDE. 1456 01:11:21,120 --> 01:11:25,120 YES? 1457 01:11:25,120 --> 01:11:26,040 >> YES. 1458 01:11:26,040 --> 01:11:26,440 >> OKAY. 1459 01:11:26,440 --> 01:11:27,400 THANK YOU. 1460 01:11:27,400 --> 01:11:30,360 SO, AS DR. RUTTER SAID, I HAVE 1461 01:11:30,360 --> 01:11:33,040 THE PRIVILEGE OF SERVING IN TWO 1462 01:11:33,040 --> 01:11:34,880 LEADERSHIP ROLES AT NIH. 1463 01:11:34,880 --> 01:11:37,680 I'D LIKE TO SHOW MY HATS, THE 1464 01:11:37,680 --> 01:11:39,320 HAT OF COSWD, AS MENTIONED, I 1465 01:11:39,320 --> 01:11:41,840 WEAR THE HAT OF CO-LEAD OF NIH 1466 01:11:41,840 --> 01:11:43,600 UNITE INITIATIVE TO END 1467 01:11:43,600 --> 01:11:44,480 STRUCTURAL RACISM. 1468 01:11:44,480 --> 01:11:47,520 AND BOTH OF THEM ARE FOCUSED ON 1469 01:11:47,520 --> 01:11:49,960 ASSURING WE TAKE ADVANTAGE OF 1470 01:11:49,960 --> 01:11:52,000 FULL RANGE OF TALENT THAT'S 1471 01:11:52,000 --> 01:11:52,680 AVAILABLE OUT THERE. 1472 01:11:52,680 --> 01:11:57,720 I HAVE A THIRD ROLE, NO HAT YET, 1473 01:11:57,720 --> 01:11:59,000 CO-LEAD OF THE NIH DIVERSITY, 1474 01:11:59,000 --> 01:12:01,080 EQUITY, AND INCLUSION AND 1475 01:12:01,080 --> 01:12:01,840 ACCESSIBILITY STRATEGIC PLAN. 1476 01:12:01,840 --> 01:12:04,360 LET ME TELL YOU WHY THESE 1477 01:12:04,360 --> 01:12:05,160 ACTIVITIES ARE NECESSARY. 1478 01:12:05,160 --> 01:12:07,000 I DON'T REALLY NEED TO TELL YOU. 1479 01:12:07,000 --> 01:12:08,320 I THINK YOU ALREADY KNOW, THAT 1480 01:12:08,320 --> 01:12:10,920 THE SORTS OF PROBLEMS THAT WE'RE 1481 01:12:10,920 --> 01:12:13,120 TRYING TO ADDRESS IN BIOMEDICINE 1482 01:12:13,120 --> 01:12:20,560 ARE LIKE TRYING TO DESCRIBE AN 1483 01:12:20,560 --> 01:12:21,800 ELEPHANT SIGHTLESSLY. 1484 01:12:21,800 --> 01:12:26,160 WE NEED TO COME COME BASED ON 1485 01:12:26,160 --> 01:12:26,960 VIEWPOINTS, DISCIPLINES, 1486 01:12:26,960 --> 01:12:28,240 EXPERIENCE, GEOGRAPHY, OFTEN 1487 01:12:28,240 --> 01:12:30,000 RELATED TO DEMOGRAPHIC 1488 01:12:30,000 --> 01:12:32,040 CHARACTERISTICS, AS WE TALK 1489 01:12:32,040 --> 01:12:34,240 ABOUT COMMENTARY FROM LAST 1490 01:12:34,240 --> 01:12:34,640 NOVEMBER. 1491 01:12:34,640 --> 01:12:36,040 LET ME TALK AT A HIGH LEVEL 1492 01:12:36,040 --> 01:12:39,600 ABOUT WHAT'S HAPPENING WITH THE 1493 01:12:39,600 --> 01:12:40,400 DEIA STRATEGIC PLAN, DIVERSITY, 1494 01:12:40,400 --> 01:12:42,680 EQUITY, AND INCLUSION AND 1495 01:12:42,680 --> 01:12:43,040 ACCESSIBILITY. 1496 01:12:43,040 --> 01:12:48,160 THINGS GOING ON WITHIN MY 1497 01:12:48,160 --> 01:12:49,720 OFFICE, AND NIH UNITE 1498 01:12:49,720 --> 01:12:50,360 INITIATIVE. 1499 01:12:50,360 --> 01:12:51,320 THE DEIA STRATEGIC PLAN IS 1500 01:12:51,320 --> 01:12:57,240 COMING ABOUT AS A RESULT OF TWO 1501 01:12:57,240 --> 01:12:58,440 MANDATES ONE FROM LEGISLATION 1502 01:12:58,440 --> 01:13:00,400 THAT LED TO FISCAL YEAR 21 1503 01:13:00,400 --> 01:13:03,720 BUDGET FOR NIH THAT CALLED FOR A 1504 01:13:03,720 --> 01:13:06,040 DIVERSITY, EQUITY, AND INCLUSION 1505 01:13:06,040 --> 01:13:07,000 STRATEGIC PLAN, INCLUDING SHORT- 1506 01:13:07,000 --> 01:13:09,920 AND LONG-TERM GOALS TO ADDRESS 1507 01:13:09,920 --> 01:13:10,600 RACIAL, ETHNIC, GENDER 1508 01:13:10,600 --> 01:13:12,880 DISPARITIES AT NIH AS WELL AS TO 1509 01:13:12,880 --> 01:13:15,200 IDENTIFY AND ADDRESS BARRIERS TO 1510 01:13:15,200 --> 01:13:19,680 ACCESS, IN ACCESS TO NIH FUNDING 1511 01:13:19,680 --> 01:13:20,440 BY INVESTIGATORS, RESEARCH IN 1512 01:13:20,440 --> 01:13:21,520 HEALTH DISPARITIES. 1513 01:13:21,520 --> 01:13:25,560 AS WRITTEN, THE RECORD LANGUAGE 1514 01:13:25,560 --> 01:13:28,680 CALLED FOR THAT PLAN WITHIN 180 1515 01:13:28,680 --> 01:13:30,760 DAYS, IN LAW DECEMBER OF 2020. 1516 01:13:30,760 --> 01:13:33,240 WE, NIH, WENT TO THE LEGISLATORS 1517 01:13:33,240 --> 01:13:35,240 AND POINTED OUT IT WAS A LOT 1518 01:13:35,240 --> 01:13:37,280 THAT WAS CHANGING AROUND THAT 1519 01:13:37,280 --> 01:13:39,040 TIME AND IT WOULD BE MUCH BETTER 1520 01:13:39,040 --> 01:13:41,800 PRODUCT IF WE HAD A LONGER 1521 01:13:41,800 --> 01:13:43,000 TIMELINE FOR DEVELOPING THAT 1522 01:13:43,000 --> 01:13:45,560 PLAN, AND WERE ABLE TO NEGOTIATE 1523 01:13:45,560 --> 01:13:48,800 THE PLAN WOULD BE DELIVERED LATE 1524 01:13:48,800 --> 01:13:49,920 SPRING, EARLY SUMMER OF 2021, 1525 01:13:49,920 --> 01:13:50,680 RIGHT AROUND THIS TIME. 1526 01:13:50,680 --> 01:13:53,920 WE HAVE IN THE INTERIM BEEN 1527 01:13:53,920 --> 01:13:55,160 GIVING QUARTERLY UPDATES TO 1528 01:13:55,160 --> 01:13:56,720 WHAT'S CALENDAR THE FOUR 1529 01:13:56,720 --> 01:13:57,120 CORNERS. 1530 01:13:57,120 --> 01:14:01,520 SO LEADS IN THE HOUSE AND SENATE 1531 01:14:01,520 --> 01:14:04,240 FOR ALLOCATION AND 1532 01:14:04,240 --> 01:14:04,920 APPROPRIATION. 1533 01:14:04,920 --> 01:14:06,960 AFTER DECEMBER 20 OF 2020, WE 1534 01:14:06,960 --> 01:14:08,920 HAD A NEW ADMINISTRATION COME 1535 01:14:08,920 --> 01:14:11,200 IN, ONE OF THE FIRST EXECUTIVE 1536 01:14:11,200 --> 01:14:15,720 ORDERS FROM THE BIDEN 1537 01:14:15,720 --> 01:14:16,960 ADMINISTRATION IS EXECUTIVE 1538 01:14:16,960 --> 01:14:19,880 ORDER 14035, CALLS FOR 1539 01:14:19,880 --> 01:14:20,760 DIVERSITY, EQUITY, INCLUSION, 1540 01:14:20,760 --> 01:14:21,760 AND ACCESSIBILITY PLAN FOR 1541 01:14:21,760 --> 01:14:22,920 FEDERAL WORKFORCE. 1542 01:14:22,920 --> 01:14:25,280 WE'VE COMBINED THE TWO GOALS IN 1543 01:14:25,280 --> 01:14:27,320 WHAT IS BEING DEVELOPED. 1544 01:14:27,320 --> 01:14:28,520 THERE WAS A GOVERNMENT-WIDE 1545 01:14:28,520 --> 01:14:31,280 STRATEGIC PLAN THAT GOT ISSUED 1546 01:14:31,280 --> 01:14:33,920 NOVEMBER 23, A ROADMAP TO 1547 01:14:33,920 --> 01:14:34,880 IMPLEMENTING THIS EXECUTIVE 1548 01:14:34,880 --> 01:14:36,080 ORDER. 1549 01:14:36,080 --> 01:14:38,480 IT CALLED FOR AGENCIES LIKE HHS 1550 01:14:38,480 --> 01:14:42,000 TO DEVELOP A PLAN BY MARCH OF 1551 01:14:42,000 --> 01:14:45,480 THIS YEAR, AND NIH AS AN 1552 01:14:45,480 --> 01:14:46,800 OPERATING GIVING UNDER HHS IS, 1553 01:14:46,800 --> 01:14:48,200 AS I SAID, LOOKING TO GET OUR 1554 01:14:48,200 --> 01:14:48,640 PLAN. 1555 01:14:48,640 --> 01:14:51,040 WE HOPE TO HAVE IT COMPLETED BY 1556 01:14:51,040 --> 01:14:54,240 THE END OF JUNE AND PUBLISHED 1557 01:14:54,240 --> 01:14:55,960 MAYBE MID-JULY, AN UPDATE ON 1558 01:14:55,960 --> 01:14:57,440 THAT JUNE 10 AT THE ADVISORY 1559 01:14:57,440 --> 01:15:00,680 COMMITTEE TO THE DIRECTOR 1560 01:15:00,680 --> 01:15:01,160 MEETING. 1561 01:15:01,160 --> 01:15:04,120 WHAT WE SEE IS THAT THIS SHOULD 1562 01:15:04,120 --> 01:15:06,520 BE SOMETHING THAT HAS BROAD 1563 01:15:06,520 --> 01:15:07,920 VISION AND ASPIRATIONS FOR ALL 1564 01:15:07,920 --> 01:15:10,160 OF NIH, VERY BROAD SCOPE TO IT, 1565 01:15:10,160 --> 01:15:12,320 THUS WE HAVE MORE THAN 100 STAFF 1566 01:15:12,320 --> 01:15:14,840 MEMBERS ACROSS NIH WORKING ON 1567 01:15:14,840 --> 01:15:15,000 IT. 1568 01:15:15,000 --> 01:15:18,560 WE'VE SPENT A LOT OF TIME 1569 01:15:18,560 --> 01:15:19,120 ARTICULATING NIH DEFINITIONS 1570 01:15:19,120 --> 01:15:20,960 WITH DIVERSITY, EQUITY, AND 1571 01:15:20,960 --> 01:15:26,760 INCLUSION AND ACCESSIBILITY, 1572 01:15:26,760 --> 01:15:27,720 LANGUAGE MATTERS. 1573 01:15:27,720 --> 01:15:29,600 WE ARE DEVELOPING EXAMPLES OF 1574 01:15:29,600 --> 01:15:30,360 ACCOMPLISHMENTS, CONVEYING 1575 01:15:30,360 --> 01:15:35,320 PRIORITIES FOR THE NEXT FIVE 1576 01:15:35,320 --> 01:15:36,040 YEARS, SAMPLE ACTIVITIES, 1577 01:15:36,040 --> 01:15:38,120 IMPORTANTLY WE NEED TO PROVIDE 1578 01:15:38,120 --> 01:15:40,520 ACCOUNTABILITY, SO WE'RE LOOKING 1579 01:15:40,520 --> 01:15:42,520 AT MEASURES OF PROGRESS, AND WE 1580 01:15:42,520 --> 01:15:44,480 GATHERED INTERNAL INPUT. 1581 01:15:44,480 --> 01:15:47,200 WE'VE GOTTEN EXTERNAL INPUT, 1582 01:15:47,200 --> 01:15:48,200 PARTICULARLY FROM RFI. 1583 01:15:48,200 --> 01:15:50,480 AND THAT'S THE SCOPE OF THE 1584 01:15:50,480 --> 01:15:52,360 PLAN, TO ARTICULATE NIH'S VISION 1585 01:15:52,360 --> 01:15:53,000 FOR STRENGTHENING DIVERSITY, 1586 01:15:53,000 --> 01:15:55,960 EQUITY, AND INCLUSION AND 1587 01:15:55,960 --> 01:15:57,480 ACCESSIBILITY, TO CAPTURE 1588 01:15:57,480 --> 01:15:58,920 ACTIVITIES THE NIH WORKFORCE 1589 01:15:58,920 --> 01:15:59,560 WILL UNDERTAKE TO MEET THE 1590 01:15:59,560 --> 01:16:02,520 VISION OF THE STRATEGIC PLAN, 1591 01:16:02,520 --> 01:16:09,880 AND TO HARMONIZE THIS, NIH-WIDE 1592 01:16:09,880 --> 01:16:12,520 STRATEGIC PLAN FLAME WORK, 1593 01:16:12,520 --> 01:16:13,280 ORGANIZED AROUND THREE KEY 1594 01:16:13,280 --> 01:16:15,440 AREAS, ONE IN THE WORKFORCE, 1595 01:16:15,440 --> 01:16:17,960 DIFFERENT FROM YOUR STANDARD NIH 1596 01:16:17,960 --> 01:16:18,160 PLAN. 1597 01:16:18,160 --> 01:16:20,040 STANDARD NIH PLAN YOU HAVE 1598 01:16:20,040 --> 01:16:21,920 RESEARCH FIRST AND THEN OTHER 1599 01:16:21,920 --> 01:16:22,240 ISSUES. 1600 01:16:22,240 --> 01:16:24,000 BUT BECAUSE THIS IS VERY 1601 01:16:24,000 --> 01:16:24,760 PEOPLE-FOCUSED WE THOUGHT THIS 1602 01:16:24,760 --> 01:16:27,600 SHOULD BE THE FIRST OBJECTIVE, 1603 01:16:27,600 --> 01:16:29,880 NIH WORKFORCE, AND THEN 1604 01:16:29,880 --> 01:16:31,240 WORKFORCE AT INSTITUTIONS 1605 01:16:31,240 --> 01:16:32,080 SUPPORTED BY NIH. 1606 01:16:32,080 --> 01:16:36,560 WE HAVE AS A SECOND OBJECTIVE TO 1607 01:16:36,560 --> 01:16:41,080 GROW AND SUSTAIN DEIA THROUGH 1608 01:16:41,080 --> 01:16:43,480 STRUCTURAL AND CULTURAL CHANGE, 1609 01:16:43,480 --> 01:16:44,680 FAMILIAR STEWARDSHIPS, 1610 01:16:44,680 --> 01:16:45,560 PUBLIC/PRIVATE PARTNERSHIPS AND 1611 01:16:45,560 --> 01:16:46,600 ENGAGEMENTS, ACCOUNTABILITY AND 1612 01:16:46,600 --> 01:16:48,960 CONFIDENCE, MANAGEMENT AND 1613 01:16:48,960 --> 01:16:49,400 OPERATIONS. 1614 01:16:49,400 --> 01:16:51,520 THIRD, RESEARCH OBJECTIVE, ON 1615 01:16:51,520 --> 01:16:53,800 THE WORKFORCE, HEALTH RESEARCH. 1616 01:16:53,800 --> 01:17:02,040 WE HOPE THAT YOU'VE HAD A CHANCE 1617 01:17:02,040 --> 01:17:04,080 TO CONTRIBUTE TO THE RFI, IF NOT 1618 01:17:04,080 --> 01:17:05,840 TUNE IN TO THE DIRECTOR MEETING 1619 01:17:05,840 --> 01:17:07,680 WITH ANOTHER PUBLIC DISCUSSION 1620 01:17:07,680 --> 01:17:10,480 OF THIS, AND HOPEFULLY WE WILL 1621 01:17:10,480 --> 01:17:12,880 PUBLISH SOON. 1622 01:17:12,880 --> 01:17:14,400 THEN FROM THE COSWD PERSPECTIVE 1623 01:17:14,400 --> 01:17:16,120 WE'VE BEEN WORKING HARD ON 1624 01:17:16,120 --> 01:17:17,320 DEVELOPING OUR OWN STRATEGIC 1625 01:17:17,320 --> 01:17:18,680 PLAN, AND IN FACT IT WAS 1626 01:17:18,680 --> 01:17:20,680 RELEASED AT THE BEGINNING OF 1627 01:17:20,680 --> 01:17:22,360 MARCH OF THIS YEAR. 1628 01:17:22,360 --> 01:17:25,560 IT OUTLINES WHAT OUR VISION IS 1629 01:17:25,560 --> 01:17:28,280 FOR 22 THROUGH 26. 1630 01:17:28,280 --> 01:17:33,000 WE HAVE A VISION OF ENABLING NIH 1631 01:17:33,000 --> 01:17:34,120 AND NIH-FUNDED INSTITUTIONS TO 1632 01:17:34,120 --> 01:17:36,840 BENEFIT FROM THE NATION'S FULL 1633 01:17:36,840 --> 01:17:38,160 RANGE OF TALENT, BECAUSE WE KNOW 1634 01:17:38,160 --> 01:17:40,360 THAT THERE'S A LOT OF TALENT OUT 1635 01:17:40,360 --> 01:17:41,840 THERE. 1636 01:17:41,840 --> 01:17:44,400 AND OUR GOAL IN DOING SO IS NOT 1637 01:17:44,400 --> 01:17:46,280 ONLY TO ADDRESS EQUITY AND 1638 01:17:46,280 --> 01:17:47,920 JUSTICE, BUT TO FOSTER 1639 01:17:47,920 --> 01:17:49,000 CREATIVITY AND INNOVATION IN 1640 01:17:49,000 --> 01:17:51,960 SCIENCE. 1641 01:17:51,960 --> 01:17:53,360 I WILL BE SHARE SOME DATA 1642 01:17:53,360 --> 01:17:54,040 RELEVANT TO THAT. 1643 01:17:54,040 --> 01:17:57,440 OUR MISSION IS TO BE THE NIH 1644 01:17:57,440 --> 01:17:59,760 THOUGHT LEADER IN THE SCIENTIFIC 1645 01:17:59,760 --> 01:18:00,960 WORKFORCE DIVERSITY, USING 1646 01:18:00,960 --> 01:18:02,920 EVIDENCE-BASED APPROACHES TO 1647 01:18:02,920 --> 01:18:04,000 CATALYZE CULTURES OF INCLUSIVE 1648 01:18:04,000 --> 01:18:04,320 EXCELLENCE. 1649 01:18:04,320 --> 01:18:06,960 HOW DO WE ENVISION DOING THIS? 1650 01:18:06,960 --> 01:18:08,400 BY BUILDING THE EVIDENCE, USING 1651 01:18:08,400 --> 01:18:12,760 NIH AS A TEST BED FOR MANY 1652 01:18:12,760 --> 01:18:13,440 INTERVENTIONS, BY DISSEMINATING 1653 01:18:13,440 --> 01:18:15,480 EVIDENCE ACROSS THE BIOMEDICAL 1654 01:18:15,480 --> 01:18:16,800 RESEARCH ECOSYSTEM, AND BY 1655 01:18:16,800 --> 01:18:23,880 ACTING ON THE EVIDENCE BY 1656 01:18:23,880 --> 01:18:24,320 ADVANCING INTEGRATIVE 1657 01:18:24,320 --> 01:18:25,480 INSTITUTION-WIDE SYSTEMS. 1658 01:18:25,480 --> 01:18:27,000 WE'RE THINKING BROADLY ABOUT 1659 01:18:27,000 --> 01:18:27,920 DIVERSITY. 1660 01:18:27,920 --> 01:18:30,760 AKIN TO THE NIH NOTICE OF 1661 01:18:30,760 --> 01:18:32,560 INTEREST AND DIVERSITY FROM 1662 01:18:32,560 --> 01:18:34,400 2019. 1663 01:18:34,400 --> 01:18:37,960 LET ME EMPHASIZE THAT THE 1664 01:18:37,960 --> 01:18:40,800 CATEGORIES HERE ARE EXAMPLES, 1665 01:18:40,800 --> 01:18:42,280 NOT AN EXHAUSTIVE LISTING OF 1666 01:18:42,280 --> 01:18:43,520 GROUPS UNDERREPRESENTED IN THE 1667 01:18:43,520 --> 01:18:45,440 BIOMEDICAL SCIENCES BUT COMES 1668 01:18:45,440 --> 01:18:48,080 DIRECTLY FROM THAT NOTICE, FROM 1669 01:18:48,080 --> 01:18:50,280 2019, WHICH GIVES AS EXAMPLES 1670 01:18:50,280 --> 01:18:51,280 INDIVIDUALS FROM RACIAL AND 1671 01:18:51,280 --> 01:18:53,400 ETHNIC GROUPS SHOWN BY THE 1672 01:18:53,400 --> 01:18:54,800 NATIONAL SCIENCE FOUNDATION TO 1673 01:18:54,800 --> 01:18:55,720 BE UNDERREPRESENTED IN 1674 01:18:55,720 --> 01:18:57,440 HEALTH-RELATED SCIENCES ON A 1675 01:18:57,440 --> 01:18:59,720 NATIONAL BASIS. 1676 01:18:59,720 --> 01:19:00,960 INDIVIDUALS WITH DISABILITIES. 1677 01:19:00,960 --> 01:19:02,840 INDIVIDUALS FROM A DISADVANTAGED 1678 01:19:02,840 --> 01:19:03,160 BACKGROUND. 1679 01:19:03,160 --> 01:19:04,240 IF YOU LOOKED, YOU KNOW THERE 1680 01:19:04,240 --> 01:19:05,680 ARE MULTIPLE CATEGORIES BY WHICH 1681 01:19:05,680 --> 01:19:06,960 ONE COULD BE CONSIDERED 1682 01:19:06,960 --> 01:19:08,280 DISADVANTAGED, YOU HAVE TO HAVE 1683 01:19:08,280 --> 01:19:11,120 TWO OR MORE OF THEM, LIKE HAVING 1684 01:19:11,120 --> 01:19:15,000 BEEN ON A SCHOOL LUNCH PROGRAM, 1685 01:19:15,000 --> 01:19:16,400 RURAL BACKGROUND, THAT SORT. 1686 01:19:16,400 --> 01:19:17,640 WOMEN AT GRADUATE LEVEL AND 1687 01:19:17,640 --> 01:19:19,840 BEYOND IN SCIENTIFIC FIELDS. 1688 01:19:19,840 --> 01:19:22,640 I SHARE THIS WITH YOU TO 1689 01:19:22,640 --> 01:19:24,480 DEMONSTRATE WE'RE THINKING 1690 01:19:24,480 --> 01:19:25,600 BROADLY, WHEREAS THE UNITE 1691 01:19:25,600 --> 01:19:27,160 INITIATIVE IS VERY FOCUSED ON 1692 01:19:27,160 --> 01:19:28,880 RACIAL AND ETHNIC EQUITY. 1693 01:19:28,880 --> 01:19:30,200 SO WE'RE THINKING BROADLY ABOUT 1694 01:19:30,200 --> 01:19:31,200 ALL OF THOSE DIFFERENT GROUPS 1695 01:19:31,200 --> 01:19:34,720 THAT NEED TO BE AT THE TABLE TO 1696 01:19:34,720 --> 01:19:36,200 ADVANCE SCIENCE HERE. 1697 01:19:36,200 --> 01:19:39,600 SO, SOME EXAMPLES OF THINGS THAT 1698 01:19:39,600 --> 01:19:41,040 WE'RE DOING. 1699 01:19:41,040 --> 01:19:42,800 WE'VE LAUNCHED JUST THIS MARCH 1700 01:19:42,800 --> 01:19:44,320 SOMETHING CALLED THE 21ST 1701 01:19:44,320 --> 01:19:45,520 CENTURY SCHOLARS PROGRAM. 1702 01:19:45,520 --> 01:19:50,440 THE GOAL HERE IS TO DEVELOP AN 1703 01:19:50,440 --> 01:19:53,440 INCLUSIVE CULTURE BY HAVING A 1704 01:19:53,440 --> 01:19:55,600 COHORT OF EXTRAMURAL PROGRAM 1705 01:19:55,600 --> 01:19:57,880 STAFF WHO HAVE BUILT A COMMUNITY 1706 01:19:57,880 --> 01:19:59,880 WHO HAVE GOTTEN EXTRA MENTORING, 1707 01:19:59,880 --> 01:20:02,840 WHO HAD ENHANCEMENT OF THEIR 1708 01:20:02,840 --> 01:20:06,920 SKILLS, TO BECOME BASICALLY DEIA 1709 01:20:06,920 --> 01:20:12,960 AMBASSADORS, MODELED AFTER THE 1710 01:20:12,960 --> 01:20:13,680 DISTINGUISHED SCHOLARS PROGRAM 1711 01:20:13,680 --> 01:20:15,960 AT NIH THAT'S BEEN SUCCESSFUL 1712 01:20:15,960 --> 01:20:17,400 INCREASING DIVERSITY OF TENURE 1713 01:20:17,400 --> 01:20:20,000 TRACK SCIENTISTS IN INTRAMURAL 1714 01:20:20,000 --> 01:20:20,360 PROGRAM. 1715 01:20:20,360 --> 01:20:24,200 HERE THE VISION IS THAT, YES, IT 1716 01:20:24,200 --> 01:20:26,240 MAY HELP INCREASE DIVERSITY OF 1717 01:20:26,240 --> 01:20:28,320 EXTRAMURAL PROGRAM STAFF, BUT 1718 01:20:28,320 --> 01:20:30,080 MAY ALSO TRANSLATE INTO 1719 01:20:30,080 --> 01:20:31,600 DIFFERENCES IN WAY FUNDING 1720 01:20:31,600 --> 01:20:32,520 OPPORTUNITY ANNOUNCEMENTS ARE 1721 01:20:32,520 --> 01:20:35,680 WRITTEN IN THE FUTURE, OR WHO 1722 01:20:35,680 --> 01:20:36,440 GETS INVITED TO SCIENTIFIC 1723 01:20:36,440 --> 01:20:38,320 MEETINGS OR WHO ENDS UP BEING 1724 01:20:38,320 --> 01:20:39,360 PICKED UP ON DISCRETIONARY PAY 1725 01:20:39,360 --> 01:20:43,160 BY THE I.C.s. 1726 01:20:43,160 --> 01:20:45,560 THE FIRST GROUP WE HAVE OUR 1727 01:20:45,560 --> 01:20:47,400 TEST -- OUR PILOT GROUP THAT'S 1728 01:20:47,400 --> 01:20:50,040 GOING ON RIGHT NOW, 13 PROGRAM 1729 01:20:50,040 --> 01:20:50,920 PARTICIPANTS, 6 MENTORS. 1730 01:20:50,920 --> 01:20:53,760 THEY ARE BUILDING A 1731 01:20:53,760 --> 01:20:54,760 SELF-REINFORCING CULTURE THAT 1732 01:20:54,760 --> 01:20:58,360 FOCUSES ON THE SCIENCE OF 1733 01:20:58,360 --> 01:21:00,080 SCIENTIFIC WORKFORCE DIVERSITY. 1734 01:21:00,080 --> 01:21:01,640 AND THEY MEET ONCE A MONTH. 1735 01:21:01,640 --> 01:21:04,600 THEY GET TO HEAR FROM EXPERTS IN 1736 01:21:04,600 --> 01:21:04,800 DEIA. 1737 01:21:04,800 --> 01:21:06,800 THEY DO A JOURNAL CLUB LOOKING 1738 01:21:06,800 --> 01:21:07,440 AT LITERATURE. 1739 01:21:07,440 --> 01:21:09,920 THEY HAVE JUST GOTTEN LAUNCHED 1740 01:21:09,920 --> 01:21:12,120 IN DOING WHAT WE CALL COSWD 1741 01:21:12,120 --> 01:21:14,200 CHALLENGE, A PROJECT TO ADVANCE 1742 01:21:14,200 --> 01:21:17,720 DEIA PRINCIPLES HERE AT NIH. 1743 01:21:17,720 --> 01:21:22,320 AND WE WILL SEE WHETHER THIS IS 1744 01:21:22,320 --> 01:21:23,400 SUCCESSFUL, COME SEPTEMBER WHEN 1745 01:21:23,400 --> 01:21:25,480 THE PILOT PROJECT IS DONE WE 1746 01:21:25,480 --> 01:21:29,200 DEEM IT TO BE SUCCESSFUL, THUS 1747 01:21:29,200 --> 01:21:30,840 FAR LOOKS LIKE IT'S DOING WELL. 1748 01:21:30,840 --> 01:21:35,880 WE'LL REPEAT IT ON ANNUAL BASIS 1749 01:21:35,880 --> 01:21:37,720 FOR FOUR OR FIVE YEARS WITH THE 1750 01:21:37,720 --> 01:21:39,640 HOPE WE'LL HAVE A CRITICAL MASS 1751 01:21:39,640 --> 01:21:43,600 OF INDIVIDUALS WITH A RIPPLE 1752 01:21:43,600 --> 01:21:46,960 EFFECT ACROSS I.C.s AND NIH. 1753 01:21:46,960 --> 01:21:48,520 IN TERMS OF DISSEMINATING 1754 01:21:48,520 --> 01:21:50,560 EVIDENCE WE STARTED THE 1755 01:21:50,560 --> 01:21:51,280 SCIENTIFIC WORKFORCE DIVERSITY 1756 01:21:51,280 --> 01:21:52,360 SEMINAR SERIES THIS PAST FALL. 1757 01:21:52,360 --> 01:21:55,120 ON TUESDAY OF THIS WEEK, WE HAD 1758 01:21:55,120 --> 01:21:58,360 THE FINAL OFFERING OF THE 21-22 1759 01:21:58,360 --> 01:21:59,760 SEASON, HOW DOES DIVERSITY 1760 01:21:59,760 --> 01:22:00,640 IMPACT SCIENCE. 1761 01:22:00,640 --> 01:22:02,040 WE WERE EXCITED. 1762 01:22:02,040 --> 01:22:04,960 WE HAD MORE THAN 500 PEOPLE WHO 1763 01:22:04,960 --> 01:22:08,560 ACTIVELY ATTENDED THE SESSION. 1764 01:22:08,560 --> 01:22:13,880 WE HAD OUTSTANDING SPEAKERS, DR. 1765 01:22:13,880 --> 01:22:18,600 ISLER GAVE US OPENING REMARKS. 1766 01:22:18,600 --> 01:22:24,960 DOCTORS SMITH-D.O.E.RR, FREEMAN, 1767 01:22:24,960 --> 01:22:25,800 KUAN AND SANTANGELO WITH THE 1768 01:22:25,800 --> 01:22:33,800 IMPACT OF DIVERSITY ON SCIENCE. 1769 01:22:33,800 --> 01:22:39,040 DR. TILGHMAN GAVE CONCLUDING 1770 01:22:39,040 --> 01:22:40,360 REMARKS, SUCH RICHNESS OF 1771 01:22:40,360 --> 01:22:42,520 THOUGHT WE DIDN'T GET TO DELVE 1772 01:22:42,520 --> 01:22:45,280 IN GREAT DEPTH INTO ALL OF THE 1773 01:22:45,280 --> 01:22:47,040 QUESTIONS PUT FORWARD BY THE 1774 01:22:47,040 --> 01:22:49,760 PEOPLE PARTICIPATING BUT WE GOT 1775 01:22:49,760 --> 01:22:55,320 TO TALK AT THE TOP LEVEL, THE 1776 01:22:55,320 --> 01:22:56,880 WAY WE WOULD HAVE LIKED ABOUT 1777 01:22:56,880 --> 01:22:57,960 THEMES AND TAKEAWAY POINTS, WHAT 1778 01:22:57,960 --> 01:22:59,000 ELSE NEEDS TO BE DONE IN THE 1779 01:22:59,000 --> 01:23:00,160 RESEARCH IN THIS AREA. 1780 01:23:00,160 --> 01:23:02,560 SO IT WAS REALLY STIMULATING. 1781 01:23:02,560 --> 01:23:05,400 IF YOU DIDN'T GET A CHANCE TO 1782 01:23:05,400 --> 01:23:07,240 PARTICIPATE, THE VIDEOTAPE AND 1783 01:23:07,240 --> 01:23:10,360 POWERPOINT PRESENTATIONS WILL BE 1784 01:23:10,360 --> 01:23:12,720 ON OUR WEBSITE, IN THE NEXT 1785 01:23:12,720 --> 01:23:13,480 SEVERAL DAYS. 1786 01:23:13,480 --> 01:23:14,440 THERE WILL BE MEETING 1787 01:23:14,440 --> 01:23:16,560 PROCEEDINGS THAT WILL BE POSTED 1788 01:23:16,560 --> 01:23:18,760 SOMETIME THE NEXT MANY WEEKS. 1789 01:23:18,760 --> 01:23:20,720 SO DO TAKE ADVANTAGE OF IT. 1790 01:23:20,720 --> 01:23:25,120 WE WILL BE RESUMING THIS SEMINAR 1791 01:23:25,120 --> 01:23:26,840 SERIES NEXT SEPTEMBER. 1792 01:23:26,840 --> 01:23:31,000 ACTING ON THE EVIDENCE, IT'S 1793 01:23:31,000 --> 01:23:34,160 VERY CLEAR THAT MENTORING IS 1794 01:23:34,160 --> 01:23:35,920 IMPORTANT IN FOSTERING CAREERS 1795 01:23:35,920 --> 01:23:38,920 OF GROUPS THAT DON'T NECESSARILY 1796 01:23:38,920 --> 01:23:42,680 HAVE BUILT-IN SUPPORT NETWORKS. 1797 01:23:42,680 --> 01:23:42,880 WOMEN. 1798 01:23:42,880 --> 01:23:43,240 INDIVIDUALS FROM 1799 01:23:43,240 --> 01:23:43,840 UNDERREPRESENTED RACIAL AND 1800 01:23:43,840 --> 01:23:44,240 ETHNIC GROUPS. 1801 01:23:44,240 --> 01:23:46,640 WHAT WE DID FOR THIS FISCAL YEAR 1802 01:23:46,640 --> 01:23:53,880 IS TO DEVELOP AN ADMINISTRATIVE 1803 01:23:53,880 --> 01:23:55,720 SUPPLEMENT OPPORTUNITY FOR DEIA 1804 01:23:55,720 --> 01:23:57,040 MENTORING, A SUPPLEMENT ALREADY 1805 01:23:57,040 --> 01:24:00,960 FUNDED RESEARCH, WE OPENED TO 1806 01:24:00,960 --> 01:24:03,600 MULTIPLE MECHANISMS, AND WE GOT 1807 01:24:03,600 --> 01:24:04,360 A THOUSAND INQUIRIES. 1808 01:24:04,360 --> 01:24:06,760 WE HAVE ALL SORTS OF R01 1809 01:24:06,760 --> 01:24:08,400 RECIPIENTS TRYING TO CONVINCE US 1810 01:24:08,400 --> 01:24:09,800 THEY QUALIFIED BUT HONESTLY YOU 1811 01:24:09,800 --> 01:24:13,120 EITHER HAD TO HAVE A MENTORING 1812 01:24:13,120 --> 01:24:14,440 OBJECTIVE IN YOUR R01 THAT WAS 1813 01:24:14,440 --> 01:24:16,760 REVIEWED IN THE PEER PANEL, OR 1814 01:24:16,760 --> 01:24:20,800 YOU HAD TO HAVE A PLAN TO 1815 01:24:20,800 --> 01:24:21,560 ENHANCE DIVERSE PERSPECTIVE. 1816 01:24:21,560 --> 01:24:23,880 THERE ARE VERY FEW FOAs THAT 1817 01:24:23,880 --> 01:24:26,720 CALL FOR THAT CURRENTLY, OR HAVE 1818 01:24:26,720 --> 01:24:28,680 AN ACTIVE DIVERSITY SUPPLEMENT 1819 01:24:28,680 --> 01:24:31,520 ASSOCIATED WITH R01. 1820 01:24:31,520 --> 01:24:37,760 LESS THAN 5% OF R01S HAVE 1821 01:24:37,760 --> 01:24:38,760 DIVERSITY SUPPLEMENTS. 1822 01:24:38,760 --> 01:24:40,040 NONETHELESS WE GOT A ROBUST 1823 01:24:40,040 --> 01:24:42,160 RESPONSE, I.C.s ARE REVIEWING 1824 01:24:42,160 --> 01:24:45,200 THESE AND WILL BE SENDING US TOP 1825 01:24:45,200 --> 01:24:46,720 FIVE RECOMMENDATIONS. 1826 01:24:46,720 --> 01:24:56,240 WE WILL PRIORITIZE FUNDING MEANT 1827 01:24:56,240 --> 01:24:58,120 MENTORS WHO WILL ENHANCE, BUT 1828 01:24:58,120 --> 01:24:59,640 WE'RE HOPEFUL SOME I.C.s WILL 1829 01:24:59,640 --> 01:25:01,480 PICK THIS UP. 1830 01:25:01,480 --> 01:25:05,400 ADDITIONALLY WE SEE THIS IS 1831 01:25:05,400 --> 01:25:06,520 RECOGNIZING AN UNMET NEED AND 1832 01:25:06,520 --> 01:25:07,600 ENVISION DOING IT AT LEAST AGAIN 1833 01:25:07,600 --> 01:25:09,000 NEXT YEAR. 1834 01:25:09,000 --> 01:25:12,320 FROM THE NIH UNITE PERSPECTIVE, 1835 01:25:12,320 --> 01:25:14,600 NIH UNITE WAS DEVELOPED WITH THE 1836 01:25:14,600 --> 01:25:20,080 VERY AMBITIOUS GOAL OF ENDING 1837 01:25:20,080 --> 01:25:21,440 STRUCTURAL RACISM GENERATED BY 1838 01:25:21,440 --> 01:25:30,360 THE EVENTS OF 2020 WHERE WE SAW 1839 01:25:30,360 --> 01:25:31,320 DISPROPORTIONATELY MORBIDITY AND 1840 01:25:31,320 --> 01:25:33,520 MORTALITY, FOLLOWED WITH RACIAL 1841 01:25:33,520 --> 01:25:34,840 VIOLENCE, VIDEOTAPED MURDER OF 1842 01:25:34,840 --> 01:25:37,120 GEORGE FLOYD, JUST AFTER IT WAS 1843 01:25:37,120 --> 01:25:39,040 UNVEILED, THE KILLING OF SIX 1844 01:25:39,040 --> 01:25:40,120 ASIAN WOMEN IN GEORGIA. 1845 01:25:40,120 --> 01:25:41,400 WE'VE SEEN MORE IN THE WAY OF 1846 01:25:41,400 --> 01:25:44,920 RACIAL VIOLENCE IN THE LAST MANY 1847 01:25:44,920 --> 01:25:45,480 DAYS. 1848 01:25:45,480 --> 01:25:48,280 NIH UNITE WAS UNVEILED TO 1849 01:25:48,280 --> 01:25:50,760 ADDRESS WHAT WE COULD WITHIN THE 1850 01:25:50,760 --> 01:25:53,040 BIOMEDICAL ECOSYSTEM FOR RACIAL 1851 01:25:53,040 --> 01:25:54,320 AND ETHNIC EQUITY. 1852 01:25:54,320 --> 01:25:58,240 EACH OF THE LETTERS OF UNITE 1853 01:25:58,240 --> 01:25:59,120 REPRESENTS COMMITTEE THAT'S 1854 01:25:59,120 --> 01:26:01,000 INTERACTING WORK STREAMS FOR 1855 01:26:01,000 --> 01:26:01,280 THIS. 1856 01:26:01,280 --> 01:26:03,160 ANOTHER WAY IS ENVISIONING THE 1857 01:26:03,160 --> 01:26:05,240 WAY THAT UNITE IS FOCUSED, SHOWN 1858 01:26:05,240 --> 01:26:08,440 IN THIS GRAPHIC, AGAIN FROM THE 1859 01:26:08,440 --> 01:26:12,040 SAME NATURE MEDICINE COMMENTARY, 1860 01:26:12,040 --> 01:26:21,440 A FOCUS ON HEMATOPOIESIS, -- ON 1861 01:26:21,440 --> 01:26:24,400 HEALTH DISPARITIES, AS WE 1862 01:26:24,400 --> 01:26:25,280 REQUEST INSTITUTIONS TO PAY 1863 01:26:25,280 --> 01:26:26,760 ATTENTION TO HOW THEIR HOUSE IS 1864 01:26:26,760 --> 01:26:28,800 ORDERED AS WELL. 1865 01:26:28,800 --> 01:26:30,760 HIGHLIGHTS, AGAIN, 50,000-FOOT 1866 01:26:30,760 --> 01:26:34,240 LEVEL, IN TERMS OF HEALTH 1867 01:26:34,240 --> 01:26:35,440 DISPARITIES, MINORITY AREA, 1868 01:26:35,440 --> 01:26:39,280 WE'RE COGNIZANT OF DATA THAT 1869 01:26:39,280 --> 01:26:39,960 SHOWS DISPARITIES IN LONGEVITY, 1870 01:26:39,960 --> 01:26:42,040 FOR INSTANCE. 1871 01:26:42,040 --> 01:26:44,520 THESE ARE DATA THAT SHOWS LIFE 1872 01:26:44,520 --> 01:26:46,160 EXPECTANCY FROM 1980 THROUGH TO 1873 01:26:46,160 --> 01:26:50,160 2020 FOR AFRICAN AMERICANS AND 1874 01:26:50,160 --> 01:26:51,040 BLACKS, NON-HISPANIC WHITES, 1875 01:26:51,040 --> 01:26:52,560 LATINOS, EVERYBODY HAD A 1876 01:26:52,560 --> 01:26:54,520 DECREASE IN LONGEVITY WITH THE 1877 01:26:54,520 --> 01:26:56,280 ONSET OF THE COVID PANDEMIC. 1878 01:26:56,280 --> 01:27:00,040 BUT WE KNOW THAT THERE ARE 1879 01:27:00,040 --> 01:27:01,200 PERSISTENT DISADVANTAGES FOR 1880 01:27:01,200 --> 01:27:02,520 AFRICAN AMERICANS AND BLACKS 1881 01:27:02,520 --> 01:27:05,040 RELATIVE TO WHITES, AND THERE 1882 01:27:05,040 --> 01:27:06,800 HAVE BEEN PERSISTENT ADVANTAGES 1883 01:27:06,800 --> 01:27:09,480 FOR LATINOS AND HISPANIC, 1884 01:27:09,480 --> 01:27:11,040 RELATIVE TO WHITES, BUT THE WAY 1885 01:27:11,040 --> 01:27:12,920 THIS HAS DROPPED WITH THE COVID 1886 01:27:12,920 --> 01:27:13,200 PANDEMIC. 1887 01:27:13,200 --> 01:27:14,240 WHAT ARE WE DOING? 1888 01:27:14,240 --> 01:27:16,640 ONE OF THE FIRST THINGS 1889 01:27:16,640 --> 01:27:18,400 ANNOUNCED WAS COMMON FUND 1890 01:27:18,400 --> 01:27:19,520 TRANSFORMATIVE RESEARCH TO 1891 01:27:19,520 --> 01:27:20,920 ADDRESS HEALTH DISPARITIES AND 1892 01:27:20,920 --> 01:27:21,560 ADVANCE HEALTH EQUITY 1893 01:27:21,560 --> 01:27:23,240 OPPORTUNITY, AND AT THE END OF 1894 01:27:23,240 --> 01:27:25,680 FISCAL YEAR 21 COMMITTED UP TO 1895 01:27:25,680 --> 01:27:27,960 $58 MILLION OVER THE COURSE OF 1896 01:27:27,960 --> 01:27:30,200 FIVE YEARS FOR 11 PROJECTS 1897 01:27:30,200 --> 01:27:31,320 ANNOUNCED OFFICIALLY IN OCTOBER. 1898 01:27:31,320 --> 01:27:33,640 SIX OF THOSE WERE LOOKING AT 1899 01:27:33,640 --> 01:27:34,720 THIS TOPIC IN GENERAL. 1900 01:27:34,720 --> 01:27:37,680 FIVE OF THEM WERE LOOKING AT 1901 01:27:37,680 --> 01:27:39,200 THIS TOPIC OF MINORITY-SERVING 1902 01:27:39,200 --> 01:27:41,440 INSTITUTIONS, AND THERE'S BEEN 1903 01:27:41,440 --> 01:27:42,600 FISCAL YEAR 22 COMPETITION 1904 01:27:42,600 --> 01:27:47,640 THAT'S BEEN PROVIDED AS WELL. 1905 01:27:47,640 --> 01:27:48,880 LOOKING FORWARD FISCAL YEAR 23, 1906 01:27:48,880 --> 01:27:51,600 AS A RESULT OF UNITE INITIATIVE, 1907 01:27:51,600 --> 01:27:53,240 CONCEPT OF A COMMUNITY 1908 01:27:53,240 --> 01:27:54,680 PARTNERSHIP TO ADVANCE SCIENCE 1909 01:27:54,680 --> 01:27:56,320 FOR SOCIETY HAS BEEN 1910 01:27:56,320 --> 01:27:58,560 SUCCESSFULLY BROUGHT FORWARD TO 1911 01:27:58,560 --> 01:27:59,800 THE COUNCIL OF COUNCILS. 1912 01:27:59,800 --> 01:28:01,880 YOU CAN SEE MULTIPLE INSTITUTES, 1913 01:28:01,880 --> 01:28:05,160 CENTERS, OFFICES ARE PART OF 1914 01:28:05,160 --> 01:28:05,400 THIS. 1915 01:28:05,400 --> 01:28:09,320 WHAT IS ENVISIONED IS 1916 01:28:09,320 --> 01:28:10,640 COMMUNITY-DRIVEN HEALTH EQUITY 1917 01:28:10,640 --> 01:28:11,520 STRUCTURAL INTERVENTIONS. 1918 01:28:11,520 --> 01:28:13,000 IN OTHER WORDS, LOCAL HEALTH 1919 01:28:13,000 --> 01:28:13,840 EQUITY RESEARCH ASSEMBLIES WHERE 1920 01:28:13,840 --> 01:28:15,680 YOU HAVE PEOPLE ON THE GROUND 1921 01:28:15,680 --> 01:28:17,480 SAYING WHAT IT IS THEY NEED TO 1922 01:28:17,480 --> 01:28:20,280 IMPROVE THE HEALTH OF THEIR 1923 01:28:20,280 --> 01:28:20,960 COMMUNITIES. 1924 01:28:20,960 --> 01:28:22,600 COORDINATION CENTER WORKS WITH 1925 01:28:22,600 --> 01:28:25,920 NATIONAL HEALTH EQUITY RESEARCH 1926 01:28:25,920 --> 01:28:26,360 ASSEMBLY. 1927 01:28:26,360 --> 01:28:26,960 AGAIN, COMMUNITY PEOPLE 1928 01:28:26,960 --> 01:28:30,160 EXPRESSING WHAT THE NEEDS ARE. 1929 01:28:30,160 --> 01:28:32,240 AND THEN HUB AND SPOKE 1930 01:28:32,240 --> 01:28:34,160 ARRANGEMENT OF HEALTH EQUITY 1931 01:28:34,160 --> 01:28:36,520 RESEARCH HUBS WITH SCIENTIFIC 1932 01:28:36,520 --> 01:28:38,680 SUPPORT AND PARTNERSHIPS. 1933 01:28:38,680 --> 01:28:40,600 VERY EXCITING CONCEPT. 1934 01:28:40,600 --> 01:28:43,360 INTENT TO COMMIT 23 TO $52 1935 01:28:43,360 --> 01:28:44,800 MILLION PER YEAR OVER THE COURSE 1936 01:28:44,800 --> 01:28:47,600 OF TEN YEARS WITH THIS BEING A 1937 01:28:47,600 --> 01:28:48,960 FISCAL YEAR 23 INITIATIVE. 1938 01:28:48,960 --> 01:28:53,000 IF YOU WANT TO HEAR MORE YOU CAN 1939 01:28:53,000 --> 01:28:54,880 GO TO THE VIDEOCAST, JANUARY 27 1940 01:28:54,880 --> 01:28:56,280 VIDEOCAST OF THE COUNCIL OF 1941 01:28:56,280 --> 01:28:59,520 COUNCILS PRESENTATION ON THE 1942 01:28:59,520 --> 01:28:59,800 TOPIC. 1943 01:28:59,800 --> 01:29:01,320 A HIGHLIGHT IN TERMS OF WHAT'S 1944 01:29:01,320 --> 01:29:04,560 GOING ON IN THE INTERNAL 1945 01:29:04,560 --> 01:29:05,200 WORKFORCE PERSPECTIVE, SOMETHING 1946 01:29:05,200 --> 01:29:07,280 THAT YOU HOME WILL SEE NEXT 1947 01:29:07,280 --> 01:29:08,560 COUNCIL SESSION, IF COUNCIL 1948 01:29:08,560 --> 01:29:09,680 MEETINGS ARE IN PERSON, IS 1949 01:29:09,680 --> 01:29:12,600 SOMETHING THAT WE CALL THE POWER 1950 01:29:12,600 --> 01:29:13,560 OF INCLUSIVE WORKFORCE 1951 01:29:13,560 --> 01:29:14,480 RECOGNITION PROJECT. 1952 01:29:14,480 --> 01:29:17,760 THIS IS THE BRAINCHILD OF DR. 1953 01:29:17,760 --> 01:29:18,400 JACKSON, DEPICTED HERE SECOND 1954 01:29:18,400 --> 01:29:22,120 FROM THE LEFT ON THE BOTTOM ROW. 1955 01:29:22,120 --> 01:29:25,080 SHE'S AN INTRAMURAL TENURE TRACK 1956 01:29:25,080 --> 01:29:28,160 SCIENTIST AT NIH, AND AS VERY 1957 01:29:28,160 --> 01:29:31,000 ELOQUENTLY STATED IN HER OP ED 1958 01:29:31,000 --> 01:29:32,200 RECENTLY PUBLISHED, SHE TALKS 1959 01:29:32,200 --> 01:29:35,480 ABOUT WALKING THE HALLS OF NIH, 1960 01:29:35,480 --> 01:29:37,680 AND NOT SEEING HERSELF 1961 01:29:37,680 --> 01:29:41,120 REPRESENTED AND HOW THAT LEAVES 1962 01:29:41,120 --> 01:29:43,240 HER FEELING NOT INCLUDED. 1963 01:29:43,240 --> 01:29:44,440 AND YOU'VE BEEN IN BUILDING ONE, 1964 01:29:44,440 --> 01:29:48,400 THIS IS DOWN THE HALL FROM NIH 1965 01:29:48,400 --> 01:29:54,000 DIRECTOR'S OFFICE, THE ONLY BIT 1966 01:29:54,000 --> 01:29:56,320 OF DIVERSITY BEING DR. HEALEY, 1967 01:29:56,320 --> 01:29:57,320 FIRST FEMALE DIRECTOR. 1968 01:29:57,320 --> 01:30:01,000 THIS IS THE CLINICAL CENTER, 1969 01:30:01,000 --> 01:30:02,320 WITHOUT MUCH IN THE WAY OF 1970 01:30:02,320 --> 01:30:03,200 DIVERSITY UNTIL RECENTLY AS YOU 1971 01:30:03,200 --> 01:30:05,960 CAN SEE THIS IS A NEW 1972 01:30:05,960 --> 01:30:07,040 INSTALLATION WITH PEOPLE WEARING 1973 01:30:07,040 --> 01:30:11,360 FACE COVERINGS FOR THE PANDEMIC. 1974 01:30:11,360 --> 01:30:17,320 THIS PROJECT ATTEMPTS TO ADD TO 1975 01:30:17,320 --> 01:30:19,000 VISUALS, TAKING ADVANTAGE OF THE 1976 01:30:19,000 --> 01:30:21,400 GREAT VARIETY OF PEOPLE 1977 01:30:21,400 --> 01:30:23,840 NECESSARY FOR SUCCESS IN THE 1978 01:30:23,840 --> 01:30:26,320 BIOMEDICAL RESEARCH ENTERPRISE, 1979 01:30:26,320 --> 01:30:30,920 SCIENTISTS, NON-SCIENTIST, EARLY 1980 01:30:30,920 --> 01:30:31,800 CAREER PEOPLE, LATE CAREER 1981 01:30:31,800 --> 01:30:33,000 INDIVIDUALS, A VARIETY OF 1982 01:30:33,000 --> 01:30:41,240 TEXTURES AND COLORS TO REPRESENT 1983 01:30:41,240 --> 01:30:42,760 THAT RICHNESS, THIS IS BUILDING 1984 01:30:42,760 --> 01:30:44,360 31, THIS IS JUST OUTSIDE MY 1985 01:30:44,360 --> 01:30:44,600 OFFICE. 1986 01:30:44,600 --> 01:30:47,360 I'M ON THE THIRD FLOOR OF 1987 01:30:47,360 --> 01:30:50,560 BUILDING 1, ABOVE THE NIH 1988 01:30:50,560 --> 01:30:53,200 DIRECTOR OFFICE. 1989 01:30:53,200 --> 01:30:56,760 AS YOU TURN TO THE LEFT, THIS 1990 01:30:56,760 --> 01:30:58,200 LOVELY DISPLAY OF INSTITUTE AND 1991 01:30:58,200 --> 01:31:01,360 CENTER DIRECTORS, I NEED TO TAKE 1992 01:31:01,360 --> 01:31:04,040 A MOMENT TO CREDIT FRANCIS 1993 01:31:04,040 --> 01:31:05,280 COLLINS FOR THIS. 1994 01:31:05,280 --> 01:31:07,160 WHEN I ARRIVED IN 2008 IT WAS 1995 01:31:07,160 --> 01:31:11,800 NOT MUCH VARIETY AMONG THE 1996 01:31:11,800 --> 01:31:13,160 INSTITUTE AND CENTER DIRECTORS. 1997 01:31:13,160 --> 01:31:14,360 FRANCIS STEPPED DOWN IN 1998 01:31:14,360 --> 01:31:14,920 DECEMBER. 1999 01:31:14,920 --> 01:31:17,800 AS OF NOW THERE ARE TEN WOMEN 2000 01:31:17,800 --> 01:31:19,040 INSTITUTE AND CENTER DIRECTORS, 2001 01:31:19,040 --> 01:31:22,800 TWO AFRICAN AMERICANS, TWO 2002 01:31:22,800 --> 01:31:23,600 HISPANIC LATINOS, THREE ASIANS, 2003 01:31:23,600 --> 01:31:25,000 QUITE A BIT OF VARIETY. 2004 01:31:25,000 --> 01:31:26,800 THAT'S AT THE VERY TOP. 2005 01:31:26,800 --> 01:31:28,200 THERE'S A LOT OF WORK TO DO 2006 01:31:28,200 --> 01:31:36,160 BELOW THAT LEVEL AND BEYOND. 2007 01:31:36,160 --> 01:31:37,160 BUT ATTESTATION THERE'S ACTION 2008 01:31:37,160 --> 01:31:38,560 BEHIND THE WORDS. 2009 01:31:38,560 --> 01:31:43,480 ANOTHER EXAMPLE OF THE ACTION IS 2010 01:31:43,480 --> 01:31:47,520 WHAT IS BEING EXPECTED OF 2011 01:31:47,520 --> 01:31:49,960 INSTITUTE AND CENTER DIRECTORS 2012 01:31:49,960 --> 01:31:52,600 THIS FISCAL YEAR, STARTING 2013 01:31:52,600 --> 01:31:54,200 OCTOBER 1, THE PERFORMANCE PLAN, 2014 01:31:54,200 --> 01:31:56,560 THERE'S SOMETHING ABOUT LEADING 2015 01:31:56,560 --> 01:31:57,360 CHANGE, BUSINESS ACUMEN, 2016 01:31:57,360 --> 01:31:59,240 SOMETHING ABOUT LEADING PEOPLE. 2017 01:31:59,240 --> 01:32:02,640 UNDER THE LEADING PEOPLE 2018 01:32:02,640 --> 01:32:04,280 REQUIREMENT THERE'S NOW -- THERE 2019 01:32:04,280 --> 01:32:07,040 ARE EXPECTATIONS IN THE DEIA 2020 01:32:07,040 --> 01:32:07,360 SPACE. 2021 01:32:07,360 --> 01:32:09,480 HHS PUT FORWARD TWO 2022 01:32:09,480 --> 01:32:11,080 EXPECTATIONS, NIH DOUBLED THAT. 2023 01:32:11,080 --> 01:32:12,640 AND AMONG THEM IS THE 2024 01:32:12,640 --> 01:32:16,680 REQUIREMENT OF RACIAL AND ETHNIC 2025 01:32:16,680 --> 01:32:18,600 EQUITY PLAN THAT EVERY INSTITUTE 2026 01:32:18,600 --> 01:32:21,280 AND CENTER WAS TO DEVELOP THIS 2027 01:32:21,280 --> 01:32:22,000 FISCAL YEAR. 2028 01:32:22,000 --> 01:32:23,480 NOT ONLY AN I.C. DIRECTOR'S 2029 01:32:23,480 --> 01:32:28,800 PLAN, IT'S IN EVERY STAFF 2030 01:32:28,800 --> 01:32:30,440 MEMBER'S PLAN, CASCADES DOWN, SO 2031 01:32:30,440 --> 01:32:34,080 THEY CAN DO THINGS TO HELP I.C. 2032 01:32:34,080 --> 01:32:35,240 DIRECTOR BE SUCCESSFUL. 2033 01:32:35,240 --> 01:32:40,080 SO, IN TERMS OF THESE RACIAL AND 2034 01:32:40,080 --> 01:32:41,240 ETHNIC EQUITY PLANS, THE 2035 01:32:41,240 --> 01:32:45,680 EXPECTATION IS I.C.s HAVE DONE 2036 01:32:45,680 --> 01:32:47,320 A CUSTOMIZED PLAN, THEY STEP 2037 01:32:47,320 --> 01:32:49,080 BACK, LOOK AT THEIR ENVIRONMENT, 2038 01:32:49,080 --> 01:32:51,600 WHERE THERE MAY BE INEQUITIES 2039 01:32:51,600 --> 01:32:54,560 AND DEVELOP PLANS, LONG-TERM AND 2040 01:32:54,560 --> 01:32:55,240 SHORT-TERM WITH MEASURES OF 2041 01:32:55,240 --> 01:32:57,320 THINGS THEY WERE GOING TO DO TO 2042 01:32:57,320 --> 01:32:58,720 MAKE A DIFFERENCE. 2043 01:32:58,720 --> 01:33:00,160 THAT THEY WOULD IMPLEMENT THOSE 2044 01:33:00,160 --> 01:33:03,200 THINGS, LOOK AT THE OUTCOMES, 2045 01:33:03,200 --> 01:33:04,520 ANALYZE PROGRESS, LEARN FROM 2046 01:33:04,520 --> 01:33:06,640 THAT, AND LOOK AT REVISING THAT 2047 01:33:06,640 --> 01:33:08,920 ON AN ANNUAL BASIS. 2048 01:33:08,920 --> 01:33:17,360 THIS IS REQUIRED INVESTMENT OF 2049 01:33:17,360 --> 01:33:22,120 TIME, INTELLECTUAL CAPITAL, 2050 01:33:22,120 --> 01:33:22,800 MONEY. 2051 01:33:22,800 --> 01:33:25,120 GUIDANCE WAS GIVEN NOVEMBER 4. 2052 01:33:25,120 --> 01:33:30,720 BETWEEN NOVEMBER 4 AND APRIL 1 2053 01:33:30,720 --> 01:33:32,360 ICs WORKED HARD, ALL SUBMITTED 2054 01:33:32,360 --> 01:33:33,880 BY THE APRIL 1 DEADLINE. 2055 01:33:33,880 --> 01:33:34,720 VERY THOROUGH. 2056 01:33:34,720 --> 01:33:36,280 PEOPLE LEANED IN. 2057 01:33:36,280 --> 01:33:38,200 MY OFFICE ALONG WITH OFFICE OF 2058 01:33:38,200 --> 01:33:39,680 EQUITY, DIVERSITY, AND INCLUSION 2059 01:33:39,680 --> 01:33:41,200 AND HUMAN RESOURCES WAS TASKED 2060 01:33:41,200 --> 01:33:42,760 WITH DOING FIRST LEVEL OF REVIEW 2061 01:33:42,760 --> 01:33:46,600 GIVING FEEDBACK TO THE ACTING 2062 01:33:46,600 --> 01:33:48,320 PRINCIPAL DEPUTY DIRECTOR ABOUT 2063 01:33:48,320 --> 01:33:48,680 THESE. 2064 01:33:48,680 --> 01:33:51,160 WE WERE WERE OVERWHELMED. 2065 01:33:51,160 --> 01:33:53,680 EVERYONE WAS AT LEAST 15 PAGES, 2066 01:33:53,680 --> 01:33:55,240 ON AVERAGE 30 TO 45 PAGES, THERE 2067 01:33:55,240 --> 01:33:56,720 ARE 28 OF THEM, IT TOOK US A 2068 01:33:56,720 --> 01:34:00,360 WHILE BUT WE'VE BEEN ABLE TO GET 2069 01:34:00,360 --> 01:34:01,560 GIVE PRELIMINARY FEEDBACK TO 2070 01:34:01,560 --> 01:34:02,120 PRINCIPAL DEPUTY DIRECTOR. 2071 01:34:02,120 --> 01:34:05,720 WE'RE NOT GOING TO MAKE THIS 2072 01:34:05,720 --> 01:34:06,560 DEADLINE, IT'S ALREADY ALMOST 2073 01:34:06,560 --> 01:34:09,680 THE END OF MAY. 2074 01:34:09,680 --> 01:34:12,080 HOPEFULLY EARLY JUNE, THIS WILL 2075 01:34:12,080 --> 01:34:16,560 GET FORMAL FEEDBACK ABOUT THEIR 2076 01:34:16,560 --> 01:34:17,200 REAPs, INFORMALLY EVERYONE HAS 2077 01:34:17,200 --> 01:34:19,280 DONE A NICE JOB. 2078 01:34:19,280 --> 01:34:20,960 THERE'S SOMETHING CALLED OFFICE 2079 01:34:20,960 --> 01:34:23,400 OF PERSONAL MANAGEMENT MATURITY 2080 01:34:23,400 --> 01:34:24,320 MODEL AGAINST WHICH THEY WERE 2081 01:34:24,320 --> 01:34:25,320 MEASURED. 2082 01:34:25,320 --> 01:34:27,000 LEVEL 1 YOU CHECK THE BOX. 2083 01:34:27,000 --> 01:34:28,480 LEVEL 2, PRETTY GOOD. 2084 01:34:28,480 --> 01:34:29,720 LEVEL 3 VERY WELL DEVELOPED. 2085 01:34:29,720 --> 01:34:32,760 NO ONE JUST MADE A LEVEL 1. 2086 01:34:32,760 --> 01:34:35,080 AND WHAT'S HAPPENING NOW IS 2087 01:34:35,080 --> 01:34:36,720 OFFICE OF GENERAL COUNSEL WAS 2088 01:34:36,720 --> 01:34:40,160 REVIEWING TO MAKE SURE WE DIDN'T 2089 01:34:40,160 --> 01:34:41,240 OVERSTEP LEGAL BOUNDARIES, SO 2090 01:34:41,240 --> 01:34:44,800 THAT WHEN THE I.C. DIRECTORS GET 2091 01:34:44,800 --> 01:34:46,560 FEEDBACK THEY WILL GET A READOUT 2092 01:34:46,560 --> 01:34:50,920 OF WHERE THEY STAND ON THIS OPM 2093 01:34:50,920 --> 01:34:51,400 MODEL. 2094 01:34:51,400 --> 01:34:52,560 THEIR OWN DATA, AND THEN DATA 2095 01:34:52,560 --> 01:34:55,400 FOR THE OTHER I.C.s 2096 01:34:55,400 --> 01:34:56,240 ANONYMIZED, PRETTY COMPETITIVE 2097 01:34:56,240 --> 01:34:57,600 GROUP OF I.C. DIRECTORS WILL BE 2098 01:34:57,600 --> 01:34:59,760 INTERESTING TO SEE HOW THAT 2099 01:34:59,760 --> 01:35:02,880 PLAYS OUT. 2100 01:35:02,880 --> 01:35:04,720 THEY WILL GET A PRESENTATION 2101 01:35:04,720 --> 01:35:06,560 LATE JUNE OF COMMON THEMES AND 2102 01:35:06,560 --> 01:35:09,200 BEST PRACTICES, AND I WILL BE 2103 01:35:09,200 --> 01:35:10,600 MEETING WITH THEM INDIVIDUALLY 2104 01:35:10,600 --> 01:35:12,640 TO SEE WHAT THE BARRIERS AND 2105 01:35:12,640 --> 01:35:14,120 OPPORTUNITIES ARE THAT THEY HAVE 2106 01:35:14,120 --> 01:35:16,760 SEEN HERE. 2107 01:35:16,760 --> 01:35:18,800 I.C.s ARE NONETHELESS GETTING 2108 01:35:18,800 --> 01:35:20,360 STARTED IN MANY BECAUSE BY THE 2109 01:35:20,360 --> 01:35:22,760 END OF THIS FISCAL YEAR THEY ARE 2110 01:35:22,760 --> 01:35:23,960 SUPPOSED TO STEP BACK, SEE WHAT 2111 01:35:23,960 --> 01:35:24,840 THEY HAVE BEEN ABLE TO 2112 01:35:24,840 --> 01:35:28,240 ACCOMPLISH IN THE FEW MONTHS, 2113 01:35:28,240 --> 01:35:32,080 PROJECT FOR THE COMING FISCAL 2114 01:35:32,080 --> 01:35:32,800 YEAR. 2115 01:35:32,800 --> 01:35:34,640 A REALLY EXCITING OPPORTUNITY 2116 01:35:34,640 --> 01:35:36,120 HERE TO MAKE FOR LASTING 2117 01:35:36,120 --> 01:35:38,760 INSTITUTIONAL CULTURAL CHANGE. 2118 01:35:38,760 --> 01:35:42,480 TO MAKE FOR SETTING EQUITY FOR 2119 01:35:42,480 --> 01:35:42,760 ALL. 2120 01:35:42,760 --> 01:35:46,640 AND THEN THE EXTERNAL WORKFORCE, 2121 01:35:46,640 --> 01:35:47,760 WHAT MOST -- OF GREATEST 2122 01:35:47,760 --> 01:35:49,160 INTEREST TO YOU, THOSE THINGS 2123 01:35:49,160 --> 01:35:52,160 WE'RE DOING INTERNALLY CAN BE 2124 01:35:52,160 --> 01:35:54,000 ADOPTED IN OTHER SETTINGS. 2125 01:35:54,000 --> 01:35:56,040 THERE'S THE FACULTY 2126 01:35:56,040 --> 01:35:59,320 INSTITUTIONAL RECRUITMENT FOR 2127 01:35:59,320 --> 01:35:59,880 SUSTAINABLE TRANSFORMATION 2128 01:35:59,880 --> 01:36:01,360 INITIATIVE, TO CREATE CULTURES 2129 01:36:01,360 --> 01:36:01,960 OF INCLUSIVE EXCELLENCE, 2130 01:36:01,960 --> 01:36:04,360 SOMETHING YOU HEAR OVER AND OVER 2131 01:36:04,360 --> 01:36:06,680 AGAIN BUT LITERATURE SHOWS THIS 2132 01:36:06,680 --> 01:36:07,440 MAKES A SIGNIFICANT DIFFERENCE 2133 01:36:07,440 --> 01:36:10,360 IN THE ABILITY TO RECRUIT AND 2134 01:36:10,360 --> 01:36:11,920 RETAIN PEOPLE FROM MULTIPLE 2135 01:36:11,920 --> 01:36:12,440 BACKGROUNDS. 2136 01:36:12,440 --> 01:36:16,520 THIS IS ALSO MODELED AFTER THE 2137 01:36:16,520 --> 01:36:18,360 DISTINGUISHED SCHOLARS PROGRAM. 2138 01:36:18,360 --> 01:36:20,960 WHAT'S HERE IS OPPORTUNITY FOR 2139 01:36:20,960 --> 01:36:22,160 ACADEMIC RESEARCH INSTITUTIONS 2140 01:36:22,160 --> 01:36:24,680 TO DO FACULTY COHORT HIRING. 2141 01:36:24,680 --> 01:36:26,240 AGAIN, THE DATA SHOWS THAT 2142 01:36:26,240 --> 01:36:28,640 BRINGING IN GROUPS OF SCIENTISTS 2143 01:36:28,640 --> 01:36:30,080 AS OPPOSED TO ONE-OFF 2144 01:36:30,080 --> 01:36:32,640 RECRUITMENTS TENDS TO BRING IN 2145 01:36:32,640 --> 01:36:35,440 GREATER DIVERSITY, AND TENDS TO 2146 01:36:35,440 --> 01:36:36,120 HAVE REINFORCING COMMUNITY 2147 01:36:36,120 --> 01:36:37,640 THAT'S SO IMPORTANT FOR 2148 01:36:37,640 --> 01:36:38,640 RETAINING PEOPLE. 2149 01:36:38,640 --> 01:36:40,600 IT ALSO CALLS FOR INSTITUTIONS 2150 01:36:40,600 --> 01:36:47,720 TO DO THEIR OWN ASSESSMENT OF 2151 01:36:47,720 --> 01:36:49,680 WHETHER THERE'S BIAS, EQUITY, 2152 01:36:49,680 --> 01:36:51,760 WORK LIFE ISSUES, AND THE YEAR 2153 01:36:51,760 --> 01:36:53,840 21 SOLICITATION THERE WAS 2154 01:36:53,840 --> 01:36:54,520 OPPORTUNITY FOR COORDINATION AND 2155 01:36:54,520 --> 01:36:55,480 EVALUATION CENTER. 2156 01:36:55,480 --> 01:36:57,560 THIS IS A COMMON FUND 2157 01:36:57,560 --> 01:36:59,200 INITIATIVE, WITH COMMITMENT OF 2158 01:36:59,200 --> 01:37:01,920 UP TO $241 MILLION OVER THE NEXT 2159 01:37:01,920 --> 01:37:05,320 NINE YEARS. 2160 01:37:05,320 --> 01:37:07,640 SO, WITH THE FIRST, NO PUN 2161 01:37:07,640 --> 01:37:10,640 INTENDED, FIRST GROUP OF COHORTS 2162 01:37:10,640 --> 01:37:14,600 WAS FUNDED IN FISCAL YEAR 21 2163 01:37:14,600 --> 01:37:17,080 DOLLARS, HIGH AND LOW RESOURCE 2164 01:37:17,080 --> 01:37:17,640 INSTITUTIONS, COLLABORATION 2165 01:37:17,640 --> 01:37:24,200 BETWEEN BETWEEN TUSKEGEE 2166 01:37:24,200 --> 01:37:27,760 UNIVERSITY AND UNIVERSITY OF 2167 01:37:27,760 --> 01:37:28,600 ALABAMA BIRMINGHAM. 2168 01:37:28,600 --> 01:37:32,720 STAFF ARE LOOKING AT SUMMARY 2169 01:37:32,720 --> 01:37:35,880 STATEMENTS, WE'LL GET A LIST IN 2170 01:37:35,880 --> 01:37:37,280 THE NEAR FUTURE. 2171 01:37:37,280 --> 01:37:38,280 I THINK THE COMPETITION IS 2172 01:37:38,280 --> 01:37:40,000 CLOSED OR MAY BE CLOSED TO 2173 01:37:40,000 --> 01:37:40,280 CLOSING. 2174 01:37:40,280 --> 01:37:45,600 AT THE END OF THIS WE'LL HAVE AT 2175 01:37:45,600 --> 01:37:46,640 LEAST 14 COHORTS, APPROXIMATELY 2176 01:37:46,640 --> 01:37:47,880 140 EARLY CAREER SCIENTISTS WHO 2177 01:37:47,880 --> 01:37:50,720 ARE GOING TO BE SUPPORTED AT 2178 01:37:50,720 --> 01:37:53,520 THESE VARIOUS INSTITUTIONS, 2179 01:37:53,520 --> 01:37:54,920 BECOME SUCCESSFUL SCIENTISTS, TO 2180 01:37:54,920 --> 01:37:57,160 COMPETE SUCCESSFULLY FOR NIH 2181 01:37:57,160 --> 01:37:57,320 FUNDS. 2182 01:37:57,320 --> 01:38:02,160 MORE 2183 01:38:02,160 --> 01:38:03,200 MOREHOUSE WILL TRACK THIS AND 2184 01:38:03,200 --> 01:38:05,160 HELP US FIGURE OUT WHAT ARE 2185 01:38:05,160 --> 01:38:05,800 GENERALIZABLE PRINCIPLES FOR 2186 01:38:05,800 --> 01:38:09,360 THIS THAT COULD BE PUT INTO 2187 01:38:09,360 --> 01:38:10,280 OTHER FUNDING OPPORTUNITY 2188 01:38:10,280 --> 01:38:10,640 ANNOUNCEMENTS. 2189 01:38:10,640 --> 01:38:13,040 I ALLUDED TO THE PLAN TO ENHANCE 2190 01:38:13,040 --> 01:38:13,520 DIVERSE PERSPECTIVES. 2191 01:38:13,520 --> 01:38:14,920 THIS IS SOMETHING THAT WAS 2192 01:38:14,920 --> 01:38:17,040 BROUGHT FORWARD IN MARCH OF 21 2193 01:38:17,040 --> 01:38:19,600 FROM THE NIH-WIDE BRAIN 2194 01:38:19,600 --> 01:38:19,880 INITIATIVE. 2195 01:38:19,880 --> 01:38:22,440 IT LED TO A LOT OF EXCITEMENT 2196 01:38:22,440 --> 01:38:25,080 FOR THOSE INVOLVED WITH NIH AND 2197 01:38:25,080 --> 01:38:27,480 BEYOND BECAUSE FOR THE FIRST 2198 01:38:27,480 --> 01:38:31,760 TIME IT GIVES PEER REVIEWERS THE 2199 01:38:31,760 --> 01:38:32,760 OPPORTUNITY TO CONSIDER 2200 01:38:32,760 --> 01:38:36,160 DIVERSITY OF SCIENTIFIC TEAM AS 2201 01:38:36,160 --> 01:38:37,760 WELL AS SCIENCE WHEN REVIEWING 2202 01:38:37,760 --> 01:38:38,920 BECAUSE IT'S PART OF THE 2203 01:38:38,920 --> 01:38:39,680 SCORING. 2204 01:38:39,680 --> 01:38:41,840 DIVERSITY IS DEFINED BROADLY, 2205 01:38:41,840 --> 01:38:42,920 DIVERSITY OF DISCIPLINE, 2206 01:38:42,920 --> 01:38:46,040 GEOGRAPHY, KEEPING WITH NOTICE 2207 01:38:46,040 --> 01:38:47,560 OF SPECIAL INTEREST. 2208 01:38:47,560 --> 01:38:49,200 AND IT'S BEING RECOMMENDED THAT 2209 01:38:49,200 --> 01:38:52,400 THIS BE IMPLEMENTED FOR MULTIPLE 2210 01:38:52,400 --> 01:38:53,320 OTHER FUNDING OPPORTUNITY 2211 01:38:53,320 --> 01:38:57,400 ANNOUNCEMENTS. 2212 01:38:57,400 --> 01:39:01,760 NATIONAL INSTITUTE OF GENERAL 2213 01:39:01,760 --> 01:39:02,720 MEDICAL SCIENCE IS AGGRESSIVE AS 2214 01:39:02,720 --> 01:39:04,280 ARE OTHERS. 2215 01:39:04,280 --> 01:39:06,800 WE HAVE PLANS FOR EVALUATION, AS 2216 01:39:06,800 --> 01:39:09,640 THE DIRECTOR OF THE CENTER FOR 2217 01:39:09,640 --> 01:39:11,200 SCIENTIFIC REVIEW POINTS OUT WE 2218 01:39:11,200 --> 01:39:13,600 NEED TO SEE WHETHER HUMAN 2219 01:39:13,600 --> 01:39:16,400 BEHAVIOR OR HOW HUMANS WILL 2220 01:39:16,400 --> 01:39:18,040 BEHAVE WITH THIS CRITERION, SHE 2221 01:39:18,040 --> 01:39:20,160 ASKS THE QUESTION WILL A NOBEL 2222 01:39:20,160 --> 01:39:22,760 LAUREATE WHO DOESN'T DO AS WELL 2223 01:39:22,760 --> 01:39:27,280 WITH THE PEDP BUT OTHERWISE HAS 2224 01:39:27,280 --> 01:39:33,400 EQUIVALENT, A NON-NOBEL 2225 01:39:33,400 --> 01:39:35,240 LAUREATE, WHO WILL GET THE 2226 01:39:35,240 --> 01:39:35,560 BETTER SCORE? 2227 01:39:35,560 --> 01:39:38,760 ALSO COMING FROM UNITE. 2228 01:39:38,760 --> 01:39:39,400 OTHER THINGS ONGOING, SOMETIMES 2229 01:39:39,400 --> 01:39:41,400 HARD TO KEEP UP EVEN THOUGH I'M 2230 01:39:41,400 --> 01:39:43,640 A CO-LEADER OF THIS INITIATIVE. 2231 01:39:43,640 --> 01:39:45,560 THERE'S SOMETHING CALLED THE 2232 01:39:45,560 --> 01:39:46,640 SCIENCE EDUCATION PARTNERSHIP 2233 01:39:46,640 --> 01:39:48,520 AWARD PROGRAM, THAT HAS WILL BE 2234 01:39:48,520 --> 01:39:50,600 LED BY NATIONAL INSTITUTE OF 2235 01:39:50,600 --> 01:39:52,640 GENERAL MEDICAL SCIENCES, IT'S 2236 01:39:52,640 --> 01:39:57,560 AN OPPORTUNITY TO DO OUTREACH TO 2237 01:39:57,560 --> 01:40:02,840 K-12 STUDENTS TO GIVE THEM MORE 2238 01:40:02,840 --> 01:40:05,680 EXPOSURE TO STEM. 2239 01:40:05,680 --> 01:40:07,640 WE KNOW K-12 POPULATION IS 2240 01:40:07,640 --> 01:40:09,160 DIVERSE, AS COMPARED TO 2241 01:40:09,160 --> 01:40:10,800 POPULATION GETTING R01 GRANTS IN 2242 01:40:10,800 --> 01:40:11,160 NIH. 2243 01:40:11,160 --> 01:40:12,160 SCIENCE IDENTITY IS OFTEN IN 2244 01:40:12,160 --> 01:40:14,640 PLACE BY MIDDLE SCHOOL. 2245 01:40:14,640 --> 01:40:17,600 SO THE VALUE OF DOING MORE OF 2246 01:40:17,600 --> 01:40:19,600 THIS WAS SUGGESTED. 2247 01:40:19,600 --> 01:40:23,760 AND WE NOW HAVE ABOUT 17 2248 01:40:23,760 --> 01:40:24,640 INSTITUTES, CENTERS, AND OFFICES 2249 01:40:24,640 --> 01:40:29,200 WHO SIGNED ON TO THIS 2250 01:40:29,200 --> 01:40:30,160 INITIATIVE. 2251 01:40:30,160 --> 01:40:33,680 WE ALSO HAVE FOAs AND PRIZEs 2252 01:40:33,680 --> 01:40:35,320 UNDER DEVELOPMENT. 2253 01:40:35,320 --> 01:40:37,200 THERE'S AN FOA FOR CLIMATE 2254 01:40:37,200 --> 01:40:38,640 SELF-STUDIES, INITIAL FUNDS TO 2255 01:40:38,640 --> 01:40:40,360 HELP ADDRESS THINGS IDENTIFIED 2256 01:40:40,360 --> 01:40:40,800 UNDER DEVELOPMENT. 2257 01:40:40,800 --> 01:40:45,080 I LIKE TO THINK OF IT AS FIRST 2258 01:40:45,080 --> 01:40:45,440 LIGHT. 2259 01:40:45,440 --> 01:40:47,600 THERE IS UNDERDEVELOPMENT OF 2260 01:40:47,600 --> 01:40:49,360 STRUCTURED INSTITUTIONAL NEEDS 2261 01:40:49,360 --> 01:40:51,320 ASSESSMENT, ACTION PLAN, 2262 01:40:51,320 --> 01:40:52,800 DEVELOPMENT GRANTS FOR 2263 01:40:52,800 --> 01:40:55,160 MINORITY-SERVING INSTITUTIONS. 2264 01:40:55,160 --> 01:40:57,560 THERE IS UNDER DEVELOPMENT 2265 01:40:57,560 --> 01:41:00,960 INSTRUMENTATION GRANT FOR 2266 01:41:00,960 --> 01:41:03,080 MINORITY-SERVING INSTITUTIONS. 2267 01:41:03,080 --> 01:41:03,680 EXPANSION OF ADMINISTRATIVE 2268 01:41:03,680 --> 01:41:07,880 SERVICES AND ACTIVITIES PROGRAM 2269 01:41:07,880 --> 01:41:10,120 IN BUILD FOR MINORITY-SERVING 2270 01:41:10,120 --> 01:41:11,680 INSTITUTIONS, EXCELLENCE IN 2271 01:41:11,680 --> 01:41:12,960 D.E.I. INVESTIGATOR AWARD UNDER 2272 01:41:12,960 --> 01:41:13,560 DEVELOPMENT. 2273 01:41:13,560 --> 01:41:15,760 THIS IS DIFFERENT FROM THE 2274 01:41:15,760 --> 01:41:16,520 ADMINISTRATIVE SUPPLEMENT MY 2275 01:41:16,520 --> 01:41:17,960 OFFICE HAS OFFERED BECAUSE THIS 2276 01:41:17,960 --> 01:41:22,000 IS GOING TO BE A DE NOVO 2277 01:41:22,000 --> 01:41:23,560 COMPETITIVE GRANT THAT PEOPLE 2278 01:41:23,560 --> 01:41:25,440 CAN APPLY FOR WHETHER YOU'VE HAD 2279 01:41:25,440 --> 01:41:27,280 NIH FUNDING OR NOT. 2280 01:41:27,280 --> 01:41:28,000 THE ADMINISTRATIVE SUPPLEMENT 2281 01:41:28,000 --> 01:41:30,760 YOU HAVE TO ALREADY HAVE NIH 2282 01:41:30,760 --> 01:41:31,000 FUNDING. 2283 01:41:31,000 --> 01:41:34,360 BUT ALL OF THESE WERE PRESENTED 2284 01:41:34,360 --> 01:41:35,240 AT DECEMBER 10 ADVISORY 2285 01:41:35,240 --> 01:41:38,320 COMMITTEE TO THE DIRECTOR 2286 01:41:38,320 --> 01:41:38,880 MEETING. 2287 01:41:38,880 --> 01:41:39,280 IN CONCEPT. 2288 01:41:39,280 --> 01:41:41,480 AND THEY ARE ALL UNDER 2289 01:41:41,480 --> 01:41:41,760 DEVELOPMENT. 2290 01:41:41,760 --> 01:41:43,040 ANOTHER THING THAT WAS 2291 01:41:43,040 --> 01:41:46,000 PRESENTED, THAT IS WELL 2292 01:41:46,000 --> 01:41:48,720 UNDERWAY, IS A PRIZE COMPETITION 2293 01:41:48,720 --> 01:41:49,360 FOR INSTITUTIONAL EXCELLENCE AND 2294 01:41:49,360 --> 01:41:51,760 DIVERSITY, EQUITY, AND INCLUSION 2295 01:41:51,760 --> 01:41:52,560 AND ACCESSIBILITY. 2296 01:41:52,560 --> 01:41:53,080 AGAIN, DEIA. 2297 01:41:53,080 --> 01:41:55,120 MY TEAM IS TAKING THE LEAD ON 2298 01:41:55,120 --> 01:41:58,240 THIS ON BEHALF OF THE UNITE E 2299 01:41:58,240 --> 01:41:59,440 COMMITTEE AND ALL OF NIH. 2300 01:41:59,440 --> 01:42:01,280 WE HAVE MORE THAN HALF THE 2301 01:42:01,280 --> 01:42:02,040 INSTITUTES AND CENTERS WHO 2302 01:42:02,040 --> 01:42:05,560 SIGNED ON TO BE PARTNERS IN 2303 01:42:05,560 --> 01:42:05,760 THIS. 2304 01:42:05,760 --> 01:42:10,840 THE INTENT HERE IS TO 2305 01:42:10,840 --> 01:42:12,280 ACKNOWLEDGE TRANSFORMATIVE 2306 01:42:12,280 --> 01:42:14,040 CULTURES AND PROCESSES THAT HAVE 2307 01:42:14,040 --> 01:42:15,560 BEEN DEVELOPED TO ACHIEVE 2308 01:42:15,560 --> 01:42:16,880 INCLUSIVE EXCELLENCE. 2309 01:42:16,880 --> 01:42:18,720 AND TO HIGHLIGHT PRACTICES THAT 2310 01:42:18,720 --> 01:42:20,720 HAVE RESULTED IN MEASURABLE 2311 01:42:20,720 --> 01:42:22,200 CHANGE AND CREATED MORE 2312 01:42:22,200 --> 01:42:23,760 INCLUSIVE ENVIRONMENT FOR 2313 01:42:23,760 --> 01:42:25,080 STUDENTS AND FACULTY. 2314 01:42:25,080 --> 01:42:27,480 WE CURRENTLY HAVE AN RFI THAT'S 2315 01:42:27,480 --> 01:42:28,240 OUT. 2316 01:42:28,240 --> 01:42:30,640 AND REALLY SEEK YOUR INPUT 2317 01:42:30,640 --> 01:42:32,280 RELATIVE TO THE STRUCTURE OF THE 2318 01:42:32,280 --> 01:42:33,400 COMPETITION. 2319 01:42:33,400 --> 01:42:35,680 HOW WE SHOULD GO ABOUT OUTREACH, 2320 01:42:35,680 --> 01:42:37,840 JUDGING, TIMING, HOW WE SHOULD 2321 01:42:37,840 --> 01:42:38,640 DISSEMINATE WINNING SUBMISSIONS 2322 01:42:38,640 --> 01:42:41,240 AND WHAT ARE POTENTIAL BARRIERS 2323 01:42:41,240 --> 01:42:46,880 FOR INDIVIDUALS OR ORGANIZATIONS 2324 01:42:46,880 --> 01:42:48,320 TO APPLY. 2325 01:42:48,320 --> 01:42:51,120 DEADLINE IS JULY 28. 2326 01:42:51,120 --> 01:42:53,960 AND PRESUME WE GO CAN QUICKLY 2327 01:42:53,960 --> 01:42:57,920 PROCESS THAT INPUT, WE'RE 2328 01:42:57,920 --> 01:42:59,880 LOOKING TO POTENTIALLY ANNOUNCE 2329 01:42:59,880 --> 01:43:00,880 PRIZE COMPETITION FOR FISCAL 2330 01:43:00,880 --> 01:43:02,160 YEAR 23. 2331 01:43:02,160 --> 01:43:05,160 AS I SAID, THIS IS 50,000-FOOT 2332 01:43:05,160 --> 01:43:06,800 LEVEL, THERE'S A LOT MORE GOING 2333 01:43:06,800 --> 01:43:07,120 ON. 2334 01:43:07,120 --> 01:43:10,640 I WOULD ENCOURAGE YOU TO TAKE A 2335 01:43:10,640 --> 01:43:19,040 LOOK AGAIN URL IS NIH.GOV, 2336 01:43:19,040 --> 01:43:24,120 ENDING STRUCTURAL RACISM, OR 2337 01:43:24,120 --> 01:43:29,320 GOOGLE NIH UNITE. 2338 01:43:29,320 --> 01:43:31,280 WATCH THE MEETING ON FRIDAY JUNE 2339 01:43:31,280 --> 01:43:32,760 10, WHAT'S PROJECTED FOR THE 2340 01:43:32,760 --> 01:43:35,040 NEXT SIX MONTHS. 2341 01:43:35,040 --> 01:43:40,760 I WILL CLOSE WITH OUR FAVORITE 2342 01:43:40,760 --> 01:43:41,800 ADAGE. 2343 01:43:41,800 --> 01:43:43,320 GREAT MINDS THINK DIFFERENTLY. 2344 01:43:43,320 --> 01:43:45,880 THANK YOU. 2345 01:43:45,880 --> 01:43:48,240 >> THANK YOU SO MUCH, DR. 2346 01:43:48,240 --> 01:43:48,440 BERNARD. 2347 01:43:48,440 --> 01:43:50,160 THAT WAS A GREAT PRESENTATION, 2348 01:43:50,160 --> 01:43:52,480 FULL OF A LOT OF INFORMATION. 2349 01:43:52,480 --> 01:44:02,960 I WANTED TO ADD A FEW THINGS 2350 01:44:08,560 --> 01:44:10,120 THAT ERIC AND PENNY AND TEAM, 2351 01:44:10,120 --> 01:44:16,640 AND WE ALSO CORRECTED TO THE 2352 01:44:16,640 --> 01:44:17,280 FIRST INITIATIVE. 2353 01:44:17,280 --> 01:44:18,200 WE'RE ALSO GOING TO SUPPORT 2354 01:44:18,200 --> 01:44:20,960 IDEAS AROUND THIS AS WELL. 2355 01:44:20,960 --> 01:44:22,800 A LOT OF THINGS WE'RE LEARNING 2356 01:44:22,800 --> 01:44:25,280 FROM WHAT DR. BERNARD AND THE 2357 01:44:25,280 --> 01:44:26,880 UNITE TEAM IS DOING, I THINK 2358 01:44:26,880 --> 01:44:28,880 IT'S BEEN REALLY A WONDERFUL 2359 01:44:28,880 --> 01:44:32,120 INTERCHANGE ACROSS THE I.C.s 2360 01:44:32,120 --> 01:44:33,720 OF SEEING WHAT OTHERS ARE DOING, 2361 01:44:33,720 --> 01:44:35,240 WHAT WE CAN DO TOGETHER AND WHAT 2362 01:44:35,240 --> 01:44:36,640 WE CAN ADOPT AS WELL. 2363 01:44:36,640 --> 01:44:42,360 THANK YOU FOR THAT PRESENTATION. 2364 01:44:42,360 --> 01:44:43,560 I WOULD LIKE TO TURN IT OVER TO 2365 01:44:43,560 --> 01:44:46,600 THE COUNCIL FOR ANY COMMENTS OR 2366 01:44:46,600 --> 01:44:46,880 DISCUSSION. 2367 01:44:46,880 --> 01:44:48,200 ANY QUESTIONS, PLEASE USE YOUR 2368 01:44:48,200 --> 01:44:49,720 RAISE HAND FUNCTION OR JUST GO 2369 01:44:49,720 --> 01:44:52,560 AHEAD AND ENTER IT INTO THE 2370 01:44:52,560 --> 01:45:02,600 COMMENTS SECTION. 2371 01:45:02,600 --> 01:45:03,920 PAUL HARRIS, YES, PLEASE. 2372 01:45:03,920 --> 01:45:05,760 >> DR. BERNARD, THANK YOU SO 2373 01:45:05,760 --> 01:45:06,120 MUCH. 2374 01:45:06,120 --> 01:45:08,640 THAT WAS REALLY AN INTERESTING 2375 01:45:08,640 --> 01:45:09,600 OVERVIEW. 2376 01:45:09,600 --> 01:45:11,040 MY QUESTION IS WHAT HAS 2377 01:45:11,040 --> 01:45:13,920 SURPRISED YOU THE MOST IN YOUR 2378 01:45:13,920 --> 01:45:15,640 WORK OVER THE LAST YEAR AND A 2379 01:45:15,640 --> 01:45:15,840 HALF? 2380 01:45:15,840 --> 01:45:16,760 AND MY SECOND QUESTION, WHAT 2381 01:45:16,760 --> 01:45:20,360 KEEPS YOU UP AT NIGHT? 2382 01:45:20,360 --> 01:45:22,000 >> OH, WONDERFUL. 2383 01:45:22,000 --> 01:45:25,760 SO, THE THING THAT HAS SURPRISED 2384 01:45:25,760 --> 01:45:29,080 ME HAS BEEN HOW MUCH MOMENTUM 2385 01:45:29,080 --> 01:45:31,280 THERE IS. 2386 01:45:31,280 --> 01:45:32,880 WE HAD THE SERIES OF DIRECTOR 2387 01:45:32,880 --> 01:45:35,440 MEETINGS IN THE SUMMER OF 2020 2388 01:45:35,440 --> 01:45:37,640 THAT LED TO INTERNALLY UNVEILING 2389 01:45:37,640 --> 01:45:39,720 UNITE AND LATER EXTERNALLY 2390 01:45:39,720 --> 01:45:40,480 UNVEILING IT. 2391 01:45:40,480 --> 01:45:42,000 YOU HAD THAT ALIGNMENT FROM THE 2392 01:45:42,000 --> 01:45:42,680 UPPER LEADERSHIP. 2393 01:45:42,680 --> 01:45:44,640 BUT YOU HAVE SO MANY STAFF 2394 01:45:44,640 --> 01:45:46,280 MEMBERS WHO ARE FULLY ENGAGED IN 2395 01:45:46,280 --> 01:45:48,000 THE LINE. 2396 01:45:48,000 --> 01:45:49,560 UNITE ITSELF HAS ABOUT 85 2397 01:45:49,560 --> 01:45:51,520 VOLUNTEERS INVOLVED WITH IT. 2398 01:45:51,520 --> 01:45:54,920 WE HAVE THE SUBCOMMITTEE FOR 2399 01:45:54,920 --> 01:45:58,760 UNITE, CALLING THE ANTI-RACISM 2400 01:45:58,760 --> 01:45:59,400 STEERING COMMITTEE, MORE THAN 2401 01:45:59,400 --> 01:45:59,880 500 MEMBERS. 2402 01:45:59,880 --> 01:46:00,640 PEOPLE ARE EXCITED. 2403 01:46:00,640 --> 01:46:02,840 THEY FEEL THIS IS A SPECIAL 2404 01:46:02,840 --> 01:46:08,280 TIME, THAT CHANGE CAN BE MADE. 2405 01:46:08,280 --> 01:46:09,920 THEN WE HAVE EXECUTIVE OFFERED. 2406 01:46:09,920 --> 01:46:10,800 THE BIDEN ADMINISTRATION PUT 2407 01:46:10,800 --> 01:46:12,000 THROUGH A LOT OF THESE EXECUTIVE 2408 01:46:12,000 --> 01:46:15,680 ORDERS TO HAVE US FOCUS IN THIS 2409 01:46:15,680 --> 01:46:16,680 DIRECTION. 2410 01:46:16,680 --> 01:46:17,800 EVERYTHING IS ALIGNED. 2411 01:46:17,800 --> 01:46:19,480 AND I THINK WE'RE -- I HEAR FROM 2412 01:46:19,480 --> 01:46:22,400 PEOPLE WHO HAVE BEEN AT NIH MUCH 2413 01:46:22,400 --> 01:46:24,400 LONGER THAN ME, THAT THIS IS 2414 01:46:24,400 --> 01:46:25,920 JUST DIFFERENT. 2415 01:46:25,920 --> 01:46:27,680 IT'S NEVER BEEN AS FOCUSED. 2416 01:46:27,680 --> 01:46:32,000 WHAT KEEPS ME UP AT NIGHT? 2417 01:46:32,000 --> 01:46:33,040 IT'S A WONDERFUL MOMENTUM. 2418 01:46:33,040 --> 01:46:35,840 CAN WE KEEP IT UP? 2419 01:46:35,840 --> 01:46:37,680 WILL THINGS HAPPEN IN THE 2420 01:46:37,680 --> 01:46:38,840 FUTURE, SINCE WE'RE PART OF THE 2421 01:46:38,840 --> 01:46:42,680 EXECUTIVE BRANCH THAT MIGHT SLOW 2422 01:46:42,680 --> 01:46:42,960 THINGS DOWN? 2423 01:46:42,960 --> 01:46:45,080 BUT MY VIEW OF IT IS WE TAKE 2424 01:46:45,080 --> 01:46:46,840 ADVANTAGE OF OPPORTUNITIES AS 2425 01:46:46,840 --> 01:46:48,720 THEY ARE. 2426 01:46:48,720 --> 01:46:50,240 AND THE REASON THAT I THINK 2427 01:46:50,240 --> 01:46:51,320 ANY -- MOST OF WHAT WE'RE DOING 2428 01:46:51,320 --> 01:46:53,760 IS GOING TO BE REALLY ENDURING 2429 01:46:53,760 --> 01:46:57,640 IS WE'RE LOOKING IN AN 2430 01:46:57,640 --> 01:47:01,480 EVIDENCE-BASED FASHION, LOOKING 2431 01:47:01,480 --> 01:47:03,200 ACROSS LANDSCAPE, MAKING IT AN 2432 01:47:03,200 --> 01:47:04,120 EQUITABLE AND WELCOMING 2433 01:47:04,120 --> 01:47:04,760 ENVIRONMENT FOR ALL. 2434 01:47:04,760 --> 01:47:06,080 WE KNOW THAT THIS IS GOING TO 2435 01:47:06,080 --> 01:47:07,640 MAKE DIFFERENCE IN THE QUALITY 2436 01:47:07,640 --> 01:47:12,000 OF THE SCIENCE. 2437 01:47:12,000 --> 01:47:16,280 SO, EVEN OUR WORRY, MY WORRY IS 2438 01:47:16,280 --> 01:47:17,400 ALLEVIATED BY BEING AWARE OF 2439 01:47:17,400 --> 01:47:19,960 THOSE THINGS. 2440 01:47:19,960 --> 01:47:23,560 2441 01:47:23,560 --> 01:47:26,760 2442 01:47:26,760 --> 01:47:27,040 >> MATIAS. 2443 01:47:27,040 --> 01:47:29,280 >> IT'S INSPIRING TO SEE THE 2444 01:47:29,280 --> 01:47:29,920 ACTIVITIES. 2445 01:47:29,920 --> 01:47:33,000 THEY ARE NEEDED, AS OUR SOCIETY 2446 01:47:33,000 --> 01:47:34,840 IS SO POLARIZED AND IN NEED OF 2447 01:47:34,840 --> 01:47:35,080 HEALING. 2448 01:47:35,080 --> 01:47:40,800 WE AS ONE OF THE FEW REMAINING 2449 01:47:40,800 --> 01:47:42,200 INSTITUTIONS HAVE TO PLAY THAT 2450 01:47:42,200 --> 01:47:42,960 ROLE GOING FORWARD. 2451 01:47:42,960 --> 01:47:46,280 AS YOU CAN HEAR FROM MY ACCENT, 2452 01:47:46,280 --> 01:47:49,080 I'M A RECENT IMMIGRANT. 2453 01:47:49,080 --> 01:47:52,040 THAT'S ANOTHER REASON I FEEL 2454 01:47:52,040 --> 01:47:52,680 STRONGLY. 2455 01:47:52,680 --> 01:47:55,000 I'M HAPPY TO BE INCLUDED IN THE 2456 01:47:55,000 --> 01:47:56,880 OVERALL INCLUSION EFFORT. 2457 01:47:56,880 --> 01:48:00,240 YES, WE'RE VERY UNIQUE MODEL, 2458 01:48:00,240 --> 01:48:02,960 WHAT HUMANKIND CAN BE ON THIS 2459 01:48:02,960 --> 01:48:04,400 PLANET. 2460 01:48:04,400 --> 01:48:07,480 AND BUILDING FORWARD, 2461 01:48:07,480 --> 01:48:08,360 RECOGNIZING THE URGENT NEEDS 2462 01:48:08,360 --> 01:48:09,560 WE'VE FALLEN SHORT OF THESE 2463 01:48:09,560 --> 01:48:10,960 PROMISES PARTICULARLY TO PEOPLE 2464 01:48:10,960 --> 01:48:13,160 INSIDE THIS COUNTRY BUT ALSO 2465 01:48:13,160 --> 01:48:16,640 GLOBALLY I THINK IS REQUIRED. 2466 01:48:16,640 --> 01:48:18,640 I SHARE YOUR CONCERN 2467 01:48:18,640 --> 01:48:21,920 SIGNIFICANTLY AND IF WE MANAGE 2468 01:48:21,920 --> 01:48:26,720 TO INSULATE THIS ACTIVITY FROM 2469 01:48:26,720 --> 01:48:29,040 THE ENVIRONMENT, I THINK 2470 01:48:29,040 --> 01:48:31,360 WHEREVER POSSIBLE, THE IMPACT 2471 01:48:31,360 --> 01:48:32,760 CAN BE SUSTAINED AND LASTING 2472 01:48:32,760 --> 01:48:35,160 WHICH IT NEEDS TO BE. 2473 01:48:35,160 --> 01:48:39,040 IT'S EXCITING TO SEE THAT ON SO 2474 01:48:39,040 --> 01:48:41,840 MANY FACETS, MOVING FORWARD. 2475 01:48:41,840 --> 01:48:45,360 AND WE CAN HELP AND FACILITATE 2476 01:48:45,360 --> 01:48:47,560 EFFORTS AND OUR AMERICAN SOCIETY 2477 01:48:47,560 --> 01:48:48,840 OF NEPHROLOGY RELEASED TWO DAYS 2478 01:48:48,840 --> 01:48:51,280 AGO ACTUALLY A PLEA TO ALL OF US 2479 01:48:51,280 --> 01:48:54,680 IN THIS COMMUNITY WHICH HAS A 2480 01:48:54,680 --> 01:48:58,200 BROAD OUTREACH INTO REALLY A LOT 2481 01:48:58,200 --> 01:49:02,280 OF UNDERSERVED POPULATIONS, 2482 01:49:02,280 --> 01:49:04,200 IRRESPECTIVE OF RACE, TO TAKE 2483 01:49:04,200 --> 01:49:06,120 THE EFFORT FROM FEDERAL, REGION, 2484 01:49:06,120 --> 01:49:08,600 LOCAL LEVELS, I WAS HAPPY TO SEE 2485 01:49:08,600 --> 01:49:10,000 HAVE YOU VERY STRONG STEM 2486 01:49:10,000 --> 01:49:11,800 EFFORTS IN PLACE HERE AS WELL 2487 01:49:11,800 --> 01:49:15,960 BECAUSE THAT'S I THINK URGENTLY 2488 01:49:15,960 --> 01:49:16,400 NEEDED. 2489 01:49:16,400 --> 01:49:17,200 THANKS SO MUCH. 2490 01:49:17,200 --> 01:49:19,840 >> THANK YOU. 2491 01:49:19,840 --> 01:49:22,640 2492 01:49:22,640 --> 01:49:26,720 ANY OTHER COMMENTS OR QUESTIONS? 2493 01:49:26,720 --> 01:49:30,360 FOR MARIE? 2494 01:49:30,360 --> 01:49:32,480 2495 01:49:32,480 --> 01:49:33,560 >> I WILL SAY TOO THERE WERE A 2496 01:49:33,560 --> 01:49:37,800 FEW COMMENTS IN THE CHAT BOX, 2497 01:49:37,800 --> 01:49:48,280 MARIE, THANKING YOU FOR THE 2498 01:49:51,400 --> 01:49:52,480 OVERVIEW AND ACROSS DEIA. 2499 01:49:52,480 --> 01:49:54,920 >> IT TAKES A TEAM, WE HAVE A 2500 01:49:54,920 --> 01:49:58,600 BIG TEAM, THANK YOU. 2501 01:49:58,600 --> 01:50:00,360 2502 01:50:00,360 --> 01:50:04,720 >> THANKS, BECKY. 2503 01:50:04,720 --> 01:50:06,080 >> A FOLLOW-UP COMMENT. 2504 01:50:06,080 --> 01:50:07,800 I CAN'T TURN MY CAMERA ON 2505 01:50:07,800 --> 01:50:09,320 BECAUSE IT'S BROKEN SO I'LL BE 2506 01:50:09,320 --> 01:50:11,560 INVISIBLE BUT ABLE TO TALK. 2507 01:50:11,560 --> 01:50:13,800 YOU KNOW, THIS IS ONE OF MANY 2508 01:50:13,800 --> 01:50:17,320 TIMES I'VE HEARD YOU SPEAK, AND 2509 01:50:17,320 --> 01:50:18,760 EACH TIME I GET EXCITED. 2510 01:50:18,760 --> 01:50:21,360 I THINK THE MOST IMPRESSIVE PART 2511 01:50:21,360 --> 01:50:25,400 OF MANY OF THESE PROGRAMS IS 2512 01:50:25,400 --> 01:50:27,360 REALLY PUTTING THAT SCIENTIFIC 2513 01:50:27,360 --> 01:50:29,680 PERSPECTIVE OF ACTUALLY STUDYING 2514 01:50:29,680 --> 01:50:30,720 WHAT'S EFFECTIVE. 2515 01:50:30,720 --> 01:50:33,200 AND SOMETIMES WE HAVE MANY GOOD 2516 01:50:33,200 --> 01:50:34,160 INTENTIONS BUT WE ACTUALLY DON'T 2517 01:50:34,160 --> 01:50:38,440 KNOW IF THOSE ARE MAKING A 2518 01:50:38,440 --> 01:50:39,120 SUBSTANTIAL DIFFERENCE, MOST 2519 01:50:39,120 --> 01:50:40,960 EFFECTIVE AND EFFICIENT, HAVE 2520 01:50:40,960 --> 01:50:42,920 THE HIGHEST QUALITY, ENGAGE THE 2521 01:50:42,920 --> 01:50:43,720 BROADEST COMMUNITY. 2522 01:50:43,720 --> 01:50:46,960 I COMMEND YOUR GROUP AND WOULD 2523 01:50:46,960 --> 01:50:49,400 ENCOURAGE YOU TO CONTINUE VERY 2524 01:50:49,400 --> 01:50:54,400 MUCH IN THAT NCATS APPROACH TO 2525 01:50:54,400 --> 01:50:55,000 EMBED THAT SCIENTIFIC 2526 01:50:55,000 --> 01:50:56,600 TRANSLATIONAL SCIENCE METHOD. 2527 01:50:56,600 --> 01:50:59,040 BUT HERE TAKING IT AROUND THAT, 2528 01:50:59,040 --> 01:51:02,520 THAT BROADER AREA OF DEIA, 2529 01:51:02,520 --> 01:51:05,560 BECAUSE I THINK THAT THAT WILL 2530 01:51:05,560 --> 01:51:06,760 REALLY FACILITATE US 2531 01:51:06,760 --> 01:51:07,320 UNDERSTANDING IN WHAT 2532 01:51:07,320 --> 01:51:09,200 SITUATIONS, WHAT'S THE BEST WAY 2533 01:51:09,200 --> 01:51:12,480 TO APPROACH, HOW DO WE REALLY DO 2534 01:51:12,480 --> 01:51:15,200 THIS IN A -- YOU KNOW, TAKING 2535 01:51:15,200 --> 01:51:15,880 THE PERSONALIZED HEALTH 2536 01:51:15,880 --> 01:51:18,800 APPROACH, HOW DO WE ALSO DO THIS 2537 01:51:18,800 --> 01:51:21,560 TO MAKE SURE OUR INTENT IS AS 2538 01:51:21,560 --> 01:51:23,200 BROAD AS POSSIBLE, IN FACT THAT 2539 01:51:23,200 --> 01:51:24,440 ALL OUR VOICES, WHETHER IT'S 2540 01:51:24,440 --> 01:51:26,280 DATA EQUITY OR WHETHER IT'S 2541 01:51:26,280 --> 01:51:27,600 INCLUSION, OR WHETHER IT'S THE 2542 01:51:27,600 --> 01:51:29,800 WAY WE DESIGN OUR STUDIES, ALL 2543 01:51:29,800 --> 01:51:33,400 THE WAY TO HOW DO WE DISSEMINATE 2544 01:51:33,400 --> 01:51:35,840 AND COMMUNICATE, AND HELP THAT 2545 01:51:35,840 --> 01:51:37,200 DISSEMINATION AND IMPLEMENTATION 2546 01:51:37,200 --> 01:51:40,080 SCIENCE MOVE FORWARD, IS JUST SO 2547 01:51:40,080 --> 01:51:40,360 CRITICAL. 2548 01:51:40,360 --> 01:51:43,480 AND, YOU KNOW, I LOOK FORWARD 2549 01:51:43,480 --> 01:51:45,800 TO -- I'M SURE EVERYBODY HERE 2550 01:51:45,800 --> 01:51:46,680 DOES -- WORKING TOGETHER BECAUSE 2551 01:51:46,680 --> 01:51:48,680 WE ALL HAVE A REAL COMMITMENT TO 2552 01:51:48,680 --> 01:51:51,360 THIS MOVING FORWARD. 2553 01:51:51,360 --> 01:51:52,360 >> THANK YOU. 2554 01:51:52,360 --> 01:51:53,880 >> THANKS FOR THOSE COMMENTS, 2555 01:51:53,880 --> 01:51:54,800 BECKY. 2556 01:51:54,800 --> 01:51:55,960 I COULDN'T AGREE MORE. 2557 01:51:55,960 --> 01:51:57,800 YOU KNOW, I DO THINK THAT A LOT 2558 01:51:57,800 --> 01:52:01,320 OF THESE EFFORTS THAT NIH IS 2559 01:52:01,320 --> 01:52:04,920 DOING, THAT MARIE TALKED ABOUT 2560 01:52:04,920 --> 01:52:06,600 TODAY, AND THERE'S SO MANY MORE. 2561 01:52:06,600 --> 01:52:07,760 CAN'T COVER EVERYTHING. 2562 01:52:07,760 --> 01:52:11,880 BUT TO ALSO SEE THEM START TO 2563 01:52:11,880 --> 01:52:12,920 REALLY PLAY OUT IN THE 2564 01:52:12,920 --> 01:52:15,040 COMMUNITIES THAT WE'VE BEEN 2565 01:52:15,040 --> 01:52:19,520 INTERACTING WITH FOR SO LONG, 2566 01:52:19,520 --> 01:52:20,840 SEEING THESE EFFORTS START TO 2567 01:52:20,840 --> 01:52:22,560 REALLY SEE THAT DIFFERENCE IN 2568 01:52:22,560 --> 01:52:25,960 CHANGE HAPPENING. 2569 01:52:25,960 --> 01:52:27,640 AND I THINK THAT THAT'S SUCCESS, 2570 01:52:27,640 --> 01:52:31,880 IF YOU WILL, THAT WILL BEGET 2571 01:52:31,880 --> 01:52:33,600 SUCCESS, WILL BEGET MORE OF 2572 01:52:33,600 --> 01:52:34,760 THESE KINDS OF ACTIVITIES. 2573 01:52:34,760 --> 01:52:35,800 OF COURSE, THAT'S WHAT WE'RE 2574 01:52:35,800 --> 01:52:36,600 STRIVING FOR. 2575 01:52:36,600 --> 01:52:41,000 THANK YOU FOR THOSE COMMENTS. 2576 01:52:41,000 --> 01:52:49,280 ANY OTHER COMMENTS AT THIS 2577 01:52:49,280 --> 01:52:50,280 POINT? 2578 01:52:50,280 --> 01:52:50,600 OKAY. 2579 01:52:50,600 --> 01:52:52,080 WELL, IT LOOKS LIKE THERE ARE NO 2580 01:52:52,080 --> 01:52:52,920 FURTHER COMMENTS FOR YOU. 2581 01:52:52,920 --> 01:52:56,200 THANK YOU SO MUCH FOR THIS 2582 01:52:56,200 --> 01:52:57,120 PRESENTATION, MARIE. 2583 01:52:57,120 --> 01:52:58,680 I WOULD IMAGINE THAT WE WILL BE 2584 01:52:58,680 --> 01:53:00,800 ASKING YOU BACK IN THE FUTURE AS 2585 01:53:00,800 --> 01:53:03,120 WE CONTINUE TO WORK THROUGH A 2586 01:53:03,120 --> 01:53:04,440 LOT OF THESE ACTIVITIES, AND GET 2587 01:53:04,440 --> 01:53:06,000 SOME UPDATES ALONG THE WAY. 2588 01:53:06,000 --> 01:53:08,160 SO WE LOOK FORWARD TO THAT TIME. 2589 01:53:08,160 --> 01:53:11,120 UNTIL THEN, THANK YOU AGAIN FOR 2590 01:53:11,120 --> 01:53:11,760 YOUR PRESENTATION. 2591 01:53:11,760 --> 01:53:13,240 AND ALL THE WORK THAT YOU'RE 2592 01:53:13,240 --> 01:53:15,480 DOING. 2593 01:53:15,480 --> 01:53:19,760 2594 01:53:19,760 --> 01:53:20,080 OKAY. 2595 01:53:20,080 --> 01:53:23,600 I THINK -- NEXT ON THE AGENDA IS 2596 01:53:23,600 --> 01:53:27,640 OUR PROGRAM UPDATE FROM DPI, LIZ 2597 01:53:27,640 --> 01:53:28,160 OTTINGER. 2598 01:53:28,160 --> 01:53:29,040 WE'RE AHEAD OF SCHEDULE. 2599 01:53:29,040 --> 01:53:30,360 LIZ, I WANT TO CHECK IN. 2600 01:53:30,360 --> 01:53:31,480 I SEE YOU'RE ON HERE. 2601 01:53:31,480 --> 01:53:33,560 ARE YOU OKAY WITH MOVING FORWARD 2602 01:53:33,560 --> 01:53:36,640 OR SHOULD WE TAKE A QUICK BREAK 2603 01:53:36,640 --> 01:53:40,400 AND THEN RESUME? 2604 01:53:40,400 --> 01:53:40,760 >> HI, JONI. 2605 01:53:40,760 --> 01:53:42,320 I'M FINE WITH WHATEVER IS BEST 2606 01:53:42,320 --> 01:53:44,240 FOR EVERYONE. 2607 01:53:44,240 --> 01:53:44,680 >> OKAY. 2608 01:53:44,680 --> 01:53:46,560 WHAT DO PEOPLE THINK, A QUICK 2609 01:53:46,560 --> 01:53:49,080 FIVE-MINUTE BREAK OR PUSH 2610 01:53:49,080 --> 01:53:49,640 THROUGH? 2611 01:53:49,640 --> 01:53:50,920 >> PUSH THROUGH. 2612 01:53:50,920 --> 01:53:54,280 >> I SEE THUMBS UP, PUSH 2613 01:53:54,280 --> 01:53:54,880 THROUGH. 2614 01:53:54,880 --> 01:53:55,120 OKAY. 2615 01:53:55,120 --> 01:53:57,760 ANNA, ARE YOU GOOD WITH US 2616 01:53:57,760 --> 01:54:04,320 PUSHING THROUGH? 2617 01:54:04,320 --> 01:54:05,480 I THINK YOU'RE OVERRULED. 2618 01:54:05,480 --> 01:54:06,720 >> I WAS CHECKING WITH LIZ TO 2619 01:54:06,720 --> 01:54:08,520 SEE IF WE COULD GO EARLY SO 2620 01:54:08,520 --> 01:54:12,640 WE'RE GOOD TO GO. 2621 01:54:12,640 --> 01:54:16,200 >> I'LL INTRODUCE LYNN OTTINGER, 2622 01:54:16,200 --> 01:54:18,160 HEAD OF PROJECT MANAGEMENT, 2623 01:54:18,160 --> 01:54:19,280 DIVISION OF PRE-CLINICAL 2624 01:54:19,280 --> 01:54:20,000 INNOVATION AT NCATS. 2625 01:54:20,000 --> 01:54:26,800 WE'RE EXCITED TO HAVE HER HERE 2626 01:54:26,800 --> 01:54:28,880 TODAY TO GIVE AN UPDATE. 2627 01:54:28,880 --> 01:54:30,160 LIZ, I'LL TURN IT OVER TO YOU. 2628 01:54:30,160 --> 01:54:33,040 THANK YOU FOR BEING HERE. 2629 01:54:33,040 --> 01:54:33,320 >> THANKS. 2630 01:54:33,320 --> 01:54:34,520 HI, EVERYONE. 2631 01:54:34,520 --> 01:54:35,080 GOOD AFTERNOON. 2632 01:54:35,080 --> 01:54:39,480 IF YOU GO TO THE NEXT SLIDE, AT 2633 01:54:39,480 --> 01:54:42,640 THE LAST COUNCIL MEETING IN JUNE 2634 01:54:42,640 --> 01:54:46,040 2021, SCIENTIFIC DIRECTOR OF THE 2635 01:54:46,040 --> 01:54:50,360 DIVISION OF PRE-CLINICAL 2636 01:54:50,360 --> 01:54:54,640 INNOVATION, DR. ANTON SENINOF 2637 01:54:54,640 --> 01:54:58,760 PRESENTED A LARGER OVERVIEW. 2638 01:54:58,760 --> 01:55:00,600 I WANT TO REORIENT TO DIFFERENT 2639 01:55:00,600 --> 01:55:02,360 BRANCHES THAT MAKE UP OUR 2640 01:55:02,360 --> 01:55:03,320 DIVISION, THE STRUCTURE. 2641 01:55:03,320 --> 01:55:06,080 WHAT I'M GOING TO FOCUS ON IS 2642 01:55:06,080 --> 01:55:07,080 THE THERAPEUTIC DEVELOPMENT 2643 01:55:07,080 --> 01:55:09,720 BRANCH YOU SEE IN GREEN. 2644 01:55:09,720 --> 01:55:12,840 THAT IS LED BY DR. DON LO. 2645 01:55:12,840 --> 01:55:15,280 I'LL GIVE AN OVERVIEW OF HOW WE 2646 01:55:15,280 --> 01:55:17,880 OPERATE WITHIN THE BRANCH AND 2647 01:55:17,880 --> 01:55:20,000 FOCUS ON SPECIFIC EXAMPLES OF 2648 01:55:20,000 --> 01:55:24,920 HOW WE ADVANCE THERAPEUTIC 2649 01:55:24,920 --> 01:55:25,880 DEVELOPMENT PROJECTS AND 2650 01:55:25,880 --> 01:55:30,520 INITIATIVES AND FOCUS ON RARE 2651 01:55:30,520 --> 01:55:31,600 AND NEGLECTED DISEASE SPACE. 2652 01:55:31,600 --> 01:55:34,640 I'D LIKE TO SHOW OUR PROCESS, 2653 01:55:34,640 --> 01:55:35,640 OUR PROGRESS, OUR CONTRIBUTIONS, 2654 01:55:35,640 --> 01:55:37,440 AND THEN THE VALUE THAT WE'VE 2655 01:55:37,440 --> 01:55:39,480 CREATED AND TO DO THAT BY 2656 01:55:39,480 --> 01:55:40,720 ILLUSTRATING SOME EXAMPLES OF 2657 01:55:40,720 --> 01:55:41,120 OUR PROJECTS. 2658 01:55:41,120 --> 01:55:45,080 SO IF YOU GO TO THE NEXT SLIDE. 2659 01:55:45,080 --> 01:55:48,480 THIS IS AN OVERVIEW OF OUR 2660 01:55:48,480 --> 01:55:48,760 STRUCTURE. 2661 01:55:48,760 --> 01:55:50,000 AND SO AS I THINK JONI AND 2662 01:55:50,000 --> 01:55:52,760 OTHERS HAVE POINTED OUT FOR DPI, 2663 01:55:52,760 --> 01:55:54,520 WE DO A LOT THROUGH 2664 01:55:54,520 --> 01:55:55,920 COLLABORATION, THAT'S OUR THEME. 2665 01:55:55,920 --> 01:55:57,040 AND THE DEVELOPMENT OF 2666 01:55:57,040 --> 01:55:58,240 PLATFORMS. 2667 01:55:58,240 --> 01:55:59,320 THIS IS OUR PRE-CLINICAL 2668 01:55:59,320 --> 01:56:00,040 DEVELOPMENT PLATFORM. 2669 01:56:00,040 --> 01:56:01,240 AND WHAT YOU CAN SEE HERE IS 2670 01:56:01,240 --> 01:56:04,440 WHAT WE HAVE, WE HAVE DIFFERENT 2671 01:56:04,440 --> 01:56:06,440 FUNCTIONAL GROUPS THAT WORK 2672 01:56:06,440 --> 01:56:09,560 TOGETHER ON OUR PROJECTS FROM 2673 01:56:09,560 --> 01:56:11,760 EARLY DISCOVERY, OUR BIOLOGY, 2674 01:56:11,760 --> 01:56:15,600 CHEMISTRY GROUPS, WE HAVE THE 2675 01:56:15,600 --> 01:56:17,160 DMPK, ALL THE DIFFERENT AREAS IN 2676 01:56:17,160 --> 01:56:18,360 DRUG DEVELOPMENT. 2677 01:56:18,360 --> 01:56:20,400 WE HAVE THE EXPERTISE IN ORDER 2678 01:56:20,400 --> 01:56:22,600 TO WORK TOGETHER ON PROJECTS. 2679 01:56:22,600 --> 01:56:26,800 WE HAVE SAFETY AND TOXICOLOGY 2680 01:56:26,800 --> 01:56:28,520 GROUP. 2681 01:56:28,520 --> 01:56:32,080 A CHEMISTRY, INFORMING AND 2682 01:56:32,080 --> 01:56:33,520 CONTROL GROUP, AND PROJECT 2683 01:56:33,520 --> 01:56:35,240 MANAGEMENT AND REGULATORY 2684 01:56:35,240 --> 01:56:35,880 SUPPORT. 2685 01:56:35,880 --> 01:56:38,840 BELOW YOU SEE THE CHEVRON, 2686 01:56:38,840 --> 01:56:41,000 TYPICAL WAY A DRUG DEVELOPMENT 2687 01:56:41,000 --> 01:56:42,000 PATHWAY IS DEMONSTRATED AS 2688 01:56:42,000 --> 01:56:42,560 SHOWN. 2689 01:56:42,560 --> 01:56:45,920 I JUST WANT TO FOCUS THAT MOST 2690 01:56:45,920 --> 01:56:50,320 OF OUR PROJECTS FOCUS IN THE 2691 01:56:50,320 --> 01:56:51,200 LEAD OPTIMIZATION AND 2692 01:56:51,200 --> 01:56:52,080 PRE-CLINICAL DEVELOPMENT SPACE, 2693 01:56:52,080 --> 01:56:56,440 AS YOU CAN SEE HERE, CIRCLED IN 2694 01:56:56,440 --> 01:56:56,600 RED. 2695 01:56:56,600 --> 01:56:58,000 AND I JUST WANT TO POINT OUT 2696 01:56:58,000 --> 01:57:00,320 THAT AS I SAID BEFORE, THESE 2697 01:57:00,320 --> 01:57:02,360 GROUPS ARE HIGHLY INTEGRATED. 2698 01:57:02,360 --> 01:57:05,040 IN ORDER TO WORK TOGETHER ON THE 2699 01:57:05,040 --> 01:57:07,040 PROJECTS, WE TRY TO HELP WITH 2700 01:57:07,040 --> 01:57:14,280 PROJECTS THAT HAVE HIGH 2701 01:57:14,280 --> 01:57:14,840 TRANSLATIONAL IMPACT. 2702 01:57:14,840 --> 01:57:17,240 NEXT SLIDE. 2703 01:57:17,240 --> 01:57:19,880 THIS IS A CURRENT PICTURE, 2704 01:57:19,880 --> 01:57:21,920 SNAPSHOT OF OUR THERAPEUTIC 2705 01:57:21,920 --> 01:57:22,760 DEVELOPMENT PORTFOLIO. 2706 01:57:22,760 --> 01:57:25,520 ON THE LEFT-HAND SIDE YOU CAN 2707 01:57:25,520 --> 01:57:27,880 SEE DIFFERENT PROGRAMS IN THE 2708 01:57:27,880 --> 01:57:29,360 THERAPEUTICS DEVELOPMENT BRANCH. 2709 01:57:29,360 --> 01:57:30,560 AGAIN, HOW THESE PROGRAMS FUNNEL 2710 01:57:30,560 --> 01:57:33,200 THROUGH THE DIFFERENT PHASES OF 2711 01:57:33,200 --> 01:57:36,040 DEVELOPMENT TO OUR ULTIMATE 2712 01:57:36,040 --> 01:57:37,920 MISSION OF ADVANCING TRANSLATION 2713 01:57:37,920 --> 01:57:39,800 TO BRING NEW THERAPIES TO 2714 01:57:39,800 --> 01:57:40,120 PEOPLE. 2715 01:57:40,120 --> 01:57:42,600 AND IF YOU LOOK BELOW, WHAT YOU 2716 01:57:42,600 --> 01:57:44,160 CAN SEE IS THE NUMBER OF 2717 01:57:44,160 --> 01:57:46,280 PROGRAMS THAT WE HAVE IN THE 2718 01:57:46,280 --> 01:57:49,080 DIFFERENT PHASES. 2719 01:57:49,080 --> 01:57:51,080 AND, AGAIN, FOCUSING ON 2720 01:57:51,080 --> 01:57:52,520 PRE-CLINICAL DEVELOPMENT, WE 2721 01:57:52,520 --> 01:57:53,720 CURRENTLY HAVE ABOUT 15 2722 01:57:53,720 --> 01:57:55,200 PROGRAMS, IN THAT SPACE. 2723 01:57:55,200 --> 01:57:57,960 WE ALSO IF YOU LOOK DOWN BELOW 2724 01:57:57,960 --> 01:58:00,720 HAVE SEVERAL OTHER INITIATIVES 2725 01:58:00,720 --> 01:58:02,880 AND BIOLOGICAL DEVELOPMENT 2726 01:58:02,880 --> 01:58:05,080 PROGRAMS THAT ARE NOT PART -- 2727 01:58:05,080 --> 01:58:06,800 NOT SEPARATE DRUG DEVELOPMENT 2728 01:58:06,800 --> 01:58:08,440 PROGRAMS BUT ARE TRANSLATIONAL 2729 01:58:08,440 --> 01:58:10,640 INITIATIVES TO HELP SUPPORT DRUG 2730 01:58:10,640 --> 01:58:11,200 DEVELOPMENT. 2731 01:58:11,200 --> 01:58:13,280 AND I WILL BE TALKING ABOUT ONE 2732 01:58:13,280 --> 01:58:15,040 OF THOSE AS THE LAST EXAMPLE TO 2733 01:58:15,040 --> 01:58:17,240 ALSO GIVE YOU AN EXAMPLE THERE. 2734 01:58:17,240 --> 01:58:21,600 IF YOU GO TO THE NEXT SLIDE, 2735 01:58:21,600 --> 01:58:24,200 THIS IS JUST TAKING US BACK 2736 01:58:24,200 --> 01:58:27,080 AGAIN TO THE SPACE THAT WE WORK 2737 01:58:27,080 --> 01:58:27,840 IN, PRE-CLINICAL SPACE. 2738 01:58:27,840 --> 01:58:29,760 WHAT I WANTED TO HIGHLIGHT IS 2739 01:58:29,760 --> 01:58:31,760 THAT IF YOU LOOK, AGAIN, THERE 2740 01:58:31,760 --> 01:58:33,840 ARE ALL THESE ACTIVITIES THAT 2741 01:58:33,840 --> 01:58:35,240 TAKE PLACE WITHIN THAT SPACE. 2742 01:58:35,240 --> 01:58:38,000 AND AS WE ALL KNOW THIS IS NOT A 2743 01:58:38,000 --> 01:58:38,520 LINEAR SPACE. 2744 01:58:38,520 --> 01:58:41,040 THERE'S A LOT OF DYNAMIC 2745 01:58:41,040 --> 01:58:43,600 INTERACTION OF STUDIES AND 2746 01:58:43,600 --> 01:58:45,600 SCIENCE THAT TAKE PLACE, AND 2747 01:58:45,600 --> 01:58:45,880 CHALLENGES. 2748 01:58:45,880 --> 01:58:48,240 A LOT OF SCIENTIFIC AND 2749 01:58:48,240 --> 01:58:49,640 OPERATIONAL CHALLENGES IN DRUG 2750 01:58:49,640 --> 01:58:50,040 DEVELOPMENT. 2751 01:58:50,040 --> 01:58:51,680 AND WHAT I WANTED TO POINT OUT 2752 01:58:51,680 --> 01:58:54,960 IS THAT AS YOU CAN SEE THERE'S A 2753 01:58:54,960 --> 01:58:56,360 LOT -- ALL OF THESE ACTIVITIES, 2754 01:58:56,360 --> 01:58:57,800 WE DON'T NECESSARILY WHEN WE 2755 01:58:57,800 --> 01:58:59,360 TAKE ON A PROJECT DO ALL OF 2756 01:58:59,360 --> 01:59:00,520 THESE ACTIVITIES FOR A 2757 01:59:00,520 --> 01:59:01,720 PARTICULAR PROJECT. 2758 01:59:01,720 --> 01:59:05,280 BUT IF WE NEED TO, WE CAN TAKE 2759 01:59:05,280 --> 01:59:07,560 IT -- WE DO TAKE PROJECTS FROM 2760 01:59:07,560 --> 01:59:09,640 START A LEAD CANDIDATE ALL THE 2761 01:59:09,640 --> 01:59:11,200 WAY TO THE INVESTIGATIONAL NEW 2762 01:59:11,200 --> 01:59:12,360 DRUG APPLICATION WHICH IS THE 2763 01:59:12,360 --> 01:59:16,000 ULTIMATE GOAL TO BE ABLE TO 2764 01:59:16,000 --> 01:59:17,800 FOLLOW TO TRANSITION OUR 2765 01:59:17,800 --> 01:59:18,760 PROJECTS INTO CLINICAL 2766 01:59:18,760 --> 01:59:19,040 DEVELOPMENT. 2767 01:59:19,040 --> 01:59:20,240 AND THE LAST THING I WANTED TO 2768 01:59:20,240 --> 01:59:22,680 POINT OUT IS THAT WE DO HELP 2769 01:59:22,680 --> 01:59:24,000 PROJECTS BECAUSE YOU'LL SEE SOME 2770 01:59:24,000 --> 01:59:25,800 OF OUR OUTCOMES ARE THAT 2771 01:59:25,800 --> 01:59:27,720 CLINICAL TRIALS ARE ONGOING. 2772 01:59:27,720 --> 01:59:30,080 WE DO HELP PROJECTS IN THE 2773 01:59:30,080 --> 01:59:31,400 CLINICAL TRIAL SPACE, SOME OF 2774 01:59:31,400 --> 01:59:33,200 THOSE ARE FOR INSTANCE IN THE 2775 01:59:33,200 --> 01:59:35,040 RARE DISEASE SPACE WE RUN THOSE 2776 01:59:35,040 --> 01:59:38,880 CLINICAL TRIALS AT THE NIH 2777 01:59:38,880 --> 01:59:41,520 CLINICAL CENTER, OR WE'LL 2778 01:59:41,520 --> 01:59:45,480 PROVIDE REGULATORY SUPPORT IF 2779 01:59:45,480 --> 01:59:47,440 MORE DRUG PRODUCT IS NEEDED OR 2780 01:59:47,440 --> 01:59:49,080 TOXICOLOGY STUDIES. 2781 01:59:49,080 --> 01:59:51,840 WE DO PARTICIPATE IN CLINICAL 2782 01:59:51,840 --> 01:59:52,560 AREAS OF DRUG DEVELOPMENT. 2783 01:59:52,560 --> 01:59:57,520 IF YOU GO TO THE NEXT SLIDE, I 2784 01:59:57,520 --> 02:00:00,360 READ A PAPER, TALKING ABOUT 2785 02:00:00,360 --> 02:00:04,280 WHAT'S THE MAGIC SAUCE OF 2786 02:00:04,280 --> 02:00:04,840 COLLABORATIONS AND 2787 02:00:04,840 --> 02:00:06,600 COLLABORATORS, AND FOR US THE 2788 02:00:06,600 --> 02:00:10,200 MAGIC SAUCE I THINK IS OUR TEAM 2789 02:00:10,200 --> 02:00:12,200 SCIENCE BASED APPROACH ACROSS 2790 02:00:12,200 --> 02:00:12,400 NCATS. 2791 02:00:12,400 --> 02:00:14,360 ALL OF OUR PROJECTS WORK IN THIS 2792 02:00:14,360 --> 02:00:14,840 FASHION. 2793 02:00:14,840 --> 02:00:17,400 AND WHAT WE'RE TRYING TO DO IS 2794 02:00:17,400 --> 02:00:18,320 HAVE A COORDINATED TEAM, AND SO 2795 02:00:18,320 --> 02:00:21,240 WHAT I'D LIKE TO POINT OUT IS 2796 02:00:21,240 --> 02:00:22,680 PROJECT MANAGEMENT THERE, 2797 02:00:22,680 --> 02:00:26,720 BECAUSE THAT'S BEEN A VERY 2798 02:00:26,720 --> 02:00:28,600 STRONG SUPPORT TO OUR PROJECTS, 2799 02:00:28,600 --> 02:00:30,760 AND HAVING PROJECT MANAGEMENT SO 2800 02:00:30,760 --> 02:00:32,880 THAT YOU CAN ACTUALLY KEEP A 2801 02:00:32,880 --> 02:00:34,280 PROJECT MOVING FORWARD AND DRIVE 2802 02:00:34,280 --> 02:00:36,560 AND COORDINATE ALL THESE OTHER 2803 02:00:36,560 --> 02:00:37,240 ACTIVITIES. 2804 02:00:37,240 --> 02:00:39,760 SO THAT THE PROJECT KEEPS 2805 02:00:39,760 --> 02:00:40,280 ADVANCING. 2806 02:00:40,280 --> 02:00:42,520 AND SO, AGAIN, OUR MAIN GOAL IN 2807 02:00:42,520 --> 02:00:43,600 THIS PRE-CLINICAL PLATFORM IS 2808 02:00:43,600 --> 02:00:45,360 THAT WE TAKE A PROJECT AND TRY 2809 02:00:45,360 --> 02:00:47,960 TO PUT THE RIGHT PIECES TOGETHER 2810 02:00:47,960 --> 02:00:51,200 IN ORDER TO MOVE THAT PROJECT 2811 02:00:51,200 --> 02:00:51,920 INTO CLINICAL TESTING. 2812 02:00:51,920 --> 02:00:56,080 SO IF YOU GO TO THE NEXT SLIDE. 2813 02:00:56,080 --> 02:00:57,840 SO, AGAIN, WHAT I'M GOING TO 2814 02:00:57,840 --> 02:01:00,360 FOCUS ON IS THE RARE AND 2815 02:01:00,360 --> 02:01:01,760 NEGLECTED DISEASE PROJECTS IN 2816 02:01:01,760 --> 02:01:05,080 OUR PORTFOLIO AND GIVE YOU SOME 2817 02:01:05,080 --> 02:01:07,560 EXAMPLES OF THOSE PROJECTS THAT 2818 02:01:07,560 --> 02:01:08,120 WE'VE WORKED ON, AND WHAT I 2819 02:01:08,120 --> 02:01:10,640 WANTED TO POINT OUT WHICH I'M 2820 02:01:10,640 --> 02:01:12,240 SURE MOST PEOPLE ARE AWARE OF, 2821 02:01:12,240 --> 02:01:14,400 THERE'S A LOT OF CHALLENGES AND 2822 02:01:14,400 --> 02:01:15,680 OPPORTUNITIES, AS WE WERE SAYING 2823 02:01:15,680 --> 02:01:20,160 A LOT OF IT IS SCIENTIFIC AND 2824 02:01:20,160 --> 02:01:22,040 OPERATIONAL AND REGULATORY 2825 02:01:22,040 --> 02:01:22,880 CHALLENGES, DRUG DEVELOPMENT, 2826 02:01:22,880 --> 02:01:27,000 ESPECIALLY IN RARE AND NEGLECTED 2827 02:01:27,000 --> 02:01:27,920 DISEASE SPACE. 2828 02:01:27,920 --> 02:01:30,000 WHAT I FOCUSED ON FIRST IS RARE 2829 02:01:30,000 --> 02:01:31,000 DISEASE PROBLEM. 2830 02:01:31,000 --> 02:01:33,280 AND IN RARE DISEASES, AS WE ALL 2831 02:01:33,280 --> 02:01:35,800 KNOW, THERE'S GREATER THAN 7,000 2832 02:01:35,800 --> 02:01:36,640 RARE DISEASES, THERE'S ABOUT 30 2833 02:01:36,640 --> 02:01:38,640 MILLION PEOPLE IN THE U.S. THAT 2834 02:01:38,640 --> 02:01:39,760 ARE AFFECTED. 2835 02:01:39,760 --> 02:01:44,000 THERE'S LESS THAN 10% APPROVED 2836 02:01:44,000 --> 02:01:46,240 THERAPIES, ABOUT 50% DISEASES 2837 02:01:46,240 --> 02:01:48,280 THAT CHILDREN ARE AFFECTED. 2838 02:01:48,280 --> 02:01:50,040 AND SO WITH ALL THESE 2839 02:01:50,040 --> 02:01:53,760 CHALLENGES, ESPECIALLY WITH THE 2840 02:01:53,760 --> 02:01:56,240 SMALL RARE DISEASE POPULATIONS, 2841 02:01:56,240 --> 02:01:58,600 WHICH TRANSLATE INTO CLINICAL 2842 02:01:58,600 --> 02:02:01,600 TRIAL DIFFICULTIES, ALSO 2843 02:02:01,600 --> 02:02:03,800 COMMERCIAL DEVELOPMENT 2844 02:02:03,800 --> 02:02:05,440 DIFFICULTY, AGAIN, AS WE'RE 2845 02:02:05,440 --> 02:02:08,200 TRYING TO LOOK FOR 2846 02:02:08,200 --> 02:02:10,360 OPPORTUNITIES, AS THE 2847 02:02:10,360 --> 02:02:11,800 DEVELOPMENT BRANCH, TO ADVANCE 2848 02:02:11,800 --> 02:02:13,880 AND HELP RARE DISEASES AND 2849 02:02:13,880 --> 02:02:16,920 NEGLECTED DISEASE DEVELOP NEW 2850 02:02:16,920 --> 02:02:17,280 THERAPIES. 2851 02:02:17,280 --> 02:02:20,320 AS JONI SAYS, YOU KNOW, IT'S 2852 02:02:20,320 --> 02:02:22,520 MORE THERAPIES TO MORE PEOPLE. 2853 02:02:22,520 --> 02:02:26,760 AND SO THAT'S OUR MAIN MISSION. 2854 02:02:26,760 --> 02:02:30,360 IF YOU GO TO THE NEXT SLIDE, 2855 02:02:30,360 --> 02:02:31,920 THIS IS OUR THERAPEUTICS 2856 02:02:31,920 --> 02:02:35,400 DEVELOPMENT PORTFOLIO, RARE AND 2857 02:02:35,400 --> 02:02:35,800 NEGLECTED SPACE. 2858 02:02:35,800 --> 02:02:37,080 AND WHAT I WANTED TO POINT OUT 2859 02:02:37,080 --> 02:02:39,160 IS IF YOU LOOK ON THE LEFT YOU 2860 02:02:39,160 --> 02:02:41,480 CAN SEE THAT GREATER THAN 50% OF 2861 02:02:41,480 --> 02:02:44,440 THE PROJECTS THAT WE WORK ON ARE 2862 02:02:44,440 --> 02:02:46,280 EITHER RARE DISEASES WHICH IS 2863 02:02:46,280 --> 02:02:48,800 ABOUT 49% OF OUR PORTFOLIO, OR 2864 02:02:48,800 --> 02:02:50,600 NEGLECTED DISEASES WHICH IS 2865 02:02:50,600 --> 02:02:51,320 ABOUT 5%. 2866 02:02:51,320 --> 02:02:54,120 AND IF YOU LOOK AT THE PROGRAMS 2867 02:02:54,120 --> 02:02:55,240 ALSO, THAT'S JUST SHOWING ACROSS 2868 02:02:55,240 --> 02:02:56,760 THE DIFFERENT PROGRAMS THAT I 2869 02:02:56,760 --> 02:02:58,320 MENTIONED, YOU CAN SEE THAT WE 2870 02:02:58,320 --> 02:03:00,600 HAVE, YOU KNOW, RARE AND 2871 02:03:00,600 --> 02:03:02,680 NEGLECTED DISEASE PROJECTS, MOST 2872 02:03:02,680 --> 02:03:04,200 OF OUR PROGRAMS. 2873 02:03:04,200 --> 02:03:06,400 WE ALSO HAVE A WIDE DIVERSITY IF 2874 02:03:06,400 --> 02:03:08,800 YOU LOOK BELOW IN THERAPEUTIC 2875 02:03:08,800 --> 02:03:10,680 AREAS, AGAIN WE DON'T FOCUS ON 2876 02:03:10,680 --> 02:03:12,440 ONE THERAPEUTIC AREA. 2877 02:03:12,440 --> 02:03:14,280 IT'S REALLY PROJECT DRIVEN, 2878 02:03:14,280 --> 02:03:18,000 WHERE CAN WE MAKE AN IMPACT, 2879 02:03:18,000 --> 02:03:21,320 WHAT PROJECT NEEDS HELP IN ORDER 2880 02:03:21,320 --> 02:03:22,840 TO ADVANCE THE THERAPEUTICS. 2881 02:03:22,840 --> 02:03:24,120 AND WE ALSO WORK, IF YOU LOOK ON 2882 02:03:24,120 --> 02:03:25,960 THE RIGHT, IN A CHANGE OF 2883 02:03:25,960 --> 02:03:26,720 MODALITIES. 2884 02:03:26,720 --> 02:03:29,720 WE ALSO WORK IN BIOLOGICS, AND 2885 02:03:29,720 --> 02:03:31,640 WE ALSO WORK AT SMALL MOLECULES. 2886 02:03:31,640 --> 02:03:35,840 IF YOU GO TO THE NEXT SLIDE 2887 02:03:35,840 --> 02:03:39,640 AGAIN, THE FIRST EXAMPLE THAT 2888 02:03:39,640 --> 02:03:41,640 I'D LIKE TO DISCUSS AND 2889 02:03:41,640 --> 02:03:44,240 HIGHLIGHT IS THE RARE DISEASES 2890 02:03:44,240 --> 02:03:45,680 DRUG DEVELOPMENT FOR DISEASES OF 2891 02:03:45,680 --> 02:03:46,640 LOW PREVALENCE WHICH MEANS 2892 02:03:46,640 --> 02:03:49,840 THERE'S A SMALL NUMBER OF 2893 02:03:49,840 --> 02:03:50,080 PATIENTS. 2894 02:03:50,080 --> 02:03:52,280 AND, AGAIN, THE CHALLENGES ARE 2895 02:03:52,280 --> 02:03:53,360 THE SAME BUT, AGAIN, THIS REALLY 2896 02:03:53,360 --> 02:03:55,560 HAS TO DO WITH THE SMALL NUMBER 2897 02:03:55,560 --> 02:03:57,080 OF PATIENTS, THAT'S WHAT I WANT 2898 02:03:57,080 --> 02:03:59,600 TO FOCUS ON IN THIS FIRST 2899 02:03:59,600 --> 02:04:00,040 EXAMPLE. 2900 02:04:00,040 --> 02:04:02,200 THE OPPORTUNITIES OF HOW WE CAN 2901 02:04:02,200 --> 02:04:05,160 COLLABORATE AND WORK ON A 2902 02:04:05,160 --> 02:04:06,160 THERAPEUTIC FOR A PROJECT. 2903 02:04:06,160 --> 02:04:11,200 SO, IF YOU LOOK AT THE NEXT 2904 02:04:11,200 --> 02:04:18,760 SLIDE, THIS PROJECT IS A 2905 02:04:18,760 --> 02:04:22,440 TREATMENT FOR DYSPLASIA, LEAD 2906 02:04:22,440 --> 02:04:24,560 INVESTIGATORS AT MASS GENERAL 2907 02:04:24,560 --> 02:04:24,920 HOSPITAL. 2908 02:04:24,920 --> 02:04:26,760 AND THIS IS WHAT YOU COULD SAY 2909 02:04:26,760 --> 02:04:29,720 IS AN ULTRA RARE DISEASE, LESS 2910 02:04:29,720 --> 02:04:30,880 THAN 30 KNOWN CASES. 2911 02:04:30,880 --> 02:04:33,680 IT'S A DISEASE OF BONE 2912 02:04:33,680 --> 02:04:37,320 DEVELOPMENT AND MINERAL 2913 02:04:37,320 --> 02:04:38,000 HOMEOSTASIS, INCREASED CALCIUM, 2914 02:04:38,000 --> 02:04:39,480 IF YOU LOOK ON THE RIGHT WHAT 2915 02:04:39,480 --> 02:04:44,080 YOU CAN SEE IT'S A RECEPTOR, 2916 02:04:44,080 --> 02:04:44,960 PARATHYROID HORMONE RECEPTOR 2917 02:04:44,960 --> 02:04:46,400 TYPE 1, WHICH HAS MUTATIONS 2918 02:04:46,400 --> 02:04:47,880 WHICH CAUSES THE PROTEIN TO BE 2919 02:04:47,880 --> 02:04:52,840 IN AN ACTIVE STATE OR TO BE ON. 2920 02:04:52,840 --> 02:04:54,200 AND THERE'S NO EFFECTIVE 2921 02:04:54,200 --> 02:04:55,360 TREATMENTS CURRENTLY, AND IF YOU 2922 02:04:55,360 --> 02:04:58,000 LOOK IN THE UPPER RIGHT WHAT 2923 02:04:58,000 --> 02:04:59,720 HAPPENS IS THAT THESE CHILDREN, 2924 02:04:59,720 --> 02:05:00,760 BECAUSE IT AFFECTS CHILDREN AT 2925 02:05:00,760 --> 02:05:04,120 AN EARLY AGE, THEY HAVE TO 2926 02:05:04,120 --> 02:05:04,800 UNDERGO MULTIPLE REPEATED 2927 02:05:04,800 --> 02:05:06,880 ORTHOPEDIC SURGERIES TO CORRECT 2928 02:05:06,880 --> 02:05:09,160 BONE DEFECTS. 2929 02:05:09,160 --> 02:05:14,880 AND SO OUR COLLABORATORS AT MASS 2930 02:05:14,880 --> 02:05:16,440 GENERAL FOUND A POTENTIAL 2931 02:05:16,440 --> 02:05:17,080 PEPTIDE. 2932 02:05:17,080 --> 02:05:20,920 IF YOU LOOK AT RECEPTOR, WHAT 2933 02:05:20,920 --> 02:05:23,880 THIS PEPTIDE DOES, IT ACTUALLY 2934 02:05:23,880 --> 02:05:25,640 SHIFTS THE RECEPTOR TO THE OFF 2935 02:05:25,640 --> 02:05:25,840 STATE. 2936 02:05:25,840 --> 02:05:28,560 AND SO THIS IS A POTENTIAL 2937 02:05:28,560 --> 02:05:30,560 PEPTIDE DRUG, BUT, AGAIN, THE 2938 02:05:30,560 --> 02:05:33,080 BIG CHALLENGE IS CURRENTLY 2939 02:05:33,080 --> 02:05:35,600 THERE'S ONLY ONE ADULT PATIENT 2940 02:05:35,600 --> 02:05:37,680 THAT'S KNOWN, THAT COULD 2941 02:05:37,680 --> 02:05:40,760 PARTICIPATE FOR THE PHASE 1/2 2942 02:05:40,760 --> 02:05:43,240 TRIAL AROUND NEEDS TO BE 2943 02:05:43,240 --> 02:05:44,520 TRANSITION TO SMALL NUMBER OF 2944 02:05:44,520 --> 02:05:45,480 PEDIATRIC PATIENTS. 2945 02:05:45,480 --> 02:05:47,400 THEY ARE SEVERELY AFFECTED WITH 2946 02:05:47,400 --> 02:05:48,960 THE BONE DEFECTS. 2947 02:05:48,960 --> 02:05:50,480 HOW DO WE DO DRUG DEVELOPMENT 2948 02:05:50,480 --> 02:05:53,120 FOR SUCH A SMALL PATIENT 2949 02:05:53,120 --> 02:05:53,440 POPULATION? 2950 02:05:53,440 --> 02:05:57,040 IF YOU GO TO THE NEXT SLIDE. 2951 02:05:57,040 --> 02:05:59,040 WHAT WE BELIEVE IN HERE AT NCATS 2952 02:05:59,040 --> 02:06:00,880 AND WHAT OUR WHOLE THEME IS, 2953 02:06:00,880 --> 02:06:08,440 AGAIN, IS HOW DO WE BUILD A PLAT 2954 02:06:08,440 --> 02:06:09,760 FORM, COLLABORATIVE ECOSYSTEM. 2955 02:06:09,760 --> 02:06:12,280 WE'VE BEEN WORKING WITH THE 2956 02:06:12,280 --> 02:06:14,560 JANSON DISEASE FOUNDATION, THE 2957 02:06:14,560 --> 02:06:16,320 PATIENT FOUNDATION, WHICH 2958 02:06:16,320 --> 02:06:17,840 CONNECTS THE KEY PARTNERS, YOU 2959 02:06:17,840 --> 02:06:19,720 HAVE PATIENTS WHO ENGAGE IN 2960 02:06:19,720 --> 02:06:22,080 CLINICAL RESEARCH, YOU HAVE THE 2961 02:06:22,080 --> 02:06:23,640 RESEARCHERS AND CLINICIANS ON 2962 02:06:23,640 --> 02:06:25,480 THE RIGHT-HAND SIDE THERE, THEY 2963 02:06:25,480 --> 02:06:26,960 PROVIDE THE SCIENTIFIC AND 2964 02:06:26,960 --> 02:06:28,800 DISEASE EXPERTISE, CARE FOR THE 2965 02:06:28,800 --> 02:06:31,840 PATIENTS, AND REALLY THAT LINK 2966 02:06:31,840 --> 02:06:37,840 BETWEEN THE SCIENCE AND THE 2967 02:06:37,840 --> 02:06:38,120 PATIENTS. 2968 02:06:38,120 --> 02:06:38,880 TDB PRE-CLINICAL PROJECT, WE 2969 02:06:38,880 --> 02:06:42,040 COME IN AND WE'VE BEEN PROVIDING 2970 02:06:42,040 --> 02:06:44,200 DRUG DEVELOPMENT EXPERTISE TO 2971 02:06:44,200 --> 02:06:45,080 ENABLE IND COORDINATING ALL 2972 02:06:45,080 --> 02:06:46,840 PARTS OF THE PROJECT TRYING TO 2973 02:06:46,840 --> 02:06:48,720 ENABLE THAT TRANSITION FROM 2974 02:06:48,720 --> 02:06:49,840 PRE-CLINICAL TO CLINICAL. 2975 02:06:49,840 --> 02:06:52,320 AND THEN WE'RE WORKING WITH THE 2976 02:06:52,320 --> 02:06:56,680 NIH CLINICAL CENTER, WORKING 2977 02:06:56,680 --> 02:06:59,760 WITH DR. SHAH AT NIDDK, DR. 2978 02:06:59,760 --> 02:07:02,280 COLLINS AT NIDCR, TO RUN THE 2979 02:07:02,280 --> 02:07:03,480 NATURAL HISTORY AND EXECUTE THE 2980 02:07:03,480 --> 02:07:04,240 CLINICAL TRIALS. 2981 02:07:04,240 --> 02:07:06,360 AGAIN, IT'S BRINGING ALL THE 2982 02:07:06,360 --> 02:07:07,520 PIECES TOGETHER FOR THAT PROJECT 2983 02:07:07,520 --> 02:07:10,480 SO THAT WE CAN MOVE IT AND DRIVE 2984 02:07:10,480 --> 02:07:10,880 IT FORWARD. 2985 02:07:10,880 --> 02:07:14,120 IF YOU LOOK AT THE NEXT SLIDE, 2986 02:07:14,120 --> 02:07:17,280 AGAIN, ANY SORT OF REITERATES 2987 02:07:17,280 --> 02:07:19,800 WHAT WE SAID BEFORE IN TERMS OF 2988 02:07:19,800 --> 02:07:21,760 DEVELOPING AN ECOSYSTEM BUT ALSO 2989 02:07:21,760 --> 02:07:24,080 WHAT WE ALWAYS GO BY, IT'S 2990 02:07:24,080 --> 02:07:27,800 REALLY IMPORTANT, TO REMEMBER 2991 02:07:27,800 --> 02:07:31,160 THERAPEUTIC STARTS AND ENDS WITH 2992 02:07:31,160 --> 02:07:32,240 THE PATIENT, IMPORTANT 2993 02:07:32,240 --> 02:07:33,040 ESPECIALLY WITH A SMALL NUMBER 2994 02:07:33,040 --> 02:07:33,640 OF PATIENTS. 2995 02:07:33,640 --> 02:07:35,360 YOU HAVE TO BE CLOSELY ALIGNED 2996 02:07:35,360 --> 02:07:36,200 WORKING WITH THOSE PATIENTS IN 2997 02:07:36,200 --> 02:07:39,040 ORDER TO BE ABLE TO RUN THE 2998 02:07:39,040 --> 02:07:39,520 CLINICAL TRIALS. 2999 02:07:39,520 --> 02:07:41,240 AND SO AGAIN THIS PROJECT 3000 02:07:41,240 --> 02:07:43,320 STARTED WITH OUTREACH, AND WAS 3001 02:07:43,320 --> 02:07:47,400 DRIVEN BY THE PATIENT 3002 02:07:47,400 --> 02:07:49,680 FOUNDATION, THERE'S NINA MAZAR, 3003 02:07:49,680 --> 02:07:54,720 FOUNDER OF JANSEN'S FOUNDATION, 3004 02:07:54,720 --> 02:07:55,360 CONNECTED RESEARCHERS, 3005 02:07:55,360 --> 02:07:56,960 CLINICIANS, DRUG DEVELOPERS, 3006 02:07:56,960 --> 02:07:58,640 REACHED OUT TO TDP AND IS 3007 02:07:58,640 --> 02:08:00,280 PARTICIPATING IN THE NATURAL 3008 02:08:00,280 --> 02:08:02,000 HISTORY STUDY AND SO ARE THE 3009 02:08:02,000 --> 02:08:09,400 OTHER PATIENTS IN THE JANSSEN 3010 02:08:09,400 --> 02:08:09,960 FOUNDATION. 3011 02:08:09,960 --> 02:08:12,160 YOU WERE ABLE TO IDENTIFY 3012 02:08:12,160 --> 02:08:14,480 POTENTIAL THERAPEUTIC CANDIDATE, 3013 02:08:14,480 --> 02:08:15,520 DID THE INITIAL EFFICACY 3014 02:08:15,520 --> 02:08:16,640 STUDIES, TESTING IN MOUSE MODEL 3015 02:08:16,640 --> 02:08:17,960 OF THE DISEASE. 3016 02:08:17,960 --> 02:08:19,600 YOU SEE ON THE BOTTOM, IF YOU 3017 02:08:19,600 --> 02:08:21,560 LOOK AT THE GREEN BOX, WHAT YOU 3018 02:08:21,560 --> 02:08:24,880 CAN SEE IS THE IA IN RED WHEN 3019 02:08:24,880 --> 02:08:25,680 YOU GIVE THE PEPTIDE TO THE 3020 02:08:25,680 --> 02:08:27,280 MOUSE MODEL AND ON THE LEFT IS 3021 02:08:27,280 --> 02:08:28,560 THE VEHICLE. 3022 02:08:28,560 --> 02:08:29,960 YOU CAN SEE THAT IT CORRECTS 3023 02:08:29,960 --> 02:08:31,520 SOME OF THE BONE DEFECTS AND 3024 02:08:31,520 --> 02:08:33,040 MAKES THE BONE LOOK MORE LIKE 3025 02:08:33,040 --> 02:08:39,760 THE WILD TYPE ON THE FAR LEFT. 3026 02:08:39,760 --> 02:08:41,400 IN PRE-CLINICAL DEVELOPMENT THE 3027 02:08:41,400 --> 02:08:44,120 PROGRESS OF THE PROJECT WE'VE 3028 02:08:44,120 --> 02:08:45,760 COMPLETED THE GMP MANUFACTURING 3029 02:08:45,760 --> 02:08:46,440 OF THE FORMULATION, FORMULATION 3030 02:08:46,440 --> 02:08:48,840 OF THE DRUG CANDIDATE, WE'RE 3031 02:08:48,840 --> 02:08:51,240 CURRENT LIP IN THE GLP 3032 02:08:51,240 --> 02:08:51,880 TOXICOLOGY, MOVING TOWARD 3033 02:08:51,880 --> 02:08:53,960 REGULATORY IND SUPPORT. 3034 02:08:53,960 --> 02:08:55,840 WE'RE ALSO DEVELOPING CLINICAL 3035 02:08:55,840 --> 02:08:59,120 ASSAYS, AGAIN, TO HELP THAT 3036 02:08:59,120 --> 02:08:59,640 COORDINATION BETWEEN 3037 02:08:59,640 --> 02:09:00,440 PRE-CLINICAL AND CLINICAL. 3038 02:09:00,440 --> 02:09:02,080 SO WE'RE STARTING WITH THE END 3039 02:09:02,080 --> 02:09:03,840 IN MIND. 3040 02:09:03,840 --> 02:09:05,920 WE'VE BEEN VERY INVOLVED IN 3041 02:09:05,920 --> 02:09:06,760 COMMUNICATING WITH THE 3042 02:09:06,760 --> 02:09:07,880 CLINICIANS AND WITH THE PATIENTS 3043 02:09:07,880 --> 02:09:09,840 IN ORDER TO DESIGN THE WHOLE 3044 02:09:09,840 --> 02:09:11,680 PROGRAM ABOUT BEING ABLE TO DO 3045 02:09:11,680 --> 02:09:14,600 THE PHASE 1 AND PHASE 2, IN THAT 3046 02:09:14,600 --> 02:09:15,640 N-of-1 PATIENT TO START. 3047 02:09:15,640 --> 02:09:18,280 AND SO WHAT WE THINK IS CRITICAL 3048 02:09:18,280 --> 02:09:26,720 THAT WE CAN ALSO CONTRIBUTE HERE 3049 02:09:26,720 --> 02:09:27,680 AT TBD IS DISSEMINATION TO 3050 02:09:27,680 --> 02:09:30,200 PROVIDE INFORMATION HOW DO YOU 3051 02:09:30,200 --> 02:09:31,960 DO -- WHAT IS REGULATORY PATH, 3052 02:09:31,960 --> 02:09:35,040 HOW DOES THIS OCCUR WHEN WE HAVE 3053 02:09:35,040 --> 02:09:36,680 THESE SMALL NUMBER OF PATIENTS 3054 02:09:36,680 --> 02:09:39,760 AND ALSO HOW TO TRANSITION IT TO 3055 02:09:39,760 --> 02:09:41,160 THE ACTUAL PEDIATRIC POPULATION 3056 02:09:41,160 --> 02:09:42,600 TO DO A SMOOTH TRANSITION THAT 3057 02:09:42,600 --> 02:09:44,880 CAN BE TESTED IN THAT POPULATION 3058 02:09:44,880 --> 02:09:47,200 ALSO, SO WE CAN GET TO THE 3059 02:09:47,200 --> 02:09:48,800 ULTIMATE GOAL OF HOPEFULLY 3060 02:09:48,800 --> 02:09:52,640 IMPROVING THE LIVES OF THE 3061 02:09:52,640 --> 02:09:54,440 PATIENTS AS THIS TREATMENT 3062 02:09:54,440 --> 02:09:54,640 WORKS. 3063 02:09:54,640 --> 02:09:56,920 THAT'S ONE EXAMPLE, I'VE TRIED 3064 02:09:56,920 --> 02:09:58,640 TO SHOW THE ECOSYSTEM THAT WE 3065 02:09:58,640 --> 02:10:01,760 WORK ON TO DEVELOP OUR PLATFORM 3066 02:10:01,760 --> 02:10:02,720 AND TO OPERATIONALIZE IT. 3067 02:10:02,720 --> 02:10:04,480 SO IF YOU LOOK AT THE NEXT 3068 02:10:04,480 --> 02:10:07,320 SLIDE, I'M GOING TO TALK ABOUT 3069 02:10:07,320 --> 02:10:08,200 THE NEGLECTED TROPICAL DISEASES 3070 02:10:08,200 --> 02:10:10,800 BECAUSE WE ALSO WORK IN THIS 3071 02:10:10,800 --> 02:10:11,120 SPACE. 3072 02:10:11,120 --> 02:10:13,880 AND THE PROBLEM HERE IS THAT 3073 02:10:13,880 --> 02:10:16,760 THERE ARE 20 NEGLECTED TROPICAL 3074 02:10:16,760 --> 02:10:20,360 DISEASES DEFINED BY W.H.O., 3075 02:10:20,360 --> 02:10:23,200 GREATER THAN ONE BILLION PEOPLE 3076 02:10:23,200 --> 02:10:26,400 AFFECTED, GREATER THAN TWO 3077 02:10:26,400 --> 02:10:27,040 BILLION AT RISK. 3078 02:10:27,040 --> 02:10:30,080 0.5BILLION CHILDREN AT RISK FROM 3079 02:10:30,080 --> 02:10:31,560 THESE DISEASE, AFFECTS POOREST 3080 02:10:31,560 --> 02:10:33,480 AND MOST VULNERABLE PEOPLE. 3081 02:10:33,480 --> 02:10:35,360 AGAIN, YOU HAVE THOSE SAME 3082 02:10:35,360 --> 02:10:36,680 CHALLENGES IN THE DRUG 3083 02:10:36,680 --> 02:10:39,920 DEVELOPMENT SPACE, AND, AGAIN, 3084 02:10:39,920 --> 02:10:42,080 BECAUSE OF THE LOW-RESOURCE 3085 02:10:42,080 --> 02:10:42,760 SETTINGS THERE'S ALSO A LOT OF 3086 02:10:42,760 --> 02:10:45,520 EQUITY, HOW DO YOU GET IT TO ALL 3087 02:10:45,520 --> 02:10:46,480 THE PATIENTS. 3088 02:10:46,480 --> 02:10:48,360 AND SO, AGAIN, THE OPPORTUNITIES 3089 02:10:48,360 --> 02:10:50,880 THAT WE'VE TRIED TO WORK TOWARDS 3090 02:10:50,880 --> 02:10:51,560 TO ACTUALLY FACE THESE 3091 02:10:51,560 --> 02:10:54,520 CHALLENGES WE WERE ABLE TO DO A 3092 02:10:54,520 --> 02:10:59,320 PROJECT IN COLLABORATION, NEXT 3093 02:10:59,320 --> 02:11:02,920 SLIDE, ABLE TO WORK WITH DNDI, 3094 02:11:02,920 --> 02:11:06,000 DRUGS FOR NEGLECTED DISEASE 3095 02:11:06,000 --> 02:11:13,240 INITIATIVE, DEVELOPMENT FOR THE 3096 02:11:13,240 --> 02:11:16,600 TREATMENT OF SLEEPING SICKNESS. 3097 02:11:16,600 --> 02:11:20,560 LAURENT FRAISSE IS LEAD 3098 02:11:20,560 --> 02:11:24,240 INVESTIGATOR, THE FIRST THAT HAS 3099 02:11:24,240 --> 02:11:27,440 COMMENT OUT OF DNDI. 3100 02:11:27,440 --> 02:11:29,280 THIS SPREADS, INFECTION THROUGH 3101 02:11:29,280 --> 02:11:31,920 A FLY BITE, INTO THE 3102 02:11:31,920 --> 02:11:38,480 BLOODSTREAM, IT TRANSFERS INTO 3103 02:11:38,480 --> 02:11:40,040 THE CEREBROSPINAL FLUID AND 3104 02:11:40,040 --> 02:11:41,240 LEADS TO DIFFERENT STAGE OF 3105 02:11:41,240 --> 02:11:49,040 DISEASE UNTIL YOU HAVE COMA AND 3106 02:11:49,040 --> 02:11:50,960 DEATH, MOSTLY AFFECTS THE 3107 02:11:50,960 --> 02:11:54,720 POOREST AND OF IN AFRICA, 3108 02:11:54,720 --> 02:11:55,800 8.5 MILLION PEOPLE. 3109 02:11:55,800 --> 02:11:58,320 THE GOAL OF THE W.H.O. IS THE 3110 02:11:58,320 --> 02:11:59,520 ACTUAL ELIMINATION OF THIS 3111 02:11:59,520 --> 02:12:03,000 DISEASE, HOW DO YOU CHANGE THE 3112 02:12:03,000 --> 02:12:03,600 TREATMENT PARADIGM? 3113 02:12:03,600 --> 02:12:06,200 AND AGAIN IF YOU LOOK ON THE 3114 02:12:06,200 --> 02:12:08,720 LEFT HERE CURRENT TREATMENTS 3115 02:12:08,720 --> 02:12:11,640 HAVE HIGH -- ARE VERY TOXIC, A 3116 02:12:11,640 --> 02:12:13,640 LOT OF SIDE EFFECTS, AND 3117 02:12:13,640 --> 02:12:14,920 TREATMENT DURATION AND COST, SO 3118 02:12:14,920 --> 02:12:21,080 IT'S NOT OPTIMAL TO TREAT ALL 3119 02:12:21,080 --> 02:12:21,400 PEOPLE. 3120 02:12:21,400 --> 02:12:22,800 WHAT THEY SLOWLY WORKED TOWARDS 3121 02:12:22,800 --> 02:12:28,840 IN 2018 IS ORAL TREATMENT, HAVE 3122 02:12:28,840 --> 02:12:34,320 GOTTEN TO 10-DAY APPROVAL OF 3123 02:12:34,320 --> 02:12:35,400 FEXINIDAZOLE, A GAME CHANGER, 3124 02:12:35,400 --> 02:12:36,480 SIMPLER TREATMENT. 3125 02:12:36,480 --> 02:12:38,200 YOU WANT MORE ACCESSIBILITY AND 3126 02:12:38,200 --> 02:12:38,520 COMPLIANCE. 3127 02:12:38,520 --> 02:12:40,840 THE BEST WAY WOULD BE IF YOU HAD 3128 02:12:40,840 --> 02:12:49,280 AN ORAL SINGLE DOSE DRUG, THAT'S 3129 02:12:49,280 --> 02:12:51,280 WHAT ACOZIBAROLE WILL PROVIDE. 3130 02:12:51,280 --> 02:12:54,760 IT'S A DIAGNOSE AND TREAT SO YOU 3131 02:12:54,760 --> 02:12:56,200 COULD - ONCE YOU KNOW A PERSON 3132 02:12:56,200 --> 02:12:59,080 HAS IT YOU COULD QUICKLY TREAT 3133 02:12:59,080 --> 02:13:00,800 IT, AIDING IN ELIMINATION. 3134 02:13:00,800 --> 02:13:03,320 AND SO OUR INVOLVEMENT IN THIS 3135 02:13:03,320 --> 02:13:05,600 PROJECT IS, AGAIN, SOMETIMES ONE 3136 02:13:05,600 --> 02:13:07,160 STUDY, ONE PIECE, ONE PILL MIGHT 3137 02:13:07,160 --> 02:13:08,920 BE ALL THAT'S NEEDED. 3138 02:13:08,920 --> 02:13:10,880 AND SO EVEN THOUGH THEY HAD A 3139 02:13:10,880 --> 02:13:13,640 LOT OF THIS PROJECT ONGOING, IN 3140 02:13:13,640 --> 02:13:14,920 ORDER TO ACTUALLY REGISTER IT 3141 02:13:14,920 --> 02:13:18,000 THEY CAME UP AGAINST THAT THEY 3142 02:13:18,000 --> 02:13:19,640 NEEDED A CHRONIC GLP TOXICOLOGY 3143 02:13:19,640 --> 02:13:21,680 STUDY AS KEY REQUIREMENT FOR 3144 02:13:21,680 --> 02:13:23,120 REGULATORY APPROVAL, AND AT THE 3145 02:13:23,120 --> 02:13:24,120 TIME THEY NEEDED SOME -- THEY 3146 02:13:24,120 --> 02:13:26,320 WERE ASKING US IF WE COULD 3147 02:13:26,320 --> 02:13:27,080 PROVIDE THAT RESOURCE. 3148 02:13:27,080 --> 02:13:28,400 AND SO WE WORKED CLOSELY WITH 3149 02:13:28,400 --> 02:13:31,720 THEM IN ORDER TO GET THAT STUDY 3150 02:13:31,720 --> 02:13:38,600 DONE, AND AS A RESULT IN 2021 3151 02:13:38,600 --> 02:13:39,240 DNDI INTERNALLY NAMED THIS 3152 02:13:39,240 --> 02:13:41,520 PROJECT OF THE YEAR IN THE 3153 02:13:41,520 --> 02:13:42,720 CLINICAL SPACE. 3154 02:13:42,720 --> 02:13:44,600 THEY ACKNOWLEDGED THEY FELT 3155 02:13:44,600 --> 02:13:45,720 NCATS TEAM IS GREATLY 3156 02:13:45,720 --> 02:13:47,000 RESPONSIBLE FOR THIS SUCCESS. 3157 02:13:47,000 --> 02:13:52,240 AND SO WHERE IS THIS NOW? 3158 02:13:52,240 --> 02:13:58,160 SANOFI AND W.H.O. ARE PARTNERS 3159 02:13:58,160 --> 02:13:59,160 TO PROVIDE ACOZIBAROLE FREE 3160 02:13:59,160 --> 02:14:03,320 THROUGH PUBLIC HEALTH SYSTEMS IN 3161 02:14:03,320 --> 02:14:04,400 COUNTRIES, DNDI COMPLETED 3162 02:14:04,400 --> 02:14:06,760 PIVOTAL PHASE 2/PHASE 3 CLINICAL 3163 02:14:06,760 --> 02:14:07,560 TRIALS, MOVING TOWARDS 3164 02:14:07,560 --> 02:14:08,360 REGISTRATION. 3165 02:14:08,360 --> 02:14:10,360 SO, AGAIN, WE FEEL LIKE WE MADE 3166 02:14:10,360 --> 02:14:12,320 AN IMPORTANT CONTRIBUTION HERE. 3167 02:14:12,320 --> 02:14:14,240 WE ADDED IMPACT FOR GLOBAL 3168 02:14:14,240 --> 02:14:14,600 HEALTH. 3169 02:14:14,600 --> 02:14:16,120 AND IN THIS CASE IT WAS LIKE 3170 02:14:16,120 --> 02:14:19,280 THIS ONE PIECE THAT WE WERE ABLE 3171 02:14:19,280 --> 02:14:19,840 TO CONTRIBUTE. 3172 02:14:19,840 --> 02:14:24,240 SO GO TO THE NEXT SLIDE. 3173 02:14:24,240 --> 02:14:25,440 NEXT AREA OF, AGAIN, 3174 02:14:25,440 --> 02:14:28,360 REPRESENTING A PROJECT OF HOW WE 3175 02:14:28,360 --> 02:14:31,000 CAN AGAIN GET MORE TREATMENTS TO 3176 02:14:31,000 --> 02:14:33,240 MORE PATIENTS, MORE RAPIDLY, IS 3177 02:14:33,240 --> 02:14:34,920 REPURPOSING FOR RARE DISEASES. 3178 02:14:34,920 --> 02:14:38,280 AND SO HERE IT OFFERS AN 3179 02:14:38,280 --> 02:14:39,840 OPPORTUNITY AND CHALLENGE IF YOU 3180 02:14:39,840 --> 02:14:41,600 CAN FIND ONE DRUG TO TREAT 3181 02:14:41,600 --> 02:14:42,000 MULTIPLE DISEASES. 3182 02:14:42,000 --> 02:14:44,440 I'D LIKE TO GIVE AN EXAMPLE OF A 3183 02:14:44,440 --> 02:14:55,080 PROJECT THAT WE WORKED ON, NEXT. 3184 02:14:55,680 --> 02:15:00,080 WE REPURPOSED A EUROPEAN UNIT, 3185 02:15:00,080 --> 02:15:04,400 THE LEAD IS ALSO A PROFESSOR AT 3186 02:15:04,400 --> 02:15:05,360 BOSTON UNIVERSITY. 3187 02:15:05,360 --> 02:15:07,760 , THE GROUP OF INHERITED BLOOD 3188 02:15:07,760 --> 02:15:09,320 DISORDERS PRIMARILY AFFECT RED 3189 02:15:09,320 --> 02:15:10,400 BLOOD CELL PRODUCTION AND 3190 02:15:10,400 --> 02:15:11,800 STRUCTURE, YOU CAN SEE ON THE 3191 02:15:11,800 --> 02:15:13,160 RIGHT THOSE ARE BLOOD SMEARS. 3192 02:15:13,160 --> 02:15:15,560 I'M SURE MOST PEOPLE MAY BE 3193 02:15:15,560 --> 02:15:20,280 FAMILIAR WITH THE SICKLE CELL 3194 02:15:20,280 --> 02:15:21,000 SHAPE. 3195 02:15:21,000 --> 02:15:23,000 IT'S A RARE DISEASE, THERE'S 3196 02:15:23,000 --> 02:15:25,400 ONLY 2,000, SICKLE CELL IS ALSO 3197 02:15:25,400 --> 02:15:26,320 RARE, THERE'S ABOUT 100,000 3198 02:15:26,320 --> 02:15:28,920 CASES IN THE U.S. 3199 02:15:28,920 --> 02:15:30,960 WHAT YOU CAN SEE, MINORITY 3200 02:15:30,960 --> 02:15:33,160 POPULATIONS ARE AT HIGH RISK. 3201 02:15:33,160 --> 02:15:34,680 AND IT'S ALSO A SIGNIFICANT 3202 02:15:34,680 --> 02:15:37,880 HEALTH PROBLEM IN MORE THAN 160 3203 02:15:37,880 --> 02:15:40,360 COUNTRIES WORLDWIDE. 3204 02:15:40,360 --> 02:15:42,720 GLOBALLY THERE'S OVER 330,000 3205 02:15:42,720 --> 02:15:43,800 AFFECTED INFANTS BORN ANNUALLY 3206 02:15:43,800 --> 02:15:45,560 WITH THESE DISEASES. 3207 02:15:45,560 --> 02:15:47,520 SO EVEN THOUGH THERE ARE SOME 3208 02:15:47,520 --> 02:15:50,000 THERAPEUTICS THAT HAVE BEEN IN 3209 02:15:50,000 --> 02:15:53,960 USE LIKE THERE'S BONE MARROW 3210 02:15:53,960 --> 02:15:56,040 TRANSPLANT, THERE'S HYDROXYUREA, 3211 02:15:56,040 --> 02:15:57,680 AND WORKING TOWARDS GENE 3212 02:15:57,680 --> 02:15:59,440 THERAPY, SOME OF THE CURRENT 3213 02:15:59,440 --> 02:16:01,040 THERAPIES HAVE A LOT OF SIDE 3214 02:16:01,040 --> 02:16:04,280 EFFECTS ASSOCIATED WITH THEM AND 3215 02:16:04,280 --> 02:16:05,680 THEY ARE NOT AS -- AND GENE 3216 02:16:05,680 --> 02:16:07,520 THERAPY MAY NOT BE AS ACCESSIBLE 3217 02:16:07,520 --> 02:16:11,680 TO ALL OF THE POPULATION, TO 3218 02:16:11,680 --> 02:16:12,760 HAVE EQUITY AND CARE. 3219 02:16:12,760 --> 02:16:14,320 IT'S IMPORTANT TO FIND OTHER 3220 02:16:14,320 --> 02:16:15,080 MOLECULES. 3221 02:16:15,080 --> 02:16:16,160 THIS IS A POTENTIAL SMALL 3222 02:16:16,160 --> 02:16:16,480 MOLECULE. 3223 02:16:16,480 --> 02:16:18,680 IT'S A DRUG THAT WAS APPROVED 3224 02:16:18,680 --> 02:16:20,200 GREATER THAN 40 YEARS AGO. 3225 02:16:20,200 --> 02:16:22,960 IT WAS ONLY PART OF A 3226 02:16:22,960 --> 02:16:25,800 COMBINATION DRUG SO PART OF A 3227 02:16:25,800 --> 02:16:27,520 PARKINSON'S -- FOR PARKINSON'S 3228 02:16:27,520 --> 02:16:28,600 DISEASE APPROVED BY EMA AND 3229 02:16:28,600 --> 02:16:29,400 HEALTH CANADA. 3230 02:16:29,400 --> 02:16:30,600 THE QUESTION, AGAIN, IN THIS 3231 02:16:30,600 --> 02:16:32,920 PROJECT WAS WHAT NEW DATA WOULD 3232 02:16:32,920 --> 02:16:39,480 BE NEEDED FOR APPROVAL IN 3233 02:16:39,480 --> 02:16:40,600 HEMOGLOBINOPATHIES? 3234 02:16:40,600 --> 02:16:42,320 NEXT SLIDE. 3235 02:16:42,320 --> 02:16:43,600 SO AGAIN HEMOGLOBINOPATHIES, TWO 3236 02:16:43,600 --> 02:16:45,520 DISEASES, WHAT THEY HAVE IS THEY 3237 02:16:45,520 --> 02:16:47,480 HAVE MUTATIONS IN THE 3238 02:16:47,480 --> 02:16:48,120 BETA-GLOBIN GENE OF HEMOGLOBIN, 3239 02:16:48,120 --> 02:16:52,960 ON THE RIGHT IS MOLECULE WITH 3240 02:16:52,960 --> 02:16:56,920 HEMOGLOBIN, AND THE BETA SUBUNIT 3241 02:16:56,920 --> 02:16:59,080 WHERE MUTATIONS OCCUR. 3242 02:16:59,080 --> 02:17:00,320 THEY HAVE A COMMON TARGET 3243 02:17:00,320 --> 02:17:00,760 MECHANISM OF ACTION. 3244 02:17:00,760 --> 02:17:09,360 IF YOU LOOK IN GREEN, THAT IS 3245 02:17:09,360 --> 02:17:10,800 GAMMAGLOBIN SUBUNIT, IT GOES 3246 02:17:10,800 --> 02:17:14,280 DOWN AFTER BIRTH, AND 3247 02:17:14,280 --> 02:17:21,000 BETA-GLOBIN EXPECT GLOWS UP, 3248 02:17:21,000 --> 02:17:22,040 MUTATIONS TAKE HOLD, ONSET OF 3249 02:17:22,040 --> 02:17:22,320 SYMPTOMS. 3250 02:17:22,320 --> 02:17:24,720 IF YOU LOOK ON RED AND FOLLOW 3251 02:17:24,720 --> 02:17:27,640 THE GREEN, WITH THE WHOLE 3252 02:17:27,640 --> 02:17:29,080 PREMISE OR THOUGHT TO TARGET 3253 02:17:29,080 --> 02:17:30,520 THIS COMMON MECHANISM OF ACTION. 3254 02:17:30,520 --> 02:17:34,800 YOU CAN SEE BY FOUR WEEKS IF YOU 3255 02:17:34,800 --> 02:17:39,080 GIVE THE BEN, YOU HAVE INCREASE 3256 02:17:39,080 --> 02:17:40,280 IN FETAL HEMOGLOBIN EXPRESSION. 3257 02:17:40,280 --> 02:17:44,080 IF YOU GO TO THE NEXT SLIDE, HOW 3258 02:17:44,080 --> 02:17:47,280 WERE WE, AGAIN, ABLE TO USE OUR 3259 02:17:47,280 --> 02:17:49,000 PRE-CLINICAL PLATFORM AND ABLE 3260 02:17:49,000 --> 02:17:50,720 TO REPOSITION THIS TO ACCELERATE 3261 02:17:50,720 --> 02:17:52,920 DRUG DEVELOPMENT FOR THIS 3262 02:17:52,920 --> 02:17:54,520 PARTICULAR MOLECULE? 3263 02:17:54,520 --> 02:17:56,720 IT TURNS OUT THAT A LOT OF THE 3264 02:17:56,720 --> 02:17:58,720 INFORMATION WAS NOT ABLE TO BE 3265 02:17:58,720 --> 02:18:03,960 USED BECAUSE, AGAIN, IT WAS 40 3266 02:18:03,960 --> 02:18:05,400 YEARS OLD, PART OF A 3267 02:18:05,400 --> 02:18:06,080 COMBINATION. 3268 02:18:06,080 --> 02:18:09,040 A LOT OF PRE-CLINICAL STUDIES WE 3269 02:18:09,040 --> 02:18:11,640 WERE ABLE TO DO, ACQUIRED 3270 02:18:11,640 --> 02:18:13,440 EXISTING GENE API AND TO MOVE 3271 02:18:13,440 --> 02:18:16,040 THIS FORWARD AND GET IT TO AN 3272 02:18:16,040 --> 02:18:18,800 IND, WE STARTED THE PROJECT IN 3273 02:18:18,800 --> 02:18:21,640 2014, AND AS YOU CAN SEE BY 2019 3274 02:18:21,640 --> 02:18:24,680 WE WERE ABLE TO CLEAR THE 3275 02:18:24,680 --> 02:18:26,640 INDs, ABLE TO SAFELY PROCEED 3276 02:18:26,640 --> 02:18:29,680 INTO THE CLINIC AND ALSO IN 3277 02:18:29,680 --> 02:18:31,000 HEALTH CANADA. 3278 02:18:31,000 --> 02:18:32,120 AGAIN, WE COLLABORATE WITH 3279 02:18:32,120 --> 02:18:34,560 OTHER, HOW DO WE BRING THESE 3280 02:18:34,560 --> 02:18:37,200 PIECES TOGETHER, FOR CLINICAL 3281 02:18:37,200 --> 02:18:38,680 COLLABORATED, NHLBI PROVIDED THE 3282 02:18:38,680 --> 02:18:38,920 FUNDING. 3283 02:18:38,920 --> 02:18:42,720 SO CURRENTLY IT'S CALLED THE 3284 02:18:42,720 --> 02:18:49,120 BENEFITS TRIAL, PHASE 1B FOR 3285 02:18:49,120 --> 02:18:50,600 BETA CELL-ASSEMIA, SITES IN THE 3286 02:18:50,600 --> 02:18:51,360 U.S. AND CANADA. 3287 02:18:51,360 --> 02:18:55,880 GO TO THE NEXT SLIDE. 3288 02:18:55,880 --> 02:18:57,320 THERE'S THE NEXT EXAMPLE. 3289 02:18:57,320 --> 02:19:00,600 THIS IS THE SPACE OF GENE 3290 02:19:00,600 --> 02:19:01,840 THERAPIES, WITH A LOT OF 3291 02:19:01,840 --> 02:19:03,960 OPPORTUNITIES FOR RARE DISEASES. 3292 02:19:03,960 --> 02:19:07,800 85% OF RARE AND ULTRA RARE 3293 02:19:07,800 --> 02:19:09,320 DISEASES, PATHOGENIC VARIANTS 3294 02:19:09,320 --> 02:19:11,880 ARE IN SINGLE GENES THAT 3295 02:19:11,880 --> 02:19:13,920 REGULATE THAT PRODUCT FUNCTION. 3296 02:19:13,920 --> 02:19:15,360 AND ON THE LEFT-HAND SIDE THERE 3297 02:19:15,360 --> 02:19:18,840 AGAIN IN THE PIE WHAT YOU SEE IS 3298 02:19:18,840 --> 02:19:21,720 770 DRUGS APPROVED FOR RARE 3299 02:19:21,720 --> 02:19:23,600 DISEASES, AND THERE'S ONLY 7% SO 3300 02:19:23,600 --> 02:19:25,880 FAR APPROVED FOR CELL AND GENE 3301 02:19:25,880 --> 02:19:26,440 THERAPIES. 3302 02:19:26,440 --> 02:19:28,400 BUT THERE'S A LOT OF OPPORTUNITY 3303 02:19:28,400 --> 02:19:29,840 AND PROMISE THAT'S BEING HELD 3304 02:19:29,840 --> 02:19:31,240 THERE IN RARE DISEASES, AND MANY 3305 02:19:31,240 --> 02:19:35,640 OF THE RARE DISEASES HAVE THAT 3306 02:19:35,640 --> 02:19:38,480 LOW PREVALENCE AGAIN, WITH THE 3307 02:19:38,480 --> 02:19:40,640 GENE THERAPY COULD BE A GOOD 3308 02:19:40,640 --> 02:19:43,280 CURE OR SOLUTION FOR TRYING TO 3309 02:19:43,280 --> 02:19:44,800 PROVIDE THERAPEUTICS TO THOSE 3310 02:19:44,800 --> 02:19:46,440 LOW PREVALENCE DISEASES. 3311 02:19:46,440 --> 02:19:48,080 SO, AGAIN, THERE'S MANY 3312 02:19:48,080 --> 02:19:48,600 CHALLENGES. 3313 02:19:48,600 --> 02:19:50,040 AND I JUST WOULD LIKE TO SHOW 3314 02:19:50,040 --> 02:19:53,440 YOU HOW WE HAVE TRIED TO GO 3315 02:19:53,440 --> 02:19:54,440 ABOUT PARTICIPATING IN THE 3316 02:19:54,440 --> 02:19:56,960 DEVELOPMENT OF CELL AND GENE 3317 02:19:56,960 --> 02:19:59,560 THERAPIES, OVERCOMING SOME 3318 02:19:59,560 --> 02:20:00,480 CHALLENGES AND PROVIDING 3319 02:20:00,480 --> 02:20:01,760 OPPORTUNITIES TO THE RARE 3320 02:20:01,760 --> 02:20:02,280 DISEASE COMMUNITY. 3321 02:20:02,280 --> 02:20:06,560 SO IF YOU GO TO THE NEXT SLIDE. 3322 02:20:06,560 --> 02:20:08,840 OUR GOAL IS TO BUILD AN 3323 02:20:08,840 --> 02:20:10,840 ACCESSIBLE GENE THERAPY 3324 02:20:10,840 --> 02:20:11,120 PLATFORM. 3325 02:20:11,120 --> 02:20:13,920 YOU'VE HEARD DR. P.J. BROOKS 3326 02:20:13,920 --> 02:20:14,920 TALK ABOUT THIS. 3327 02:20:14,920 --> 02:20:21,600 MANY PROJECTS HE HAS ONGOING IN 3328 02:20:21,600 --> 02:20:24,200 THE EXTRAMURAL IN 2016 NIH 3329 02:20:24,200 --> 02:20:26,560 INTRAMURAL ESTABLISHED GENE 3330 02:20:26,560 --> 02:20:28,200 THERAPY DEVELOPMENT 3331 02:20:28,200 --> 02:20:29,920 INFRASTRUCTURE ALSO, AND THE 3332 02:20:29,920 --> 02:20:31,880 THERAPEUTICS FOR RARE AND 3333 02:20:31,880 --> 02:20:33,680 NEGLECTED DISEASE PARTNERS WITH 3334 02:20:33,680 --> 02:20:34,960 NCI FREDERICK WHICH HAD 3335 02:20:34,960 --> 02:20:36,360 MANUFACTURING CAPABILITIES IN 3336 02:20:36,360 --> 02:20:39,760 ORDER TO WORK ON MANUFACTURING 3337 02:20:39,760 --> 02:20:40,680 FOR THESE DRUG PRODUCTS. 3338 02:20:40,680 --> 02:20:42,880 AND SO THERE WERE TWO PROJECTS 3339 02:20:42,880 --> 02:20:47,800 WE WORKED ON, TRYING TO BUILD UP 3340 02:20:47,800 --> 02:20:48,880 MANUFACTURING CAPABILITIES, AND 3341 02:20:48,880 --> 02:20:51,280 TO HAVE LESSONS LEARNED AND 3342 02:20:51,280 --> 02:20:52,920 UNDERSTAND WHAT'S INVOLVED IN 3343 02:20:52,920 --> 02:20:53,600 MANUFACTURING GENE THERAPIES. 3344 02:20:53,600 --> 02:21:02,320 AND SO THERE WAS A GENE THERAPY 3345 02:21:02,320 --> 02:21:06,200 FOR L-AMINO ACID DECARBOXYLASEDE 3346 02:21:06,200 --> 02:21:09,560 ENCY, A LEAD COLLABORATOR 3347 02:21:09,560 --> 02:21:11,880 WITH WHAT IS NOW PPG 3348 02:21:11,880 --> 02:21:13,120 THERAPEUTICS, WORKING THROUGH 3349 02:21:13,120 --> 02:21:14,920 THE EEU REGISTRATION OF THIS 3350 02:21:14,920 --> 02:21:16,000 MOLECULE. 3351 02:21:16,000 --> 02:21:24,640 IN 2016 WE ALSO WORKED WITH DR. 3352 02:21:24,640 --> 02:21:29,440 DWIGHT KOEBERL AT DUKE, WAS 3353 02:21:29,440 --> 02:21:31,760 ASKBIO, TRANSFERRED TO BAYER FOR 3354 02:21:31,760 --> 02:21:33,200 POMPE DISEASE TO AID IN 3355 02:21:33,200 --> 02:21:34,480 MANUFACTURING OF THAT DRUG 3356 02:21:34,480 --> 02:21:34,920 PRODUCT. 3357 02:21:34,920 --> 02:21:36,440 CLINICAL TRIALS WERE SUPPORTED 3358 02:21:36,440 --> 02:21:37,840 BY NIAMS. 3359 02:21:37,840 --> 02:21:41,720 SO, AGAIN, THERE'S A LOT OF 3360 02:21:41,720 --> 02:21:43,920 COLLABORATION AND COORDINATION 3361 02:21:43,920 --> 02:21:45,520 AMONG DIFFERENT RESOURCES ACROSS 3362 02:21:45,520 --> 02:21:48,200 NCATS AND NIH. 3363 02:21:48,200 --> 02:21:50,640 IN 2017 THERE WAS A CONCEPT 3364 02:21:50,640 --> 02:21:52,560 CLEARANCE APPROVED BY NCATS 3365 02:21:52,560 --> 02:21:55,000 COUNCIL WHICH WAS NCATS 3366 02:21:55,000 --> 02:21:56,120 COLLABORATIVE RARE PLATFORM 3367 02:21:56,120 --> 02:21:58,040 VECTOR GENE THERAPY TRIAL. 3368 02:21:58,040 --> 02:21:59,160 AND THIS INVOLVES THREE 3369 02:21:59,160 --> 02:22:00,800 DIFFERENT DIVISIONS AND OFFICES 3370 02:22:00,800 --> 02:22:05,480 OF NCATS, WHICH IS THERAPEUTICS 3371 02:22:05,480 --> 02:22:07,040 DEVELOPMENT BRANCH, OUR NEW 3372 02:22:07,040 --> 02:22:09,240 DIVISION OF RARE DISEASE 3373 02:22:09,240 --> 02:22:10,400 RESEARCH AND INNOVATION, WHICH 3374 02:22:10,400 --> 02:22:12,680 DR. P.J. BROOKS IS NOW THE 3375 02:22:12,680 --> 02:22:14,040 ACTING DIRECTOR, AND OFFICE OF 3376 02:22:14,040 --> 02:22:17,400 STRATEGIC ALLIANCE WHICH IS LED 3377 02:22:17,400 --> 02:22:18,080 BY LILLY FORTILLA. 3378 02:22:18,080 --> 02:22:20,320 WHAT'S COME OUT OF THAT IS THAT 3379 02:22:20,320 --> 02:22:22,760 IN 2019 ONE OF THE PROGRAMS 3380 02:22:22,760 --> 02:22:24,440 THAT'S BEEN INITIATED, I'M GOING 3381 02:22:24,440 --> 02:22:29,240 TO BE TALKING ABOUT OUR 3382 02:22:29,240 --> 02:22:31,560 INTRAMURAL CONTRIBUTIONS, THE 3383 02:22:31,560 --> 02:22:34,480 INITIATION OF THE PAVE-GT 3384 02:22:34,480 --> 02:22:34,720 PROGRAM. 3385 02:22:34,720 --> 02:22:37,360 NEXT SLIDE. 3386 02:22:37,360 --> 02:22:39,920 THIS IS THE PAVE-GT WEBSITE. 3387 02:22:39,920 --> 02:22:42,640 AGAIN, OUR WHOLE MISSION IS TO 3388 02:22:42,640 --> 02:22:43,920 TRY TO PROVIDE ACCESSIBILITY. 3389 02:22:43,920 --> 02:22:50,800 PART OF THAT ACCESSIBILITY IS TO 3390 02:22:50,800 --> 02:22:52,000 THE INFORMATION SO EVERYBODY CAN 3391 02:22:52,000 --> 02:22:53,720 DEVELOP A PLATFORM, WHICH IS A 3392 02:22:53,720 --> 02:22:56,400 ROAD MAP FOR OTHERS SO THEY CAN 3393 02:22:56,400 --> 02:22:58,240 SEE WHAT HAPPENS DURING THIS 3394 02:22:58,240 --> 02:22:59,560 DRUG DEVELOPMENT PROCESS AND 3395 02:22:59,560 --> 02:23:01,120 HAVE ACCESS TO DETAILED 3396 02:23:01,120 --> 02:23:01,640 INFORMATION. 3397 02:23:01,640 --> 02:23:04,720 ON THE RIGHT-HAND SIDE WE DID A 3398 02:23:04,720 --> 02:23:06,400 MARKER PAPER THAT YOU CAN SEE 3399 02:23:06,400 --> 02:23:07,880 THERE THAT WAS PUBLISHED. 3400 02:23:07,880 --> 02:23:10,280 AND SO OVERALL WHAT WE'RE TRYING 3401 02:23:10,280 --> 02:23:14,120 TO DO IS INCREASE EFFICIENCIES, 3402 02:23:14,120 --> 02:23:15,760 ENHANCE COLLABORATION, LEVERAGE 3403 02:23:15,760 --> 02:23:17,640 EXISTING RESOURCES AND 3404 02:23:17,640 --> 02:23:18,480 EXPERTISE, INCREASE 3405 02:23:18,480 --> 02:23:21,040 ACCESSIBILITY, AS I SAID, AND 3406 02:23:21,040 --> 02:23:22,480 MOST OF ALL DISSEMINATE BEST 3407 02:23:22,480 --> 02:23:24,280 PRACTICES AND SHARE INFORMATION. 3408 02:23:24,280 --> 02:23:29,160 SO THAT THIS CAN ACTUALLY BE A 3409 02:23:29,160 --> 02:23:32,160 PLATFORM THAT HELPS OTHERS. 3410 02:23:32,160 --> 02:23:33,720 NEXT SLIDE. 3411 02:23:33,720 --> 02:23:35,760 SO, AGAIN, HERE'S OUR -- THIS 3412 02:23:35,760 --> 02:23:37,120 GOAL PERMEATES THROUGHOUT THAT 3413 02:23:37,120 --> 02:23:39,960 CAN WE USE COMMON PROCESSES EVEN 3414 02:23:39,960 --> 02:23:41,400 IN THE PRE-CLINICAL SPACE ACROSS 3415 02:23:41,400 --> 02:23:43,360 THE PLATFORM, AND THEN CAN WE 3416 02:23:43,360 --> 02:23:44,440 MAKE THAT DATA PUBLICLY 3417 02:23:44,440 --> 02:23:47,040 AVAILABLE TO MAKE THIS MORE OF A 3418 02:23:47,040 --> 02:23:47,480 PLATFORM. 3419 02:23:47,480 --> 02:23:49,680 AND SO, AGAIN, WE'RE 3420 02:23:49,680 --> 02:23:52,800 COLLABORATING WITH INTRAMURAL 3421 02:23:52,800 --> 02:23:56,680 LABS, WE'RE COLLABORATING WITH 3422 02:23:56,680 --> 02:24:02,880 DR. VAN DIDDY AT NHGRI FOR PCMI 3423 02:24:02,880 --> 02:24:08,840 AND MMAB ON THE LEFT, AND WITH 3424 02:24:08,840 --> 02:24:17,600 NINDS FOR THE CONGENITAL 3425 02:24:17,600 --> 02:24:18,720 MYASTHENIC SYNDROMES, WORKING 3426 02:24:18,720 --> 02:24:21,320 TOGETHER, WE FORMED THIS LARGE 3427 02:24:21,320 --> 02:24:23,000 TEAM AND THERAPEUTIC DEVELOPMENT 3428 02:24:23,000 --> 02:24:26,360 BRANCH IS DOING THE FULL 3429 02:24:26,360 --> 02:24:28,880 IND-ENABLING STUDIES FROM 3430 02:24:28,880 --> 02:24:30,960 SCALEUP PROCESS AND DEVELOPMENT, 3431 02:24:30,960 --> 02:24:33,520 GMP MANUFACTURING, TRYING TO 3432 02:24:33,520 --> 02:24:35,200 DEVELOP PROCESSES, GET 3433 02:24:35,200 --> 02:24:38,080 STANDARDIZED ASSAYS, AND TO SEE, 3434 02:24:38,080 --> 02:24:40,280 AGAIN, IF WE CAN THEN TRANSMIT 3435 02:24:40,280 --> 02:24:41,920 OR SHARE THAT INFORMATION WITH 3436 02:24:41,920 --> 02:24:45,640 THE COMMUNITY, WE'RE DOING ALL 3437 02:24:45,640 --> 02:24:46,760 THE DMPK, IND-ENABLING STUDIES 3438 02:24:46,760 --> 02:24:50,800 ARE ONGOING AND WE'RE WORKING ON 3439 02:24:50,800 --> 02:24:54,160 THE FIRST PCCA AND OTHER THREE 3440 02:24:54,160 --> 02:24:54,480 ALSO. 3441 02:24:54,480 --> 02:24:57,120 AND I JUST WANT TO POINT OUT 3442 02:24:57,120 --> 02:24:59,440 THESE ARE HUGE TEAMS, IT DOES 3443 02:24:59,440 --> 02:25:01,360 TAKE A HUGE TEAM TO COORDINATE 3444 02:25:01,360 --> 02:25:04,080 AND BRING ALL OF THIS TOGETHER, 3445 02:25:04,080 --> 02:25:08,000 AND THERE'S ABOUT 60 3446 02:25:08,000 --> 02:25:09,080 PRE-CLINICAL DEVELOPMENT 3447 02:25:09,080 --> 02:25:09,720 SCIENTISTS, NCATS, THERAPEUTICS 3448 02:25:09,720 --> 02:25:11,520 DEVELOPMENT BRANCH WITH THE 3449 02:25:11,520 --> 02:25:13,680 CROs AND CMOs THAT ARE DOING 3450 02:25:13,680 --> 02:25:15,880 SOME OF THESE LATE-STAGE STUDIES 3451 02:25:15,880 --> 02:25:17,600 AND IN COLLABORATION WITH ALL OF 3452 02:25:17,600 --> 02:25:18,800 THE OTHER INSTITUTES AT NIH THAT 3453 02:25:18,800 --> 02:25:22,320 ARE WORKING ON THIS PLATFORM 3454 02:25:22,320 --> 02:25:22,600 TOGETHER. 3455 02:25:22,600 --> 02:25:25,800 SO IF YOU GO TO THE NEXT SLIDE. 3456 02:25:25,800 --> 02:25:28,880 AS I SAID, ONE OF OUR KEY 3457 02:25:28,880 --> 02:25:31,200 DRIVERS HERE IS DISSEMINATION OF 3458 02:25:31,200 --> 02:25:31,840 OUR ACTIVITIES. 3459 02:25:31,840 --> 02:25:33,680 WE STARTED WITH THE PLATFORM 3460 02:25:33,680 --> 02:25:36,760 LAUNCH WHICH YOU'VE SEEN BEFORE, 3461 02:25:36,760 --> 02:25:39,840 I THINK YOU HEARD FROM THE 3462 02:25:39,840 --> 02:25:42,280 DIVISION OF RARE DISEASES 3463 02:25:42,280 --> 02:25:43,480 INNOVATION, RARE DISEASE -- 3464 02:25:43,480 --> 02:25:50,040 SORRY, I'M LEARNING THE ACRONYM 3465 02:25:50,040 --> 02:25:51,120 MYSELF. 3466 02:25:51,120 --> 02:25:53,840 IT USED TO BE ORDR, WEBSITE AND 3467 02:25:53,840 --> 02:25:54,520 MARKER PAPER. 3468 02:25:54,520 --> 02:25:57,480 WE'RE TRYING TO DO THIS 3469 02:25:57,480 --> 02:26:00,640 PRE-CLINICAL PLAYBOOK WHERE WE 3470 02:26:00,640 --> 02:26:03,040 ALSO WOULD LIKE TO WRITE WHITE 3471 02:26:03,040 --> 02:26:04,680 COVERS ELABORATING ON KNOW-HOW 3472 02:26:04,680 --> 02:26:06,880 OF DRUG DEVELOPMENT, SHARING 3473 02:26:06,880 --> 02:26:08,000 PROGRAM METHODS, PRE-CLINICAL 3474 02:26:08,000 --> 02:26:08,640 DEVELOPMENT, RELATED SCIENTIFIC 3475 02:26:08,640 --> 02:26:12,320 ARTICLES SO YOU CAN HAVE A 3476 02:26:12,320 --> 02:26:14,200 PRE-CLINICAL PLAY BOOK AND 3477 02:26:14,200 --> 02:26:14,960 REGULATORY SUBMISSIONS AND 3478 02:26:14,960 --> 02:26:16,720 COMMUNICATIONS WHICH WE THINK 3479 02:26:16,720 --> 02:26:20,360 ARE ONE OF THE KEY AREAS THAT WE 3480 02:26:20,360 --> 02:26:22,960 CAN DISSEMINATE. 3481 02:26:22,960 --> 02:26:24,920 WE ALREADY ESTABLISHED WE GOT 3482 02:26:24,920 --> 02:26:35,440 ORPHAN ORPHAN DRUG DESIGNATION, 3483 02:26:36,160 --> 02:26:39,240 WE'RE NAVIGATING, AND CAN SHARE 3484 02:26:39,240 --> 02:26:41,800 THE COMPLETE APPLICATION THAT WE 3485 02:26:41,800 --> 02:26:42,440 SUBMITTED. 3486 02:26:42,440 --> 02:26:45,280 WE HAD AN INTERACT MEETING, WITH 3487 02:26:45,280 --> 02:26:48,160 THE FDA, THAT'S A PRE-IND 3488 02:26:48,160 --> 02:26:50,000 MEETING WHERE YOU CAN TALK VERY 3489 02:26:50,000 --> 02:26:51,520 EARLY ON ABOUT THE DEVELOPMENT 3490 02:26:51,520 --> 02:26:51,920 PROCESS. 3491 02:26:51,920 --> 02:26:54,280 SO WE HOPE TO ALSO HAVE A WHITE 3492 02:26:54,280 --> 02:26:55,600 PAPER AND TO SHARE THAT 3493 02:26:55,600 --> 02:26:56,760 INFORMATION AND HOW WE WENT 3494 02:26:56,760 --> 02:26:58,880 ABOUT THAT, WHAT WE SUBMITTED, 3495 02:26:58,880 --> 02:27:00,720 WHAT WERE THE FDA RESPONSES TO 3496 02:27:00,720 --> 02:27:01,400 OUR QUESTIONS. 3497 02:27:01,400 --> 02:27:03,720 AND THEN WE PLAN TO SHARE ALL 3498 02:27:03,720 --> 02:27:05,320 THE OTHER REGULATORY PACKAGES 3499 02:27:05,320 --> 02:27:08,200 AND ALL THE INFORMATION AS THESE 3500 02:27:08,200 --> 02:27:10,040 PROJECTS MOVE FORWARD IN 3501 02:27:10,040 --> 02:27:10,400 DEVELOPMENT. 3502 02:27:10,400 --> 02:27:11,560 AND AS THEY MOVE INTO THE CLINIC 3503 02:27:11,560 --> 02:27:14,320 WE HOPE TO HAVE A CLINICAL 3504 02:27:14,320 --> 02:27:16,840 PLAYBOOK WHERE WE CAN SHARE 3505 02:27:16,840 --> 02:27:18,360 BIOMARKERS AND NATURAL HISTORY 3506 02:27:18,360 --> 02:27:19,520 DOCUMENTATION AND SHARE THE 3507 02:27:19,520 --> 02:27:20,320 CLINICAL DATA. 3508 02:27:20,320 --> 02:27:24,600 AND SO, AGAIN, IT'S A PLATFORM 3509 02:27:24,600 --> 02:27:27,240 TO TRY TO OPERATIONALIZE, TO 3510 02:27:27,240 --> 02:27:28,440 SHARE THE INFORMATION, TO 3511 02:27:28,440 --> 02:27:30,520 DISSEMINATE AND HELP THE 3512 02:27:30,520 --> 02:27:31,040 COMMUNITY. 3513 02:27:31,040 --> 02:27:35,120 SO, IF YOU GO TO THE LAST 3514 02:27:35,120 --> 02:27:37,400 EXAMPLE, IN THIS LAST EXAMPLE I 3515 02:27:37,400 --> 02:27:38,960 WANTED TO TALK, AGAIN, YOU KNOW, 3516 02:27:38,960 --> 02:27:41,040 OUR MISSION IS ALSO 3517 02:27:41,040 --> 02:27:42,800 TRANSLATIONAL INITIATIVES AND 3518 02:27:42,800 --> 02:27:43,640 PROCESS OF TRANSLATION. 3519 02:27:43,640 --> 02:27:46,680 AND SO I WANTED TO TALK ABOUT 3520 02:27:46,680 --> 02:27:49,320 THIS GAP BETWEEN THE SCIENTIFIC 3521 02:27:49,320 --> 02:27:51,480 RESEARCH AND TRANSLATION TO 3522 02:27:51,480 --> 02:27:52,920 THERAPIES FOR RARE DISEASES. 3523 02:27:52,920 --> 02:27:54,320 ONE INITIATIVE IN WHICH WE'RE 3524 02:27:54,320 --> 02:27:55,040 TRYING TO ADDRESS THIS, SO, 3525 02:27:55,040 --> 02:27:56,680 AGAIN, IF YOU LOOK HERE ON THE 3526 02:27:56,680 --> 02:28:04,800 LEFT, WHAT YOU CAN SEE FROM A 3527 02:28:04,800 --> 02:28:07,560 PAPER IN 2018 PUBLICATIONS, 3528 02:28:07,560 --> 02:28:08,320 SCIENTIFIC INFORMATION IS MUCH 3529 02:28:08,320 --> 02:28:11,840 GREATER THAN TRANSLATING TO THE 3530 02:28:11,840 --> 02:28:12,600 ACTUAL THERAPEUTICS AND 3531 02:28:12,600 --> 02:28:15,560 APPROVALS, IF YOU SEE FOR FDA 3532 02:28:15,560 --> 02:28:15,880 AND EMA. 3533 02:28:15,880 --> 02:28:18,840 AND SO THERE'S THIS GAP BETWEEN 3534 02:28:18,840 --> 02:28:21,280 THE SCIENCE AND ACTUAL APPROVALS 3535 02:28:21,280 --> 02:28:22,320 FOR RARE DISEASES. 3536 02:28:22,320 --> 02:28:23,960 AND SO, AGAIN, IT'S THE 3537 02:28:23,960 --> 02:28:25,160 CHALLENGES AND, YOU KNOW, THE 3538 02:28:25,160 --> 02:28:27,480 WAY THAT WE'RE THINKING ABOUT 3539 02:28:27,480 --> 02:28:30,880 THIS THAT DATA EXISTS BUT IT'S 3540 02:28:30,880 --> 02:28:31,640 NOT COLLECTIVELY ORGANIZED, ALL 3541 02:28:31,640 --> 02:28:33,360 WE SHARE TO EXTRACT THAT 3542 02:28:33,360 --> 02:28:33,720 INFORMATION. 3543 02:28:33,720 --> 02:28:35,760 AND 3544 02:28:35,760 --> 02:28:37,360 AND SO THE OPPORTUNITIES CAN WE 3545 02:28:37,360 --> 02:28:41,040 APPLY ADVANCES IN DATA AND 3546 02:28:41,040 --> 02:28:42,240 INFORMATION TECHNOLOGIES, AND 3547 02:28:42,240 --> 02:28:44,200 BUILD INFORMATICS PLATFORM TO 3548 02:28:44,200 --> 02:28:45,840 MAKE THIS RARE DISEASE 3549 02:28:45,840 --> 02:28:46,840 INFORMATION MORE ACCESSIBLE. 3550 02:28:46,840 --> 02:28:51,040 AS YOU KNOW, WE HAVE SEVERAL OF 3551 02:28:51,040 --> 02:28:52,440 THESE ACTIVITIES ACROSS NCATS, 3552 02:28:52,440 --> 02:28:54,120 AND WHAT WE'RE AGAIN HOPING TO 3553 02:28:54,120 --> 02:28:56,160 DO IS THAT ALL OF THIS, THEY ARE 3554 02:28:56,160 --> 02:28:59,040 ALL GOOD INITIATIVES THAT CAN 3555 02:28:59,040 --> 02:29:01,400 INTEGRATE MORE INFORMATION 3556 02:29:01,400 --> 02:29:01,680 TOGETHER. 3557 02:29:01,680 --> 02:29:03,280 FOR INSTANCE, THE GUARD PLATFORM 3558 02:29:03,280 --> 02:29:06,440 WHICH YOU'VE ALL HEARD ABOUT, 3559 02:29:06,440 --> 02:29:07,840 IT'S VERY ESTABLISHED, REALLY 3560 02:29:07,840 --> 02:29:08,760 PROVIDES THE PATIENTS THE 3561 02:29:08,760 --> 02:29:12,760 INFORMATION THAT THEY NEED WHEN 3562 02:29:12,760 --> 02:29:14,000 THEY ARE FIRST DIAGNOSED, AND 3563 02:29:14,000 --> 02:29:15,320 WHAT WE'VE BUILT HERE WHICH I'LL 3564 02:29:15,320 --> 02:29:17,160 TALK ABOUT IS THAT WE'VE 3565 02:29:17,160 --> 02:29:18,800 ACTUALLY TRIED TO INTEGRATE SOME 3566 02:29:18,800 --> 02:29:24,320 OF THE PARTS OF GUARD. 3567 02:29:24,320 --> 02:29:28,040 OUR ONTOLOGY COMES FROM GUARD. 3568 02:29:28,040 --> 02:29:29,680 WE'VE BEEN TRYING TO BUILD A 3569 02:29:29,680 --> 02:29:32,920 RARE SOURCE USING BIG DATA 3570 02:29:32,920 --> 02:29:34,040 APPROACH TO UNDERSTAND HOW RARE 3571 02:29:34,040 --> 02:29:38,840 DISEASES ARE GROUP, IF WE CAN 3572 02:29:38,840 --> 02:29:40,800 GROUP THEM ACCORDING TO THEIR, 3573 02:29:40,800 --> 02:29:42,480 YOU KNOW, PATHWAYS, CAN WE FIND 3574 02:29:42,480 --> 02:29:44,440 WAYS OR NEW WAYS THEY CAN BE 3575 02:29:44,440 --> 02:29:47,200 TREATED BY SIMILAR MOLECULES OR 3576 02:29:47,200 --> 02:29:48,000 THE SAME MOLECULE. 3577 02:29:48,000 --> 02:29:52,120 AND SO, AGAIN, WE'RE TRYING TO 3578 02:29:52,120 --> 02:29:55,040 BRING TOGETHER CURRENTLY THE 3579 02:29:55,040 --> 02:29:56,480 GENES, VARIANTS, PROTEINS, 3580 02:29:56,480 --> 02:29:57,440 DISEASE INFORMATION, AND 3581 02:29:57,440 --> 02:29:58,440 EVENTUALLY WE'LL ADD OTHER 3582 02:29:58,440 --> 02:30:00,520 INFORMATION BUT, AGAIN, THIS WAS 3583 02:30:00,520 --> 02:30:02,200 STARTING ON THE MOLECULAR 3584 02:30:02,200 --> 02:30:03,160 INTERACTION LEVEL, AND SO WE 3585 02:30:03,160 --> 02:30:05,880 HOPE THAT IT MEETS WITH ALL THE 3586 02:30:05,880 --> 02:30:06,680 OTHER INFORMATION RESOURCES. 3587 02:30:06,680 --> 02:30:09,480 AND THAT OTHERS ALSO CAN 3588 02:30:09,480 --> 02:30:11,480 INTEGRATE THEIR INFORMATION SO 3589 02:30:11,480 --> 02:30:17,280 THAT WE MAKE THIS VERY 3590 02:30:17,280 --> 02:30:18,360 INTEROPEARABLE. 3591 02:30:18,360 --> 02:30:19,720 WE'RE TRYING TO INTEGRATE DATA 3592 02:30:19,720 --> 02:30:20,760 WE HAVE ACCESS TO. 3593 02:30:20,760 --> 02:30:24,080 IF YOU GO TO THE NEXT SLIDE, HOW 3594 02:30:24,080 --> 02:30:26,560 DID WE GO ABOUT THIS? 3595 02:30:26,560 --> 02:30:29,520 AGAIN, WE'RE TRYING TO CREATE A 3596 02:30:29,520 --> 02:30:30,520 SEARCHABLE, ACCESSIBLE, USER 3597 02:30:30,520 --> 02:30:31,480 FRIENDLY RESOURCE. 3598 02:30:31,480 --> 02:30:33,800 AND WE WERE STARTING IT BY 3599 02:30:33,800 --> 02:30:35,120 TRAINING THE PLATFORM THROUGH 3600 02:30:35,120 --> 02:30:36,480 MANUAL CREATION OF SOME OF THE 3601 02:30:36,480 --> 02:30:37,160 DISEASE LITERATURE. 3602 02:30:37,160 --> 02:30:39,600 IT WAS BASED ON PROJECTS THAT WE 3603 02:30:39,600 --> 02:30:43,040 WORKED ON, IN OUR THERAPEUTIC 3604 02:30:43,040 --> 02:30:43,680 DEVELOPMENT PLATFORM. 3605 02:30:43,680 --> 02:30:45,640 AND WE HAVE WORKED ON 3606 02:30:45,640 --> 02:30:49,720 INTEGRATING THE KNOWN PUBLIC 3607 02:30:49,720 --> 02:30:51,000 DATABASES, AND THEN DEVELOPING 3608 02:30:51,000 --> 02:30:52,760 MODULES FOR AUTOMATING MINING OF 3609 02:30:52,760 --> 02:30:53,960 LITERATURE AND EXPANDING THAT TO 3610 02:30:53,960 --> 02:30:58,480 THE 7,000 RARE DISEASES, AGAIN 3611 02:30:58,480 --> 02:31:00,760 USING ALL THE -- HAVE ACCESS TO 3612 02:31:00,760 --> 02:31:04,160 PLATFORMS THAT ALREADY EXIST AND 3613 02:31:04,160 --> 02:31:05,440 HOPEFULLY OTHER PLATFORMS CAN, 3614 02:31:05,440 --> 02:31:06,480 YOU KNOW, INTEGRATE INTO THIS 3615 02:31:06,480 --> 02:31:06,920 ALSO. 3616 02:31:06,920 --> 02:31:11,840 SO IF YOU LOOK ON THE NEXT 3617 02:31:11,840 --> 02:31:15,960 SLIDE, AGAIN, WE'VE STARTED WITH 3618 02:31:15,960 --> 02:31:17,080 SOME REAL TRAINING PILOT 3619 02:31:17,080 --> 02:31:23,080 TRAINING PROJECTS, WHAT WE'RE 3620 02:31:23,080 --> 02:31:24,160 DOING IS LITERATURE MINING, TO 3621 02:31:24,160 --> 02:31:25,880 BRING THE INFORMATION WE COULD 3622 02:31:25,880 --> 02:31:27,240 TOGETHER FOR THESE DISEASES. 3623 02:31:27,240 --> 02:31:32,200 AND SO WE STARTED WITH CREATIN 3624 02:31:32,200 --> 02:31:34,360 TRANSPORTER DEFICIENCY, AND WE 3625 02:31:34,360 --> 02:31:38,440 DID A VERY MANUAL DETAILED 3626 02:31:38,440 --> 02:31:39,040 CURATION OF LITERATURE AND 3627 02:31:39,040 --> 02:31:41,240 BROUGHT IN ALL OF THE KNOWN 3628 02:31:41,240 --> 02:31:41,840 VARIANT DATABASES. 3629 02:31:41,840 --> 02:31:44,000 IF YOU SEE THERE ON THE RIGHT 3630 02:31:44,000 --> 02:31:46,520 THERE'S THE PROTEIN, IT'S A 3631 02:31:46,520 --> 02:31:47,320 TRANSMEMBRANE PROTEIN. 3632 02:31:47,320 --> 02:31:50,840 AND ALL OF THE MUTATIONS ARE 3633 02:31:50,840 --> 02:31:52,520 HIGHLIGHTED ON THE PROTEIN. 3634 02:31:52,520 --> 02:31:53,880 YOU CAN SEE THE PROTEIN 3635 02:31:53,880 --> 02:31:56,280 STRUCTURE WITH EACH OF THE 3636 02:31:56,280 --> 02:31:58,000 MUTATIONS, AND YOU CAN ALSO -- 3637 02:31:58,000 --> 02:31:59,880 IT'S HARD TO SEE, BUT IN THE 3638 02:31:59,880 --> 02:32:01,280 BOTTOM RIGHT IS ACTUALLY THE 3639 02:32:01,280 --> 02:32:07,000 ACTIVITY OF EACH OF THOSE 3640 02:32:07,000 --> 02:32:09,040 MUTATIONS USING A CREATINE 3641 02:32:09,040 --> 02:32:09,720 TRANSPORTER ASSAY INTEGRATED 3642 02:32:09,720 --> 02:32:14,480 INTO THE FIRST INVESTIGATION OF 3643 02:32:14,480 --> 02:32:16,000 THIS BIOINFORMATIC DATABASE. 3644 02:32:16,000 --> 02:32:18,120 WHAT WE FOUND BY DOING ONE CASE 3645 02:32:18,120 --> 02:32:20,760 STUDY IF YOU LOOK AT THE 3646 02:32:20,760 --> 02:32:21,880 VARIANTS, ALL VARIANTS, YOU 3647 02:32:21,880 --> 02:32:24,280 LOOKED AT THE PUBLIC DATABASES, 3648 02:32:24,280 --> 02:32:28,120 THERE WAS NOT A GREAT DEAL OF 3649 02:32:28,120 --> 02:32:30,160 OVERLAP, WHAT WAS IN 3650 02:32:30,160 --> 02:32:31,600 ClinVar, ONE OF THE, YOU 3651 02:32:31,600 --> 02:32:34,120 KNOW, VERY WELL KNOWN, WHERE 3652 02:32:34,120 --> 02:32:36,520 PEOPLE PUT THEIR VARIANTS, WE 3653 02:32:36,520 --> 02:32:39,200 CURATED 132. 3654 02:32:39,200 --> 02:32:45,040 THERE WERE 406, ONLY 43 -- 53 3655 02:32:45,040 --> 02:32:46,960 OVERLAPS, ON PATHOGENIC, EVEN 3656 02:32:46,960 --> 02:32:48,280 LESS, ONLY 18 OVERLAPS BETWEEN 3657 02:32:48,280 --> 02:32:51,120 WHAT WAS CURATED IN LITERATURE 3658 02:32:51,120 --> 02:32:54,760 VERSUS WHAT IS ACTUALLY IN 3659 02:32:54,760 --> 02:32:55,000 ClinVar. 3660 02:32:55,000 --> 02:32:58,360 IF YOU GO TO THE NEXT SLIDE, SO, 3661 02:32:58,360 --> 02:33:01,200 AGAIN, WHAT I WANT TO POINT OUT, 3662 02:33:01,200 --> 02:33:03,600 THIS IS A HIGHLY COLLABORATIVE 3663 02:33:03,600 --> 02:33:04,480 EFFORT. 3664 02:33:04,480 --> 02:33:08,480 AGAIN, WE'RE WORKING WITH NCI AT 3665 02:33:08,480 --> 02:33:09,000 FREDERICK, NATIONAL CANCER 3666 02:33:09,000 --> 02:33:09,360 INSTITUTE 3667 02:33:09,360 --> 02:33:11,520 THE REASON WE WORKED WITH THEM 3668 02:33:11,520 --> 02:33:15,640 IS THAT THEY HAVE A LOT OF TOOLS 3669 02:33:15,640 --> 02:33:17,080 AND THEY ALREADY ARE 3670 02:33:17,080 --> 02:33:17,720 INFRASTRUCTURE BUILT SO, AGAIN, 3671 02:33:17,720 --> 02:33:19,200 WE'RE NOT TRYING TO REINVENT THE 3672 02:33:19,200 --> 02:33:20,840 WHEEL AND BUILD SOMETHING NEW. 3673 02:33:20,840 --> 02:33:23,240 WE'RE TRYING TO INTEGRATE AND 3674 02:33:23,240 --> 02:33:25,280 SEE IF WE CAN INTEGRATE DATA 3675 02:33:25,280 --> 02:33:27,080 INTO WHAT THEY HAVE ALREADY 3676 02:33:27,080 --> 02:33:27,520 ESTABLISHED. 3677 02:33:27,520 --> 02:33:29,800 SO WE'RE ALSO COLLABORATING WITH 3678 02:33:29,800 --> 02:33:33,200 OTHER INSTITUTES, AS YOU CAN 3679 02:33:33,200 --> 02:33:34,960 SEE, NICHD, AND NINDS, AND WE 3680 02:33:34,960 --> 02:33:37,000 HOPE TO COLLABORATE WITH OTHER 3681 02:33:37,000 --> 02:33:37,800 NIH INSTITUTES BECAUSE SOME OF 3682 02:33:37,800 --> 02:33:39,240 THE DATA THAT WE WOULD REALLY 3683 02:33:39,240 --> 02:33:40,960 LIKE TO HARNESS IS FROM THE 3684 02:33:40,960 --> 02:33:43,160 NATURAL HISTORY STUDY THAT THE 3685 02:33:43,160 --> 02:33:44,800 NIH CLINICAL CENTER IS ONE WAY 3686 02:33:44,800 --> 02:33:49,280 WE CAN CONTRIBUTE IN NEW DATA 3687 02:33:49,280 --> 02:33:50,160 INTO THIS DATABASE. 3688 02:33:50,160 --> 02:33:55,000 SO IF YOU GO TO THE NEXT SLIDE. 3689 02:33:55,000 --> 02:33:57,920 SO, THOSE WERE THE FIVE EXAMPLES 3690 02:33:57,920 --> 02:34:01,920 THAT I HOPE SHOWED YOU, I GAVE A 3691 02:34:01,920 --> 02:34:03,320 GOOD REPRESENTATION OF 3692 02:34:03,320 --> 02:34:04,080 PRE-CLINICAL DEVELOPMENT 3693 02:34:04,080 --> 02:34:04,520 PLATFORMS. 3694 02:34:04,520 --> 02:34:08,240 AND HOW WE TRY TO ADD VALUE TO 3695 02:34:08,240 --> 02:34:10,840 PROJECTS OF HIGH TRANSLATIONAL 3696 02:34:10,840 --> 02:34:11,560 IMPACT. 3697 02:34:11,560 --> 02:34:12,840 AND MOVE THINGS INTO THE CLINIC 3698 02:34:12,840 --> 02:34:14,680 FOR TESTING AND NEW THERAPIES 3699 02:34:14,680 --> 02:34:15,120 FOR PATIENTS. 3700 02:34:15,120 --> 02:34:18,520 AND THIS IS A SNAPSHOT, OF 3701 02:34:18,520 --> 02:34:20,360 OUTCOMES THAT WE THOUGHT, AGAIN, 3702 02:34:20,360 --> 02:34:22,800 THIS IS MEASUREMENTS OF INDs 3703 02:34:22,800 --> 02:34:26,640 AND PHASE 1, PHASE 2s, AND 3704 02:34:26,640 --> 02:34:28,880 NATURAL HISTORY STUDIES THAT 3705 02:34:28,880 --> 02:34:31,080 WE'VE SUPPORTED. 3706 02:34:31,080 --> 02:34:33,160 AND SO, AGAIN, WE'VE HAD 44 3707 02:34:33,160 --> 02:34:39,240 INDs SINCE THE START OF THE 3708 02:34:39,240 --> 02:34:42,280 PROGRAMS, AND THAT'S 32 INDs 3709 02:34:42,280 --> 02:34:43,560 BECAUSE THE PROGRAM STARTED 3710 02:34:43,560 --> 02:34:45,400 MANY -- SOME STARTED BEFORE 3711 02:34:45,400 --> 02:34:46,840 NCATS WAS ESTABLISHED, AND CAME 3712 02:34:46,840 --> 02:34:49,760 INTO NCATS, SO SINCE NCATS WAS 3713 02:34:49,760 --> 02:34:51,120 ESTABLISHED THERE'S BEEN 32 3714 02:34:51,120 --> 02:34:52,640 INDs, SO, AGAIN, WE DON'T 3715 02:34:52,640 --> 02:34:54,200 ALWAYS DO THE WHOLE IND. 3716 02:34:54,200 --> 02:34:56,640 SOMETIMES IT'S THE PIECES THAT 3717 02:34:56,640 --> 02:34:58,800 WE CONTRIBUTE, BRINGING PIECES 3718 02:34:58,800 --> 02:34:59,040 TOGETHER. 3719 02:34:59,040 --> 02:35:00,120 AND, AGAIN, THE CLINICAL TRIALS 3720 02:35:00,120 --> 02:35:03,080 HAVE EITHER BEEN AT THE NIH 3721 02:35:03,080 --> 02:35:06,560 CLINICAL CENTER IF FOR RARE 3722 02:35:06,560 --> 02:35:07,440 DISEASES OR WITH COLLABORATORS, 3723 02:35:07,440 --> 02:35:09,120 INITIATED BY WHO WE'VE 3724 02:35:09,120 --> 02:35:09,960 COLLABORATED WITH. 3725 02:35:09,960 --> 02:35:12,320 AND SO AS JONI SAID, WHAT WE 3726 02:35:12,320 --> 02:35:14,160 WANTED TO HIGHLIGHT WAS THAT ONE 3727 02:35:14,160 --> 02:35:16,240 OF OUR CONTRIBUTIONS TO A 3728 02:35:16,240 --> 02:35:19,840 PROJECT HAS LED TO AN ACTUAL 3729 02:35:19,840 --> 02:35:21,040 APPROVAL OF A DRUG, AND WHAT WE 3730 02:35:21,040 --> 02:35:23,680 HOPE IN THE FUTURE AS JONI SAID 3731 02:35:23,680 --> 02:35:25,400 OUR MANTRA IS DECADE AHEAD, MORE 3732 02:35:25,400 --> 02:35:26,640 TREATMENTS FOR ALL PEOPLE, MORE 3733 02:35:26,640 --> 02:35:27,920 QUICKLY, IF YOU GO TO THE NEXT 3734 02:35:27,920 --> 02:35:31,640 SLIDE I THINK I'M JUST GOING TO 3735 02:35:31,640 --> 02:35:34,720 END WITH THE APPROVAL, SO THIS 3736 02:35:34,720 --> 02:35:38,560 WAS A FIRST FDA DRUG APPROVAL 3737 02:35:38,560 --> 02:35:40,360 THAT CAME FROM A CONTRIBUTION 3738 02:35:40,360 --> 02:35:43,640 THAT WE MADE TO A THERAPEUTIC 3739 02:35:43,640 --> 02:35:45,120 DEVELOPMENT PROJECT. 3740 02:35:45,120 --> 02:35:50,760 SO TDB WORKED ON A COLLABORATION 3741 02:35:50,760 --> 02:35:55,440 ON NOVEL AZOLE CLASS OF 3742 02:35:55,440 --> 02:35:58,360 ANTI-FUNGAL DRUG ON CRYPTOCOCCAL 3743 02:35:58,360 --> 02:35:59,200 MENINGITIS, DID PRE-CLINICAL 3744 02:35:59,200 --> 02:35:59,520 STUDIES. 3745 02:35:59,520 --> 02:36:04,240 WHAT CAME OUT WAS A PLATFORM FOR 3746 02:36:04,240 --> 02:36:07,280 THE MANUFACTURING WHERE IP WAS 3747 02:36:07,280 --> 02:36:09,280 GENERATED, AND WE DEVELOPED 3748 02:36:09,280 --> 02:36:11,280 CRITICAL PROCESS CHEMISTRY, ALL 3749 02:36:11,280 --> 02:36:14,360 METHODS FOR LARGE SCALE 3750 02:36:14,360 --> 02:36:20,080 MANUFACTURING, THAT WERE ALL 3751 02:36:20,080 --> 02:36:24,000 LICENSED BY VIAMET, ACQUIRED BY 3752 02:36:24,000 --> 02:36:25,960 MYCOVIA IN 2018, WERE ABLE TO 3753 02:36:25,960 --> 02:36:27,000 APPLY CHEMISTRY METHODS TO 3754 02:36:27,000 --> 02:36:27,360 APPROVAL. 3755 02:36:27,360 --> 02:36:31,280 YOU CAN SEE ON RIGHT CURRENT CEO 3756 02:36:31,280 --> 02:36:33,640 OF MYCOVIA COMMENTED THEY WERE 3757 02:36:33,640 --> 02:36:35,160 GRATEFUL FOR THE COLLABORATIVE 3758 02:36:35,160 --> 02:36:40,000 INTERACTIONS THEY HAD FOR THE 3759 02:36:40,000 --> 02:36:45,600 PROCESS DEVELOPMENT FOR VH1 129 3760 02:36:45,600 --> 02:36:49,520 NOW, NOW VT-1161, FOR MUJOVA, 3761 02:36:49,520 --> 02:36:51,840 FOR CHRONIC YEAST INFECTION. 3762 02:36:51,840 --> 02:36:54,360 AGAIN, IT'S FOR WOMEN'S HEALTH. 3763 02:36:54,360 --> 02:36:56,160 SO WE FEEL THAT, YOU KNOW, WE'VE 3764 02:36:56,160 --> 02:36:59,760 HAD A GREAT VALUE ADDED, IN HOW 3765 02:36:59,760 --> 02:37:07,120 WE WERE ABLE TO HELP IN THE 3766 02:37:07,120 --> 02:37:08,200 DEVELOPMENT OF THIS DRUG. 3767 02:37:08,200 --> 02:37:08,960 I'LL END THERE. 3768 02:37:08,960 --> 02:37:09,960 I NEED TO THANK EVERYBODY 3769 02:37:09,960 --> 02:37:11,840 BECAUSE THIS IS A TEAM EFFORT, 3770 02:37:11,840 --> 02:37:13,240 LIKE EVERYONE IS SAYING. 3771 02:37:13,240 --> 02:37:17,920 AND EVERYTHING WE DO IN OUR TDB 3772 02:37:17,920 --> 02:37:19,880 PROGRAM IS A TEAM EFFORT WITH 3773 02:37:19,880 --> 02:37:21,440 OUR COLLABORATORS, EVERYBODY 3774 02:37:21,440 --> 02:37:23,520 HERE AT NIH, OUTSIDE OF NIH, AND 3775 02:37:23,520 --> 02:37:25,120 ALL OF OUR FUNCTIONAL TEAMS THAT 3776 02:37:25,120 --> 02:37:26,680 WORK TOGETHER ON ALL OF THE 3777 02:37:26,680 --> 02:37:28,200 PROJECTS SO I WANT TO SEND OUT A 3778 02:37:28,200 --> 02:37:29,880 REALLY BIG THANK YOU TO 3779 02:37:29,880 --> 02:37:32,240 EVERYBODY THAT WE WORK ON ALL OF 3780 02:37:32,240 --> 02:37:33,240 OUR PROGRAMS WITH. 3781 02:37:33,240 --> 02:37:34,680 AND LASTLY I THINK IT'S JUST 3782 02:37:34,680 --> 02:37:36,080 OPEN FOR DISCUSSION, IF ANYONE 3783 02:37:36,080 --> 02:37:36,800 HAS ANY QUESTIONS. 3784 02:37:36,800 --> 02:37:41,040 AND THANK YOU FOR LISTENING. 3785 02:37:41,040 --> 02:37:44,000 >> LIZ, THANK YOU FOR THE 3786 02:37:44,000 --> 02:37:44,960 TREMENDOUS OVERVIEW, REALLY 3787 02:37:44,960 --> 02:37:46,040 TERRIFIC. 3788 02:37:46,040 --> 02:37:49,080 I THINK WE HAVE A FEW 3789 02:37:49,080 --> 02:37:50,000 OPPORTUNITIES TO HEAR SOME 3790 02:37:50,000 --> 02:37:51,200 DISCUSSION OR QUESTIONS. 3791 02:37:51,200 --> 02:37:54,280 FIRST I WANT TO ASK ANDREW, HE 3792 02:37:54,280 --> 02:37:57,200 PUT INTO THE CHAT THE IDEA OF, 3793 02:37:57,200 --> 02:37:59,520 WELL, THIS PAPER THAT WAS 3794 02:37:59,520 --> 02:38:01,480 PUBLISHED RECENTLY, AND I WAS 3795 02:38:01,480 --> 02:38:03,520 WONDERING, ANDREW, IF YOU 3796 02:38:03,520 --> 02:38:05,160 WOULDN'T MIND SAYING A FEW WORDS 3797 02:38:05,160 --> 02:38:06,600 ABOUT THAT MANY BECAUSE I THINK 3798 02:38:06,600 --> 02:38:07,480 IT'S SORT OF HIGHLIGHTING THE 3799 02:38:07,480 --> 02:38:09,360 IDEA OF WHAT WE DO PUTTING 3800 02:38:09,360 --> 02:38:10,680 PIECES TOGETHER AND CONNECTING 3801 02:38:10,680 --> 02:38:12,600 THE DOTS. 3802 02:38:12,600 --> 02:38:12,960 >> SURE. 3803 02:38:12,960 --> 02:38:19,040 WELL, THIS IS A CASE STUDY ABOUT 3804 02:38:19,040 --> 02:38:23,080 THE AADC DEFICIENT INFANTS THAT 3805 02:38:23,080 --> 02:38:29,120 NCATS PLAYED A CRITICAL ROLE 3806 02:38:29,120 --> 02:38:30,680 PARTNERING WITH AGILLUS. 3807 02:38:30,680 --> 02:38:33,840 IT'S A SINGLE GENE MUTATION THAT 3808 02:38:33,840 --> 02:38:35,280 BASICALLY PREVENTS INFANTS FROM 3809 02:38:35,280 --> 02:38:36,800 PRODUCING DOPAMINE IN THE BRAIN. 3810 02:38:36,800 --> 02:38:38,760 MOST OF YOU KNOW FAR BETTER THAN 3811 02:38:38,760 --> 02:38:40,280 I DO THAT WITHOUT DOPAMINE WE 3812 02:38:40,280 --> 02:38:44,000 AREN'T ABLE TO ENGAGE IN MOTOR 3813 02:38:44,000 --> 02:38:44,560 FUNCTIONS. 3814 02:38:44,560 --> 02:38:46,760 AND THIS TAIWANESE DOCTOR, PAUL 3815 02:38:46,760 --> 02:38:49,400 HU, DEVELOPED THE GENE THERAPY 3816 02:38:49,400 --> 02:38:51,120 THAT ULTIMATELY WAS TAKEN 3817 02:38:51,120 --> 02:38:54,520 FORWARD THROUGH COMBINATION OF 3818 02:38:54,520 --> 02:38:57,280 GRANTS FROM NCATS AND AGILLUS 3819 02:38:57,280 --> 02:39:00,200 IS, AND AFTER THE FDA SAW THE 3820 02:39:00,200 --> 02:39:01,360 PHASE 2 DATA, THEY SAID YOU 3821 02:39:01,360 --> 02:39:03,280 DON'T NEED TO DO A PHASE 3, YOU 3822 02:39:03,280 --> 02:39:05,280 CAN APPLY FOR A BIOLOGICS 3823 02:39:05,280 --> 02:39:09,600 LICENSE BECAUSE THE RESULTS WERE 3824 02:39:09,600 --> 02:39:10,600 JUST SO DRAMATIC. 3825 02:39:10,600 --> 02:39:11,920 INFANTS THAT COULDN'T MOVE, 3826 02:39:11,920 --> 02:39:14,560 COULDN'T LIFT ARMS, COULDN'T SIT 3827 02:39:14,560 --> 02:39:16,760 UP, COULDN'T MOVE AROUND, THEY 3828 02:39:16,760 --> 02:39:19,520 ACTUALLY STARTED CRAWLING AND 3829 02:39:19,520 --> 02:39:20,800 EVENTUALLY WALKING. 3830 02:39:20,800 --> 02:39:24,040 REALLY KIND OF A MIRACULOUS 3831 02:39:24,040 --> 02:39:24,360 THERAPEUTIC. 3832 02:39:24,360 --> 02:39:25,840 AND THIS WOULD NOT HAVE HAPPENED 3833 02:39:25,840 --> 02:39:26,880 WITHOUT NCATS. 3834 02:39:26,880 --> 02:39:28,880 JUST A REALLY EXTRAORDINARY 3835 02:39:28,880 --> 02:39:31,480 EXAMPLE OF WHAT YOU ALL HAVE 3836 02:39:31,480 --> 02:39:34,360 ACCOMPLISHED OVER A VERY SHORT 3837 02:39:34,360 --> 02:39:35,640 PERIOD OF TIME. 3838 02:39:35,640 --> 02:39:37,520 >> THANKS, ANDREW. 3839 02:39:37,520 --> 02:39:39,800 I APPRECIATE THAT. 3840 02:39:39,800 --> 02:39:41,560 YEAH, HOPEFULLY WE CAN GET PAST 3841 02:39:41,560 --> 02:39:42,760 THE FIREWALL SO THAT OTHERS CAN 3842 02:39:42,760 --> 02:39:47,680 SEE THE PAPER AS WELL. 3843 02:39:47,680 --> 02:39:48,440 APPRECIATE THAT. 3844 02:39:48,440 --> 02:39:54,160 I SAW MARSHAL HAD A HAND UP 3845 02:39:54,160 --> 02:39:54,680 EARLIER. 3846 02:39:54,680 --> 02:39:55,960 >> GREAT PRESENTATION. 3847 02:39:55,960 --> 02:39:56,920 I'VE BEEN WORKING WITH Y'ALL'S 3848 02:39:56,920 --> 02:39:58,360 GROUP IN THE PAST. 3849 02:39:58,360 --> 02:39:59,840 WE ACTUALLY DEVELOPED SOME RARE 3850 02:39:59,840 --> 02:40:01,920 DISEASE DEVICES YEARS AGO WE 3851 02:40:01,920 --> 02:40:02,560 LICENSED OUT, HOPEFULLY SOMEDAY 3852 02:40:02,560 --> 02:40:05,640 THEY WILL COME TO A CLINIC NEAR 3853 02:40:05,640 --> 02:40:05,840 YOU. 3854 02:40:05,840 --> 02:40:08,480 BUT YOUR PROGRAM WHERE YOU'RE 3855 02:40:08,480 --> 02:40:10,200 LOOKING AT CATEGORIZING AND 3856 02:40:10,200 --> 02:40:11,720 STRUCTURING THE RARE DISEASE, I 3857 02:40:11,720 --> 02:40:13,840 THINK THERE'S SOME GOLD IN THAT 3858 02:40:13,840 --> 02:40:15,040 THERE MINE FROM THE STANDPOINT 3859 02:40:15,040 --> 02:40:16,800 OF THOSE ARE THINGS THAT COULD 3860 02:40:16,800 --> 02:40:20,640 ALSO BE ADAPTED FOR MOLECULAR 3861 02:40:20,640 --> 02:40:21,240 VARIATION CHARACTERIZATION. 3862 02:40:21,240 --> 02:40:24,880 YOU KNOW, KIND OF LIKE HOW WE 3863 02:40:24,880 --> 02:40:28,080 USE KEG IN BIOCHEMICAL PATHWAYS 3864 02:40:28,080 --> 02:40:35,400 TO TIE THINGS TOGETHER, USEFUL 3865 02:40:35,400 --> 02:40:37,480 TO MOLECULAR GENETICS FIELD AS 3866 02:40:37,480 --> 02:40:39,880 WELL, SO KEEP THAT IN MIND. 3867 02:40:39,880 --> 02:40:44,400 >> GREAT. 3868 02:40:44,400 --> 02:40:45,200 >> MATIAS? 3869 02:40:45,200 --> 02:40:48,360 >> YEAH, CONGRATULATIONS. 3870 02:40:48,360 --> 02:40:49,840 REALLY INSPIRING AND FASCINATING 3871 02:40:49,840 --> 02:40:51,920 TO SEE WHERE YOU CAN FILL IN 3872 02:40:51,920 --> 02:40:54,640 GAPS AND PUSH THINGS FORWARD. 3873 02:40:54,640 --> 02:40:57,400 AND OBVIOUSLY WE HAVE MORE THAN 3874 02:40:57,400 --> 02:41:00,360 7,000 CASES WHO NEED YOUR HELP. 3875 02:41:00,360 --> 02:41:03,080 I THINK IT'S A CHALLENGE 3876 02:41:03,080 --> 02:41:03,800 OBVIOUSLY. 3877 02:41:03,800 --> 02:41:06,240 WHAT I REALLY LOVE TO SEE AND 3878 02:41:06,240 --> 02:41:09,240 LOVE TO HEAR FROM YOU HOW NCATS 3879 02:41:09,240 --> 02:41:12,240 AND NIH AND THE COMMUNITY CAN BE 3880 02:41:12,240 --> 02:41:14,800 MORE HELPFUL TO HELP YOU 3881 02:41:14,800 --> 02:41:18,720 WHENEVER YOU GET TO A WALL YOU 3882 02:41:18,720 --> 02:41:21,560 BREAK DOWN AN IMPEDIMENT FOR 3883 02:41:21,560 --> 02:41:22,360 DEVELOPMENT, FINDING THE RIGHT 3884 02:41:22,360 --> 02:41:25,200 PARTNER TO TAKE THE MOLECULE 3885 02:41:25,200 --> 02:41:26,760 FORWARD WITH RESOURCES, FUNDING, 3886 02:41:26,760 --> 02:41:28,960 TEAMS, WHO CAN OFFLOAD THE 3887 02:41:28,960 --> 02:41:31,800 WORKLOAD YOU HAVE. 3888 02:41:31,800 --> 02:41:37,440 WE HAVE A VERY VIABLE, VERY WELL 3889 02:41:37,440 --> 02:41:38,360 RESOURCED BIOMEDICAL PRIVATE 3890 02:41:38,360 --> 02:41:40,880 COMMUNITY WHO IS NOT ENGAGING IN 3891 02:41:40,880 --> 02:41:42,840 SOME OF THESE PROBLEMS BECAUSE 3892 02:41:42,840 --> 02:41:47,520 FOR THEM IT'S TOO RISK/BENEFIT 3893 02:41:47,520 --> 02:41:49,080 RATIO NOT BENEFICIAL. 3894 02:41:49,080 --> 02:41:50,080 AS YOU'RE DE-RISKING THAT 3895 02:41:50,080 --> 02:41:51,680 OPPORTUNITIES BECOMES VIABLE AND 3896 02:41:51,680 --> 02:41:56,280 CAN PUSH THINGS FORWARD INTO 3897 02:41:56,280 --> 02:41:58,360 CLINICAL PIPELINES. 3898 02:41:58,360 --> 02:42:01,240 AND ESTABLISHING PUBLIC/PRIVATE 3899 02:42:01,240 --> 02:42:04,600 PARTNERSHIPS IS NON-TRIVIAL, I 3900 02:42:04,600 --> 02:42:07,120 WOULD LOVE TO HEAR WHAT'S 3901 02:42:07,120 --> 02:42:14,360 WORKING, AND WHERE SOME OF THE 3902 02:42:14,360 --> 02:42:15,680 WALLS ARE IMPEDING. 3903 02:42:15,680 --> 02:42:16,880 >> YEAH, THAT'S ALWAYS BEEN ONE 3904 02:42:16,880 --> 02:42:18,800 OF OUR -- WE KEEP THAT IN OUR 3905 02:42:18,800 --> 02:42:19,080 MIND. 3906 02:42:19,080 --> 02:42:20,920 HOPEFULLY, I DON'T KNOW IF LILLY 3907 02:42:20,920 --> 02:42:23,560 IS ON TOO, OR DON, WHEN WE'RE -- 3908 02:42:23,560 --> 02:42:25,520 WE TRY TO THINK HOW DO WE GET 3909 02:42:25,520 --> 02:42:28,600 THIS TO THE NEXT PARTNER, RIGHT? 3910 02:42:28,600 --> 02:42:32,880 AND HOW DO WE -- WE'VE HAD SOME 3911 02:42:32,880 --> 02:42:33,120 SUCCESS. 3912 02:42:33,120 --> 02:42:35,280 YOU KNOW, A LOT OF -- WELL, SOME 3913 02:42:35,280 --> 02:42:37,880 PROJECTS COME IN, THEY ACTUALLY 3914 02:42:37,880 --> 02:42:39,400 HAVE A SMALL BIOTECH 3915 02:42:39,400 --> 02:42:41,400 COLLABORATOR, BUT I THINK IT'S 3916 02:42:41,400 --> 02:42:43,040 MORE IN THE ACADEMIC SPACE, 3917 02:42:43,040 --> 02:42:43,600 RIGHT? 3918 02:42:43,600 --> 02:42:46,080 WHEN PEOPLE COME IN AND THEN HOW 3919 02:42:46,080 --> 02:42:47,480 DO WE HELP BRING THEM THE 3920 02:42:47,480 --> 02:42:49,280 PARTNERS THEY NEED TO TAKE IT 3921 02:42:49,280 --> 02:42:51,240 FORWARD, AND I THINK WE THINK 3922 02:42:51,240 --> 02:42:53,720 ABOUT THIS A LOT ALSO IN THE 3923 02:42:53,720 --> 02:42:55,720 GENE THERAPY SPACE BECAUSE OF 3924 02:42:55,720 --> 02:42:59,040 THE SMALL NUMBER OF PATIENTS, 3925 02:42:59,040 --> 02:43:00,520 HOW CAN THAT, YOU KNOW, WE'RE 3926 02:43:00,520 --> 02:43:03,160 GOING TO TREAT THE PATIENTS THAT 3927 02:43:03,160 --> 02:43:05,560 EXIST, YOU KNOW, CURRENTLY, BUT, 3928 02:43:05,560 --> 02:43:07,520 AGAIN, IF IT'S A THERAPY THAT'S 3929 02:43:07,520 --> 02:43:08,960 HELPFUL, HOW DOES THAT KEEP 3930 02:43:08,960 --> 02:43:10,600 GOING, RIGHT? 3931 02:43:10,600 --> 02:43:12,000 HOW DOES IT, YOU KNOW, BE ABLE 3932 02:43:12,000 --> 02:43:14,040 TO HELP PATIENTS IN THE FUTURE. 3933 02:43:14,040 --> 02:43:16,080 SO I THINK THOSE ARE ALL 3934 02:43:16,080 --> 02:43:18,720 QUESTIONS THAT WE HAVE THOUGHT 3935 02:43:18,720 --> 02:43:21,320 ABOUT, BUT I'M GOING TO SEE IF 3936 02:43:21,320 --> 02:43:23,920 ANYONE -- I THINK WE'RE STILL AT 3937 02:43:23,920 --> 02:43:24,920 THAT -- WE'VE BEEN FOCUSED MORE 3938 02:43:24,920 --> 02:43:26,880 RIGHT NOW ON TRYING TO 3939 02:43:26,880 --> 02:43:28,680 OPERATIONALIZE AND TO REALLY 3940 02:43:28,680 --> 02:43:30,200 UNDERSTAND THE PATHWAY, BUT I 3941 02:43:30,200 --> 02:43:31,720 THINK FOR THE N-of-1 AND 3942 02:43:31,720 --> 02:43:33,480 SMALL DISEASES I THINK THIS IS A 3943 02:43:33,480 --> 02:43:34,760 CRITICAL COMPONENT THAT WE THINK 3944 02:43:34,760 --> 02:43:41,160 ABOUT AS THINGS GET MUCH MORE 3945 02:43:41,160 --> 02:43:44,000 TOWARDS PRECISION MEDICINE ALSO. 3946 02:43:44,000 --> 02:43:45,720 >> THIS IS DISEASE OF N-of-1, 3947 02:43:45,720 --> 02:43:48,040 AND IT ISN'T, BECAUSE THERE'S A 3948 02:43:48,040 --> 02:43:51,320 BILLION DOLLAR MARKET BEHIND 3949 02:43:51,320 --> 02:43:57,440 THAT, BECAUSE JUST TALKING HERE, 3950 02:43:57,440 --> 02:43:58,440 HYPER PARATHYROIDISM IS THE 3951 02:43:58,440 --> 02:44:01,560 SCOURGE OF PEOPLE CAN END STAGE 3952 02:44:01,560 --> 02:44:02,920 KIDNEY DISEASE, YOU'RE 3953 02:44:02,920 --> 02:44:04,480 DESCRIBING EFFECTIVE STRATEGY TO 3954 02:44:04,480 --> 02:44:06,480 BLOCK RECEPTOR WHICH IS 3955 02:44:06,480 --> 02:44:07,760 CHRONICALLY ACTIVATED IN CHRONIC 3956 02:44:07,760 --> 02:44:12,160 KIDNEY DISEASE AND END STAGE 3957 02:44:12,160 --> 02:44:14,240 RENAL DISEASE, POTENTIALLY A 3958 02:44:14,240 --> 02:44:15,800 HUGE DOWNSTREAM MARKET 3959 02:44:15,800 --> 02:44:18,280 AVAILABLE, HOPEFULLY IF THAT IS 3960 02:44:18,280 --> 02:44:20,400 NEGOTIATED YOU GETS SIGNIFICANT 3961 02:44:20,400 --> 02:44:22,240 RETURN OF THAT INVESTMENT 3962 02:44:22,240 --> 02:44:23,880 EMPOWERING YOU TO DO MORE WORK 3963 02:44:23,880 --> 02:44:28,800 IN THAT SPACE SO REALLY STARTING 3964 02:44:28,800 --> 02:44:29,880 AND CONTINUOUSLY REEVALUATING 3965 02:44:29,880 --> 02:44:32,520 THE PROGRAMS YOU'RE MAKING 3966 02:44:32,520 --> 02:44:37,880 AGAINST THESE OPPORTUNITIES TO 3967 02:44:37,880 --> 02:44:40,760 OBVIOUSLY FOR THE APPROACH, GENE 3968 02:44:40,760 --> 02:44:42,280 THERAPY, REALLY ENABLING AND 3969 02:44:42,280 --> 02:44:44,600 EMPOWERING THE WORK BUT 3970 02:44:44,600 --> 02:44:46,840 CONSTANTLY POKING THE PRIVATE 3971 02:44:46,840 --> 02:44:52,120 SECTOR TO SEE WHICH OF YOUR 3972 02:44:52,120 --> 02:44:53,440 PLATFORMS CAN BE LEVERAGED ABOVE 3973 02:44:53,440 --> 02:44:55,320 AND BEYOND WHAT YOU DO, SOME 3974 02:44:55,320 --> 02:44:57,080 INVESTMENT YOU CAN DO MORE GOOD 3975 02:44:57,080 --> 02:44:58,040 GOING FORWARD. 3976 02:44:58,040 --> 02:44:58,280 >> YEAH. 3977 02:44:58,280 --> 02:44:59,640 AT ONE POINT, I DON'T KNOW HOW 3978 02:44:59,640 --> 02:45:02,200 MANY YEARS AGO, MAYBE BACK IN 3979 02:45:02,200 --> 02:45:04,720 2013 OR 14, WE DID HAVE KIND OF 3980 02:45:04,720 --> 02:45:05,720 A SHOWCASE, RIGHT? 3981 02:45:05,720 --> 02:45:08,000 WE TRIED TO HAVE A MEETING WHERE 3982 02:45:08,000 --> 02:45:09,520 WE TALKED ABOUT ALL OF OUR 3983 02:45:09,520 --> 02:45:12,800 PROJECTS AND WE OPENED IT UP, IT 3984 02:45:12,800 --> 02:45:15,240 WAS IN BOSTON ACTUALLY, TRYING 3985 02:45:15,240 --> 02:45:17,640 TO SEE WHO MIGHT BE INTERESTED 3986 02:45:17,640 --> 02:45:19,640 AND SO MAYBE WE HAVE TO DO 3987 02:45:19,640 --> 02:45:23,000 SOMETHING LIKE THAT AGAIN, I 3988 02:45:23,000 --> 02:45:24,760 THINK WE CALLED -- WE MADE 3989 02:45:24,760 --> 02:45:26,520 PEOPLE AWARE OF WHAT WE'RE 3990 02:45:26,520 --> 02:45:29,600 WORKING ON AND SEE IF THERE IS 3991 02:45:29,600 --> 02:45:32,200 ANY INTEREST TO ACTUALLY FIND 3992 02:45:32,200 --> 02:45:34,200 PARTNERS, LIKE YOU SAID, IF 3993 02:45:34,200 --> 02:45:34,760 THERE ARE OTHER INDICATIONS 3994 02:45:34,760 --> 02:45:36,840 WHERE, YOU KNOW, THERE COULD BE 3995 02:45:36,840 --> 02:45:38,480 AN EXPANSION OF SOMETHING, WE'RE 3996 02:45:38,480 --> 02:45:39,680 PROBABLY NOT AWARE EITHER. 3997 02:45:39,680 --> 02:45:41,960 LIKE YOU SAID, THERE'S A LOT 3998 02:45:41,960 --> 02:45:44,600 GOING ON IN CLINICAL 3999 02:45:44,600 --> 02:45:45,600 INVESTIGATORS, WHAT THEY ARE 4000 02:45:45,600 --> 02:45:48,080 DOING IN THE CLINIC, RIGHT, THAT 4001 02:45:48,080 --> 02:45:49,440 COULD ACTUALLY HAVE APPLICATION. 4002 02:45:49,440 --> 02:45:50,680 BUT MAYBE WE DON'T KNOW ABOUT 4003 02:45:50,680 --> 02:45:53,480 EACH OTHER, RIGHT? 4004 02:45:53,480 --> 02:45:56,480 >> AND COMMERCIAL LANDSCAPE HAS 4005 02:45:56,480 --> 02:45:57,440 SIGNIFICANTLY ACCELERATED FOR 4006 02:45:57,440 --> 02:45:59,520 RARE DISEASE, OVER THE LAST TEN 4007 02:45:59,520 --> 02:46:00,040 YEARS. 4008 02:46:00,040 --> 02:46:03,240 WE HAD FDA PANEL EARLIER THIS 4009 02:46:03,240 --> 02:46:07,440 WEEK, WITH, YOU KNOW, NCATS, AND 4010 02:46:07,440 --> 02:46:10,480 FDA WHERE I THINK I HEARD FROM 4011 02:46:10,480 --> 02:46:14,880 TINA WE HAD OVER 900 ATTENDEES 4012 02:46:14,880 --> 02:46:16,720 LOOKING AT MY LINK, THERE WAS A 4013 02:46:16,720 --> 02:46:20,880 LOT OF INTEREST FOLLOWING FROM 4014 02:46:20,880 --> 02:46:23,960 THOSE, IN ALSO SEEING 4015 02:46:23,960 --> 02:46:25,800 COMMERCIALLY VIABLE STRATEGIES. 4016 02:46:25,800 --> 02:46:28,880 SO DON'T UNDERESTIMATE THE POWER 4017 02:46:28,880 --> 02:46:31,080 AND IMPACT YOU CAN HAVE IF YOU 4018 02:46:31,080 --> 02:46:33,720 CAN PARTNER AND THERE BY, YOU 4019 02:46:33,720 --> 02:46:36,000 KNOW, KEEP BREAKING DOWN THESE 4020 02:46:36,000 --> 02:46:38,760 BOUNDARIES AND MAKING SOME OF 4021 02:46:38,760 --> 02:46:39,520 THESE PROJECTS VIABLE FOR 4022 02:46:39,520 --> 02:46:44,320 PRIVATE SECTOR AND I WAS HOPING 4023 02:46:44,320 --> 02:46:47,680 THAT MARCUS WOULD UNMUTE AND 4024 02:46:47,680 --> 02:46:52,520 JOIN BECAUSE IT'S VERY MUCH A A 4025 02:46:52,520 --> 02:46:55,040 TOPIC CLOSE TO YOUR HEART. 4026 02:46:55,040 --> 02:46:56,320 >> ELIZABETH, THIS IS MARSHALL, 4027 02:46:56,320 --> 02:46:59,560 COME DOWN THE STREET TWO OR 4028 02:46:59,560 --> 02:47:03,040 THREE MILES, WE'LL GIVE YOU A 4029 02:47:03,040 --> 02:47:05,560 VENUE, LIVE CAST, AT OUR 4030 02:47:05,560 --> 02:47:06,200 FACILITY. 4031 02:47:06,200 --> 02:47:07,200 WE'VE GOT BEAUTIFUL AUDITORIUMS, 4032 02:47:07,200 --> 02:47:09,240 ALSO AREAS YOU COULD WORK IN. 4033 02:47:09,240 --> 02:47:11,240 LET US KNOW AND WE'LL HELP YOU 4034 02:47:11,240 --> 02:47:14,280 SET IT UP. 4035 02:47:14,280 --> 02:47:16,040 >> SOUNDS GREAT. 4036 02:47:16,040 --> 02:47:16,920 THANK YOU. 4037 02:47:16,920 --> 02:47:18,360 >> THANK YOU. 4038 02:47:18,360 --> 02:47:18,880 >> GO AHEAD. 4039 02:47:18,880 --> 02:47:23,800 >> WHAT WHY WERE YOU GOING TO 4040 02:47:23,800 --> 02:47:24,920 SAY? 4041 02:47:24,920 --> 02:47:25,680 >> YOU GO FIRST. 4042 02:47:25,680 --> 02:47:28,400 >> THANK YOU FOR THAT 4043 02:47:28,400 --> 02:47:28,760 PRESENTATION. 4044 02:47:28,760 --> 02:47:31,720 THAT WAS HELPFUL TO SEE 4045 02:47:31,720 --> 02:47:34,200 PRODUCTIVITY OVER TIME FOR THE 4046 02:47:34,200 --> 02:47:34,560 DIVISION. 4047 02:47:34,560 --> 02:47:38,240 ONE QUESTION THAT COMES TO MIND, 4048 02:47:38,240 --> 02:47:40,200 OBVIOUSLY WE'VE ALL SEEN THIS 4049 02:47:40,200 --> 02:47:42,080 METRIC PRESENTED IN TERMS OF THE 4050 02:47:42,080 --> 02:47:45,920 COST OF DRUG DEVELOPMENT, I'M 4051 02:47:45,920 --> 02:47:48,200 CURIOUS TO KNOW CUMULATIVELY HOW 4052 02:47:48,200 --> 02:47:50,440 MUCHS THAT NCATS PUT INTO THE -- 4053 02:47:50,440 --> 02:47:51,480 I'M NOT SAYING INTO ALL THE 4054 02:47:51,480 --> 02:47:52,680 ACTIVITIES BUT ACTIVITIES YOU 4055 02:47:52,680 --> 02:47:54,120 HAVE FUNDED, DO YOU HAVE AN 4056 02:47:54,120 --> 02:47:55,120 ACCOUNTING OF HOW MUCH YOU'VE 4057 02:47:55,120 --> 02:47:58,200 SPENT ON THESE THINGS THAT LEAD 4058 02:47:58,200 --> 02:48:00,840 TO THE 44 INDs AND POTENTIAL 4059 02:48:00,840 --> 02:48:04,360 FOR APPROVALS THAT MIGHT HAPPEN 4060 02:48:04,360 --> 02:48:04,960 THIS YEAR? 4061 02:48:04,960 --> 02:48:08,600 IS THERE A NUMBER? 4062 02:48:08,600 --> 02:48:12,000 IT CAN BE A BALLPARK NUMBER, I'M 4063 02:48:12,000 --> 02:48:15,760 NOT EXPECTING SOMETHING THAT HAS 4064 02:48:15,760 --> 02:48:16,120 PRECISION. 4065 02:48:16,120 --> 02:48:20,120 >> YEAH, I DON'T KNOW, AGAIN -- 4066 02:48:20,120 --> 02:48:22,280 >> I SEEM TO ALWAYS GIVE TASKS 4067 02:48:22,280 --> 02:48:25,560 TO NCATS THAT REQUIRES THEM TO 4068 02:48:25,560 --> 02:48:28,600 DO MORE WORK OFF CYCLE LIKE WITH 4069 02:48:28,600 --> 02:48:29,520 ADMINISTRATIVE SUPPLEMENTS, NOW 4070 02:48:29,520 --> 02:48:31,080 ASKING FOR HOW MUCH MONEY DID 4071 02:48:31,080 --> 02:48:32,120 YOU ACTUALLY SPEND ON THIS. 4072 02:48:32,120 --> 02:48:34,080 BUT IF THERE IS A WAY TO 4073 02:48:34,080 --> 02:48:36,080 UNDERSTAND THAT, I THINK THAT 4074 02:48:36,080 --> 02:48:37,280 WOULD BE -- ANOTHER SELLING 4075 02:48:37,280 --> 02:48:38,880 POINT, IF YOU WILL. 4076 02:48:38,880 --> 02:48:40,760 THE WAY TO PROBABLY THINK ABOUT 4077 02:48:40,760 --> 02:48:42,800 THAT IS WHATEVER YOU SPEND, I'M 4078 02:48:42,800 --> 02:48:44,800 SURE IT'S NOT $2 BILLION, RIGHT? 4079 02:48:44,800 --> 02:48:47,000 WHATEVER YOU SPENT, YOU CAN 4080 02:48:47,000 --> 02:48:47,960 ESSENTIALLY POINT OUT IT'S 4081 02:48:47,960 --> 02:48:49,280 CATALYTIC IN THE CONTEXT OF 4082 02:48:49,280 --> 02:48:50,600 ESSENTIALLY THE OTHER MONIES IT 4083 02:48:50,600 --> 02:48:51,600 HAS BROUGHT IN. 4084 02:48:51,600 --> 02:48:53,800 THEREFORE HAS LED TO THIS. 4085 02:48:53,800 --> 02:48:57,920 THAT'S THE NARRATIVE I WOULD BE 4086 02:48:57,920 --> 02:49:00,480 INTERESTED IN SHOWCASING. 4087 02:49:00,480 --> 02:49:01,880 >> YEAH, AND WE'RE SAYING -- 4088 02:49:01,880 --> 02:49:04,400 I'LL JUST ADD TO THIS A COUPLE 4089 02:49:04,400 --> 02:49:04,880 THINGS. 4090 02:49:04,880 --> 02:49:06,360 ONE IS THAT WE'RE -- THIS IS 4091 02:49:06,360 --> 02:49:07,480 SOMETHING WE'RE ACTIVELY LOOKING 4092 02:49:07,480 --> 02:49:07,760 INTO. 4093 02:49:07,760 --> 02:49:10,000 IT'S NOT AS EASY AS YOU MIGHT 4094 02:49:10,000 --> 02:49:10,960 THINK IT IS. 4095 02:49:10,960 --> 02:49:14,680 YOU PROBABLY DO THINK IT'S NOT 4096 02:49:14,680 --> 02:49:15,120 EASY. 4097 02:49:15,120 --> 02:49:17,760 >> I CAN APPRECIATE IT'S NOT 4098 02:49:17,760 --> 02:49:17,960 EASY. 4099 02:49:17,960 --> 02:49:18,840 I'VE OBVIOUSLY WORKED ON THE 4100 02:49:18,840 --> 02:49:19,400 OTHER SIDE. 4101 02:49:19,400 --> 02:49:20,840 IT'S NEVER EASY TO DO THE 4102 02:49:20,840 --> 02:49:22,240 ACCOUNTING BUT IT IS SOMETHING 4103 02:49:22,240 --> 02:49:24,920 THAT I THINK IS USEFUL WHEN 4104 02:49:24,920 --> 02:49:26,400 YOU'RE MAKING THIS CASE. 4105 02:49:26,400 --> 02:49:28,680 >> WE'RE ACTIVELY WORKING ON 4106 02:49:28,680 --> 02:49:31,560 SOMETHING LIKE THIS, AND I DON'T 4107 02:49:31,560 --> 02:49:33,000 THINK I CAN GIVE NECESSARILY A 4108 02:49:33,000 --> 02:49:35,840 TIME WHEN WE'RE GOING TO BE 4109 02:49:35,840 --> 02:49:37,920 COMPLETING WHAT WE'RE EVALUATING 4110 02:49:37,920 --> 02:49:39,880 AT THE MOMENT BUT AT SOME POINT 4111 02:49:39,880 --> 02:49:41,200 I HOPE WE CAN SHARE SOME OF THAT 4112 02:49:41,200 --> 02:49:42,320 INFORMATION BACK WITH YOU. 4113 02:49:42,320 --> 02:49:44,040 YEAH, WE'RE LOOKING INTO IT. 4114 02:49:44,040 --> 02:49:46,800 DON, YOU PROBABLY HAVE SOMETHING 4115 02:49:46,800 --> 02:49:47,800 TO ADD AS WELL. 4116 02:49:47,800 --> 02:49:50,400 THE OTHER THING I WAS GOING TO 4117 02:49:50,400 --> 02:49:54,080 ADD TO THE CONVERSATION WITHIN 4118 02:49:54,080 --> 02:49:55,960 THE BGTC CONSORTIUM, GENE 4119 02:49:55,960 --> 02:49:59,400 THERAPY SPACE, WE'RE GOING TO BE 4120 02:49:59,400 --> 02:50:02,960 LOOKING REALLY HARD AT THE 4121 02:50:02,960 --> 02:50:04,800 COMMERCIALIZATION POTENTIAL AND 4122 02:50:04,800 --> 02:50:08,760 THE IDEA OF -- THE WAY WE'RE 4123 02:50:08,760 --> 02:50:10,920 THINKING ABOUT THE 4124 02:50:10,920 --> 02:50:13,120 DEMOCRATIZATION OF INFORMATION, 4125 02:50:13,120 --> 02:50:13,680 BIOLOGY GENERATION, VECTOR 4126 02:50:13,680 --> 02:50:15,640 GENERATION, AND I THINK THAT'S 4127 02:50:15,640 --> 02:50:19,360 GOING TO ADD TO THIS VERY 4128 02:50:19,360 --> 02:50:21,560 COMPLEX SPACE OF, YOU KNOW, HOW 4129 02:50:21,560 --> 02:50:23,600 THAT'S GOING TO PLAY INTO THE 4130 02:50:23,600 --> 02:50:24,880 COST SAVINGS IN TERMS OF DOING 4131 02:50:24,880 --> 02:50:25,800 THIS KIND OF WORK. 4132 02:50:25,800 --> 02:50:27,800 I JUST WANTED TO ADD THAT AS 4133 02:50:27,800 --> 02:50:28,000 WELL. 4134 02:50:28,000 --> 02:50:29,640 THAT I THINK WE'RE GOING LEARN A 4135 02:50:29,640 --> 02:50:32,720 LOT FROM THAT PARTICULAR PROJECT 4136 02:50:32,720 --> 02:50:32,880 TOO. 4137 02:50:32,880 --> 02:50:35,240 DON, DO YOU HAVE ANYTHING TO ADD 4138 02:50:35,240 --> 02:50:36,000 ABOUT THE IND? 4139 02:50:36,000 --> 02:50:40,040 >> YEAH, I WAS GOING TO COMMENT 4140 02:50:40,040 --> 02:50:42,120 MORE GENERALLY. 4141 02:50:42,120 --> 02:50:46,040 INDEED IT'S A LITTLE HARD TO 4142 02:50:46,040 --> 02:50:47,720 DECONVOLVE AND AGGREGATE COST, 4143 02:50:47,720 --> 02:50:49,320 BUT CAN DEFINITELY GET SOME 4144 02:50:49,320 --> 02:50:49,640 SENSE. 4145 02:50:49,640 --> 02:50:55,200 BUT I THOUGHT I WOULD GIVE THE 4146 02:50:55,200 --> 02:50:56,120 GENERAL BLANKET ANSWER CERTAINLY 4147 02:50:56,120 --> 02:50:58,280 OUR DEVELOPMENT COSTS ARE NOT 4148 02:50:58,280 --> 02:50:59,600 CHEAPER. 4149 02:50:59,600 --> 02:51:00,600 AND THE GOVERNMENT DOESN'T 4150 02:51:00,600 --> 02:51:01,240 REALLY WORK FASTER. 4151 02:51:01,240 --> 02:51:05,640 AND SO IN A WAY WHEN WE LOOK 4152 02:51:05,640 --> 02:51:07,040 BACK, RETROSPECTIVELY IT'S MORE 4153 02:51:07,040 --> 02:51:15,560 ALONG THE LINES OF WHAT DR. 4154 02:51:15,560 --> 02:51:16,680 KRETZLER WAS SAYING, WE'RE STUCK 4155 02:51:16,680 --> 02:51:19,080 AT THIS OR THAT STAGE BECAUSE 4156 02:51:19,080 --> 02:51:20,840 IT'S ANSWER ACADEMIC LAB, OR 4157 02:51:20,840 --> 02:51:23,480 SMALL BIOTECH, SO IN A WAY 4158 02:51:23,480 --> 02:51:25,200 ANOTHER QUESTION THAT CAME UP I 4159 02:51:25,200 --> 02:51:30,480 THINK HAS TO DO WITH TIMING, OF 4160 02:51:30,480 --> 02:51:34,120 OUR ROLE, OR THE FINANCIAL 4161 02:51:34,120 --> 02:51:34,480 BENEFITS. 4162 02:51:34,480 --> 02:51:36,080 ALONG WITH THAT IF WE LOOK BACK 4163 02:51:36,080 --> 02:51:39,440 AT THE PORTFOLIO IN A WAY OUR 4164 02:51:39,440 --> 02:51:42,200 BIGGEST IMPACT IS REALLY NEVER A 4165 02:51:42,200 --> 02:51:44,600 SIDE-BY-SIDE SUBSTITUTE. 4166 02:51:44,600 --> 02:51:46,160 SO IF SOMETHING COSTS $100 4167 02:51:46,160 --> 02:51:47,720 MILLION, WE PROVIDE IN-KIND 4168 02:51:47,720 --> 02:51:49,880 SUPPORT FOR A COUPLE MILLION 4169 02:51:49,880 --> 02:51:51,880 DOLLARS, THAT'S NOT THE VALUE. 4170 02:51:51,880 --> 02:51:55,480 THE VALUE IS MORE OF WHAT LIZ IS 4171 02:51:55,480 --> 02:51:58,200 SAYING, THAT WHATEVER THAT RISK 4172 02:51:58,200 --> 02:52:00,360 PIECE IS, THAT IS NOT TENABLE IN 4173 02:52:00,360 --> 02:52:01,480 THE COMMERCIAL SPACE OR 4174 02:52:01,480 --> 02:52:02,600 FOUNDATION SPACE, BUT IT'S A 4175 02:52:02,600 --> 02:52:04,920 RISK THAT WE'RE ABLE TO ABSORB, 4176 02:52:04,920 --> 02:52:07,520 THAT'S THE MAJOR CONTRIBUTION. 4177 02:52:07,520 --> 02:52:10,800 SO IN A WAY, THAT'S WHY WE 4178 02:52:10,800 --> 02:52:12,080 AREN'T ALWAYS TALKING ABOUT DRUG 4179 02:52:12,080 --> 02:52:13,960 PER DOLLARS BUT RATHER WHAT KIND 4180 02:52:13,960 --> 02:52:18,560 OF RISK CAN WE ABSORB WHEN OUR 4181 02:52:18,560 --> 02:52:20,520 ROI IS PUBLIC HEALTH, IT'S NOT 4182 02:52:20,520 --> 02:52:22,320 ABOUT AN IMMEDIATE FINANCIAL 4183 02:52:22,320 --> 02:52:22,880 RETURN. 4184 02:52:22,880 --> 02:52:25,360 I THINK THAT DE-RISKING IS WHAT 4185 02:52:25,360 --> 02:52:28,240 ALLOWS US TO HAVE A MAJOR IMPACT 4186 02:52:28,240 --> 02:52:32,280 IN THE ECOSYSTEM AND TO HAVE 4187 02:52:32,280 --> 02:52:34,240 SUCH A LARGE ACTUALLY HIGH 4188 02:52:34,240 --> 02:52:35,920 SUCCESS RATE IN INDs, BECAUSE 4189 02:52:35,920 --> 02:52:38,320 WE'RE ABLE IN TERMS OF NOT 4190 02:52:38,320 --> 02:52:39,400 HAVING A COMMERCIAL ROI 4191 02:52:39,400 --> 02:52:40,600 EXPECTATION TO STICK WITH THE 4192 02:52:40,600 --> 02:52:43,880 PROJECT AND KEEP IT GOING AND WE 4193 02:52:43,880 --> 02:52:46,600 ONLY FAIL A PROJECT WHEN IT'S 4194 02:52:46,600 --> 02:52:47,720 SCIENTIFIC FAILURE, NOT BECAUSE 4195 02:52:47,720 --> 02:52:49,120 WE'VE RUN OUT OF MONEY OR DON'T 4196 02:52:49,120 --> 02:52:52,840 HAVE THE RIGHT TEAM ON BOARD, ET 4197 02:52:52,840 --> 02:52:53,400 CETERA. 4198 02:52:53,400 --> 02:52:56,800 ANYWAY, JUST TO VOLUNTEER MAYBE 4199 02:52:56,800 --> 02:53:00,320 ANOTHER AXIS TO PLOT OUR WORK ON 4200 02:53:00,320 --> 02:53:02,800 IS THE RISK AXIS AS OPPOSED TO 4201 02:53:02,800 --> 02:53:05,360 MONEY PER SE. 4202 02:53:05,360 --> 02:53:06,680 4203 02:53:06,680 --> 02:53:10,360 >> I DID WANT TO POINT OUT, I 4204 02:53:10,360 --> 02:53:12,720 SAW LILLY PUT IN THE STRATEGIC 4205 02:53:12,720 --> 02:53:15,240 ALLIANCE, THAT COLLABORATION AND 4206 02:53:15,240 --> 02:53:17,080 PARTNERING HAS PLAYED A KEY ROLE 4207 02:53:17,080 --> 02:53:18,840 LIKE IN ALL OF OUR PROJECTS, YOU 4208 02:53:18,840 --> 02:53:21,800 KNOW, SO THAT'S A REALLY KEY 4209 02:53:21,800 --> 02:53:23,440 COMPONENT THAT WE'VE ALWAYS 4210 02:53:23,440 --> 02:53:25,520 WORKED VERY CLOSELY WITH LILLY'S 4211 02:53:25,520 --> 02:53:28,040 GROUP IN ORDER TO THINK ABOUT 4212 02:53:28,040 --> 02:53:29,240 THE PARTNERING ASPECTS AND 4213 02:53:29,240 --> 02:53:30,440 COLLABORATION ASPECTS BECAUSE WE 4214 02:53:30,440 --> 02:53:34,360 HAVE TO DO THAT THROUGHOUT A 4215 02:53:34,360 --> 02:53:42,240 PROJECT AS WE'RE COLLABORATING 4216 02:53:42,240 --> 02:53:43,440 WITH OTHERS. 4217 02:53:43,440 --> 02:53:46,720 THERE'S A COUPLE OTHER HANDS UP. 4218 02:53:46,720 --> 02:53:47,720 >> GO AHEAD. 4219 02:53:47,720 --> 02:53:50,360 >> I JUST WANTED TO BUILD OFF OF 4220 02:53:50,360 --> 02:53:50,880 THAT. 4221 02:53:50,880 --> 02:53:58,320 ELIZABETH, I APPRECIATED YOU 4222 02:53:58,320 --> 02:54:02,920 RECOGNIZING THE ROLES JANSEN 4223 02:54:02,920 --> 02:54:04,360 FOUNDATION HAVE, ONE POWER IS 4224 02:54:04,360 --> 02:54:07,240 POWER TO CONVENE AND BRING 4225 02:54:07,240 --> 02:54:08,120 PARTNERS TOGETHER. 4226 02:54:08,120 --> 02:54:11,040 BUILDING OFF THE LAST 4227 02:54:11,040 --> 02:54:14,440 CONVERSATION WE HAD AROUND THE 4228 02:54:14,440 --> 02:54:15,120 PUBLIC/PRIVATE PARTNERSHIPS AND 4229 02:54:15,120 --> 02:54:17,400 HANDOFFS, THE MORE THAT NCATS 4230 02:54:17,400 --> 02:54:19,520 CAN CONTINUE TO HELP PUT THESE 4231 02:54:19,520 --> 02:54:21,880 CASE STUDIES TOGETHER AND 4232 02:54:21,880 --> 02:54:24,280 HIGHLIGHT THE ROLE THAT 4233 02:54:24,280 --> 02:54:27,800 PATIENTOS HELPED TO PLAY AS WE 4234 02:54:27,800 --> 02:54:32,080 KNOW MANY TIMES THIS FUNDING AND 4235 02:54:32,080 --> 02:54:33,920 INNOVATIONS START WITH PATIENT 4236 02:54:33,920 --> 02:54:35,320 ADVOCACY ORGANIZATIONS, HELPING 4237 02:54:35,320 --> 02:54:37,720 WITH EARLY FUNDING AND ADVOCACY 4238 02:54:37,720 --> 02:54:38,920 THE FEDERAL GOVERNMENT OWN 4239 02:54:38,920 --> 02:54:40,480 STARTS FUNDING STREAMS IN THESE 4240 02:54:40,480 --> 02:54:42,320 DISEASE SPACES, AND IT'S REALLY 4241 02:54:42,320 --> 02:54:44,080 IMPORTANT THAT WE CONTINUE TO 4242 02:54:44,080 --> 02:54:50,080 CLOSE THAT FEEDBACK LOOP SO WE 4243 02:54:50,080 --> 02:54:50,960 CAN MAKE SURE THAT EVERYBODY 4244 02:54:50,960 --> 02:54:56,240 UNDERSTANDS WHAT HAPPENS AT THE 4245 02:54:56,240 --> 02:54:57,000 END, FUNDING STARTING OFFED WITH 4246 02:54:57,000 --> 02:55:04,080 THE ORGANIZATION, IF IT ENDS IN 4247 02:55:04,080 --> 02:55:06,160 A THERAPY AFTER HANDOFFS WE 4248 02:55:06,160 --> 02:55:09,240 DON'T LOSE THE THREAD THIS 4249 02:55:09,240 --> 02:55:10,880 STARTED WITH EARLY ADVOCACY, 4250 02:55:10,880 --> 02:55:13,440 CONVENING STAKEHOLDERS AND 4251 02:55:13,440 --> 02:55:15,240 PARTNERS AND ACADEMICS AND 4252 02:55:15,240 --> 02:55:16,560 CLINICIANS WHO MAY NOT HAVE COME 4253 02:55:16,560 --> 02:55:18,200 TOGETHER WITHOUT THE FIRST 4254 02:55:18,200 --> 02:55:19,080 PATIENT ADVOCACY MEETING, I 4255 02:55:19,080 --> 02:55:20,080 APPRECIATE YOU HIGHLIGHTED THAT 4256 02:55:20,080 --> 02:55:22,400 AS WE THINK ABOUT CONTINUING 4257 02:55:22,400 --> 02:55:23,360 MESSAGING MAKING SURE WE DON'T 4258 02:55:23,360 --> 02:55:24,560 LOSE THE THREAT. 4259 02:55:24,560 --> 02:55:28,600 >> I TOTALLY AGREE. 4260 02:55:28,600 --> 02:55:30,040 THAT'S SUPERPOWER ON QUITE A FEW 4261 02:55:30,040 --> 02:55:31,440 PROJECTS, TALKED ABOUT WRITING 4262 02:55:31,440 --> 02:55:32,800 UP OTHER CASE STUDIES WHERE 4263 02:55:32,800 --> 02:55:41,520 THERE HAS BEEN A LOT OF POWER 4264 02:55:41,520 --> 02:55:44,360 WHY PATIENT ADVOCACY, EVEN THE 4265 02:55:44,360 --> 02:55:46,320 CREATINE TRANSPORTER I MENTIONED 4266 02:55:46,320 --> 02:55:47,520 PROPELLED, LIKE NOBODY WAS 4267 02:55:47,520 --> 02:55:49,600 WORKING IN THE FIELD, AND THEN A 4268 02:55:49,600 --> 02:55:51,760 PATIENT ADVOCACY GROUP WAS 4269 02:55:51,760 --> 02:55:53,560 FORMED AND ACTUALLY HAD THEIR 4270 02:55:53,560 --> 02:55:57,040 FIRST SCIENTIFIC MEETING THAT 4271 02:55:57,040 --> 02:55:57,600 BROUGHT TOGETHER DIFFERENT 4272 02:55:57,600 --> 02:55:59,240 INDUSTRY CAME IN AND YOU NO 4273 02:55:59,240 --> 02:55:59,800 THERE'S SEVERAL COMPANIES 4274 02:55:59,800 --> 02:56:01,640 WORKING ON THE DISEASE SO AGAIN 4275 02:56:01,640 --> 02:56:03,480 IT WAS A CATALYST THAT ALSO 4276 02:56:03,480 --> 02:56:07,640 STARTED WITH WORKING WITH THE 4277 02:56:07,640 --> 02:56:08,200 PATIENT GROUPS. 4278 02:56:08,200 --> 02:56:10,200 >> I WANT TO SAY THESE CASE 4279 02:56:10,200 --> 02:56:14,040 STUDIES THAT HAVE BEEN BROUGHT 4280 02:56:14,040 --> 02:56:16,960 FORWARD, THEY HAVE JUST -- THEY 4281 02:56:16,960 --> 02:56:19,600 HAVE MADE ME JUMP FOR JOY. 4282 02:56:19,600 --> 02:56:20,720 THEY ARE THRILLING STORIES. 4283 02:56:20,720 --> 02:56:23,240 I DON'T THINK THE GENERAL PUBLIC 4284 02:56:23,240 --> 02:56:26,640 KNOWS THIS. 4285 02:56:26,640 --> 02:56:28,040 THEY ARE CAPTIVATING. 4286 02:56:28,040 --> 02:56:31,640 I DO THINK THERE'S AN 4287 02:56:31,640 --> 02:56:34,640 OPPORTUNITY TO -- ROAD SHOW FOR 4288 02:56:34,640 --> 02:56:35,480 PURPOSE OF HAVING MORE 4289 02:56:35,480 --> 02:56:36,880 COLLABORATION IS GREAT BUT FROM 4290 02:56:36,880 --> 02:56:39,560 MESSAGING TO THE GENERAL PUBLIC, 4291 02:56:39,560 --> 02:56:41,720 I MEAN, REALLY COULDN'T BELIEVE 4292 02:56:41,720 --> 02:56:44,880 THE STORY THAT WAS TOLD WHEN YOU 4293 02:56:44,880 --> 02:56:48,080 ASKED FOR THE FEATURE ARTICLE 4294 02:56:48,080 --> 02:56:49,920 SENT AROUND, THAT'S AN 4295 02:56:49,920 --> 02:56:54,200 INCREDIBLE STORY. 4296 02:56:54,200 --> 02:56:54,840 YOUR WHOLE PRESENTATION, 4297 02:56:54,840 --> 02:56:55,560 ELIZABETH, WAS GREAT. 4298 02:56:55,560 --> 02:56:56,600 I JUST WANT TO HEAR MORE. 4299 02:56:56,600 --> 02:57:01,880 I DON'T THINK THE WORLD KNOWS. 4300 02:57:01,880 --> 02:57:04,040 4301 02:57:04,040 --> 02:57:05,160 >> THANK YOU. 4302 02:57:05,160 --> 02:57:07,000 >> YEAH, THANK YOU, KELLY. 4303 02:57:07,000 --> 02:57:11,400 YEAH, WE'RE TRYING TO USE THE 4304 02:57:11,400 --> 02:57:13,840 MEGA HORN, IS THAT WHAT THAT IS 4305 02:57:13,840 --> 02:57:15,040 THAT YOU TALK INTO IN. 4306 02:57:15,040 --> 02:57:15,320 >> RIGHT. 4307 02:57:15,320 --> 02:57:16,600 >> TRYING TO GET THE MESSAGES 4308 02:57:16,600 --> 02:57:17,960 OUT THERE. 4309 02:57:17,960 --> 02:57:22,120 I AGREE, WE NEED TO DO MORE OF 4310 02:57:22,120 --> 02:57:22,320 THAT. 4311 02:57:22,320 --> 02:57:25,840 AND I HAD THE SAME REACTION WHEN 4312 02:57:25,840 --> 02:57:27,760 LIZ WAS GIVING HER PRACTICE 4313 02:57:27,760 --> 02:57:29,160 PRESENTATION, JUST SUPER EXCITED 4314 02:57:29,160 --> 02:57:31,360 ABOUT THE WORK. 4315 02:57:31,360 --> 02:57:32,560 AND RECOGNIZING THAT THESE ARE 4316 02:57:32,560 --> 02:57:36,200 ALL CASES WE NEED TO SOMEHOW 4317 02:57:36,200 --> 02:57:37,240 CREATE INTO VIGNETTES AND MAKE 4318 02:57:37,240 --> 02:57:39,440 SURE THE PUBLIC IS AWARE THAT'S 4319 02:57:39,440 --> 02:57:40,200 GOING ON. 4320 02:57:40,200 --> 02:57:43,040 >> YEAH, VIGNETTE IS THE RIGHT 4321 02:57:43,040 --> 02:57:43,480 WORD. 4322 02:57:43,480 --> 02:57:43,960 >> YEAH. 4323 02:57:43,960 --> 02:57:49,080 >> ANDREW, YOU HAVE YOUR HAND 4324 02:57:49,080 --> 02:57:49,880 UP. 4325 02:57:49,880 --> 02:57:53,440 >> YEAH, FOLLOWING UP ON THE 4326 02:57:53,440 --> 02:57:57,600 RESPONSE DON GAVE ABOUT RATE OF 4327 02:57:57,600 --> 02:57:59,040 RETURN OR SOME KIND OF MEASURE 4328 02:57:59,040 --> 02:58:07,560 OF IMPACT ACCOUNT , AND I POSTED 4329 02:58:07,560 --> 02:58:10,200 ABOUT A CASE STUDY IN 2016 4330 02:58:10,200 --> 02:58:12,280 LOOKING AT NCATS RARE DISEASE 4331 02:58:12,280 --> 02:58:14,240 PORTFOLIO, IN A CASE STUDY 4332 02:58:14,240 --> 02:58:18,760 PROVIDES SOME NUMBERS THAT 4333 02:58:18,760 --> 02:58:19,920 RAHESH IS LOOKING FOR. 4334 02:58:19,920 --> 02:58:22,400 WHAT WAS SAID BEFORE IS 4335 02:58:22,400 --> 02:58:24,960 CONFIRMED THAT NCATS IS NOT 4336 02:58:24,960 --> 02:58:26,440 NECESSARILY FASTER IN TERMS OF 4337 02:58:26,440 --> 02:58:28,800 THE CLINICAL TRIALS THEY HAVE 4338 02:58:28,800 --> 02:58:31,080 RUN OR WORK THAT'S LED TO THE 4339 02:58:31,080 --> 02:58:34,040 INDs, BUT IT IS TRUE THEY HAVE 4340 02:58:34,040 --> 02:58:35,720 HIGHER SUCCESS RATES BUT THERE'S 4341 02:58:35,720 --> 02:58:36,680 ANOTHER MEASURE OF IMPACT, I 4342 02:58:36,680 --> 02:58:38,880 KNOW THIS IS NOT SOMETHING THAT 4343 02:58:38,880 --> 02:58:40,360 NCATS IS FOCUSED ON, BUT AS AN 4344 02:58:40,360 --> 02:58:42,400 ECONOMIST IT IS SOMETHING I'M 4345 02:58:42,400 --> 02:58:45,000 FOCUSED ON WHICH IS THE 4346 02:58:45,000 --> 02:58:47,400 FINANCIAL IMPACT THAT NCATS HAS 4347 02:58:47,400 --> 02:58:47,600 HAD. 4348 02:58:47,600 --> 02:58:49,040 A COUPLE INTERESTING DATA POINTS 4349 02:58:49,040 --> 02:58:52,240 THAT YOU MIGHT CONSIDER, ONE IS 4350 02:58:52,240 --> 02:58:57,280 THAT IN THE AADC CASE STUDY 4351 02:58:57,280 --> 02:58:59,040 AGILLUS IS BIOTHERAPEUTICS WAS 4352 02:58:59,040 --> 02:59:02,200 COLLABORATING WITH NCATS, THE 4353 02:59:02,200 --> 02:59:06,560 REASON I GOT INVOLVED WAS 4354 02:59:06,560 --> 02:59:08,560 BECAUSE AGILLUS HAD A HARD TIME 4355 02:59:08,560 --> 02:59:09,680 RAISING MONEY. 4356 02:59:09,680 --> 02:59:11,960 I WAS INTRODUCED BY A MUTUAL 4357 02:59:11,960 --> 02:59:14,240 ACQUAINTANCE TO AGILLUS, AND IN 4358 02:59:14,240 --> 02:59:16,880 TALKING WITH THEM IT WAS PRETTY 4359 02:59:16,880 --> 02:59:20,160 CLEAR THAT IF IT HADN'T BEEN FOR 4360 02:59:20,160 --> 02:59:21,000 NCATS COLLABORATION, THEY WOULD 4361 02:59:21,000 --> 02:59:22,640 NOT HAVE GOTTEN AS FAR AS THEY 4362 02:59:22,640 --> 02:59:24,080 DID, AND JUST TO GIVE AN IDEA OF 4363 02:59:24,080 --> 02:59:29,560 HOW FAR THEY DID GET, AFTER A 4364 02:59:29,560 --> 02:59:32,440 FEW MONTHS PASSED, THE PHASE 2 4365 02:59:32,440 --> 02:59:37,840 READOUT, THEY WERE ACQUIRED BY 4366 02:59:37,840 --> 02:59:39,320 PTC FOR APPROXIMATELY $900 4367 02:59:39,320 --> 02:59:39,760 MILLION. 4368 02:59:39,760 --> 02:59:42,880 ONE THERAPY. 4369 02:59:42,880 --> 02:59:43,280 AND TEN PATIENTS. 4370 02:59:43,280 --> 02:59:44,000 $900 MILLION. 4371 02:59:44,000 --> 02:59:45,160 SO THAT GIVES A LITTLE BIT OF A 4372 02:59:45,160 --> 02:59:50,080 SENSE OF THE KIND OF IMPACT THAT 4373 02:59:50,080 --> 02:59:52,040 NCATS HAS HAD, AND IN THE 2016 4374 02:59:52,040 --> 02:59:54,240 CASE STUDY THERE WAS A SIMILAR 4375 02:59:54,240 --> 02:59:56,200 EXAMPLE WHERE ONE OF THE THINGS 4376 02:59:56,200 --> 02:59:58,920 I WAS INTERESTED IN WAS WHAT ARE 4377 02:59:58,920 --> 03:00:02,480 THE R01 OF AN NCATS PORTFOLIO, 4378 03:00:02,480 --> 03:00:04,840 IF WE TOOK 28 RARE DISEASE 4379 03:00:04,840 --> 03:00:06,680 THERAPEUTICS IN THE PORTFOLIO AT 4380 03:00:06,680 --> 03:00:13,400 THAT TIME, WHAT WOULD THE ROI 4381 03:00:13,400 --> 03:00:14,000 HAVE BEEN? 4382 03:00:14,000 --> 03:00:17,960 WE TALKED TO VENTURE CAPITALISTS 4383 03:00:17,960 --> 03:00:19,720 TO PROVIDE A BACK OF THE 4384 03:00:19,720 --> 03:00:21,000 ENVELOPE VALUATION, THE PAPER 4385 03:00:21,000 --> 03:00:26,600 WAS SUBMITTED AND REJECTED BY 4386 03:00:26,600 --> 03:00:27,920 SCIENCE TRANSLATIONAL MEDICINE, 4387 03:00:27,920 --> 03:00:29,640 THEY SAID THESE NUMBERS ARE MADE 4388 03:00:29,640 --> 03:00:30,000 UP. 4389 03:00:30,000 --> 03:00:31,000 AND FROM AN ECONOMIST POINT OF 4390 03:00:31,000 --> 03:00:32,280 VIEW THAT'S WHAT WE DO. 4391 03:00:32,280 --> 03:00:35,280 WE END UP MAKING UP THESE 4392 03:00:35,280 --> 03:00:36,240 RESULTS BECAUSE THOSE ARE THE 4393 03:00:36,240 --> 03:00:38,000 FOLKS ENDING UP PAYING FOR IT. 4394 03:00:38,000 --> 03:00:40,720 TURNED OUT WHILE OUR PAPER WAS 4395 03:00:40,720 --> 03:00:43,040 BEING REVIEWED, AFTER WE HAD 4396 03:00:43,040 --> 03:00:45,120 GOTTEN BACK THAT REJECTION, TWO 4397 03:00:45,120 --> 03:00:48,280 OF THE 28 PROJECTS THAT NCATS 4398 03:00:48,280 --> 03:00:51,680 WAS INVOLVED IN, THEY WERE 4399 03:00:51,680 --> 03:00:53,920 AFFILIATED WITH COMPANIES THAT 4400 03:00:53,920 --> 03:00:56,840 WERE ACQUIRED BY BIG PHARMA. 4401 03:00:56,840 --> 03:00:58,800 AND THE ACQUISITION PRICES AND 4402 03:00:58,800 --> 03:01:00,440 DEAL TERMS WERE NOT DISCLOSED, 4403 03:01:00,440 --> 03:01:02,960 BUT IF YOU LOOK AT THE STOCK 4404 03:01:02,960 --> 03:01:06,680 PRICE REACTIONS, OF THOSE TWO 4405 03:01:06,680 --> 03:01:09,520 COMPANIES IT ACQUIRED, THE TWO 4406 03:01:09,520 --> 03:01:12,400 TARGETS, THE STOCK PRICE 4407 03:01:12,400 --> 03:01:15,480 INCREASES IN THE ACQUIRER'S 4408 03:01:15,480 --> 03:01:16,600 AMOUNTED TO $650 MILLION, 4409 03:01:16,600 --> 03:01:18,120 ONE-DAY STOCK PRICE CHANGES. 4410 03:01:18,120 --> 03:01:20,520 SOY ONCE WE RESUBMITTED THAT TO 4411 03:01:20,520 --> 03:01:24,360 SCIENCE TRANSLATIONAL MEDICINE 4412 03:01:24,360 --> 03:01:26,320 THEY THEN PUBLISHED THE PAPER. 4413 03:01:26,320 --> 03:01:27,160 >> GREAT ANECDOTE. 4414 03:01:27,160 --> 03:01:29,600 >> IT IS A GREAT ANECDOTE. 4415 03:01:29,600 --> 03:01:32,400 THANK YOU FOR TELLING THE STORY. 4416 03:01:32,400 --> 03:01:34,360 AND HOW WE CAN CONTINUE TO 4417 03:01:34,360 --> 03:01:38,480 FOLLOW THAT SORT OF IDEA IS -- I 4418 03:01:38,480 --> 03:01:40,240 WISH THERE WERE AN EASY WAY TO 4419 03:01:40,240 --> 03:01:43,000 DO THAT. 4420 03:01:43,000 --> 03:01:44,080 SO ANDREW MIGHT NEED TO PICK 4421 03:01:44,080 --> 03:01:48,320 YOUR BRAIN A LITTLE BIT ABOUT 4422 03:01:48,320 --> 03:01:48,560 THAT. 4423 03:01:48,560 --> 03:01:50,640 >> JUST THE FACT HE TOLD A STORY 4424 03:01:50,640 --> 03:01:52,640 ABOUT A SINGLE ASSET WITH TEN 4425 03:01:52,640 --> 03:01:53,840 PATIENTS THAT EXITED FOR MORE 4426 03:01:53,840 --> 03:01:57,360 THAN THE ANNUAL BUDGET OF NCATS 4427 03:01:57,360 --> 03:01:59,320 IS ASTONISHING. 4428 03:01:59,320 --> 03:02:02,200 THE NOTION THAT SOME OF THAT 4429 03:02:02,200 --> 03:02:06,480 SHOULDN'T FLOW BACK TO NCATS IS 4430 03:02:06,480 --> 03:02:08,960 TOUGH TO STOMACH, AS A TAXPAYER. 4431 03:02:08,960 --> 03:02:12,040 I MEAN, YOU MAY NOT HAVE -- I 4432 03:02:12,040 --> 03:02:13,240 UNDERSTAND THAT THERE ARE 4433 03:02:13,240 --> 03:02:14,520 PROCESSES IN PLACE AND I KNOW 4434 03:02:14,520 --> 03:02:21,680 THAT THEY TOOK THE RISK AND GREW 4435 03:02:21,680 --> 03:02:23,920 IT, BUT THAT IS THE MISSION OF 4436 03:02:23,920 --> 03:02:25,920 NCATS IN ACTION, BUT YOU GUYS 4437 03:02:25,920 --> 03:02:30,680 ARE NOT GETTING THE FLOWBACK AND 4438 03:02:30,680 --> 03:02:32,320 REVENUE. 4439 03:02:32,320 --> 03:02:33,160 PERHAPS THAT'S FINE. 4440 03:02:33,160 --> 03:02:33,360 BUT -- 4441 03:02:33,360 --> 03:02:37,200 >> CAN I SAY SOMETHING IN THAT 4442 03:02:37,200 --> 03:02:37,800 CONTEXT? 4443 03:02:37,800 --> 03:02:41,760 >> IT'S ACTUALLY AS LONG AS THAT 4444 03:02:41,760 --> 03:02:44,400 BECOMES PUBLIC KNOWLEDGE, AND 4445 03:02:44,400 --> 03:02:46,040 FACILITATES AND ADVANCES AND 4446 03:02:46,040 --> 03:02:50,320 INCREASES THE UPTAKE OF THE 4447 03:02:50,320 --> 03:02:51,720 OUTPUT FROM THE OPERATION, 4448 03:02:51,720 --> 03:02:55,360 THERE'S SIGNIFICANT RISK AND A 4449 03:02:55,360 --> 03:02:57,720 REASON WHY THESE ASSETS ARE 4450 03:02:57,720 --> 03:02:59,720 MOVED AT THAT AREA, AND I THINK 4451 03:02:59,720 --> 03:03:02,560 THIS IS THE KEY PIECE, THE 4452 03:03:02,560 --> 03:03:05,160 CONCEPT OR WHATEVER IS THE BEST 4453 03:03:05,160 --> 03:03:09,600 VENUE TO DO THAT, IT'S CRITICAL 4454 03:03:09,600 --> 03:03:12,840 THAT, YES, WHENEVER AN ASSET IS 4455 03:03:12,840 --> 03:03:14,160 DE-RISKED, PRIVATE SECTOR CAN 4456 03:03:14,160 --> 03:03:16,240 TAKE ON THE RISK AND WILL REMAIN 4457 03:03:16,240 --> 03:03:17,880 SIGNIFICANT, THERE WILL BE 4458 03:03:17,880 --> 03:03:19,000 SIGNIFICANT INVESTMENTS NEEDED 4459 03:03:19,000 --> 03:03:22,360 WHICH NCATS OR THE PUBLIC SECTOR 4460 03:03:22,360 --> 03:03:23,240 CANNOT STOMACH. 4461 03:03:23,240 --> 03:03:25,760 THAT I THINK, THAT IS A SUCCESS 4462 03:03:25,760 --> 03:03:26,440 MODEL. 4463 03:03:26,440 --> 03:03:30,520 WHICH REALLY WORKS WELL, 4464 03:03:30,520 --> 03:03:31,120 OBVIOUSLY RESOURCES HAVE 4465 03:03:31,120 --> 03:03:32,880 INCREASED OVER THE LAST DECADE 4466 03:03:32,880 --> 03:03:36,600 TO DO THAT IN THE PRIVATE 4467 03:03:36,600 --> 03:03:36,840 SECTOR. 4468 03:03:36,840 --> 03:03:38,360 IF YOU CAN FACILITATE THAT WOULD 4469 03:03:38,360 --> 03:03:41,080 BE FULLY ALINED WITH WHAT I CAN 4470 03:03:41,080 --> 03:03:43,040 SEE AS KEY MISSION POINT. 4471 03:03:43,040 --> 03:03:44,280 >> JONI, YOU USED THAT GRAPHIC 4472 03:03:44,280 --> 03:03:45,680 THE OTHER DAY WHICH YOU USED 4473 03:03:45,680 --> 03:03:47,080 ONCE BEFORE WITH US WHICH I 4474 03:03:47,080 --> 03:03:51,360 LOVE, WHICH IS YOUR METAPHOR OF 4475 03:03:51,360 --> 03:03:52,480 A PIPELINE. 4476 03:03:52,480 --> 03:03:56,440 AND ACCELERATING WHAT FLOWS 4477 03:03:56,440 --> 03:03:57,840 THROUGH THAT PIPELINE. 4478 03:03:57,840 --> 03:04:00,040 AND THAT PIPELINE IS A VALUE 4479 03:04:00,040 --> 03:04:00,440 CHAIN. 4480 03:04:00,440 --> 03:04:04,080 THESE ARE JUST REALLY CONCRETE 4481 03:04:04,080 --> 03:04:05,920 VIGNETTES TOLD TODAY THAT ARE 4482 03:04:05,920 --> 03:04:07,280 SHOWING THE TIGHTLY COUPLED 4483 03:04:07,280 --> 03:04:09,560 RELATIONSHIP IN THAT VALUE 4484 03:04:09,560 --> 03:04:09,960 CHAIN. 4485 03:04:09,960 --> 03:04:11,400 AND THAT VALUE, I'M VERY 4486 03:04:11,400 --> 03:04:12,400 INTERESTED IN THE ECONOMICS OF 4487 03:04:12,400 --> 03:04:14,160 IT EVEN THOUGH I KNOW THAT'S NOT 4488 03:04:14,160 --> 03:04:17,400 MOSTLY WHAT WE TALK ABOUT IN 4489 03:04:17,400 --> 03:04:19,800 THESE MEETINGS. 4490 03:04:19,800 --> 03:04:20,720 SO, I DON'T KNOW. 4491 03:04:20,720 --> 03:04:22,200 I'D BE HAPPY TO SPEAK WITH 4492 03:04:22,200 --> 03:04:25,240 ANYBODY MORE ABOUT THIS. 4493 03:04:25,240 --> 03:04:27,200 I THINK THERE'S SOME REAL 4494 03:04:27,200 --> 03:04:27,520 OPPORTUNITIES. 4495 03:04:27,520 --> 03:04:31,040 I'D BE HAPPY TO HELP WITH A ROAD 4496 03:04:31,040 --> 03:04:32,080 SHOW AS WELL. 4497 03:04:32,080 --> 03:04:35,080 THERE'S JUST SO MUCH VALUE YOU 4498 03:04:35,080 --> 03:04:36,280 GUYS ARE CREATING. 4499 03:04:36,280 --> 03:04:37,680 IT'S REALLY -- I'M ON THE EDGE 4500 03:04:37,680 --> 03:04:47,920 OF MY SEAT. 4501 03:04:56,320 --> 03:04:58,240 >> YOU'RE ONTO SOMETHING HERE. 4502 03:04:58,240 --> 03:04:59,880 >> IN THE EARLY DAYS OF SETTING 4503 03:04:59,880 --> 03:05:05,280 UP NCATS I WORKED WITH VENTURE 4504 03:05:05,280 --> 03:05:06,560 CAPITALISTS TO TALK ABOUT 4505 03:05:06,560 --> 03:05:08,200 MONETIZING PIECE, THE IDEA YOU 4506 03:05:08,200 --> 03:05:12,160 COULD FIND A WAY IF YOU DID FUND 4507 03:05:12,160 --> 03:05:13,920 THESE THINGS THAT COMPONENT OF 4508 03:05:13,920 --> 03:05:16,360 THAT REVENUE WOULD FLOW BACK TO 4509 03:05:16,360 --> 03:05:17,720 WHATEVER INSTITUTE AT THAT TIME, 4510 03:05:17,720 --> 03:05:18,880 IT HADN'T BEEN NAMED, LET'S SAY 4511 03:05:18,880 --> 03:05:20,680 THE NIH, BACK TO THE GOVERNMENT. 4512 03:05:20,680 --> 03:05:23,600 WE DID SOME SIMPLE BACK OF THE 4513 03:05:23,600 --> 03:05:24,520 ENVELOPE CALCULATIONS, BECAUSE 4514 03:05:24,520 --> 03:05:26,600 WHAT HAPPENS IS THAT THINK ABOUT 4515 03:05:26,600 --> 03:05:30,320 WHAT THE NIH DOES, IT FUNDS 4516 03:05:30,320 --> 03:05:32,840 WORK, MULTIPLE ACADEMIC 4517 03:05:32,840 --> 03:05:34,680 INSTITUTIONS, STANFORD, M.I.T., 4518 03:05:34,680 --> 03:05:35,720 UNIVERSITY OF IOWA, WHATEVER, 4519 03:05:35,720 --> 03:05:39,280 GETS LICENSED TO A COMPANY, AND 4520 03:05:39,280 --> 03:05:41,080 THE ROYALTY STREAM GOES BACK TO 4521 03:05:41,080 --> 03:05:42,040 THE GRANTEE. 4522 03:05:42,040 --> 03:05:43,800 BUT THE GRANTEE NEVER CHOOSES TO 4523 03:05:43,800 --> 03:05:45,400 SEND ANY PORTION OF THAT BACK TO 4524 03:05:45,400 --> 03:05:49,920 THE FUNDER BECAUSE THERE'S NO -- 4525 03:05:49,920 --> 03:05:51,560 BECAUSE OF THE DOLE ACT, IT'S 4526 03:05:51,560 --> 03:05:53,320 NOT WRITTEN INTO LAW, BUT THE 4527 03:05:53,320 --> 03:05:56,160 THING WE WERE EXPLORING AT THAT 4528 03:05:56,160 --> 03:05:59,560 BECAUSE ALL IDEAS WERE WELCOME 4529 03:05:59,560 --> 03:06:03,040 TO PUT AN AMENDMENT, IF GRANTEES 4530 03:06:03,040 --> 03:06:04,160 GOT THAT SOME PERCENTAGE OF 4531 03:06:04,160 --> 03:06:06,680 ROYALTY INCOME WOULD COME BACK 4532 03:06:06,680 --> 03:06:08,280 TO THE GOVERNMENT. 4533 03:06:08,280 --> 03:06:10,920 IF WE DID THAT FOR ALL DRUGS 4534 03:06:10,920 --> 03:06:13,320 LICENSED PATENTS FROM THE PATENT 4535 03:06:13,320 --> 03:06:14,960 ESTATE FUNDED BY NIH WORK THE 4536 03:06:14,960 --> 03:06:16,720 NIH WOULD BE EVERGREEN, NOT JUST 4537 03:06:16,720 --> 03:06:16,920 NCATS. 4538 03:06:16,920 --> 03:06:21,480 WE WOULDN'T NEED TO ASK THE 4539 03:06:21,480 --> 03:06:22,560 TAXPAYER FOR ADDITIONAL 4540 03:06:22,560 --> 03:06:22,920 APPROPRIATIONS. 4541 03:06:22,920 --> 03:06:25,640 BECAUSE THE REVENUE WOULD BE 4542 03:06:25,640 --> 03:06:26,920 GREATER THAN $30, $40 BILLION A 4543 03:06:26,920 --> 03:06:27,400 YEAR. 4544 03:06:27,400 --> 03:06:29,200 THAT WOULD COME BACK. 4545 03:06:29,200 --> 03:06:34,480 BUT WHEN WE ACTUALLY DID SOME 4546 03:06:34,480 --> 03:06:36,000 CONVERSATIONS WITH DEANS OF 4547 03:06:36,000 --> 03:06:37,960 UNIVERSITIES, BECAUSE WE WANTED 4548 03:06:37,960 --> 03:06:40,720 TO SEE, PRESSURE TEST THIS, IT 4549 03:06:40,720 --> 03:06:42,080 WAS A CATEGORICAL NO. 4550 03:06:42,080 --> 03:06:43,760 THERE'S NO WAY I'M PARTING WITH 4551 03:06:43,760 --> 03:06:44,520 A PENNY, RIGHT? 4552 03:06:44,520 --> 03:06:46,080 AND GIVING IT BACK TO THE NIH 4553 03:06:46,080 --> 03:06:48,120 BECAUSE EVERYBODY WANTS TO KEEP 4554 03:06:48,120 --> 03:06:50,440 THAT FOR THEIR LOCAL FUNDING, 4555 03:06:50,440 --> 03:06:53,440 PUT UP A NEW BUILDING, WHATEVER. 4556 03:06:53,440 --> 03:06:55,160 ADDITIONAL OFFICE SPACE, ET 4557 03:06:55,160 --> 03:06:55,360 CETERA. 4558 03:06:55,360 --> 03:06:58,560 SO, YOU KNOW, I THINK IT'S A 4559 03:06:58,560 --> 03:07:00,760 VERY DIFFICULT THING TO 4560 03:07:00,760 --> 03:07:01,360 NAVIGATE. 4561 03:07:01,360 --> 03:07:02,360 THE GOODWILL PIECE AND FACT 4562 03:07:02,360 --> 03:07:04,240 WE'RE DOING IT, ET CETERA, BUT 4563 03:07:04,240 --> 03:07:06,400 IF YOU WANT TO MAKE THAT HAPPEN 4564 03:07:06,400 --> 03:07:09,400 IT'S ABOUT THE MONEY, RIGHT? 4565 03:07:09,400 --> 03:07:10,840 THE MONEY HAS TO COME BACK TO BE 4566 03:07:10,840 --> 03:07:12,880 ABLE TO DO THAT. 4567 03:07:12,880 --> 03:07:14,200 THE ONLY MECHANISM IS TO 4568 03:07:14,200 --> 03:07:15,640 PROBABLY WRITE IT INTO LAW. 4569 03:07:15,640 --> 03:07:17,800 SO IF SOMEBODY HERE IS POLICY 4570 03:07:17,800 --> 03:07:18,400 MINDED, SOMEBODY ESSENTIALLY 4571 03:07:18,400 --> 03:07:19,920 COULD COME UP WITH A CREATIVE 4572 03:07:19,920 --> 03:07:21,720 TIME, RIGHT TIME IN HISTORY TO 4573 03:07:21,720 --> 03:07:22,960 DO, THEN WE'LL CHANGE THE ENTIRE 4574 03:07:22,960 --> 03:07:28,080 BUSINESS. 4575 03:07:28,080 --> 03:07:28,760 4576 03:07:28,760 --> 03:07:30,040 >> SOUNDS EASY. 4577 03:07:30,040 --> 03:07:30,560 >> YEP. 4578 03:07:30,560 --> 03:07:31,520 >> CHAD? 4579 03:07:31,520 --> 03:07:32,560 >> I WANT TO COMMENT. 4580 03:07:32,560 --> 03:07:34,560 I THINK THE POLICY IS STILL THE 4581 03:07:34,560 --> 03:07:37,400 SAME BUT SO WHEN I HAVE AN R01, 4582 03:07:37,400 --> 03:07:41,200 AND I MAKE A PATENT, AS WAS 4583 03:07:41,200 --> 03:07:44,640 COMMENTED TO, THE NIH HAS NO 4584 03:07:44,640 --> 03:07:45,440 PART OF THAT. 4585 03:07:45,440 --> 03:07:47,640 THEY HAVE GIVEN UP ALL RIGHTS OF 4586 03:07:47,640 --> 03:07:49,360 THE PATENT TO THE UNIVERSITY. 4587 03:07:49,360 --> 03:07:52,360 HOWEVER, WHEN I HAD MY NCATS 4588 03:07:52,360 --> 03:07:54,640 GRANT, AND DISCOVERED SOME 4589 03:07:54,640 --> 03:07:55,720 MOLECULES THROUGH NCATS, NCATS 4590 03:07:55,720 --> 03:07:57,120 HOLDS ON TO THAT PATENT. 4591 03:07:57,120 --> 03:08:01,840 SO THEY WERE A CO-INVENTOR, I 4592 03:08:01,840 --> 03:08:04,160 BELIEVE THAT'S STILL THE POLICY. 4593 03:08:04,160 --> 03:08:06,000 THERE IS A MECHANISM FOR MONEY 4594 03:08:06,000 --> 03:08:08,320 TO COME BACK, IF NCATS IS 4595 03:08:08,320 --> 03:08:11,480 INVOLVED IN THE PATENT 4596 03:08:11,480 --> 03:08:12,200 DISCOVERY. 4597 03:08:12,200 --> 03:08:14,200 FOR THESE EXAMPLES YOU GAVE I'M 4598 03:08:14,200 --> 03:08:17,080 NOT SURE IF NCATS WAS INVOLVED 4599 03:08:17,080 --> 03:08:18,920 IN GETTING NEXT GENERATION 4600 03:08:18,920 --> 03:08:21,560 PATENTS, BUT I'VE ALSO BEEN IN A 4601 03:08:21,560 --> 03:08:24,960 BLUEPRINT GRANT WHERE WE TOOK AN 4602 03:08:24,960 --> 03:08:27,880 NCATS DISCOVERY, WHICH NCATS HAD 4603 03:08:27,880 --> 03:08:29,560 PARTIAL PATENT CONNECTION, AND 4604 03:08:29,560 --> 03:08:33,800 THEN WE DID THE NEXT GENERATION 4605 03:08:33,800 --> 03:08:36,360 OF THAT, AND I BELIEVE THAT THE 4606 03:08:36,360 --> 03:08:39,360 BLUEPRINT WAS NOT PART OF THAT 4607 03:08:39,360 --> 03:08:39,640 PATENT. 4608 03:08:39,640 --> 03:08:39,960 SO, -- 4609 03:08:39,960 --> 03:08:40,920 >> THAT'S RIGHT. 4610 03:08:40,920 --> 03:08:42,880 WHEN I SET UP THE BLUEPRINT 4611 03:08:42,880 --> 03:08:44,400 PROGRAM WE DID NOT PUT THAT IN 4612 03:08:44,400 --> 03:08:44,880 PLACE. 4613 03:08:44,880 --> 03:08:46,480 ONE OF THE CHALLENGES WAS THAT 4614 03:08:46,480 --> 03:08:47,040 PEOPLE WEREN'T NECESSARILY 4615 03:08:47,040 --> 03:08:49,360 COMING TO THE NINDS AT THAT TIME 4616 03:08:49,360 --> 03:08:51,320 TO REQUEST THAT MONEY IF THEY 4617 03:08:51,320 --> 03:08:52,640 NEEDED TO SHARE, THE 4618 03:08:52,640 --> 03:08:54,160 INTELLECTUAL PROPERTY WITH THE 4619 03:08:54,160 --> 03:08:54,480 NIH. 4620 03:08:54,480 --> 03:08:55,920 THE INTRAMURAL PART OF NCATS WAS 4621 03:08:55,920 --> 03:08:58,080 ABLE TO DO THAT BUT IN THE 4622 03:08:58,080 --> 03:08:59,200 EXTRAMURAL SIDE THAT'S VERY 4623 03:08:59,200 --> 03:09:00,720 DIFFICULT TO DO. 4624 03:09:00,720 --> 03:09:02,280 >> YEAH, ON A PERSONAL LEVEL 4625 03:09:02,280 --> 03:09:03,880 BECAUSE OF THAT, THAT BLUEPRINT, 4626 03:09:03,880 --> 03:09:06,680 YOU KNOW, WE WOULD HAVE EASILY 4627 03:09:06,680 --> 03:09:08,400 GIVEN UP THAT RIGHT TO THE 4628 03:09:08,400 --> 03:09:10,800 PATENT THAT THEY HELPED US 4629 03:09:10,800 --> 03:09:11,520 DEVELOP. 4630 03:09:11,520 --> 03:09:12,760 I THINK YOU HAVE A LOT OF 4631 03:09:12,760 --> 03:09:15,840 LEVERAGE BECAUSE THE P.I., WE'RE 4632 03:09:15,840 --> 03:09:16,880 DESPERATE FOR FUNDS TO TAKE IT 4633 03:09:16,880 --> 03:09:19,720 TO THE NEXT LEVEL AND CAN GO TO 4634 03:09:19,720 --> 03:09:20,720 DEANS, HEY, WE NEED THIS MONEY, 4635 03:09:20,720 --> 03:09:22,560 WE'RE GOING TO GIVE UP A PART OF 4636 03:09:22,560 --> 03:09:23,800 THE ROYALTIES, IF IT GOES DOWN 4637 03:09:23,800 --> 03:09:24,440 THAT ROAD. 4638 03:09:24,440 --> 03:09:26,200 SO THAT COULD BE ANOTHER OPTION, 4639 03:09:26,200 --> 03:09:27,640 IF YOU USE THE P.I.s TO 4640 03:09:27,640 --> 03:09:29,280 LEVERAGE THE DEANS TO GIVE A 4641 03:09:29,280 --> 03:09:31,560 PART OF THAT PATENT BACK TO NIH. 4642 03:09:31,560 --> 03:09:34,120 BUT JUST WANTED TO POINT OUT THE 4643 03:09:34,120 --> 03:09:35,720 ODD DETAILS. 4644 03:09:35,720 --> 03:09:36,800 >> THANK YOU. 4645 03:09:36,800 --> 03:09:40,120 >> I'LL POINT OUT JUST AN 4646 03:09:40,120 --> 03:09:42,080 EXPERIENCE WE HAD, SO ACTUALLY 4647 03:09:42,080 --> 03:09:43,360 INTRODUCED US TO A TECHNOLOGY 4648 03:09:43,360 --> 03:09:44,600 GROUP OVER AT UNIVERSITY OF 4649 03:09:44,600 --> 03:09:48,120 MARYLAND, WE WENT ON TO DEVELOP 4650 03:09:48,120 --> 03:09:49,320 TWO DEVICES WORKING WITH THEM, 4651 03:09:49,320 --> 03:09:50,760 DID NOT RECEIVE MONEY FROM NIH 4652 03:09:50,760 --> 03:09:53,480 BUT WHEN WE FILED A PATENT NIH 4653 03:09:53,480 --> 03:09:56,040 DID INSIST ON A PERCENTAGE OF 4654 03:09:56,040 --> 03:09:56,800 THE PATENT. 4655 03:09:56,800 --> 03:09:58,520 SO SOMETIMES EVEN IF MONEY 4656 03:09:58,520 --> 03:10:00,720 DOESN'T COME OUT, NIH DOES STILL 4657 03:10:00,720 --> 03:10:04,760 GET A PERCENTAGE OF THOSE. 4658 03:10:04,760 --> 03:10:06,960 WE DIDN'T BALK, IT WAS FINE WITH 4659 03:10:06,960 --> 03:10:07,120 US. 4660 03:10:07,120 --> 03:10:12,200 IT WAS INTERESTING, NOT BECAUSE 4661 03:10:12,200 --> 03:10:14,040 IT WAS NOT OF -- BECAUSE IT WAS 4662 03:10:14,040 --> 03:10:15,520 NOT A FUNDED PROJECT. 4663 03:10:15,520 --> 03:10:17,800 >> IT WAS A CO-INVENTION IN THE 4664 03:10:17,800 --> 03:10:19,200 INTRAMURAL PROGRAM. 4665 03:10:19,200 --> 03:10:19,760 >> ACTUALLY, IT WASN'T. 4666 03:10:19,760 --> 03:10:21,880 "THEY" DID THE INTRODUCTION. 4667 03:10:21,880 --> 03:10:25,000 IT 4668 03:10:25,000 --> 03:10:26,640 WE WERE FINE WITH THEM HAVING A 4669 03:10:26,640 --> 03:10:28,200 PERCENTAGE, HAPPY TO TALK TO YOU 4670 03:10:28,200 --> 03:10:29,520 ABOUT IT ANOTHER TIME. 4671 03:10:29,520 --> 03:10:29,840 >> OKAY. 4672 03:10:29,840 --> 03:10:35,960 >> ANDREW, YOUR HAND IS UP. 4673 03:10:35,960 --> 03:10:39,040 YOU'RE ON MUTE. 4674 03:10:39,040 --> 03:10:45,320 >> SORRY ABOUT THAT. . 4675 03:10:45,320 --> 03:10:47,160 I WANTED TO RESPOND ABOUT THE 4676 03:10:47,160 --> 03:10:49,040 POINT AND KELLY'S QUESTION ABOUT 4677 03:10:49,040 --> 03:10:52,560 NCATS GETTING BACK SOME OF THE 4678 03:10:52,560 --> 03:10:53,360 VALUE CREATED. 4679 03:10:53,360 --> 03:10:54,320 TWO THINGS. 4680 03:10:54,320 --> 03:10:56,480 ONE, THAT'S A VERY OF VERY 4681 03:10:56,480 --> 03:10:59,240 COMPLICATED QUESTION BECAUSE IF 4682 03:10:59,240 --> 03:11:01,320 NCATS WERE TO GET PAID FOR THE 4683 03:11:01,320 --> 03:11:03,760 THINGS IT DOES, AND GET INVOLVED 4684 03:11:03,760 --> 03:11:05,240 IN COMMERCIAL KINDS OF 4685 03:11:05,240 --> 03:11:07,040 ARRANGEMENTS, I THINK THAT WOULD 4686 03:11:07,040 --> 03:11:09,440 ACTUALLY CREATE ALL SORTS OF 4687 03:11:09,440 --> 03:11:11,080 CONFLICTS THAT WOULD UNDERMINE 4688 03:11:11,080 --> 03:11:11,840 THE NCATS MISSION. 4689 03:11:11,840 --> 03:11:14,120 AND SO I THINK THERE IS AN 4690 03:11:14,120 --> 03:11:15,480 IMPORTANT SEPARATION BETWEEN 4691 03:11:15,480 --> 03:11:16,880 PUBLIC AND PRIVATE ACTIVITIES, 4692 03:11:16,880 --> 03:11:18,400 AND THAT WAS WRITTEN INTO LAW 4693 03:11:18,400 --> 03:11:19,520 FOR THAT REASON. 4694 03:11:19,520 --> 03:11:21,680 HOWEVER, I THINK THERE IS AN 4695 03:11:21,680 --> 03:11:23,440 IMPORTANT POINT ABOUT NCATS 4696 03:11:23,440 --> 03:11:26,840 BEING ABLE TO GET A MUCH BIGGER 4697 03:11:26,840 --> 03:11:28,160 FOOTPRINT IN TERMS OF IMPACT IF 4698 03:11:28,160 --> 03:11:30,120 IT WERE ABLE TO COLLABORATE WITH 4699 03:11:30,120 --> 03:11:32,840 THE PRIVATE SECTOR. 4700 03:11:32,840 --> 03:11:35,240 AND TO RAHESH'S POINT, AFTER THE 4701 03:11:35,240 --> 03:11:38,560 PAPER, THE CASE STUDY IN 2016 4702 03:11:38,560 --> 03:11:42,280 WAS PUBLISHED, THERE WAS AN 4703 03:11:42,280 --> 03:11:44,440 NCATS HOSTED OPEN HOUSE FOR SOME 4704 03:11:44,440 --> 03:11:47,520 OF THE POTENTIAL PRIVATE SECTOR 4705 03:11:47,520 --> 03:11:49,800 INVESTORS THAT I HAD BEEN 4706 03:11:49,800 --> 03:11:52,200 TALKING TO ABOUT NCATS AND 4707 03:11:52,200 --> 03:11:53,200 POSSIBLY COLLABORATING WITH 4708 03:11:53,200 --> 03:11:55,520 NCATS IN A SOMEWHAT MORE DIRECT 4709 03:11:55,520 --> 03:11:56,040 FASHION. 4710 03:11:56,040 --> 03:11:58,360 I BROUGHT THESE INDIVIDUALS DOWN 4711 03:11:58,360 --> 03:12:04,160 TO D.C., FOR THIS MEETING, AT 4712 03:12:04,160 --> 03:12:07,440 THE NCATS FACILITIES, AND THIS 4713 03:12:07,440 --> 03:12:08,800 GROUP INCLUDED REPRESENTATIVES 4714 03:12:08,800 --> 03:12:12,440 FROM THE VENTURE CAPITAL 4715 03:12:12,440 --> 03:12:15,080 COMMUNITY, HEDGE FUND COMMUNITY, 4716 03:12:15,080 --> 03:12:16,920 DRUG ROYALTY INVESTMENT 4717 03:12:16,920 --> 03:12:18,040 COMPANIES, AND WITHIN 24 HOURS 4718 03:12:18,040 --> 03:12:20,560 AFTER COMING BACK FROM THAT 4719 03:12:20,560 --> 03:12:22,640 MEETING AT NCATS, ONE OF THE 4720 03:12:22,640 --> 03:12:24,600 HEDGE FUNDS SENT CHRIS AUSTIN A 4721 03:12:24,600 --> 03:12:26,040 LETTER OF INTENT SAYING THEY 4722 03:12:26,040 --> 03:12:29,200 WOULD BE HAPPY TO INVEST $200 4723 03:12:29,200 --> 03:12:30,720 MILLION IF THEY COULD GET ACCESS 4724 03:12:30,720 --> 03:12:34,360 TO SOME OF THE IP IN THE NCATS 4725 03:12:34,360 --> 03:12:36,200 PORTFOLIO, THEY WOULD PROVIDE 4726 03:12:36,200 --> 03:12:37,960 THEIR OWN FUNDING. 4727 03:12:37,960 --> 03:12:39,280 AND CHRIS' REACTION WAS, WELL, 4728 03:12:39,280 --> 03:12:41,360 WHAT DO WE DO WITH THIS? 4729 03:12:41,360 --> 03:12:42,720 WE'RE NOT AUTHORIZED TO DO THIS 4730 03:12:42,720 --> 03:12:44,080 KIND OF A DEAL. 4731 03:12:44,080 --> 03:12:47,600 AND SO OVER THE COURSE OF THE 4732 03:12:47,600 --> 03:12:48,880 FOLLOWING SEVERAL MONTHS CHRIS 4733 03:12:48,880 --> 03:12:53,640 TALKED WITH A NUMBER OF 4734 03:12:53,640 --> 03:12:57,120 STAKEHOLDERS WITHIN NIH, LILLY 4735 03:12:57,120 --> 03:13:00,080 PORETILLO WAS INVOLVED, THE 4736 03:13:00,080 --> 03:13:01,280 CONCLUSION WAS ALONG THE LINES 4737 03:13:01,280 --> 03:13:03,240 YOU NEED AN ACT OF CONGRESS TO 4738 03:13:03,240 --> 03:13:08,280 BE ABLE TO ALLOW NCATS TO ENGAGE 4739 03:13:08,280 --> 03:13:09,760 IN THESE PUBLIC/PRIVATE 4740 03:13:09,760 --> 03:13:11,200 PARTNERSHIPS AT WHICH POINT I 4741 03:13:11,200 --> 03:13:14,200 DISCUSSED SOME OF THIS WITH 4742 03:13:14,200 --> 03:13:16,680 CONGRESSMAN JUAN VARGAS, 4743 03:13:16,680 --> 03:13:18,040 REPRESENTATIVE FROM SAN DIEGO, 4744 03:13:18,040 --> 03:13:19,320 FROM -- YEAH, SAN DIEGO. 4745 03:13:19,320 --> 03:13:22,280 HE'S VERY INTERESTED IN BIOTECH 4746 03:13:22,280 --> 03:13:23,360 ISSUES BECAUSE OF COURSE SAN 4747 03:13:23,360 --> 03:13:29,720 DIEGO HAS HAD A VIBRANT BIOTECH 4748 03:13:29,720 --> 03:13:30,720 COMMUNITY. 4749 03:13:30,720 --> 03:13:35,520 HE SPONSORED THE VARGAS ROONEY 4750 03:13:35,520 --> 03:13:41,080 PETERS BUILD, THE RARE DISEASE 4751 03:13:41,080 --> 03:13:45,480 BILL OF 2018 GIVING NIH 4752 03:13:45,480 --> 03:13:49,760 AUTHORITY TO CREATE A PRO SHALL 4753 03:13:49,760 --> 03:13:50,760 DID SHALL PUBLIC/PRIVATE 4754 03:13:50,760 --> 03:13:51,040 PARTNERSHIP. 4755 03:13:51,040 --> 03:13:54,240 THAT BILL NEVER GOT OFF THE 4756 03:13:54,240 --> 03:13:57,880 GROUND BECAUSE OF INFIGHTING 4757 03:13:57,880 --> 03:13:58,880 WITH REPUBLICANS AND DEMOCRATS 4758 03:13:58,880 --> 03:14:00,840 BUT DID GET SOME TRACTION AND 4759 03:14:00,840 --> 03:14:04,280 THEN THE PANDEMIC HIT, AND THAT 4760 03:14:04,280 --> 03:14:05,320 PUT EVERYTHING ON HOLD. 4761 03:14:05,320 --> 03:14:16,040 I THINK THERE'S AN OPPORTUNITY. 4762 03:14:16,040 --> 03:14:17,880 >> IF I MIGHT -- ANDREW BROUGHT 4763 03:14:17,880 --> 03:14:20,280 THIS UP, THE ORIGINAL 4764 03:14:20,280 --> 03:14:23,840 DISCUSSIONS THAT I MENTIONED WE 4765 03:14:23,840 --> 03:14:25,560 CONVENED BCs, ET CETERA, WE 4766 03:14:25,560 --> 03:14:26,560 HAD ADDRESSED THIS ISSUE IN 4767 03:14:26,560 --> 03:14:31,560 TERMS OF, YOU KNOW, HOW WOULD WE 4768 03:14:31,560 --> 03:14:33,440 AVOID CONFLICT OF INTEREST. 4769 03:14:33,440 --> 03:14:35,400 WE COULD TALK BIT OFFLINE, 4770 03:14:35,400 --> 03:14:36,080 STRAIGHTFORWARD MECHANISMS WHERE 4771 03:14:36,080 --> 03:14:37,040 THE MONEY DOESN'T HAVE TO COME 4772 03:14:37,040 --> 03:14:38,920 BACK TO THE SOURCE FROM WHICH IT 4773 03:14:38,920 --> 03:14:40,200 CAME, FOR EXAMPLE, TO AVOID 4774 03:14:40,200 --> 03:14:41,080 CONFLICT OF INTEREST. 4775 03:14:41,080 --> 03:14:45,920 IT GOES INTO A CENTRAL PART. 4776 03:14:45,920 --> 03:14:48,400 THE COLOR OF MONEY GETS WASHED, 4777 03:14:48,400 --> 03:14:51,600 DIFFERENT WAYS TO DO THIS. 4778 03:14:51,600 --> 03:14:54,160 THAT WILL BE ABOVE BOARD AND CAN 4779 03:14:54,160 --> 03:14:55,080 ACTUALLY MAKE IT HAPPEN. 4780 03:14:55,080 --> 03:14:58,600 I DON'T THINK THE MECHANISMS ARE 4781 03:14:58,600 --> 03:14:58,840 DIFFICULT. 4782 03:14:58,840 --> 03:15:01,080 IT'S WILL POWER, THE DESIRE, THE 4783 03:15:01,080 --> 03:15:04,360 POLITICAL WILL TO WANT TO DO IT, 4784 03:15:04,360 --> 03:15:06,600 THAT REQUIRES CONSTITUENTS IN 4785 03:15:06,600 --> 03:15:07,880 THEIR -- ONE CONGRESSMAN PUTTING 4786 03:15:07,880 --> 03:15:09,760 A BILL THERE IS FINE, SAN DIEGO 4787 03:15:09,760 --> 03:15:14,120 MIGHT WANT TO DO IT, BUT IF 4788 03:15:14,120 --> 03:15:18,000 HARVARD HOSPITALS AND SAN 4789 03:15:18,000 --> 03:15:18,960 FRANCISCO PLACES, STANFORDS OF 4790 03:15:18,960 --> 03:15:21,920 THE WORLD SAY NO, WE DON'T WANT 4791 03:15:21,920 --> 03:15:24,000 TO DO THAT, THE BOTTOM LINE WE 4792 03:15:24,000 --> 03:15:25,880 WOULD HAVE TO GET THE ACADEMIC 4793 03:15:25,880 --> 03:15:28,880 COMMUNITY OR DEANS OF THE 4794 03:15:28,880 --> 03:15:31,320 ACADEMIC COMMUNITY TO APPRECIATE 4795 03:15:31,320 --> 03:15:33,600 HOW IF THEY LEND SUPPORT THERE 4796 03:15:33,600 --> 03:15:35,760 WOULD BE A WIN-WIN SOLUTION. 4797 03:15:35,760 --> 03:15:38,080 THAT'S WHAT NEEDS TO BE 4798 03:15:38,080 --> 03:15:38,400 STRUCTURED. 4799 03:15:38,400 --> 03:15:40,400 >> CAN I SUGGEST THIS WOULD BE A 4800 03:15:40,400 --> 03:15:42,200 GOOD TOPIC TO REVISIT IN THE 4801 03:15:42,200 --> 03:15:44,120 NEXT FEW MONTHS. 4802 03:15:44,120 --> 03:15:45,320 THE REASON BEING THAT I THINK A 4803 03:15:45,320 --> 03:15:47,960 LOT OF THINGS HAVE CHANGED. 4804 03:15:47,960 --> 03:15:49,360 IN PARTICULAR WHAT HAS CHANGED 4805 03:15:49,360 --> 03:15:51,480 NOT SO MUCH ON ACADEMIC MEDICAL 4806 03:15:51,480 --> 03:15:53,560 SIDE BUT RATHER IN THE 4807 03:15:53,560 --> 03:15:55,640 INVESTMENT COMMUNITY IS THE 4808 03:15:55,640 --> 03:15:57,280 NOTION OF IMPACT INVESTING. 4809 03:15:57,280 --> 03:15:58,920 THAT'S A BUZZWORD THAT'S NOW 4810 03:15:58,920 --> 03:16:00,000 BECOME MUCH, MUCH MORE IMPORTANT 4811 03:16:00,000 --> 03:16:02,400 THAN IT WAS BACK IN 2018. 4812 03:16:02,400 --> 03:16:07,040 AND I THINK THERE ARE NOW A LOT 4813 03:16:07,040 --> 03:16:08,960 MORE WILLING INVESTORS, 4814 03:16:08,960 --> 03:16:10,280 INSTITUTIONAL INVESTORS, MUTUAL 4815 03:16:10,280 --> 03:16:12,840 FUND COMPLEXES, AND LARGE 4816 03:16:12,840 --> 03:16:13,680 ORGANIZATIONS, THAT ARE 4817 03:16:13,680 --> 03:16:15,480 INTERESTED IN SEEING THEIR MONEY 4818 03:16:15,480 --> 03:16:17,200 NOT ONLY HAVE FINANCIAL RETURN 4819 03:16:17,200 --> 03:16:18,760 BUT TO HAVE SOCIAL IMPACT AND I 4820 03:16:18,760 --> 03:16:20,400 CAN'T THINK OF ANYTHING MORE 4821 03:16:20,400 --> 03:16:21,720 IMPACTFUL THAN WHAT NCATS IS 4822 03:16:21,720 --> 03:16:22,280 DOING. 4823 03:16:22,280 --> 03:16:26,320 I THINK WE SHOULD REVISIT THAT. 4824 03:16:26,320 --> 03:16:28,320 >> YEAH, I'M SITTING HERE 4825 03:16:28,320 --> 03:16:29,720 THINKING TOO THAT BY REVISITING 4826 03:16:29,720 --> 03:16:31,600 PERHAPS THIS IS SOMETHING WE 4827 03:16:31,600 --> 03:16:34,840 NEED EVEN A WORK GROUP 4828 03:16:34,840 --> 03:16:38,360 COUNCIL-BASED WORK GROUP TO BE 4829 03:16:38,360 --> 03:16:40,520 CHEWING ON A VARIETY OF 4830 03:16:40,520 --> 03:16:43,280 OPPORTUNITIES BUT ALSO THE 4831 03:16:43,280 --> 03:16:44,480 BARRIERS TO REACH THOSE 4832 03:16:44,480 --> 03:16:47,880 OPPORTUNITIES GIVEN WHERE WE 4833 03:16:47,880 --> 03:16:48,080 ARE. 4834 03:16:48,080 --> 03:16:49,520 THAT'S GOING TO TAKE A VARIETY 4835 03:16:49,520 --> 03:16:52,520 OF US TO DIG DEEPER TO SEE WHAT 4836 03:16:52,520 --> 03:16:54,760 SOME OPTIONS COULD BE. 4837 03:16:54,760 --> 03:16:57,840 I AGREE I THINK THIS IS WORTH 4838 03:16:57,840 --> 03:17:00,040 PURSUING BECAUSE I HAVE ALSO 4839 03:17:00,040 --> 03:17:03,920 CONSIDERED THE IDEA THAT EVEN IF 4840 03:17:03,920 --> 03:17:06,240 WE HAVE AN OPPORTUNITY FUND, AS 4841 03:17:06,240 --> 03:17:08,200 WE POINTED TO, WHETHER OR NOT 4842 03:17:08,200 --> 03:17:10,480 THAT MAKES US EVERGREEN IT CAN 4843 03:17:10,480 --> 03:17:10,960 CERTAINLY HELP CREATE 4844 03:17:10,960 --> 03:17:12,120 OPPORTUNITIES FOR A VARIETY OF 4845 03:17:12,120 --> 03:17:15,680 OTHER ACTIVITIES TO BE DONE. 4846 03:17:15,680 --> 03:17:17,760 AND THAT'S -- THAT WOULD BE 4847 03:17:17,760 --> 03:17:18,880 REALLY, REALLY HELPFUL FOR A 4848 03:17:18,880 --> 03:17:20,000 VARIETY OF REASONS. 4849 03:17:20,000 --> 03:17:21,400 BUT MAYBE THERE ARE SOME 4850 03:17:21,400 --> 03:17:23,360 PARAMETERS AROUND THAT, I DON'T 4851 03:17:23,360 --> 03:17:23,560 KNOW. 4852 03:17:23,560 --> 03:17:26,440 THAT WOULD MAKE IT EVEN MORE 4853 03:17:26,440 --> 03:17:26,760 PALATABLE. 4854 03:17:26,760 --> 03:17:28,120 HAVING A FOCUSED EFFORT TO TALK 4855 03:17:28,120 --> 03:17:32,040 THROUGH A LOT OF THESE ISSUES 4856 03:17:32,040 --> 03:17:33,360 MUCH MORE DEEPLY MIGHT -- WE 4857 03:17:33,360 --> 03:17:36,320 MIGHT BE RIPE FOR THAT. 4858 03:17:36,320 --> 03:17:37,480 SO STAY TUNED. 4859 03:17:37,480 --> 03:17:40,160 AND WE CAN REVISIT THIS AS WELL 4860 03:17:40,160 --> 03:17:41,440 OVER THE COMING MONTHS AND 4861 03:17:41,440 --> 03:17:42,680 CERTAINLY AT THE NEXT COUNCIL 4862 03:17:42,680 --> 03:17:44,960 TOO. 4863 03:17:44,960 --> 03:17:48,240 4864 03:17:48,240 --> 03:17:49,880 ANY OTHER QUESTIONS AT THIS 4865 03:17:49,880 --> 03:17:50,280 POINT? 4866 03:17:50,280 --> 03:17:52,040 THAT WAS A GREAT, GREAT, GREAT 4867 03:17:52,040 --> 03:17:52,560 DISCUSSION. 4868 03:17:52,560 --> 03:17:54,680 THANK YOU. 4869 03:17:54,680 --> 03:17:59,840 4870 03:17:59,840 --> 03:17:59,960 4871 03:17:59,960 --> 03:18:02,800 THORNY AND OPTIMISTIC. 4872 03:18:02,800 --> 03:18:04,680 4873 03:18:04,680 --> 03:18:04,960 ALL RIGHT. 4874 03:18:04,960 --> 03:18:07,400 LIZ, THANK YOU SO MUCH. 4875 03:18:07,400 --> 03:18:09,240 YOU WERE ON THE HOT SEAT FOR A 4876 03:18:09,240 --> 03:18:11,800 WHILE THERE. 4877 03:18:11,800 --> 03:18:12,640 APPRECIATE EVERYTHING THERE. 4878 03:18:12,640 --> 03:18:14,280 >> GREAT DISCUSSION. 4879 03:18:14,280 --> 03:18:15,920 OKAY. 4880 03:18:15,920 --> 03:18:16,720 BYE. 4881 03:18:16,720 --> 03:18:19,120 >> THANK YOU. 4882 03:18:19,120 --> 03:18:19,320 OKAY. 4883 03:18:19,320 --> 03:18:20,840 ANNA, ARE THERE ANY UPDATES YOU 4884 03:18:20,840 --> 03:18:24,400 NEWED TO BRING -- NEED TO BRING 4885 03:18:24,400 --> 03:18:25,240 TO OUR ATTENTION? 4886 03:18:25,240 --> 03:18:26,080 >> I DO NOT. 4887 03:18:26,080 --> 03:18:27,720 WE'RE AT A POINT WE CAN ADJOURN 4888 03:18:27,720 --> 03:18:29,520 AFTER YOU MAKE ANY PARTING 4889 03:18:29,520 --> 03:18:31,480 COMMENTS YOU'D LIKE TO. 4890 03:18:31,480 --> 03:18:31,800 >> OKAY. 4891 03:18:31,800 --> 03:18:33,120 WELL, WE'RE NOT CLOSING OUT JUST 4892 03:18:33,120 --> 03:18:33,320 YET. 4893 03:18:33,320 --> 03:18:38,040 I'M NOT GOING TO USE THE GAVEL. 4894 03:18:38,040 --> 03:18:39,160 AND I THINK THAT'S -- WE'LL 4895 03:18:39,160 --> 03:18:40,680 LEAVE THE LIGHT ON FOR YOU 4896 03:18:40,680 --> 03:18:43,760 TONIGHT AND WE'LL SEE YOU 4897 03:18:43,760 --> 03:18:44,520 TOMORROW. 4898 03:18:44,520 --> 03:18:46,240 WE WILL RECONVENE AT 1 P.M. 4899 03:18:46,240 --> 03:18:48,920 SO PLEASE BE SURE TO DO THE 4900 03:18:48,920 --> 03:18:50,320 CONNECTION AT 12:45 TO MAKE SURE 4901 03:18:50,320 --> 03:18:52,160 YOU'RE IN AND WITH THAT I THINK 4902 03:18:52,160 --> 03:18:53,680 WE CAN ADJOURN FOR THE DAY. 4903 03:18:53,680 --> 03:18:55,800 THANK YOU FOR THE GREAT 4904 03:18:55,800 --> 03:18:56,000 DISCUSSION. 4905 03:18:56,000 --> 00:00:00,000 SEE YOU TOMORROW.